Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis : systematic review and economic evaluation by Melendez-Torres, G. J. et al.
HEALTH TECHNOLOGY ASSESSMENT
VOLUME 21 ISSUE 52 SEPTEMBER 2017
ISSN 1366-5278
DOI 10.3310/hta21520
Clinical effectiveness and cost-effectiveness of 
beta-interferon and glatiramer acetate for  
treating multiple sclerosis: systematic review  
and economic evaluation
GJ Melendez-Torres, Peter Auguste, Xavier Armoiry,  
Hendramoorthy Maheswaran, Rachel Court,  
Jason Madan, Alan Kan, Stephanie Lin, Carl Counsell,  
Jacoby Patterson, Jeremy Rodrigues, Olga Ciccarelli,  
Hannah Fraser and Aileen Clarke

Clinical effectiveness and cost-effectiveness
of beta-interferon and glatiramer acetate
for treating multiple sclerosis: systematic
review and economic evaluation
GJ Melendez-Torres,1* Peter Auguste,1
Xavier Armoiry,1 Hendramoorthy Maheswaran,1
Rachel Court,1 Jason Madan,1 Alan Kan,1
Stephanie Lin,1 Carl Counsell,2 Jacoby Patterson,3
Jeremy Rodrigues,4 Olga Ciccarelli,5 Hannah Fraser1
and Aileen Clarke1
1Warwick Evidence, Division of Health Sciences, Warwick Medical School,
University of Warwick, Coventry, UK
2Divison of Applied Health Sciences, University of Aberdeen, Aberdeen, UK
3Independent research consultant, Windsor, UK
4Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal
Sciences, University of Oxford, Oxford, UK
5Department of Neuroinflammation, Institute of Neurology, University College
London, London, UK
*Corresponding author
Declared competing interests of authors: Olga Ciccarelli received consultancy fees from Novartis,
Biogen Idec Ltd General Electric and Genzyme. All payments were made to her employer, the UCL Institute
of Neurology. She also received reimbursement from Novartis and the European Committee for Treatment
and Research in Multiple Sclerosis (ECTRIMS) for attending a symposium and funds from the UK MS
Society, Engineering and Physical Sciences Research Council (EPSRC), University College London Hospitals
NHS Foundation Trust and UCL Hospitals Biomedical Research Centre for research. Aileen Clarke is an
editor of the journal Health Technology Assessment. All payments are made to her employer, the Warwick
Medical School. Carl Counsell received funding through Biogen Idec Ltd for a departmental multiple
sclerosis (MS) nurse. He has also authored a paper that was critical of the UK risk-sharing scheme for
disease-modifying therapies in MS (Sudlow CLM, Counsell CE. Problems with UK government’s risk sharing
scheme for assessing drugs for multiple sclerosis. BMJ 2003;326:388–92). Jeremy Rodrigues holds a
fellowship at the National Institute for Health and Care Excellence. This fellowship is unremunerated.
Aileen Clarke and GJ Melendez–Torres are partly supported by the National Institute for Health Research
(NIHR) Collaboration for Leadership in Applied Health Research and Care West Midlands at the University
Hospitals Birmingham NHS Foundation Trust.
Published September 2017
DOI: 10.3310/hta21520

This report should be referenced as follows:
Melendez-Torres GJ, Auguste P, Armoiry X, Maheswaran H, Court R, Madan J, et al. Clinical
effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple
sclerosis: systematic review and economic evaluation. Health Technol Assess 2017;21(52).
Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta
Medica/EMBASE, Science Citation Index Expanded (SciSearch®) and Current Contents®/
Clinical Medicine.

Health Technology Assessment NICE TAR and DAR
ISSN 1366-5278 (Print)
ISSN 2046-4924 (Online)
Impact factor: 4.236
Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, The Cochrane Library and the Clarivate Analytics Science
Citation Index.
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).
Editorial contact: journals.library@nihr.ac.uk
The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the
report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk
Criteria for inclusion in the Health Technology Assessment journal
Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they
are of a sufficiently high scientific quality as assessed by the reviewers and editors.
Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to
minimise biases and random errors) would, in theory, permit the replication of the review by others.
HTA programme
The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research
information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS.
‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation
and long-term care.
The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute
for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC)
policy decisions.
For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta
This report
The research reported in this issue of the journal was commissioned and funded by the HTA programme on behalf of NICE as project number
13/74/01. The protocol was agreed in July 2016. The assessment report began editorial review in September 2016 and was accepted for
publication in January 2017. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up
their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for
their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material
published in this report.
This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by
authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme
or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the
interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA
programme or the Department of Health.
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Melendez-Torres et al. under the terms of a
commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of
private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for
commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials
and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland
(www.prepress-projects.co.uk).
Editor-in-Chief
Health Technology Assessment 
NIHR Journals Library
Professor Tom Walley Director, NIHR Evaluation, Trials and Studies and Director of the EME Programme, UK
NIHR Journals Library Editors
Editor-in-Chief
Professor Hywel Williams Director, HTA Programme, UK and Foundation Professor and Co-Director of the
Centre of Evidence-Based Dermatology, University of Nottingham, UK
Professor Ken Stein  Chair of HTA and EME Editorial Board and Professor of Public Health, 
University of Exeter Medical School, UK
Professor Andrée Le May  Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals)
Dr Martin Ashton-Key  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK
Professor Matthias Beck  Chair in Public Sector Management and Subject Leader (Management Group),  
Queen’s University Management School, Queen’s University Belfast, UK
Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK
Dr Eugenia Cronin  Senior Scientific Advisor, Wessex Institute, UK
Ms Tara Lamont  Scientific Advisor, NETSCC, UK
Dr Catriona McDaid  Senior Research Fellow, York Trials Unit, Department of Health Sciences, 
University of York, UK 
Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK
Professor Geoffrey Meads  Professor of Wellbeing Research, University of Winchester, UK
Professor John Norrie  Chair in Medical Statistics, University of Edinburgh, UK
Professor John Powell  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK
Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, 
University of Southampton, UK
Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK
Professor Helen Roberts  Professor of Child Health Research, UCL Institute of Child Health, UK
Professor Jonathan Ross  Professor of Sexual Health and HIV, University Hospital Birmingham, UK
Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, 
Swansea University, UK
Professor Jim Thornton  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences,  
University of Nottingham, UK
Professor Martin Underwood  Director, Warwick Clinical Trials Unit, Warwick Medical School,
University of Warwick, UK
Please visit the website for a list of members of the NIHR Journals Library Board: 
www.journalslibrary.nihr.ac.uk/about/editors
Editorial contact:  journals.library@nihr.ac.uk
NIHR Journals Library www.journalslibrary.nihr.ac.uk
Abstract
Clinical effectiveness and cost-effectiveness of beta-interferon
and glatiramer acetate for treating multiple sclerosis:
systematic review and economic evaluation
GJ Melendez-Torres,1* Peter Auguste,1 Xavier Armoiry,1
Hendramoorthy Maheswaran,1 Rachel Court,1 Jason Madan,1
Alan Kan,1 Stephanie Lin,1 Carl Counsell,2 Jacoby Patterson,3
Jeremy Rodrigues,4 Olga Ciccarelli,5 Hannah Fraser1
and Aileen Clarke1
1Warwick Evidence, Division of Health Sciences, Warwick Medical School, University of Warwick,
Coventry, UK
2Divison of Applied Health Sciences, University of Aberdeen, Aberdeen, UK
3Independent research consultant, Windsor, UK
4Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of
Oxford, Oxford, UK
5Department of Neuroinflammation, Institute of Neurology, University College London,
London, UK
*Corresponding author G.Melendez-Torres@warwick.ac.uk
Background: At the time of publication of the most recent National Institute for Health and Care
Excellence (NICE) guidance [technology appraisal (TA) 32] in 2002 on beta-interferon (IFN-β) and glatiramer
acetate (GA) for multiple sclerosis, there was insufficient evidence of their clinical effectiveness and
cost-effectiveness.
Objectives: To undertake (1) systematic reviews of the clinical effectiveness and cost-effectiveness of
IFN-β and GA in relapsing–remitting multiple sclerosis (RRMS), secondary progressive multiple sclerosis
(SPMS) and clinically isolated syndrome (CIS) compared with best supportive care (BSC) and each other,
investigating annualised relapse rate (ARR) and time to disability progression confirmed at 3 months and
6 months and (2) cost-effectiveness assessments of disease-modifying therapies (DMTs) for CIS and RRMS
compared with BSC and each other.
Review methods: Searches were undertaken in January and February 2016 in databases including The
Cochrane Library, MEDLINE and the Science Citation Index. We limited some database searches to specific
start dates based on previous, relevant systematic reviews. Two reviewers screened titles and abstracts with
recourse to a third when needed. The Cochrane tool and the Consolidated Health Economic Evaluation
Reporting Standards (CHEERS) and Philips checklists were used for appraisal. Narrative synthesis and, when
possible, random-effects meta-analysis and network meta-analysis (NMA) were performed. Cost-effectiveness
analysis used published literature, findings from the Department of Health’s risk-sharing scheme (RSS) and
expert opinion. A de novo economic model was built for CIS. The base case used updated RSS data, a NHS
and Personal Social Services perspective, a 50-year time horizon, 2014/15 prices and a discount rate of 3.5%.
Outcomes are reported as incremental cost-effectiveness ratios (ICERs). We undertook probabilistic
sensitivity analysis.
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Results: In total, 6420 publications were identified, of which 63 relating to 35 randomised controlled trials
(RCTs) were included. In total, 86% had a high risk of bias. There was very little difference between drugs in
reducing moderate or severe relapse rates in RRMS. All were beneficial compared with BSC, giving a pooled
rate ratio of 0.65 [95% confidence interval (CI) 0.56 to 0.76] for ARR and a hazard ratio of 0.70 (95% CI,
0.55 to 0.87) for time to disability progression confirmed at 3 months. NMA suggested that 20 mg of
GA given subcutaneously had the highest probability of being the best at reducing ARR. Three separate
cost-effectiveness searches identified > 2500 publications, with 26 included studies informing the narrative
synthesis and model inputs. In the base case using a modified RSS the mean incremental cost was £31,900
for pooled DMTs compared with BSC and the mean incremental quality-adjusted life-years (QALYs) were
0.943, giving an ICER of £33,800 per QALY gained for people with RRMS. In probabilistic sensitivity analysis
the ICER was £34,000 per QALY gained. In sensitivity analysis, using the assessment group inputs gave an
ICER of £12,800 per QALY gained for pooled DMTs compared with BSC. Pegylated IFN-β-1 (125 µg) was the
most cost-effective option of the individual DMTs compared with BSC (ICER £7000 per QALY gained); GA
(20 mg) was the most cost-effective treatment for CIS (ICER £16,500 per QALY gained).
Limitations: Although we built a de novo model for CIS that incorporated evidence from our systematic
review of clinical effectiveness, our findings relied on a population diagnosed with CIS before
implementation of the revised 2010 McDonald criteria.
Conclusions: DMTs were clinically effective for RRMS and CIS but cost-effective only for CIS. Both RCT
evidence and RSS data are at high risk of bias. Research priorities include comparative studies with longer
follow-up and systematic review and meta-synthesis of qualitative studies.
Study registration: This study is registered as PROSPERO CRD42016043278.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Glossary
Annualised relapse rate This indicates the number of relapses a patient would expect to have on
average every year. Differences in the annualised relapse rate are measured as a rate ratio, which suggests
the percentage difference in rate between two groups. A rate ratio of 0.75 in group 1 compared with
group 2 means that group 1 has 25% fewer relapses than group 2. In contrast, a rate ratio of 1.25
suggests that group 1 has 25% more relapses than group 2. In multiple sclerosis, an improvement of one
drug over another would be represented by a rate ratio of < 1.
Surface under the cumulative ranking curve In network meta-analyses, it is possible to rank
interventions on the size of their effect. This is carried out using the surface under the cumulative ranking
curve. A higher surface under the cumulative ranking curve means a larger magnitude of effect. For clinical
effectiveness outcomes, such as relapse rate and time to disability progression, interventions are ranked based
on how much the intervention reduces relapse or slows down disability progression. For discontinuation as a
result of adverse events, interventions are ranked on how much they increase the risk of discontinuation.
Time to disability progression This indicates how quickly a patient would expect to have disability
progression compared with another patient. This is measured as a hazard ratio. A hazard ratio of < 1 in
group 1 compared with group 2 means that group 1 will take longer to have disability progression.
Conversely, a hazard ratio of > 1 in group 1 compared with group 2 means that group 1 will have faster
disability progression on average. For example, a hazard ratio of 0.75 in group 1 compared with group 2
means that, at a point in the future, people without progression in group 1 will have a 25% less chance
of having disability progression than people without progression in group 2. In multiple sclerosis, an
improvement of one drug over another would be represented by a hazard ratio of < 1.
Time to disability progression confirmed at 3 (or 6) months To reduce the effect of ‘blips’ in
disability progression on estimates of effectiveness, many trials require that an initial sign of disability
progression be confirmed at a repeat visit 3 (or 6) months later. Thus, time to disability progression
confirmed at 3 months is simply the time to disability progression when that disability progression has
been subsequently confirmed 3 months after the visit when progression was first detected. Similarly, time
to disability progression confirmed at 6 months is the time to progression when that progression has been
subsequently confirmed 6 months after the visit when it was first detected.
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Note
This monograph is based on the Technology Assessment Report produced for NICE. The full
report contained a considerable number of data that were deemed confidential. The full
report was used by the Appraisal Committee at NICE in their deliberations. The full report
with each piece of confidential data removed and replaced by the statement ‘confidential
information (or data) removed’ is available on the NICE website: www.nice.org.uk.
The present monograph presents as full a version of the report as is possible while retaining
readability, but some sections, sentences, tables and figures have been removed. Readers
should bear in mind that the discussion, conclusions and implications for practice and research
are based on all the data considered in the original full NICE report.
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Plain English summary
Multiple sclerosis (MS) causes inflammation of the nerves. It is a leading cause of disability in the UK.This study is about two types of MS. In relapsing–remitting MS (RRMS) people have relapses, or
attacks of more severe illness and recovery. In clinically isolated syndrome (CIS) people have just one
episode but are thought to be at high risk of developing MS.
Various treatments are available for RRMS and CIS, including different types of beta-interferons and
glatiramer. We focused on these two types of drugs. In this study we looked at the clinical effectiveness
and cost-effectiveness of these drugs for RRMS and CIS.
We carried out systematic reviews of randomised controlled trials. We pooled the results on relapse rates
with time to worsening of the disease. We drew on a risk-sharing scheme set up by the Department of
Health to collect long-term information on the disease-modifying therapies. We developed our own model
for CIS.
We found that all of these drugs were clinically effective in both RRMS and CIS. The studies were at high
risk of bias and had short follow-up times. As a whole, these drugs were not cost-effective for RRMS.
We found that glatiramer was the most cost-effective option for CIS.
We think that longer-term research is needed that compares these drugs with each other. A review of
qualitative studies is also needed so that we can understand more about the preferences and experiences
of people living with MS.
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Scientific summary
Background
Multiple sclerosis (MS) is a neurodegenerative disorder characterised by inflammation and demyelination of
neurons in the brain and spinal cord. It is a leading cause of disability in working-age adults and affects
over 100,000 people in the UK. The commonest form of MS is relapsing–remitting MS or RRMS. A single
demyelinating event thought to precede MS is known as clinically isolated syndrome (CIS) and RRMS can
progress to secondary progressive MS (SPMS). Although there is currently no cure for MS, there are a
number of disease-modifying therapies (DMTs) available to help reduce the frequency of relapses and
the rate of disease progression. Beta-interferons (IFN-β) and glatiramer acetate (GA) are two such drugs.
At the time of publication of the most recent National Institute for Health and Care Excellence (NICE)
technology appraisal (TA) of these drugs in 2002 (TA32), there was insufficient evidence of their clinical
and cost-effectiveness. A risk-sharing scheme (RSS) was put in place, allowing patients to access the drugs
and the NHS to adjust prices based on cost-effectiveness data, as well as to monitor long-term outcomes.
This current study aimed to appraise the clinical effectiveness and cost-effectiveness of IFN-β and GA for
MS, integrating published evidence with data from the RSS, and also to assess their role in CIS.
This report was commissioned by the National Institute for Health Research (NIHR) Health Technology
Assessment (HTA) programme as project number ID809.
Decision problem
Our first objective was to systematically review the evidence for the clinical effectiveness of IFN-β-1a,
pegylated IFN-β-1a, IFN-β-1b and GA in people with relapsing MS (including people with RRMS and people
with SPMS with active disease, evidenced by relapses) and CIS (i.e. a single demyelinating event, who are
considered at high risk of developing subsequent MS) compared with best supportive care (BSC) without
DMTs, and with each other. The following outcomes were investigated:
l relapse rate
l transition to clinically definite MS (in the case of CIS)
l severity of relapse
l disability [e.g. Expanded Disability Status Scale (EDSS)]
l symptoms of MS such as fatigue, cognition and visual disturbance
l freedom from disease activity
l discontinuation as a result of neutralising antibodies
l mortality
l adverse effects of treatment
l health-related quality of life (HRQoL).
The second objective was to systematically review existing economic evaluations, including use of the existing
RSS model; develop a de novo economic model for CIS; assess the cost-effectiveness of the treatments
(IFN-β-1a, pegylated IFN-β-1a, IFN-β-1b and GA) for CIS and RRMS against the stated comparators, expressed
in incremental costs per quality-adjusted life-year (QALY), using a time horizon that was sufficiently long to
reflect any differences in costs or outcomes between the technologies being compared and taking a NHS
and Personal Social Services (PSS) perspective; and update model parameters and inputs to reflect available
evidence from the literature, current costs, the NICE reference case, current practice and new data from
the RSS.
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Methods
Clinical effectiveness and cost-effectiveness reviews
Searches were undertaken in January and February 2016. Several relevant systematic reviews were
identified for some populations and study types, allowing some searches to be limited by publication date
to 2012 onwards. For those populations and study types for which no suitable systematic reviews were
identified, database searches were undertaken from inception. The databases searched were The Cochrane
Library, the Cochrane MS Group Specialised Register; MEDLINE; EMBASE and the Science Citation Index.
For the cost-effectiveness review, the NHS Economic Evaluation Database (NHS EED), Research Papers in
Economics (RePEc) and the Cost-effectiveness Analysis (CEA) Registry were searched. Online trial registers
were also searched as well as company, patient and carer, professional and research group websites. The
following designs were included: randomised controlled trials (RCTs), systematic reviews, meta-analyses
and cost-effectiveness studies. The population of interest was people diagnosed with RRMS, SPMS or
CIS and the intervention was one of the designated drugs used within its marketing authorisation (and
including the recommended dose regimen). Searches of reference lists and information provided by
the manufacturers of the interventions were carried out for additional eligible studies. Two reviewers
independently screened and assessed identified titles and abstracts for inclusion, with recourse to a third
reviewer in case of disagreement. Systematic reviews used to locate primary studies were appraised using
the Assessing the Methodological Qualities of Systematic Reviews (AMSTAR) checklist, primary clinical
effectiveness studies were appraised using the Cochrane risk of bias assessment tool and health economic
studies were appraised using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS)
and Philips checklists. Narrative synthesis was undertaken. When possible, random-effects meta-analyses
and network meta-analyses (NMAs) were performed for each outcome using Stata® 14 (StataCorp LP,
College Station, TX, USA).
Cost-effectiveness methods
The RSS model is an economic analysis that was conducted to assess the cost-effectiveness of the
combined treatment effect of DMTs included in the RSS compared with BSC for people with RRMS.
It is a Markov model based on the British Columbia Multiple Sclerosis (BCMS) cohort for natural history
compared with cohorts of patients taking the intervention drugs. Drug prices were agreed with the
Department of Health as part of the RSS. We based our cost-effectiveness analysis on the RSS model,
including data from the 10-year follow-up when available. For CIS we built a de novo economic model to
assess the cost-effectiveness of the identified drugs. We used outcome values derived from our systematic
reviews of the published literature, RSS pooled cost-effectiveness data, data submitted by the companies,
expert opinion and NHS reference costs to input into the models to understand the relative costs and
effectiveness of the different interventions and to explore the different assumptions made.
We used our modified RSS model (we assumed that standardised mortality was 1.0 and excluded carers’
disutility) with clinical effectiveness inputs derived from the year 10 RSS analyses as the base case for
RRMS, with additional evidence on time to progression used in the CIS base case. We estimated mean
total costs and mean total QALYs for each intervention compared with BSC and with each other and
adopted a NHS and PSS perspective with a 50-year time horizon. Costs were in 2014/15 prices and a
discount rate of 3.5% was used. Outcomes are reported as incremental cost-effectiveness ratios (ICERs)
expressed in terms of cost per QALY gained. The models were run deterministically. We undertook
sensitivity analyses and explored uncertainty to investigate key drivers. For RRMS we undertook
probabilistic analyses with 1000 bootstrapped iterations.
Results
Clinical effectiveness results
We identified 6420 publications, of which 63 publications relating to 35 primary studies were included in
the review. In total, 86% (30/35) of the studies were at high risk of bias from either complete or partial
SCIENTIFIC SUMMARY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xxxvi
participant unblinding and studies also suffered from relatively short follow-up times; 29% (10/35) of the
studies were also found to be at high risk of bias from missing data, based on large numbers of missing
data, a difference in rates of loss to follow-up between arms or lack of reporting of imputation methods.
In 17% (6/35) of studies outcomes were not reported as stated and these studies were designated as
being at high risk of bias from selective reporting. Finally, all studies funded by drug manufacturers were
designated as being at high risk of bias. Five studies investigated DMTs for CIS, three trials investigated
SPMS and 27 compared different DMTs with each other or with placebo for RRMS using a variety
of outcomes.
For CIS, all studies found a benefit of DMTs over placebo for time to progression to MS. Rankings from the
NMA suggested that 44 µg of subcutaneous (SC) IFN-β-1a three times weekly was ranked best, followed
by 250 µg of SC IFN-β-1b every other day, 30 µg of intramuscular IFN-β-1a once a week and 20 mg of SC
GA once daily.
For RRMS there was very little difference between the different drugs in terms of reducing moderate or
severe relapse rates. Random-effects NMA gave a pooled rate ratio (RR) of 0.65 [95% confidence interval
(CI) 0.56 to 0.76] for annualised relapse rate (ARR) for all intervention drugs compared with placebo and a
hazard ratio (HR) of 0.70 (95% CI 0.55 to 0.87) for time to disability progression confirmed at 3 months.
Rankings suggested that the drug that had the highest probability of being the best at reducing the ARR
was 20 mg of SC GA once daily, followed by 125 µg of SC pegylated IFN-β-1a every 2 weeks. For time to
disability progression confirmed at 3 months, 44 µg of SC IFN-β-1a three times weekly had the highest
probability of being the most effective.
For SPMS, the three trials demonstrated a benefit of beta-IFNs over placebo for ARR, with RRs ranging
from 0.69 (95% CI 0.56 to 0.85) to 0.71 (95% CI 0.63 to 0.79). NMA suggested that 250 µg of SC
IFN-β-1b every other day was superior to the equally ranked 44 µg of SC IFN-β-1a three times weekly
and 22 µg of SC IFN-β-1a three times weekly.
Cost-effectiveness results
Our searches for systematic reviews identified 1566 records, of which nine were economic evaluation
studies. Searches for economic evaluations in CIS revealed 614 records, of which nine were selected.
Searches for primary cost-effectiveness, HRQoL, costs and resource use studies for DMTs in RRMS yielded
2451 studies, of which eight matched the inclusion criteria. The cost-effectiveness systematic review
findings suggested that models were sensitive to time horizons. Most demonstrated an acceptable ICER for
different formulations of IFN-β compared with BSC at standard levels of willingness to pay in a number of
different countries. For RRMS, however, the findings were often not generalisable and studies were
sensitive to time horizons used and starting distributions of disability.
In the RSS model submission, a mean RR of 0.72 (95% CI 0.6118 to 0.8309) for ARR and a HR of 0.7913
(95% CI 0.7705 to 0.8122) for disability progression (equivalent to our time to disability progression
confirmed at 3 months value) were reported for patients taking DMTs compared with placebo based on
year 10 analyses. Our base case, using a modified RSS model, resulted in mean incremental costs of DMTs
compared with BSC of approximately £31,900 and incremental QALYs of 0.943, resulting in an ICER of
approximately £33,800 per QALY. Probabilistic sensitivity analysis resulted in similar values, with an ICER of
approximately £34,000 per QALY. Using the results from our NMA, DMTs were approximately £23,300
more costly than BSC using our clinical effectiveness results, while conferring 1.822 more QALYs, equating
to an ICER of approximately £12,800 per QALY. Using the RSS base-case model and with individual HRs,
we found that 125 µg of pegylated (peg) IFN-β-1a (Plegridy®; Biogen Idec Ltd, Cambridge, MA, USA) was
the most cost-effective option, with an incremental cost of £17,800 and incremental QALYs of 2.559,
giving an ICER of £7000 compared with BSC. We explored varying key model input parameters, finding
that changes in the HR for disability progression had the greatest impact on the cost-effectiveness results.
A decrease in treatment effect (increase in HR by 10%) resulted in an ICER of approximately £74,500 per
QALY gained.
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For CIS we found that, compared with BSC, the optimal strategy was treatment with 20 mg of GA
(Copaxone®; Teva Pharmaceutical Industries, Petah Tikva, Israel) followed by DMTs for progression to
RRMS. This was associated with an incremental cost of £98,400 and incremental QALYs of 5.95, giving an
ICER of £16,500 per QALY. Sensitivity analyses showed that the model was most sensitive to change in the
utility of the CIS health state. However, a 10% increase still gave an ICER for 20 mg of GA of £14,500
compared with BSC, well within the normal expected levels of willingness to pay.
Discussion and conclusion
We undertook systematic reviews, appraised the RSS model and designed a de novo model for CIS to
assess the clinical effectiveness and cost-effectiveness of DMTs in MS. From our systematic reviews
we found that DMTs are effective when used for both RRMS and CIS. In our NMA, GA was the most
effective treatment at reducing the ARR. For RRMS we found that, overall, DMTs are not cost-effective at
the current level of willingness to pay of £30,000 per QALY. The individual drug with the lowest ICER
compared with BSC (£7000) was 125 µg of pegIFN-β-1a. We found that, for CIS, if DMTs are subsequently
used for RRMS, the most cost-effective option was GA.
Strengths and limitations
The strengths of this study include the rigorous and comprehensive systematic reviews and the large
number of NMAs alongside the careful assessment of manufacturers’ submissions and the RSS model. We
built a de novo decision tree model to assess cost-effectiveness in CIS and for each investigation undertook
a number of sensitivity analyses. Limitations include the limitations of the underlying studies, with the
heterogeneity of definitions, for example for progression, and subgroups, and the limitations of sparse
networks, which restricted our ability to synthesise our findings fully. More importantly, we consider that
the RCT evidence is problematic in that 30 out of 35 studies were at high risk of bias and this, along with
the short-follow up times, may not allow for adequate assessment of the effects of DMTs. It is for these
reasons that we elected to use a modified RSS model with appropriate adjustments as our base case for
the assessment of the cost-effectiveness of the DMTs, even though it is based on an observational design
with a non-contemporaneous control cohort. In addition, in the cost-effectiveness review we were unable
to identify reliable estimates of utilities for CIS, although we were able to take account of this in sensitivity
analyses. The economic model represents the care pathway to the best of our knowledge, but practice and
management may vary.
Implications for health care
We did not include formulations outside the recommended usage in the UK. Also, we should recognise
that our study was specifically designed to exclude the clinical effectiveness and cost-effectiveness of
newer MS treatments such as newer monoclonal antibodies [alemtuzumab (Lemtrada®; Sanofi Genzyme,
Cambridge, MA, USA) and daclizumab (Zinbryta®; Biogen Idec Ltd, Cambridge, MA, USA)]. This review
should be considered in conjunction with newer NICE and other guidance on the clinical effectiveness and
cost-effectiveness of these agents.
Research priorities
One key flaw in the assembled clinical effectiveness evidence was the lack of long-term follow-up. We
consider that the distinctiveness of the different stages of MS is open to question. Additionally, valuation
of health benefits continues to be a vexing area for MS and this was an issue identified in the original
guidance resulting from TA32. Additional priorities include:
l How and under what circumstances MS progresses through different types (CIS, RRMS, SPMS)
and how these transitions relate to changing imaging technologies and changes in clinical practice.
l Further research that does not concentrate on the lower end of the EDSS scale may be of value for
populations with MS, as survival and advances in support and aids for those with disabilities improve.
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l The RSS was designed to collect longer-term observational data in this area; however, a large-scale,
longitudinal randomised trial comparing active first-line agents would contribute meaningfully towards
resolving uncertainty about the remaining relative benefits of different IFN-β or GA formulations.
l We consider that a systematic review and meta-synthesis of qualitative studies relating to the lived
experience of MS, with particular attention to the dominant clinical features, for example relapse and
disability progression, would be of value. This would provide a basis for an understanding of relevant
health states and benefits that more closely matches the preferences and experiences of people living
with the target condition.
Study registration
This study is registered as PROSPERO CRD42016043278.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Introduction
Multiple sclerosis (MS) is a progressive, degenerative disease affecting the central nervous system (CNS). It
is characterised by inflammation and demyelination of the neurons, mediated by an autoimmune response
by T cells to white matter.
Although not yet fully understood, the aetiology of MS involves major genetic components,1 with two or
more genes active in causing its development.2,3 There is also a body of literature linking the development
of MS with environmental factors or hypothesising the involvement of viral infections such as Epstein–Barr
virus (EBV).4–8
Within the UK, prevalence is around 203 per 100,000 person-years, whereas incidence was 9.6 per
100,000 person-years between 1990 and 2010, with a female-to-male ratio of 2.4.9 Peak incidence is at
around 40 and 45 years of age in men and women, respectively, with peaks in prevalence at 56 and
59 years for men and women respectively.
Types of multiple sclerosis
The disease can develop and progress in three major forms: (1) relapsing–remitting MS (RRMS), (2) primary
progressive MS (PPMS) and (3) secondary progressive MS (SPMS), of which RRMS originates from a single
demyelinating event known as clinically isolated syndrome (CIS).10
Clinically isolated syndrome events are isolated events of neurological disturbance lasting for > 24 hours,
which indicate the first clinical demyelination of the CNS,11 with clinical syndromes that are monofocal in
nature (e.g. optic neuritis and transverse myelitis) or multifocal (e.g. optical neuritis, limb weakness from
transverse myelitis and cerebellar signs). Patients presenting with a clinical history of one attack are given a
diagnosis of CIS. In these cases, magnetic resonance imaging (MRI) helps to confirm whether a diagnosis
of MS can be given instead at the onset of symptoms. A diagnosis of MS requires that disseminated
in time and disseminated in space criteria are fulfilled, and these can be checked using the MRI scan
performed at the onset of CIS. Patients with CIS who fulfil the disseminated in space criteria need evidence
of disseminated in time to be diagnosed with MS; if disseminated in time criteria are not met at the
baseline scan, it is necessary to either repeat the MRI scan to check whether there is a new lesion or wait
for a second clinical attack. Notably, then, delays in the onset of a second ‘relapse’ for patients with CIS
are equivalent to delays in MS progression.
In 80% of cases, RRMS is the form of MS at time of diagnosis. In RRMS, patients experience an
exacerbation of symptoms followed by periods of remission. RRMS, as defined in research protocols, is
characterised by episodes of relapses that last for > 24–48 hours. RRMS can be subtyped as rapidly
evolving or highly active MS and, although these terms have not been precisely defined, they usually
indicate two or more relapses within 1 year, with evidence of increasing lesion frequency on MRI scans.12
This classification is mainly used in reference to newer therapies such as natalizumab (Tysabri®; Biogen
Idec Ltd, Cambridge, MA, USA) and fingolimod (Gilenya®; Novartis, Basel, Switzerland).13
Primary progressive multiple sclerosis has an older age at onset, with men having greater susceptibility,14
and is typically characterised by occasional plateaus in disease progression, with temporary minor
improvements from onset.15 Some PPMS patients experience relapses alongside disease progression.
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Secondary progressive multiple sclerosis follows on from RRMS but the disease course is progressive, with
or without temporary relapses, remissions and plateaus in symptoms.15 The transition is gradual and often
SPMS is diagnosed retrospectively.15
The natural course of the disease is highly variable, with early stages of MS potentially developing into any
of the subtypes. However, each subtype is associated with cumulative neurological dysfunction, which is
often measured using the Expanded Disability Status Scale (EDSS).16 Transition from RRMS to SPMS occurs
in 60–70% of patients initially diagnosed with RRMS, approximately 10–30 years from disease onset.
About 15% of RRMS patients may be diagnosed with ‘benign’ MS, thus avoiding the progression of
disability and conversion to SPMS.17
To date, there is no cure for MS. Currently approved drugs for MS act as immunomodulators or
immunosuppressants, with the aim of reducing the pathological inflammatory reactions and reducing
the frequency and severity of relapses and the rate of disease progression. Immunomodulation and
immunosuppressing drugs used in MS are called disease-modifying therapies (DMTs).
Disease-modifying therapies
Beta-interferons
There are currently five licensed beta-interferon (IFN-β) drugs for MS: two IFN-β-1a drugs [Avonex®
(Biogen Idec Ltd, Cambridge, MA, USA); Rebif® (Merck, Darmstadt, Germany)], pegylated (peg) IFN-β-1a
(Plegridy®; Biogen Idec Ltd, Cambridge, MA, USA) and two IFN-β-1b drugs [Betaferon® (Bayer, Leverkusen,
Germany) and Extavia® (Novartis, Basel, Switzerland)]. The two IFN-β-1b drugs are the same drug (both are
manufactured on the same production line). These five drugs are recombinant forms of natural IFN-β,
which is a 166 amino acid glycoprotein that can be produced by most body cells in response to viral
infection or other biological inducers.18 The two types of IFN-β-1a are structurally indistinguishable from
natural IFN-β whereas the two types of IFN-β-1b are non-glycosylated forms that carry two structural
changes compared with natural IFN-β (Met-1 deletion and Cys-17 to Ser mutation).
Depending on the formulation, the dose regimen is one intramuscular (IM) injection once a week (Avonex),
one subcutaneous (SC) injection three times per week (Rebif) or one SC injection every other day
(Betaferon, Extavia). Pegylated IFN-β-1a is a long-acting formulation of IFN-β-1a obtained by adding
methoxy-polyethyleneglycol-O-2-methylpropionaldehyde to IFN-β-1a, which allows less frequent
administration (one SC injection every 2 weeks).
The precise mechanism of action of IFN-β in MS is not fully understood. The immunological effects of
IFN-β that are thought to have a potential action on MS are inhibition of T-cell co-stimulation/activation
processes, modulation of anti-inflammatory and pro-inflammatory cytokines and decrease in aberrant
T-cell migration.19
The main indication for IFN-β is the treatment of RRMS. For some patients IFN-β is indicated in response
to a single demyelinating event with an active inflammatory process when there is determined to be a
high risk of development of clinically definite MS (CDMS). IFN-β-1b is also licensed for use in SPMS, as is
IFN-β-1a (44 µg three times weekly by SC injection; Rebif) in cases in which SPMS remains with ongoing
relapse activity. IFN-β drugs are not indicated for PPMS.
The most commonly reported adverse events (AEs) related to IFN-β are irritation at injection site
reactions and flu-like symptoms.20 Other AEs reported include pain, fatigue, headache and liver function
abnormalities; a rare but important side effect is nephrotic syndrome. AEs may result in treatment
discontinuation. Given the biological nature of recombinant IFN-β, patients are at risk of developing
neutralising antibodies (NABs) against IFN-β. NABs are thought to increase relapse rates and the rate of
disease progression.
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Depending on the formulation, the current annual cost per patient of IFN-β treatment in the UK, assuming
British National Formulary (BNF) list prices21 and considering a continuous treatment at the standard dose,
is between £7264 and £10,572.
Glatiramer acetate
There are two licensed formulations of glatiramer acetate (GA) (Copaxone®; Teva Pharmaceutical
Industries, Petah Tikva, Israel). GA consists of the acetate salts of synthetic polypeptides, containing four
naturally occurring amino acids. The mechanisms by which GA exerts its effects in patients with MS are
not fully understood but it is thought that it induces a broad immunomodulatory effect that modifies
immune processes that are currently believed to be responsible for the pathogenesis of MS.22
According to the Summary of Product Characteristics,22 GA is indicated for the treatment of RRMS, but not
PPMS or SPMS. The dose regimen is 20 mg daily (formulation of 20 mg/ml) or 40 mg three times a week
(formulation of 40 mg/ml) by SC injection. The most common AEs of GA are flushing, chest tightness,
sweating, palpitations, headache and anxiety.23 Injection site reactions are observed in up to half of patients.
The current annual cost of GA per patient in the UK, assuming BNF list prices21 and considering a
continuous treatment at the standard dose, is £6681–6704.
Current use in the UK
Beta-interferon and GA are currently not recommended by the National Institute for Health and Care
Excellence (NICE)24 as they were considered not to be cost-effective. However, IFN-β and GA have been
available in the NHS through a risk-sharing scheme (RSS), with the exception of Extavia (a new brand of
IFN-β-1b) and Plegridy (pegIFN-β-1a), which were released after the publication of technology appraisal
(TA) 32.24 Within the RSS, a registry has been set up to record long-term clinical outcomes of patients
receiving IFN-β and GA. This review will consider the final data from this scheme alongside the clinical
effectiveness evidence and their implications for the clinical effectiveness and cost-effectiveness of GA
and IFN-β.
Description of the health problem
Multiple sclerosis is a neurodegenerative disorder characterised by inflammation and demyelination of
neurons in the brain and spinal cord. It is a leading cause of non-traumatic disability in working-age adults
and affects over 100,000 people in the UK. Although there is currently no cure for MS, a number of DMTs
are available to help reduce the frequency of relapses and the rate of disease progression. IFN-β and GA
are two such groups of drugs. However, at the time of TA32 in 2002,24 there was insufficient evidence of
their clinical effectiveness and cost-effectiveness. A RSS was put in place, allowing patients to access the
drugs and the NHS to adjust prices based on cost-effectiveness data, as well as monitor for long-term
outcomes. This study aims to appraise the clinical effectiveness and cost-effectiveness of IFN-β and GA,
integrating evidence from the literature with data on long-term outcomes collected from the RSS.
The following sections summarise the pathogenesis, clinical course and epidemiology of MS and current
service provision for MS.
Pathogenesis
Although the precise pathogenesis of MS is unclear, our current understanding is that it stems from
autoreactive inflammatory responses targeting the myelin sheaths of CNS neurons. This inflammatory
response begins in the periphery with activation of T helper cells that recognise CNS antigens. The
subsequent inflammatory cascade leads and responds to disruption of the blood–brain barrier, allowing for
increased transepithelial migration of activated immune cells, cytokines and chemokines into the CNS.
Once in the CNS, the autoimmune response leads to demyelination and axonal degeneration.
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More recently, MS has been recognised as consisting of both neurodegenerative and inflammatory
processes.25,26 Although neurodegeneration in MS is even less well understood than inflammation, it is
thought to be mediated by degeneration of transected axons, defects in ion balance and loss of nutritional
support to glial cells surrounding neurons.27 Notably, investigations of autopsy specimens have shown
that axonal loss can occur even in areas without acute inflammation, including in grey matter and
normal-appearing white matter.28 These neurodegenerative processes are thought to be responsible for
progressive and permanent disability.
Aetiology
A large body of evidence suggests a multifactorial aetiology of MS, with some interaction of genetic and
environmental triggers causing the peripheral immune system to become activated against CNS antigens.
Although the precise interaction remains unknown, a number of risk factors for MS have been identified.
Genetic
Unsurprisingly, genetic polymorphisms linked to MS have been identified primarily in immune response
proteins. The first and most significant genetic locus was identified in the 1970s on the human leucocyte
antigen (HLA) complex.29,30 HLAs encode part of the class II major histocompatibility complex (MHC) in
humans, which presents processed foreign antigens to T cells for recognition.30,31 Variations within the HLA
region have been consistently associated with a risk of MS, with the HLA-DRB1*15:01 allele particularly
implicated.32–35 It is also thought that the HLA complex carries genetic determinants of MS clinical progression.30
Although the HLA complex has the strongest and most long-standing linkage with MS, other genes are
suspected of increasing disease susceptibility, determining age at onset and causing poorer prognoses for
specific types of MS.32 These genes have been identified based on evidence from genetic linkage studies,
microarray studies and, more recently, genome-wide association studies (GWASs).36 A seminal GWAS study
performed by the International Multiple Sclerosis Consortium and the Wellcome Trust Case Control
Consortium investigated 465,434 single-nucleotide polymorphisms in 9772 cases and 17,376 control
subjects, implicating at least 59 non-HLA genes in MS inheritance. These genes include those involved in
cytokine, immune stimulation and immunological signal transduction pathways.32
Despite substantial data on the genetic risk for MS, the rate of concordance between monozygotic twins is
modest at about 25%.37 Additionally, a study reporting genome, epigenome and ribonucleic acid (RNA)
sequences in MS-discordant monozygotic twins was able to find no substantial difference accounting for
MS discordance. Such evidence points to the involvement of other causes in MS pathogenesis.38
Viral
Among all environmental risk factors investigated in MS aetiology, EBV infection has shown the strongest
consistent evidence of association.39 EBV was first suggested as a potential causative agent of MS because
of the similarity in epidemiological distribution across age, geography, ethnicity and socioeconomic
status.40 In total, 99.5% of patients with MS test seropositive for EBV antibodies, compared with 94.2% of
the general population.41 The current evidence for a role of EBV in MS is multifaceted: prospective studies
note increased serum anti-EBV antibody titres before the onset of MS;42 a meta-analysis found that, for
both adults and children testing negative for EBV, the odds ratio (OR) for developing MS was 0.18 [for
adults, 95% confidence interval (CI) 0.13 to 0.26] compared with people who tested positive;43 and, at the
molecular level, EBV can be isolated from B-cell infiltrates in meninges.44 Although EBV is a demonstrated
risk factor for MS, its role in causation remains unproven.
Other environmental risk factors
Populations living farther from the equator, both native and foreign born, have consistently shown increased
MS risk.45–50 In one meta-analysis, this correlation persisted even after adjusting for regional differences in
genetic HLA-DRB1 alleles,50 although it was not replicated in a separate meta-analysis using incidence
instead of prevalence.51 One hypothesis is that this effect is mediated by sun exposure and vitamin D levels,
with one supporting meta-analysis of 11 studies finding lower mean serum 25-hydroxyvitamin D levels in
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patients with MS.45–49,52 Other possible explanations include confounding by socioeconomic factors or the
‘hygiene hypothesis’. Smoking is also implicated as a modest but consistent risk factor for MS, with smoking
cessation suggested as an effective public health intervention that carries numerous other benefits.39
Presentation
Clinical symptoms
Although the initial signs of MS are variable between patients, MS classically presents with focal
neurological symptoms and signs of CNS dysfunction around the third decade of life. Relapses may present
as painful loss of vision in one eye (optic neuritis), unilateral motor or sensory disturbance (corticobulbar/
spinal tract involvement), double vision/vertigo/unsteadiness (brainstem or cerebellar syndrome), Lhermitte’s
phenomenon (pain down the spine/body on flexing the neck, from a cervical cord lesion) or bilateral leg
and bladder dysfunction (spinal cord syndrome). Fatigue is a common but non-specific symptom. As MS
progresses in severity, it can also lead to cognitive decline as well as changes in mobility, bladder/bowel
function and sexual function.
Imaging features
Magnetic resonance imaging modalities have an advantage over other imaging techniques, with their
ability to dampen resonance signals from the cerebrospinal fluid (CSF) and intensify signals from sites of
inflammation.53 In sites of active inflammation, disruption of the blood–brain barrier allows lesions to
be enhanced with the administration (and take-up) of contrast, whereas chronic lesions are generally
non-enhancing. MRI formally joined the diagnostic criteria for MS in 200154 and has rapidly become a
primary tool for characterising MS severity and progression. The characteristic MRI lesion is a cerebral or
spinal plaque with high T2 signal, representing a region of demyelination with axon preservation. In the
brain, plaques representing perivenular inflammation (and potential blood–brain barrier disruption) are
known as Dawson’s fingers, and they are seen in the periventricular regions radiating perpendicularly
away from ventricles. Outside the periventricular region, plaques are also commonly found in the corpus
callosum, sub-/juxtacortical region, optic nerves and visual pathway.55 Spinal cord lesions are nearly as
common, although they more likely to be noticed clinically before MRI identification.
Pathology
Early acute-stage lesions are active plaques characterised by the breakdown of myelin, which may appear
oedematous and inflamed histologically. Subacute-stage lesions appear paler in colour and have higher
focal regions of macrophages. Chronic-stage lesions are inactive plaques with low levels of myelin
breakdown, but are characterised by gliosis, leading to the production of scar tissue.56–58 Within the
chronic stages of the lesions, attempts at remyelination occur but the process may be hampered and
unsuccessful because of the scar tissue formed by gliosis.59,60
Diagnostic criteria
The diagnosis of MS is a clinical one, with supportive roles for neuroimaging and paraclinical findings.
The fundamental requirement is for demonstrated CNS lesions disseminated in time and space. Initially,
this demonstration was purely based on clinical findings and history; however, over time, laboratory results
(such as CSF oligoclonal bands) and paraclinical evidence (such as neuroimaging) have been included as
possible bases of diagnosis.61
The McDonald criteria, newly revised in 2010,62 continue to form the standard diagnostic tool for
investigating suspected MS in research settings and, to a more flexible degree, in clinical practice.63 A MS
attack, relapse or episode is defined by ‘patient-reported symptoms or objectively observed signs typical of
an acute inflammatory demyelinating event in the CNS, current or historical, with duration of at least
24 hours, in the absence of fever or infection’.62
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The most ‘secure’ diagnoses are supported by two or more MS attacks, with objective clinical evidence of
at least one lesion and ‘reasonable historical evidence’ of the second. Patients who have had two or more
attacks with associated clinical signs of two or more separate lesions in the CNS are said to have CDMS.
If objective clinical evidence for only one lesion is found, evidence for disseminated in space can come
from T2 lesions on MRI if they occur in at least two of four locations characteristic for MS (juxtacortical,
periventricular, infratentorial, spinal cord). Evidence for disseminated in time can be provided by new T2
or contrast-enhancing lesions on MRI appearing after disease onset or the simultaneous presence of
contrast-enhancing (active) and non-enhancing (chronic) lesions on the scan performed at onset of CIS.
Patients presenting with a clinical history of one attack and objective clinical evidence of one lesion, but
without sufficient evidence of either disseminated in space or disseminated in time, are diagnosed with CIS.
Recent trends in the McDonald diagnostic criteria
The Poser et al.64 criteria for MS diagnosis were published in 1983 and included two major categories of
‘definite’ or ‘probable’ MS, each with subgroups of ‘clinical’ or ‘laboratory supported’. Diagnosis was made
based on the number of attacks and lesions with clinical evidence, paraclinical evidence and laboratory
evidence. CIS or ‘possible MS’ was not included in the criteria, as such patients were not yet involved in
research studies. The McDonald 2001 diagnostic criteria abolished the previous categories and instead
focused on evidence for disseminated in time and disseminated in space. For the first time, it also explicitly
allowed for MRI data to serve as evidence for disseminated in space and disseminated in time. Originally,
demonstration of disseminated in space meant meeting the Barkhol–Tintoré criteria65 (or showing two MRI
lesions and positive CSF) and demonstration of disseminated in time could be achieved only by enhancing
lesions appearing 3 months after a clinical event. With a 2005 revision to the criteria,66 disseminated in
time could also be demonstrated by the appearance of new T2 lesions 1 month after a ‘reference scan’
(which was required to be 3 months post clinical onset).
The McDonald 2010 revision62 further simplified previous diagnostic criteria. It allowed for lesions at two of
four areas to provide evidence of disseminated in space, as opposed to the previous Barkhol–Tintoré
criteria.65 It also simplified the disseminated in time criteria by removing the requirement that the baseline
MRI scan be carried out at least 30 days post clinical event and allowing for the presence of simultaneous
enhancing and non-enhancing lesions on the scan at onset of CIS to serve for disseminated in time. After
this revision, a diagnosis of MS could be confirmed based on just a single MRI scan (with enhancing and
non-enhancing lesions disseminated in space). Because more patients meet the disseminated in space and
disseminated in time criteria under the 2010 revision as opposed to the original guidelines or 2005
revision, more recently diagnosed patients are more likely to have a diagnosis of confirmed MS than a
diagnosis of CIS.
Prognosis
Disability as part of prognosis
Quantification of disability in MS has been used extensively to standardise characterisations of functional
disease progression. The three Kurtzke scales have commonly been used to describe MS progression. First,
the Functional Systems Scale consists of measures of functionality in eight pre-chosen systems;16 second,
the Disability Status Scale (DSS) is an 11-point scale measuring global disability;67 and, third, the EDSS is a
modification of the DSS, measuring 20 points of disability.68 The EDSS is currently used as the standard to
measure disease progression in MS.
The EDSS quantifies disability in eight functional systems, specifically focusing on pyramidal, cerebellar,
brain stem, sensory, bowel and bladder, visual and cerebral/mental function.16 An EDSS score of 0.0 would
indicate normal neurology with no impairment in any system; an EDSS score of 4 suggests full ambulation
without aid despite relatively severe disability; a score of 6 suggests needing unilateral support (e.g. cane
or crutch) to walk 100 m; and a score of 7 suggests wheelchair confinement, with an inability to walk
> 5 m with support.16
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Prognoses for disease progression
Prognostic data are primarily taken from longitudinal cohort studies, many of which can include patients
both on and off treatment. Patients who present with CIS have a 60–80% risk of developing CDMS within
10 years if they have MRI lesions at the time of presentation and a ≈20% risk if they do not (note that
this prognosis will likely change with the revised McDonald 2010 diagnostic criteria for CIS) (reviewed in
Marcus and Waubant69). RRMS is thought to last for around two decades before transition to SPMS.70 Up
to 15% of patients with RRMS may be retrospectively diagnosed with ‘benign’ MS.17 There is significantly
less consensus about the natural history of disability in the progressive phase of MS, with median times to
EDSS 6 ranging from 15 to 32 years.70 Very generally, progression to EDSS 4 is suspected to occur after
one decade, EDSS 6 after 2 decades and EDSS 7 after three decades.71,72 Median ages for EDSS 4, 6 and 7
were 42, 53 and 63 years, respectively, for a cohort study of 1844 patients in Lyon.73
Risk factors for disease progression
Multiple sclerosis is notoriously heterogeneous and, even when all known risk factors are combined, they
provide only moderate prognostic value. Generally, observational data have found male sex, older age at
onset, progressive state at onset and higher number of MRI lesions to be predictive of a poor prognosis
with faster disability progression.74,75 A recent systematic review has identified several key factors related to
relapse frequency and recovery.75 Relapse activity appears to decrease with age and disease duration and
cohort studies suggest that women experience relapses more frequently. Modifiable risk factors, including
smoking, exposure to infectious disease and discontinuation of DMTs, are also associated with increased
relapse frequency.
Relapse rates
There is some controversy over whether increased rates of relapse events represent an independent risk for
disability progression in MS. Short-term studies suggest that relapses do not entirely regress; thus, EDSS
scores, which are elevated during relapses, do not return to their previous baseline level.76 Authors of these
studies would conclude that a greater number of relapses would lead to earlier increases in EDSS scores.
Longer cohort studies, however, have noted that the number of relapses is not associated with time to
SPMS or EDSS 6.71,77 A study examining placebo groups from two large Phase III trials also noted that half
of the patients satisfying criteria for ‘confirmed progression’ (definitions ranging from a 1.0-point EDSS
increase confirmed at 3 months to a 2.0-point EDSS increase confirmed at 6 months) were erroneously
diagnosed, as their EDSS scores did not sustain progression, even through the end of the trial.78 Thus, in
short-term studies, EDSS scores measured months after relapse may still be reflecting changes in active,
not progressive, disease. These longer timescales for recovery from relapse may need greater recognition.
Most recently, a longitudinal cohort study by Leray et al.79 suggested that MS may be characterised by two
distinct phases, with phase 1 lasting from diagnosis until irreversible EDSS 3 and phase 2 lasting from EDSS
3 until EDSS 6. Notably, disability progression in phase 1 did not influence disability progression in phase 2
and, similarly to previous studies, increased rates of relapse during the first 2 years of MS influenced
only time in phase 1. Relapses after EDSS 3 were not associated with continued disability progression.
Previously characterised risk factors of sex, age at onset and relapse history were not related to disability
progression in phase 2.79 These data are in line with previous studies suggesting that, although rates of
relapse early in disease predict disease progression, relapses later in RRMS or during SPMS may not
significantly predict or influence disability progression.80,81
Prognoses for mortality
Patients with MS have an average lifespan that is 7–14 years shorter than that of matched control
subjects.82 A meta-analysis of standardised mortality rates (SMRs) found that, overall, patients had a SMR
of 2.81 compared with control subjects, which suggests 181% more mortality per year than anticipated at
any age.83 This was especially increased for those at an EDSS score of > 7.5, who, in a separate study,
were found to have a SMR of 4.0 compared with control subjects.84 One review notes that, in most cohort
studies of people with MS, MS is cited as the cause of death for between 50% and 75% of deaths. It also
notes wide variation in the proportion of deaths ascribed to MS, resulting from variations in assessment,
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interpretation and coding practices. In particular, death from suicide is inconsistently reported as MS
related, although there is a substantially increased risk of suicide among people with MS.82
Epidemiology
Prevalence and incidence
An international survey including data from 92 countries estimated the median global prevalence of MS to
be 33 per 100,000 or about 2.3 million people worldwide.63 This prevalence has been increasing in the
past few decades, primarily because of increased rates of survival and diagnosis, but a meta-regression
analysis suggested that there is also likely a true increase in the incidence of MS.51 This analysis also
suggested that the increase is primarily in women, who already face double the burden of MS compared
with men.51,85–89
A recent systematic review reported estimates for MS prevalence in the UK ranging from 97.26 per
100,000 in England in 199890 to 230.60 per 100,000 in Northern Ireland in 2008.85,91 Incidence estimates
were less common and ranged from 4.4 to 12.2 per 100,000 person-years.85 Analysis of the UK General
Practice Research Database (GPRD) between 1990 and 20109 similarly showed an estimated prevalence of
258.5 per 100,000 women and 113.1 per 100,000 men, with an incidence of 11.52 per 100,000 women
per year and 4.84 per 100,000 men per year. Incidence peaked in women at age 40 years and men at
age 45 years. Although no systematic reviews of longitudinal incidence trends specifically look at the UK,
analysis of the UK GPRD estimates that, although the overall prevalence of MS is increasing because of
increased survival, incidence has decreased by 1.5% per year (although this may be because of a decrease
in the number of false-positive diagnoses).92 This analysis estimates that 126,669 people with MS were
living in the UK in 2010, although this number may be inflated by about 20% because it includes
inaccurate diagnoses.92
Burden of disease
The effects of MS have major ramifications for patients and carers, as well as financial implications for
patients and the state.
Disability
Multiple sclerosis has a wide range of effects, ranging from mobility problems to bladder/bowel
dysfunction, sexual dysfunction, fatigue, visual disturbances, pain, depression and memory changes.93
Interviews with 301 patients in Wales found that weakness, sensory changes and ataxia were the most
commonly reported symptoms of MS,94 whereas a postal survey of 223 unrepresentative MS patients
found that fatigue, bladder/bowel problems, balance problems and muscle weakness were the ‘worst’
symptoms.93,95 In terms of functional impacts, mobility, the ability to use stairs and outdoor transport
were cited as the activities most significantly impacted by disease, whereas activities such as dressing
and feeding were more preserved.96 Surveys of mobility in randomly sampled populations of patients with
MS note that slightly less than half (41.4–53%) require walking aids or a wheelchair (EDSS 6+).96–98
Quality of life
A survey based on the EuroQoL-5 Dimensions questionnaire (EQ-5D) suggested that 82.5% of 4516
patients had experienced difficulties in their daily activities and 76% had experienced pain and problems
with mobility, with patients rating their mean health state as 5.97 out of 1099 (compared with a UK
general population rating of 8.3100). Another study with 2708 participants living with MS established a
mean utility of 0.49 (with perfect health equal to 1.00), with an inverse relationship between EDSS score
and quality of life (QoL).101 The study established that QoL was affected by the type of disease, recent
relapse and length of time since diagnosis, with SPMS demonstrating the lowest QoL of the subtypes.
The lifetime prevalence of depression in patients with MS is approximately 50%, with an estimated
annual prevalence of 20%.102 Meta-analysis showed a SMR of 2.13 for suicide compared with the general
population,83 although accuracy is difficult to assess because reporting of suicide as a cause of death
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continues to be heavily influenced by cultural biases.82 Risk factors for suicide in patients with MS may
include depression, social isolation, younger age, advanced disease subtype, low socioeconomic status and
higher EDSS score.103
Cost
A number of cost estimates for MS exist, most of them based on cost-of-illness analyses (which are
contested),104 with significant variation in methodologies and costs accounted for.93 Most recently, analyses
estimated an average cost of between £30,460 and £39,500 per person-year.105,106 Overall, indirect costs,
including those from lost employment, are projected to be greater than the direct costs of care, and costs
are greater for those in the later stages of disease.93 The estimated cost of relapse ranges from £519107
to £2115,108 depending on the level of care required.
Cross-sectional surveys of disability in patients with MS demonstrate substantial changes in levels of
employment. Surveys with an average age of respondents of 50 years have noted that most patients are
not working,96,109 with most cases of early or partial retirement the result of MS.98,109 In a study of 305
patients in England in the 1980s, 27% of patients reported a decreased standard of living because of
employment changes and care costs and 36% of carers interviewed had also had their career impacted.109
Lost employment is estimated to currently account for 34–40% of the total cost of MS.105,106
Patient expectations and perceptions of disease
The literature describing qualitative experiences of patients is not as comprehensive as that surrounding
pharmacological treatments and the pathology of MS. Collectively, however, what does exist unsurprisingly
describes the experience of symptom onset and diagnosis as a negative one.110–112 Patients inevitably
experience distress and anxiety as they become aware of symptoms112 and this can continue or be
amplified as they learn of their diagnosis; the diagnosis can, however, also be a source of relief because it
provides an explanation for symptoms.111 Receiving adequate information from health-care professionals at
the time of diagnosis can have a positive effect on patients’ well-being and self-identification of relevant
support services,111 whereas a lack of information or empathy can be linked to frustration, anxiety and
fear.112 The transition from RRMS to SPMS is also a challenging time for patients, as this requires adjusting
to new ‘realities’ and preparing for forthcoming challenges in a declining trajectory.113 A recent qualitative
systematic review emphasises the importance of support from health-care providers and an accessible
health-care system.114 A comprehensive care plan including patient and carer support alongside
therapeutics is described as key for successful management of MS.115
Current service provision
At present there is no cure for MS, but treatment options exist based on the stage and subtype of disease.
Currently approved drugs for MS act as immunomodulators or immunosuppressants, with the aim of
reducing the pathological inflammatory reactions occurring in MS and thus the frequency and severity of
relapses and the rate of disease progression.116 Management of MS also includes non-pharmacological
options such as lifestyle adjustments and rehabilitation, which are also included in the NICE guidelines for
MS management.117
Treatments to reduce the risk of relapses
Drugs aimed at reducing the risk of relapses are called DMTs. In addition to the DMTs introduced in
Chapter 2, several newer drugs are licensed for use in the UK. Five newer drugs are recommended by
NICE118–122 for the treatment of MS: alemtuzumab (Lemtrada®; Sanofi Genzyme, Cambridge, MA, USA),
dimethyl fumarate (Tecfidera®; Biogen Idec Ltd, Cambridge, MA, USA), fingolimod, natalizumab and
teriflunomide (Aubagio®; Sanofi Genzyme, Cambridge, MA, USA). A summary of these recommendations
is provided in Table 1. DMTs are indicated in the treatment of classic RRMS, with the exception of
natalizumab and fingolimod, which are recommended only in patients with highly active RRMS. Among
DMTs, IFN-β-type drugs and GA are indicated for patients with CIS.
DOI: 10.3310/hta21520 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 52
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Melendez-Torres et al. under the terms of a commissioning contract issued by the Secretary of State
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
9
Immunosuppressive agents, such as azathioprine, cyclophosphamide, mitoxantrone and methotrexate,
can also be used in the management of MS. These agents can provide potential benefit through
downregulating pathogenic mediators of MS, but can also induce severe adverse effects on the immune
system. Consequently, these drugs are indicated only in patients with aggressive forms of MS, including
patients who experience very frequent and severe relapses. They are not currently included in any
NICE guidelines, although they continue to be used for MS123 and a systematic review suggests their
effectiveness in preventing relapse recurrence.124
Treatment of acute relapses
Steroids are commonly used and recommended to treat acute relapses. Steroids are aimed at reducing
the duration of relapses by shutting down the production of inflammatory cytokines and destroying
activated lymphocytes that cause demyelination; these drugs are not, however, thought to induce long-term
benefits with regard to the course of the disease.125 NICE guidelines126 recommend the use of 0.5 g of oral
methylprednisolone daily for 5 days in the first instance and to consider 1 g of intravenous methylprednisone
daily for 3–5 days as an alternative if oral steroids are not tolerated or have failed or if hospital admission for
severe relapse or monitoring is required. Patients should not be offered a supply of steroids to administer at
home for prophylactic use for future relapses. Lastly, patient education should target the management of
potential complications, such as mental health changes or irregularities in blood glucose levels.
Pharmacological treatment of symptoms
Current NICE guidelines offer advice to health-care professionals, patients and families on the management
of MS symptoms.117 Recommendations include amantadine use for fatigue (although it does not have
marketing authorisation in this indication) and baclofen or gabapentin for spasticity, with combinations of
baclofen and gabapentin possible if individual drugs cannot reach a dosage for adequate relief.126 Other
drugs such as tizanidine (Actavis UK Ltd, Devon, UK), dantrolene (Dantrium®; Norgine Ltd, Harefield, UK)
or benzodiazepines should be considered as second- or third-line options. It should also be noted that
fampridine (Fampyra®; Biogen Idec Ltd, Cambridge, MA, USA), recently approved in Europe to improve
walking ability in people with MS, has not been recommended by NICE as a cost-effective treatment.
A systematic review, however, concluded that the absolute and comparative efficacy and tolerability of
anti-spasticity agents in MS was poorly documented and no recommendations could be made to
guide prescription.127
TABLE 1 National Institute for Health and Care Excellence TA guidelines and recommendations for DMTs
Treatment TA guidance NICE recommendation
Alemtuzumab TA312118 (May 2014) Recommended as an option, within its marketing authorisation, for
treating adults with active RRMSa
Dimethyl fumarateb TA320119 (August 2014) Recommended as an option for treating adults with active RRMS,a
only if they do not have highly active or RES RRMSc
Fingolimodb TA254120 (April 2012) Recommended as an option for the treatment of highly active RRMS
in adults, only if they have an unchanged or increased relapse rate
or ongoing severe relapses compared with the previous year despite
treatment with IFN-β
Natalizumab TA127121 (August 2007) Recommended as an option for the treatment only of RES RRMSc
Teriflunomideb TA303122 (January 2014) Recommended as an option for treating adults with active RRMSa
only if they do not have highly active or RES RRMSb
RES, rapidly evolving severe.
a Defined as two clinically significant relapses in the previous 2 years.
b Available with discount agreed by manufacturer in a patient access scheme.
c Defined by two or more disabling relapses in 1 year and one or more gadolinium-enhancing lesions on brain MRI or a
significant increase in T2 lesion load compared with previous MRI.
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For treatment of psychological changes, rivastigmine, donepezil and memantine, which are classically used
in Alzheimer’s disease, have been shown to improve cognitive impairment, but overall evidence for their
efficacy in MS patients has proved inconclusive.128 The treatment of depression includes consideration of
both psychotherapy and antidepressant medication. Commonly used medications are selective serotonin
reuptake inhibitors such as fluoxetine, paroxetine and sertraline. A recent systematic review showed that
depression severity was improved in three pharmacological studies of depression treatment in MS.129 NICE
guidelines130 state that amitriptyline can be considered to treat emotional liability.
Managing disability
Non-pharmacological treatment options are directed towards a rehabilitative approach, with specialist
assistance from a multidisciplinary team.
There is evidence that physical activity alone can improve fatigue and it has been linked to improvement in
aerobic capacity, gait parameters and QoL.131,132 Suggestions for an effective rehabilitation regime include
progression of physical activity from basic to integrated functions,133 to utilise working muscles while
avoiding muscle overload. Although randomised controlled trials (RCTs) have shown some evidence of
improved mobility and QoL from exercise interventions, systematic reviews have not reached consensus on
whether the studies – which are especially limited by small sample sizes and risk of bias from lack of
blinding – provide enough evidence to make guided exercise prescriptions.134–136 Urinary incontinence
affects approximately 75% of patients and can substantially impact on QoL.137 NICE guidelines on lower
urinary tract dysfunction in neurological disease are available and should be used to inform treatment.138
Care should also be taken in the management of the mental health of patients. Interventions should be
aimed at regular monitoring of any depressive states and mental health services should be offered
routinely to encourage participation.139 Education for all health-care providers and patients in coping
mechanisms may help improve QoL.140
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Chapter 2 Description of the technology
under assessment
In accordance with the NICE scope,141 this multiple technology appraisal (MTA) focuses on IFN-β(including pegylated IFN-β-1a) and GA.
Beta-interferons
Interferons are proteins that bind to cell surface receptors, initiating a cascade of signalling pathways
ending with the secretion of antiviral, antiproliferative and immunomodulatory gene products.142 Natural
IFN-β is a 166 amino acid glycoprotein that can be produced by most cells in response to viral infections or
other biological inducers.18 There are two types of recombinant IFN-β, known as IFN-β-1a and IFN-β-1b.
IFN-β-1a is a glycosylated form that is structurally indistinguishable from natural IFN-β;18 IFN-β-1b is a
non-glycosylated form that carries one amino acid substitution.143 Several in vitro studies have concluded
that the biological activity of some IFN-β-1a formulations is greater than that of IFN-β-1b,18,143,144 but the
clinical implications of such differences are unknown. Furthermore, these studies have not compared all of
the approved formulations of recombinant IFN-β.
The precise mechanism of action of IFN-β in MS is not fully understood, but some potential actions include
inhibition of T-cell activation, modulation of inflammatory cytokines and reduction in aberrant T-cell
migration into the CNS.19
There are currently five licensed IFN-β drugs:
l One formulation of IFN-β-1a (Avonex) is given at the recommended dosage of 30 µg [6 million
international units (IU)] once a week, administered by IM injection.
l The other formulation of IFN-β-1a (Rebif) is given at the recommended dosage of 22 µg (6 million IU)
or 44 µg (12 million IU) three times per week, administered by SC injection.
l IFN-β-1b (Betaferon and Extavia) is given at the recommended dosage of 250 µg every other day,
administered by SC injection.
l In pegIFN-β-1a (Plegridy), polyethylene glycol (PEG) is added to the N-terminus of IFN-β-1a, allowing for
less frequent administration. Its recommended dosage is 125 µg every 2 weeks, administered by
SC injection.
The current licensed indications for IFN-β are listed in Table 2. The main indication is for the treatment of
patients with RRMS. Most IFN-β drugs (Avonex, Rebif and Betaferon/Extavia) also have indications in patients
with a single demyelinating event with an active inflammatory process and at high risk of developing CDMS.
IFN-β-1b is licensed for use in patients with SPMS. IFN-β-1a (Rebif) is licensed for SPMS with ongoing relapse
activity. IFN-β drugs are not indicated for PPMS.
The most commonly reported AEs of IFN-β are injection site reactions (mainly inflammation) and flu-like
symptoms (including fever, chills and myalgias and headache), but these generally decline markedly after the
first year of treatment.20 Other AEs include hypersensitivity reactions, blood disorders (mainly leucopenia),
menstrual disorders and mood and personality changes. AEs may be responsible for treatment discontinuation.
Because of its biological nature, recombinant IFN-β also carries a risk for patients of developing NABs,145
and this is thought to reduce the treatment efficacy.146 The occurrence of NABs depends on patient-specific
factors but also treatment-specific factors such as formulation, route of administration, dosage and
frequency of administration. Given their different natures and routes of administration, the immunogenicity
of IFN-β varies among the formulations of IFN-β. A systematic review of RCTs showed that the rate of
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patients developing NABs was 2.0–18.9% for Avonex, 16.5–35.4% for Rebif and 27.3–53.3% for
Betaferon/Extavia.147 Some guidelines recommend testing patients treated with IFN-β for the presence of
NABs after 12 and 24 months of treatment.145,148 In the UK, the monitoring of NABs is not performed in
routine practice.
According to net prices listed in the BNF,21 the annual cost per patient of IFN-β in the UK is £8502 for
Avonex, £7976/£10,572 for lower doses/higher doses of Rebif and £7264 for Betaferon/Extavia. The
estimated cost in 2013–14 for IFN-β in England was £52,000,000, with 27.6% growth from 2012–13.149
As of July 2016, no biosimilar version of IFN-β is available in the UK.
Glatiramer acetate
Glatiramer acetate is a synthetic molecule containing four naturally occurring amino acids: l-glutamic acid,
l-alanine, l-tyrosine and l-lysine. It was initially created to mimic myelin basic protein, a suspected
autoimmune antigen, and induce a mouse form of MS. Surprisingly, it prevented MS induction in mice,
triggering clinical studies of GA as a treatment for MS.142 It is now thought that GA induces a broad
TABLE 2 Licensed indications for IFN-β and GA (as reflected in the NICE scope141)
Brand
name DMT Recommended usage Indications
Avonex IFN-β-1a Dose: 30 µg (6 million IU) RRMS – in clinical trials, this was characterised by two or
more acute exacerbations (relapses) in the previous 3 years
without evidence of continuous progression between
relapses; patients with a single demyelinating event with
an active inflammatory process, if it is severe enough to
warrant treatment with intravenous corticosteroids, if
alternative diagnoses have been excluded and if they are
determined to be at high risk of developing CDMS. Should
be discontinued in patients who develop progressive MS
Administration: IM injection
Frequency: once a week
Rebif IFN-β-1a Dose: 22 µg (6 million IU) or
44 µg (12 million IU)
RRMS – in clinical trials, this was characterised by two or
more relapses in the previous 2 years; patients with a
single demyelinating event with an active inflammatory
process, if alternative diagnoses have been excluded and
if they are determined to be at high risk of developing
CDMS. Efficacy has not been demonstrated in patients
with SPMS without ongoing relapse activity
Administration: SC injection
Frequency: three times weekly
Betaferon/
Extavia
IFN-β-1b Dose: 250 µg (8 million IU) Patients with a single demyelinating event with an active
inflammatory process, if it is severe enough to warrant
treatment with intravenous corticosteroids, if alternative
diagnoses have been excluded and if they are determined
to be at high risk of developing CDMS; patients with
RRMS and two or more relapses within the last 2 years;
patients with SPMS with active disease, evidenced by
relapses
Administration: SC injection
Frequency: every other day
Plegridy PegIFN-β-1a Dose: 125 µg Adult patients for the treatment of RRMS
Administration: SC injection
Frequency: every 2 weeks
Copaxone GA Dose: 20 mg or 40 mg Treatment of relapsing forms of MS. It is not indicated in
PPMS or SPMS. GA in the 20-mg formulation has been
studied in both RRMS and CISAdministration: SC injection
Frequency: daily (20 mg) or
three times weekly (40 mg)
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immunomodulatory effect, with actions including competition for the binding of antigen-presenting cells,
antagonism at specific T-cell receptors and promotion of anti-inflammatory responses in dendritic cells,
monocytes and B cells.150
Two formulations of GA are currently used: 20 mg/ml and 40 mg/ml (Copaxone), equivalent to 18 mg or
36 mg of glatiramer base respectively. The dose regimen is 20 mg daily (formulation of 20mg/ml) or 40 mg
three times a week (formulation of 40mg/ml) by SC injection (see Table 2). As of February 2016, no
generic version of Copaxone is available in the UK.
Glatiramer acetate is indicated for the treatment of patients with RRMS. It is not indicated for PPMS or
SPMS. The most common AEs of GA are flushing, chest tightness, sweating, palpitations and anxiety,23
with injection site reactions observed in up to half of patients.
The current annual cost per patient of GA in the UK is £6681–6704.149 Generic prices are not yet available.
Care pathways for beta-interferon and glatiramer acetate
Beta-interferon and GA are considered first-line treatments for RRMS, except for patients with highly active
RRMS, in which more advanced treatments (e.g. natalizumab) are considered most appropriate. Although
some patients prefer dimethyl fumarate or teriflunomide because of their oral mode of administration,
IFN-β and GA both have well-established long-term safety profiles that avoid some of the more severe side
effects presented by other drugs, for example the rare but serious complications of progressive multifocal
leukoencephalopathy associated with the reactivation of the John Cunningham virus with dimethyl
fumarate treatment. Additionally, some patients may choose not to take IFN-β or GA, especially after CIS
or if the course of MS appears to be benign. Patients receive specialist advice, including from neurologists
and nurses specialising in MS care, when choosing which DMT to initiate. It is common for MS patients
to see a neurologist about once a year for maintenance, and MRI scans are administered generally not
more than once a year. Exacerbations may be managed by local GPs or by specialist neurology services
depending on their severity and complexity.
Switching between first-line treatments mainly occurs because of side effects. Patients may escalate to a
second-line treatment if MS is highly active, that is, characterised by multiple disabling relapses in a year or
an unchanged relapse rate during first-line treatment.
On transition to SPMS – a diagnosis that is made retrospectively – patients are supposed to cease use of
drugs that are not licensed for SPMS. However, there is anecdotal evidence that patients may continue
on these drugs because of perceived benefits for relapse rate and the absence of any other treatment
for SPMS.
The UK multiple sclerosis risk-sharing scheme
The last TA for IFN-β and GA for the treatment of MS (TA3224) did not find sufficient evidence of clinical
effectiveness and cost-effectiveness to recommend treatment. The Department of Health151 set up a RSS to
provide the then-licensed formulations of IFN-β-1a (Avonex and Rebif), interferon-β-1b (Rebif) and GA
(Copaxone) to patients. Under this arrangement, the benefit of each drug would be regularly assessed
using target outcomes agreed on with the manufacturers. The price for each drug would be scaled as
necessary to reach a target level of cost-effectiveness, set at the start of the scheme as £36,000 per
quality-adjusted life-year (QALY). As part of the RSS, patients meeting the criteria for treatment were
enrolled in a cohort and monitored regularly for evidence of disability progression and treatment benefit.
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Because all patients in the RSS received treatment, a comparator cohort including patients with
measurement of disease progression without access to DMTs was needed. Several natural history cohorts
meeting these criteria exist. The 6-year interim analyses used the British Columbia cohort, which was
initiated in 1980, before DMTs were made routinely available in Canada. This cohort has prospectively
recorded EDSS scores and covers about 80% of the relevant MS population in that area, providing a rich
source of data about the natural history of MS.152,153 Patients from the British Columbia cohort who would
have met the criteria for prescribing IFN-β or GA were selected for comparison with those in the UK
RSS.153–155 Analysis of the 6-year data of the UK clinical cohort, comparing disease progression against the
historical comparator cohort, suggested that, on the whole, the DMTs included in the RSS reduced
disability progression and did so to the agreed level of cost-effectiveness.154
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Chapter 3 Definition of the decision problem
Decision problem and aim
The aim of this study was to appraise the clinical effectiveness and cost-effectiveness of IFN-β and GA
within their marketing authorisations for treating MS, as an update to TA32.24
In this assessment, IFN-β and GA were appraised using published data and taking account of additional
data on long-term outcomes from the RSS.
As requested by NICE, IFN-β and GA were compared with best supportive care (BSC). NICE141
commented that:
Since Technology Appraisal 32 was published another interferon 1b (Extavia, Novartis), a pegylated
interferon beta 1a (Plegridy, Biogen Idec [Ltd]) and a new formulation of glatiramer acetate (Copaxone,
Teva pharmaceuticals) have been granted marketing authorisations. These technologies were not
included in the risk sharing scheme because they were not appraised in Technology Appraisal 32.
It has been determined by NICE that it is relevant to include these technologies in this appraisal so
that guidance can be issued for all beta-interferons and formulations of glatiramer acetate currently
licensed for MS in the UK. Further active treatments that have been licensed and recommended by
NICE (including teriflunomide, fingolimod, natalizumab, alemtuzumab and dimethyl fumarate) will not
be considered in this appraisal.
National Institute for Health and Care Excellence (2016). Multiple Technology Appraisal.
Beta Interferon and Glatiramer Acetate for Treating Multiple Sclerosis (Review of TA32).
Final Scope Updated Post Invitation. NICE has not checked the use of its content in
publication to confirm that it accurately reflects the NICE publication from which it is taken
In addition, people with CIS were considered in this appraisal.
Objectives
Our first objective was to systematically review the evidence for the clinical effectiveness of IFN-β-1a,
pegylated IFN-β-1a, IFN-β-1b and GA in people with relapsing MS (including people with RRMS and people
with SPMS with active disease, evidenced by relapses) and CIS, that is, a single demyelinating event, who
are considered at high risk of developing subsequent MS, compared with BSC without DMTs and with
each other. The following outcomes were investigated:
l relapse rate
l transition to CDMS (in the case of CIS)
l severity of relapse
l disability (e.g. EDSS)
l symptoms of MS such as fatigue, cognition and visual disturbance
l freedom from disease activity
l discontinuation as a result of NABs
l mortality
l adverse effects of treatment
l health-related quality of life (HRQoL).
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The second objective was to systematically review existing economic evaluations, including use of the existing
RSS model; develop a de novo economic model for CIS; assess the cost-effectiveness of the treatments
(IFN-β-1a, pegylated IFN-β-1a, IFN-β-1b and GA) for CIS and RRMS against the stated comparators, expressed
in incremental costs per QALY, using a time horizon that was sufficiently long to reflect any differences in
costs or outcomes between the technologies being compared and taking a NHS and Personal Social Services
(PSS) perspective; and update model parameters and inputs to reflect available evidence from the literature,
current costs, the NICE reference case,156 current practice and new data from the RSS.
Note
This report contains reference to confidential information provided as part of the NICE appraisal process.
This information has been removed from the report and the results, discussions and conclusions of the
report do not include the confidential information. These sections are clearly marked in the report.
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Chapter 4 Methods for the assessment of
clinical effectiveness
Protocol registration
We presented our protocol to a stakeholder information meeting on 29 February 2016 and subsequently
registered it on PROSPERO as CRD42016043278.
Identification of studies
Initial scoping searches were undertaken in MEDLINE and The Cochrane Library in October 2015 to assess
the volume and type of literature relating to the assessment question and to inform further development
of the search strategy. Several relevant systematic reviews from the Cochrane Database of Systematic
Reviews were identified.157–161
The following search strategy was designed to capture RCTs of DMTs for patients with RRMS, SPMS or
CIS. An iterative procedure was used to develop the planned searches, with reference to previous
systematic reviews.157–162 Clinical searches were restricted to RCT evidence. The included and excluded
study lists from previous relevant Cochrane systematic reviews were checked.159,160 The main database
searches for MS were undertaken in January and February 2016 and were limited by date to the beginning
of 2012 onwards [the year the searches were undertaken for the broad review and network meta-analysis
(NMA) by Filippini et al.160]. This review was chosen because of the breadth of its scope, search strategy
and eligibility criteria. Other more recent reviews were considered to be more limited in terms of the types
of MS covered and the types of studies included.157,159 An additional targeted search for RCTs in CIS,
not limited by date, was performed. A full record of the searches undertaken is provided in Appendix 1.
The searches were developed for MEDLINE and adapted as appropriate for the other databases.
The search strategy included the following:
l searching of electronic bibliographic databases, including trials in progress
l scrutiny of references of included studies and relevant systematic reviews
l contact with experts in the field
l screening of websites for relevant publications.
We ran electronic searches on the following databases:
l Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group Specialised Trials Register
l MEDLINE (via Ovid)
l MEDLINE In-Process & Other Non-Indexed Citations (via Ovid)
l EMBASE (via Ovid)
l The Cochrane Library (via Wiley Online Library), including the Cochrane Database of Systematic Reviews,
Cochrane Central Register of Controlled Trials (CENTRAL), Database of Abstracts of Reviews of Effects
(DARE), NHS Economic Evaluation Database (NHS EED) and Health Technology Assessment (HTA) database
l Science Citation Index and Conference Proceedings Citation Index – Science (Web of Science)
l UK Clinical Research Network (UKCRN) Portfolio Database.
We also searched the trial registers at ClinicalTrials.gov and the World Health Organization (WHO)’s
International Clinical Trials Registry Platform (ICTRP).
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All bibliographic records identified through the electronic searches were collected in a managed reference
database. The reference lists of included studies and relevant review articles were checked and the
manufacturer websites were screened for relevant publications. The included studies and reference lists of
manufacturer submissions were checked for relevant unpublished studies and any additional published
studies. Other grey literature searches were undertaken using the online resources of the organisations
shown in Table 3. More details of these website searches are provided in Appendix 1.
TABLE 3 Online resources searched for relevant literature
Organisations Websitea
Companies
Bayer www.bayer.co.uk/http://pharma.bayer.com/
Biogen Idec Ltd www.biogen-international.com/https://www.biogen.uk.com/
Merck http://biopharma.merckgroup.com/en/index.html
Novartis www.novartis.com and www.novartis.co.uk/
Teva Pharmaceutical Industries www.tevapharm.com/research_development/http://www.tevauk.com/
Patient/carer groups
Brain and Spine Foundation www.brainandspine.org.uk
Multiple Sclerosis National Therapy Centres www.msntc.org.uk
MS UK www.ms-uk.org
Multiple Sclerosis Society www.mssociety.org.uk
Multiple Sclerosis Trust www.mstrust.org.uk
Neurological Alliance www.neural.org.uk
The Brain Charity (formerly known as
Neurosupport)
www.thebraincharity.org.uk
Sue Ryder www.sueryder.org
Professional groups
Association of British Neurologists www.theabn.org
British Neuropathological Society www.bns.org.uk
Institute of Neurology www.ucl.ac.uk/ion, www.ucl.ac.uk/ion/departments/neuroinflammation,
http://discovery.ucl.ac.uk
Primary Care Neurology Society www.p-cns.org.uk
Therapists in MS www.mstrust.org.uk/health-professionals/professional-networks/therapists-
ms-tims/research
UK MS Specialist Nurse Association www.ukmssna.org.uk
Research groups
Brain Research Trust www.brt.org.uk/research
British Neurological Research Trust www.ukscf.org, www.ukscf.org/about-us/bnrt.html
Cochrane Multiple Sclerosis and Rare Diseases
of the Central Nervous System Group
Specialised Trials Register
www.cochranelibrary.com, http://msrdcns.cochrane.org/our-reviews
National Institute for Health Research www.nihr.ac.uk/research/, www.nihr.ac.uk/industry/, www.nihr.ac.uk/
policy-and-standards/
a Websites accessed 1 August 2016.
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Inclusion criteria
We included studies that met the following criteria.
l The study design was a RCT, a systematic review or a meta-analysis.
l The population was people diagnosed with RRMS, SPMS or CIS.
l The intervention was one of the following drugs, when used within its indication (see Table 2):
¢ IFN-β-1a
¢ pegylated IFN-β-1a
¢ IFN-β–1b
¢ GA.
We included drugs only when used within their marketing authorisation, that is, when the posology in the
trial matched that in the indication, because of the extensive clinical use of these drugs and the corresponding
safety and effectiveness profile of these established dosages. A wide variety of alternative dosages has been
used across a variety of trials. It was judged that including dosages not matching the indication could present
misleading estimates of effectiveness or safety and would introduce unnecessary heterogeneity.
l The comparator was BSC without the use of DMTs or another of the interventions when used within
its indication. In this review, BSC corresponded to arms of RCTs in which patients received either
placebo added to standard care or no treatment.
l The reported outcomes included at least one of the following:
¢ relapse rate
¢ progression to MS (for patients with CIS)
¢ severity of relapse, defined as rate of steroid-treated relapses or rate of relapses graded as
moderate or severe
¢ disability, including as measured by the EDSS
¢ MS symptoms, such as fatigue, cognition and visual disturbance
¢ freedom from disease activity, defined as composite clinical and MRI outcomes
¢ mortality
¢ HRQoL
¢ treatment-related AEs
¢ discontinuation because of AEs
¢ discontinuation because of loss of effectiveness attributed to NAB formation (we did not consider
the rate of NAB formation alone because of its limited clinical relevance in practice).
l The study was a full-text report in the English language.
Exclusion criteria
We excluded:
l studies that compared an eligible intervention against an irrelevant comparator
l studies that examined an eligible intervention used with a non-recommended dose regimen
l studies reporting MRI outcomes alone
l studies reporting early compared with late treatment only
l studies that examined only MS subtypes other than those in the eligible population
l studies that examined only patients with highly active or rapidly evolving MS, as BSC is not an
appropriate comparator for these populations
l studies reported as abstracts or conference proceedings or not reported in the English language.
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Study selection process
We first examined relevant past systematic reviews (including those by Tramacere et al.,159 Filippini et al.160
and Clerico et al.158) for studies meeting the inclusion criteria. We verified the inclusion of these studies by
examining their full text.
For updated and new searches (including for studies addressing CIS), we collected all retrieved records
in a specialised database and duplicate records were identified and removed. The reviewers piloted a
screening form based on the predefined study inclusion and exclusion criteria. Subsequently, two reviewers
(Xavier Armoiry and GJ Melendez-Torres) applied the inclusion/exclusion criteria and screened all identified
bibliographic records at the title/abstract level (level I) and then at the full-text level (level II). Any disagreements
over eligibility were resolved through consensus or by a third-party reviewer (Aileen Clarke). Reasons for the
exclusion of full-text papers were documented. The study flow was documented using a Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram.163
Quality assessment strategy
Systematic reviews used to locate primary studies were appraised using the Assessing the Methodological
Qualities of Systematic Reviews (AMSTAR) checklist.164 All primary studies were appraised using the
Cochrane risk of bias assessment tool.165 Appraisal was undertaken by two reviewer (Jacoby Patterson and
Jeremy Rodrigues). Uncertainty and/or any disagreements were cross-checked with a third reviewer and
were resolved by discussion.
Data extraction strategy
For all included studies, the relevant data were extracted independently by two reviewers (Xavier Armoiry
and GJ Melendez-Torres) using a data extraction form informed by the NHS Centre for Reviews and
Dissemination.166 Uncertainty and/or any disagreements were cross-checked with another reviewer and were
resolved by discussion. The extracted data were entered into summary evidence tables (see Appendix 2 for
a sample data extraction sheet). When multiple arms were presented, of which only some were relevant to
our analysis, we extracted data only for those arms. The extracted information included:
l study characteristics [i.e. first author name, country, design, study setting, sample size in each arm,
funding source, duration of follow-up(s) and methodological features corresponding to the Cochrane
risk of bias assessment tool165]
l patient baseline characteristics [i.e. trial inclusion/exclusion criteria; number of participants enrolled and
number of participants analysed; age, race and sex; disability (including as measured by the EDSS) at
baseline; time from diagnosis of MS to study entry; and relapse rate at baseline]
l treatment characteristics (i.e. type of drug; method of administration, dose and frequency; drug
indication as stated; and definition of BSC as described by triallists)
l outcome characteristics for each included outcome reported [i.e. definition of outcome measure; timing
of measurement; scale of measurement; and effect size as presented, including mean difference, risk
ratio, OR or hazard ratio (HR) or arm-level data necessary to calculate an effect size]. Measures of
variability and statistical tests used were also extracted (standard deviation, 95% CI, standard error,
p-value).
Data preparation
Many of the included studies did not present adequate data for key findings to enable inclusion prima
facie in a meta-analysis model. We used a variety of published methods to derive the necessary data.
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Across all studies, we used data for the point of greatest maturity (i.e. last available follow-up) for which
effect sizes were estimable. In studies presenting estimates with confirmed relapses and with non-confirmed
relapses, we selected estimates with confirmed relapses.
We used rate ratios (RRs) to examine relapse outcomes [e.g. the ratio of annualised relapse rates (ARRs) in
two study arms]. We used summary statistics instead of attempting to approximate individual participant
data for each arm, in part because of the use of stratification in estimating study findings. When necessary,
we imputed standard errors by estimating the number of events in each arm (e.g. when relapse rates were
analysed using an analysis of variance, or ANOVA, model with a Gaussian link, instead of the preferred
Poisson distribution for count variables). When arm-level ARRs were presented without Poisson-based
standard errors, we generally assumed that the ARR presented for study arms was a fair approximation and
then re-estimated the standard errors for the RR using all available information on person-years of follow-up
and number of relapses. RRs were then analysed using a log-normal distribution.
We used HRs to examine time-to-event outcomes (e.g. time to first relapse or time to confirmed disability
progression). When HRs were not estimated from a Cox proportional hazards model, we used several
methods in order of priority. First, we used methods published by Tierney et al.167 to estimate the HR, in
particular using the number of patients analysed, the number of total events and the p-value derived from
a log-rank test. When these data were not available to us, we used the final predicted probabilities of
survival in each study arm (generally estimated using Kaplan–Meier curves) and estimated the cumulative
hazard using the equation –ln[S(t)], where S(t) is the probability of survival at time t. We then took the
ratio of the cumulative hazards and used the log-rank p-value to approximate the standard errors for
the HR, under the property that the p-value from the log-rank test for survival asymptotically approaches
the p-value from a likelihood ratio test derived from a Cox proportional hazards model.
We used dichotomous outcomes to examine discontinuation as a result of AEs.
Narrative synthesis and meta-analysis
Narrative synthesis of studies and meta-analyses were organised hierarchically, first by MS subtype, then by
intervention–comparator contrast and finally by each outcome for which data were available. Within each MS
subtype, we examined included studies for similarity. When studies were sufficiently similar, we estimated
both pairwise meta-analyses and NMAs. First, we pooled outcomes for each intervention–comparator
contrast and by MS subtype using random-effects meta-analysis in Stata® 14 (StataCorp LP, College Station,
TX, USA) and examined these pairwise meta-analyses for heterogeneity, measured as Cochran’s Q and I2.
Subsequently, we used the package -network-168 in Stata 14 to estimate NMAs. Because the package
-network- operates in a frequentist paradigm, there was no need to carry out sensitivity analyses on prior
distributions. When possible, we estimated meta-analyses using random effects; however, some sparse
networks, in which there were few studies for each contrast between two treatments, required the use of
a fixed-effects model. We used a common heterogeneity model, in which the between-studies variance is
assumed to be equal across comparisons.
After estimating a consistency model (i.e. in which direct evidence for a contrast between two treatments
is assumed to agree with indirect evidence for that contrast), we checked networks that were not star
shaped in design for inconsistency using two methods. We estimated a design*treatment interaction
model and examined both the design effects and the overall Wald test for evidence of inconsistency.
We also used the side-splitting method to test for differences in the effectiveness estimates between
direct and indirect evidence. When evidence of inconsistency existed, we considered the direction of
that inconsistency.
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Finally, we used a bootstrapping method to resample from our estimates of intervention effectiveness and
develop probabilities of each treatment’s position relative to the other treatments. We then used the
surface under the cumulative ranking curve (SUCRA) to produce a unified ranking of treatments.
Meta-analyses for clinically isolated syndrome
We estimated a NMA for time to CDMS in patients with CIS. This was the outcome most consistently
reported across studies and matched most closely with the decision problem in the NICE scope.141
Meta-analyses for relapsing–remitting multiple sclerosis and secondary progressive
multiple sclerosis
Relapse outcomes and relapse severity
We elected to meta-analyse the RR of relapses as an overall measure of relapses in RRMS and SPMS.
Although we narratively synthesised analyses for time to relapse and proportion free of relapses, both
measures had significant issues. In particular, time to relapse data were inconsistently presented and at
times impossible to impute whereas the proportion relapse free would have been especially dependent on
the duration of follow-up and would not have captured the impact of drugs on multiple relapses per person.
We elected to meta-analyse two measures for relapse severity in RRMS: steroid-treated relapses and
relapses described as moderate or severe. These were the most commonly reported measures.
Disability progression
We elected to meta-analyse time to disability progression as a measure of disability progression in RRMS
and SPMS. We separated estimates for disability progression confirmed at 3 months and disability
progression confirmed at 6 months, as we could not establish whether measures were commensurate.
Although we narratively synthesised the proportions of patients with disability progression and the
magnitude of EDSS change, we elected not to meta-analyse these data as they would have been especially
dependent on the duration of follow-up. In particular, data for magnitude of EDSS change would have
required extensive imputation.
Discontinuation as a result of adverse events
We estimated models for discontinuation as a result of AEs. To estimate these models, we examined three
outcomes as reported: discontinuation of the study drug as a result of AEs, discontinuation of the study as
a result of AEs and withdrawal from the study as a result of AEs. In the few studies that reported both
discontinuation of the study drug as a result of AEs and discontinuation of the study as a result of AEs,
we chose discontinuation of the study drug as a result of AEs as we believed that it would be better at
capturing the relationship between study drugs and discontinuation. We also estimated one model with
estimates of discontinuation closest to 24 months of follow-up, as available from included studies, as risk
of discontinuation as a result of AEs is not an annualised measure, such as the ARR, or an ‘instantaneous’
measure, such as the HR, and we could not reliably estimate person-years of follow-up in each arm across
all studies to convert study-level estimates to RRs.
Publication bias
If we had included > 10 studies for an intervention–comparator contrast, we would have used funnel plots
to examine studies for the presence of publication bias in pairwise comparisons.
Industry submissions regarding the effectiveness of treatments
We examined manufacturer submissions and present summaries and an appraisal of their clinical
effectiveness analyses in Chapter 6.
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Chapter 5 Results of the assessment of clinical
effectiveness
Search results
Included studies
The search identified 6420 potentially relevant records. We removed 6146 records that did not meet our
inclusion criteria at title/abstract stage, leaving 274 records to be examined at the full-text stage. Of these
studies we excluded 211, leaving 63 publications that met our inclusion criteria,170–232 corresponding to 35
primary studies. Of these primary studies, 32 were included in at least one meta-analysis. A flow diagram
describing the process of identifying the relevant literature is provided in Figure 1.
Excluded studies
The reasons for the exclusion of studies are presented both by type of reason for exclusion and for each
record individually in Appendix 3.
Systematic reviews used to locate primary studies
Three Cochrane systematic reviews were identified as being of particular relevance to this study and
contributed to the identification of original studies for inclusion.158–160
Total from 
key reviews
(n = 90)
Total from 
other sources
(n = 31)
Total from 
database searches
(n = 14,445)
Records screened after duplicates and 
records indexed as conference abstracts or 
observational studies removed
(n = 6420)
Records excluded on 
title and abstract
(n = 6146)
Full-text articles screened for eligibility 
(n = 274)
Full-text articles excluded
(n = 211)
Primary studies in narrative synthesis
(n = 35) (63 records)
Primary studies in meta-analysis 
(n = 32)
FIGURE 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart: clinical
effectiveness reviews.
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Scope and aims
Overview
The study by Filippini et al.160 aimed to review the clinical effectiveness of immunosuppressors and
immunomodulators in all MS types and to rank them based on relapse rate, disability progression and
acceptability. The study by Tramacere et al.159 aimed to review and rank these agents in RRMS specifically.
Clerico et al.158 examined the role of IFN-β-1a, IFN-β-1b and GA in delaying the conversion of CIS into MS,
although this analysis was undertaken before revised diagnostic criteria classified many CIS episodes as in
fact being RRMS.62
Diagnostic criteria used to identify studies
Tramacere et al.159 used all four sets of diagnostic criteria54,62,64,66 to identify RCTs of treatment for RRMS in
participants aged > 18 years.
Filipinni et al.160 included RCTs only, investigating the treatment of adults aged > 18 years with MS
diagnosed according to Poser et al.,64 the original McDonald criteria54 or the 2005 modified McDonald
criteria.66 This review therefore included all types of MS. However, it did not incorporate the most recent
revision of the McDonald criteria62 and so excluded CIS studies.
In contrast, Clerico et al.158 used the Poser criteria64 to identify RCTs and pseudo-randomised double-blind
trials of CIS, with reference to specific MRI findings.169 No exclusion criterion based on participant age
was specified.
Included interventions
Tramacere et al.159 included all immunomodulators and immunosuppressors, even if unlicensed. This
included the IFN-β and GA drugs specified in the NICE scope,141 as well as 11 other interventions. We
noted that the review by Tramacere et al.159 excluded the study by Calabrese et al.,188 stating that it was
non-randomised. To the best of our knowledge this study is a RCT and it has been included in our review.
The interventions studied by Filippini et al.160 included IFN-β and GA formulations that were licensed at the time
(i.e. not pegylated IFN), as well as seven other interventions. Clerico et al.158 would have included licensed IFN-β
and GA interventions (i.e. not pegylated IFN), but identified only three studies comparing IFN with placebo.
All three reviews included studies evaluating DMTs with a dose regimen currently not recommended or
authorised [e.g. IFN-β-1a (Rebif) given once weekly instead of three times weekly]. The reviews did not
account separately for the inclusion of studies with a DMT given under a non-recommended dose regimen
in a sensitivity analysis.
Outcomes
Tramacere et al.159 and Filippini et al.160 examined risk of relapse over 12 months and 24 months as a
dichotomous outcome, as well as the presence or absence of disability progression assessed using the
EDSS. In the study by Filippini et al.,160 which included progressive forms of MS as well as RRMS, risk of
disability progression was reported as the first outcome.
Both reviews assessed AEs. Filippini et al.160 also included the incidence of relapse over 36 months and
assessments of the acceptability of treatment as measured by discontinuation as a result of AEs.
Clerico et al.158 used the proportion converting to CDMS as the primary outcome, alongside the ARR and
additional MRI outcomes.
Statistical methods
In the study by Tramacere et al.,159 NMAs were performed for the primary outcomes. Random-effects models
were used within a frequentist setting. In contrast, Filippini et al.160 performed NMAs within a Bayesian
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framework. For both reviews, equal heterogeneity across comparisons was assumed and any correlations
induced by multiarm studies were accounted for. Both used SUCRA to describe the ranking of treatments.233
Review findings
Tramacere et al.159 found that, in RRMS, the SUCRA for the chance of experiencing relapse over 12 months
was 52% for GA, 36% for SC IFN-β-1a (Rebif), 33% for pegylated IFN-β-1a, 27% for IFN-β-1b and 25%
for IM IFN-β-1a (Avonex). The RR for GA compared with placebo for this outcome was 0.80 (95% CI 0.68
to 0.93), whereas all other interventions of interest did not return significant results. The ranking of
interventions of interest for the prevention of relapse over 24 months in RRMS was GA (most successful)
followed by IFN-β-1b, SC IFN-β-1a (Rebif) and IM IFN-β-1a (Avonex).
The SUCRA plots for reducing the worsening of disability over 24 months in RRMS returned results of
58% for GA, 51% for IFN-β-1b, 36% for SC IFN-β-1a (Rebif) and 21% for IM IFN-β-1a (Avonex). The only
interventions of interest with significant RRs compared with placebo were GA (0.77, 95% CI 0.64 to 0.92)
and IFN-β-1b (0.79, 95% CI 0.65 to 0.97).
Thus, in the Tramacere et al.159 review, GA performed the best of the interventions of interest. IM IFN-β-1a
(Avonex) was consistently the least effective intervention. Other interventions included in the Cochrane
review (but which were outside the scope of the current MTA) performed better, such as alemtuzumab
(SUCRA 97%, RR vs. placebo 0.40, 95% CI 0.31 to 0.51).
Filippini et al.160 returned similar rankings derived from SUCRA values for reducing the recurrence of
relapses over 12 months. However, for reducing the recurrence of relapses at 24 months, the SUCRA
values resulted in a different ranking: SC IFN-β-1a (Rebif), GA, IFN-β-1b and IM IFN-β-1a (Avonex). In terms
of reducing disability progression over 24 months, GA was ranked best (SUCRA 67%) followed by
IFN-β-1b (54%), SC IFN-β-1a (Rebif) (47%) and IM IFN-β-1a (Avonex) (18%).
In the study by Clerico et al.,158 only direct treatment comparisons were performed, using conventional
pairwise meta-analyses to compare IFN with placebo. No studies of GA were identified, but IFN was
effective compared with placebo.
Review quality
All three Cochrane reviews scored 10 out of 11 on the AMSTAR checklist and were assessed as being of
high methodological quality. Tramacere et al.159 and Filippini et al.160 inadequately reported grey literature
searching and Clerico et al.158 did not assess the risk of publication bias.
Study characteristics and methodological quality
Study and participant characteristics
We included 35 primary studies, represented by 63 articles170–232 published between 1987 and 2015, which
involved 14,623 participants randomly assigned to IFN-β, GA or placebo added to standard care or BSC
alone. The median follow-up was 24 months. Only four studies were conducted at single centres.170,181,185,188
The median number of participating centres was 30.5 (range 1–200). The majority of the studies (57.1%)
were international studies. Twenty-two (63%) were placebo-controlled studies,170–176,178–180,189,198–205,207–211,213,
225,227,228,230–232 13 (34%) were head-to-head studies, with a comparison between one IFN-β and GA or
between two IFNs,184–197,206,208,212–215,224,226,229,231 and two (6%) compared an IFN with no treatment (standard
care).76,78 Of the 22 placebo-controlled studies, three aimed to evaluate the effectiveness of DMTs that
were excluded in the scope [laquinimod (Nerventra®; Teva Pharmaceutical Industries, Petah Tikva, Israel),
daclizumab (Zinbryta®; Biogen Idec Ltd, Cambridge, MA, USA) and dimethyl fumarate] compared with
placebo, with IFN-β or GA being added as a third descriptive arm.198,199,216,230 Given the different posology
and method of administration between these agents used in the three studies (two were oral drugs, one
was an intravenous drug), the comparison of IFN-β or GA with placebo was not blinded.
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The key characteristics of the included studies are provided in Table 4. A full list of publications is provided
in Appendix 4.
Risk of bias and methodological quality
The risk of bias graphs for all MS types and for each MS type across all included studies are presented in
Figure 2. Table 5 also provides the assessment of risk of bias for each of the included studies.
Risk in randomisation or allocation methods
All studies that adequately detailed their method of randomisation (n = 21/35) used a method that was
judged to be at low risk of bias.174–175,186–192,195–200,213,216,219–220,222–224 Studies that reported methods of
allocation concealment (the concealment of study allocation before the beginning of assigned treatment)
were also judged to be at low risk of bias (n = 22/35),171,174–175,181,188–191,195–196,198–199,207,213,216–217,219–224 with the
exception of one study that used open allocation.170 All studies citing central allocation were judged as
having a low risk of bias.171,175,190,198,207,213,216–217,219–220,222
Risk in methods of blinding
In the studies examined, 86% (n = 30/35) were at high risk of bias from either complete or partial participant
unblinding.170–172,174–175,181–186,188,190,192,195–199,209,211,213,216–217,219–224 Fourteen studies, most of which were
comparisons between different active drugs, specifically did not blind participants or practitioners;170,182–186,188,
190,192,195–197,199,216 in another 15 studies, participants were initially blinded but were at high risk of unblinding
from increased rates of side effects.171–172,174–175,184,209,211,213,217,219–224 In particular, the lack of blinding in
comparisons between different drugs meant that risk of bias was imbalanced across different comparisons
for the same outcome. We designated all studies in which the rates of side effects (in particular, injection site
reactions) in one study group were double those in another to be at high risk of bias from participant
unblinding. In the two studies designated as being at low risk of bias for participant blinding, side effect
rates were not increased by a factor of two in one group compared with the other (one study tested active
vs. active treatments).191,200
Blinding of outcome assessment was made similarly difficult by injection site reactions. Blinding of outcome
assessment was designated as low risk only if injection site reaction rates were increased by less than a
factor of two in the treatment group (two studies)172,200 or if participants were specifically instructed to
cover their injection sites (eight studies).171,175,189,192,198,222–224 In nine cases, outcome assessors were
otherwise blinded but injection sites were not covered and these studies were designated to be at high risk
of bias.170,174,184,209,211,213,216–217,219 Additionally, studies in which participants were unblinded were designated
as being at high risk of bias for outcome assessment if they did not report that participants were given
specific instructions against sharing treatment information with assessors.170,182–186,188,190,192,195–199,216 All
studies that reported MRI outcomes and detailed methods for blinding of MRI assessment were found to be
at low risk of bias (n = 13/15).171–172,184,188,196,199–200,209,213,216,219–221
Risk in data analysis and reporting
In total, 29% (n = 10/35) of studies were found to be at high risk of bias from missing data, based on
large numbers of missing data, a difference in rates of loss to follow-up between arms or lack of reporting
of imputation methods.173,181,183,186,191,200,209,213,216,223 In 17% (n = 6/35) of studies, outcomes were not
reported as stated, and these were designated to be at high risk of bias from selective reporting.173,181,188,
198–199,207 Finally, all studies funded by drug manufacturers were designated as being at high risk of bias
under the ‘other’ category,171–173,175,183–184,186,189–190,192,195,197–200,207,209,213,216,219–224 as this was not covered by
other questions in the Cochrane risk of bias tool.165
Summary: study characteristics and risk of bias
We located 35 primary studies from a variety of settings and covering all of the drugs listed in the NICE
scope.141 These studies were of variable quality, with particular issues posed by risk of unblinding of
patients and outcome assessors because of injection site reactions, as well as imbalanced risk of bias from
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FIGURE 2 Risk of bias by MS type: (a) all MS types; (b) CIS; (c) RRMS; and (d) SPMS.
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open-label comparisons. Many studies were sponsored by manufacturers and most studies were at high
risk of bias because of missing data.
Clinical effectiveness: clinically isolated syndrome
Our analysis was informed by five trials.171–175 It should be noted that triallists generally examined time to
CDMS, defined using the Poser criteria64 and involving a second relapse or neurological deterioration,
although some also presented analyses examining time to ‘McDonald MS’, in which MRI findings could be
used with clinical findings to arrive at a diagnosis.
30 µg of interferon beta-1a intramuscularly once a week (Avonex) compared
with placebo
Two trials evaluated 30 µg of IM IFN-β-1a once a week, both compared with placebo.172,173
Time to diagnosis of multiple sclerosis
Both studies reported significant differences in favour of IFN-β-1a with regard to delaying time to
confirmation of CDMS, diagnosed generally by a second relapse but in some cases by progressive
neurological deterioration. The CHAMPS (Controlled High Risk Avonex Multiple Sclerosis Study) trial,172
which followed up 393 patients for up to 3 years, found a reduction in hazard of more than half (HR 0.49,
95% CI 0.33 to 0.73). The study by Pakdaman et al.,173 which followed up 202 patients for up to 3 years,
found a reduction in conversion to CDMS in the IFN-β-1a group (incidence 36.6% vs. 58.2%). We
converted this to a HR of 0.54 (95% CI 0.36 to 0.81).
Separate publications also presented analyses stratified by risk levels, site of first lesion176 and type of first
attack.177 In analyses comparing patients with monofocal disease and patients with multifocal disease at
first demyelinating event,177 patients with monofocal disease had a similar reduction in hazard to the
whole trial population (HR 0.45, 95% CI 0.27 to 0.74), whereas patients with multifocal disease had a
decreased reduction in hazard (HR 0.64, 95% CI 0.32 to 1.28).
Freedom from disease activity
The CHAMPS trial176 evaluated freedom from disease activity using several composite outcomes, each of
which showed a reduction in hazard associated with IFN-β-1a. Patients receiving IFN-β-1a were less likely to
have a composite outcome of CDMS or more than one new or enlarging T2 lesion, although this outcome
may be closer to McDonald MS (adjusted HR 0.47, 95% CI 0.36 to 0.62); of CDMS or at least one new or
enlarging T2 lesion (adjusted HR 0.55, 95% CI 0.42 to 0.71); or of CDMS, at least one new or enlarging
T2 lesion or at least one gadolinium-enhancing lesion (adjusted HR 0.60, 95% CI 0.47 to 0.78).
Adverse events and mortality
Full results for AEs are available on request. Mortality was not reported in these studies.
44 µg of interferon beta-1a subcutaneously three times a week (Rebif) compared
with placebo
One trial evaluated 44 µg of SC IFN-β-1a three times a week against placebo175 (this trial also included an
arm testing 44 µg of SC IFN-β-1a once a week, which we do not consider further here as it is not covered
by the recommended posology).
Time to diagnosis of multiple sclerosis
In the REFLEX (REbif FLEXible dosing in early MS) trial,175 340 patients in the relevant trial arms were followed
for up to 2 years and a significant reduction in hazard for conversion to CDMS was found (HR 0.48, 95% CI
0.31 to 0.73). An additional analysis examined time to conversion to McDonald MS (i.e. using MRI criteria as
well) and found a similar reduction in hazard (HR 0.49, 95% CI 0.38 to 0.64), corresponding to median days
to diagnosis of 310 compared with 97 in the IFN-β-1a and placebo groups respectively.
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Several subgroup analyses were undertaken on the study sample by risk level; key findings from Freedman
et al.178 are summarised here. In examining time to CDMS, patients with monofocal presentation (HR 0.58,
95% CI 0.40 to 0.84) and with multifocal presentation (HR 0.45, 95% CI 0.31 to 0.64) both experienced
a decreased hazard of conversion to CDMS, but type of presentation did not appear to be a significant
moderator. Similarly, an analysis that ‘rediagnosed’ patients as having McDonald MS or not based on the
revised 2010 criteria62 found that patients who were McDonald 2010 MS negative had a significantly
decreased hazard of conversion to McDonald 2005 MS (HR 0.49, p < 0.001), as did those who were
McDonald 2010 MS positive at baseline (HR 0.54, p = 0.01).
Adverse events and mortality
Full results are available on request. Mortality was not significantly different between the groups, although
no events occurred in the study drug arm and two deaths occurred in the placebo arm.
250 µg of interferon beta-1b subcutaneously every other day (Betaferon/Extavia)
compared with placebo
One trial evaluated 250 µg of SC IFN-β-1b every other day against placebo.171
Time to diagnosis of multiple sclerosis
In the BENEFIT (Betaferon®/Betaseron®/ in Newly Emerging Multiple Sclerosis for Initial Treatment) trial,171
468 patients were followed for up to 2 years. The study drug delayed time to CDMS (HR 0.50, 95% CI
0.36 to 0.70). This reduction in hazard corresponded to a difference in days to diagnosis of 618, compared
with 255 at the 25th percentile. Triallists also considered time to McDonald MS; the effect of the study
drug was similar in magnitude (HR 0.54, 95% CI 0.43 to 0.67).
Analyses stratified by risk levels, site of first lesion and type of first attack were also carried out in the
BENEFIT trial.179 In analyses comparing patients with monofocal and multifocal disease at first demyelinating
event, patients with monofocal disease had a similar reduction in hazard to the whole trial population
(HR 0.45, 95% CI 0.29 to 0.71), whereas patients with multifocal disease had a decreased reduction in
hazard (HR 0.63, 95% CI 0.40 to 0.99).
Multiple sclerosis symptoms and health-related quality of life
Patients in the BENEFIT trial were assessed for cognitive performance using the Paced Auditory Serial
Addition Test (PASAT).180 At year 2, patients receiving the study drug had greater increases in score on this
test than patients receiving placebo, including under conservative assumptions (2.0 vs. 0.6; p = 0.021).
Additionally, patient-reported physical health and HRQoL data were collected in this trial.171 Scores were
not different between groups and were stable over the trial.
Adverse events and mortality
Full results are available on request. No deaths were reported in the BENEFIT trial.171
20 mg of glatiramer acetate subcutaneously once daily (Copaxone) compared
with placebo
One trial evaluated 20 mg of SC GA once daily against placebo.174
Time to diagnosis of multiple sclerosis
The PreCISe (Presenting with Clinically Isolated Syndrome) trial174 followed up 481 patients for up to
3 years, although the trial was stopped early for benefit. Participants receiving 20 mg of SC GA once daily
had a reduced hazard of conversion to CDMS (HR 0.55, 95% CI 0.4 to 0.77), although CDMS was defined
here as the occurrence of a second exacerbation. The corresponding difference in days to diagnosis was
722, compared with 336 at the 25th percentile.
Adverse events and mortality
Full results are available on request. Mortality was not significantly different between groups, although the
PreCISe trial174 reported only one death, in the study drug arm.
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Meta-analyses: time to clinically definite multiple sclerosis
Pairwise meta-analyses
Direct evidence from comparisons is shown in Figure 3. All comparisons were against placebo. Only one
comparison, 30 µg of IM IFN-β-1a once a week compared with placebo, included more than one study.
The pooled effect size suggested that 30 µg of IM IFN-β-1a once a week reduces time to CDMS (HR 0.52,
95% CI 0.39 to 0.68), with low heterogeneity (I2 = 0%, p = 0.718).
Network meta-analyses
The set of studies reporting HRs for time to CDMS formed a connected network (Figure 4). This network
was star shaped, meaning that it contained no comparisons between active drugs. We estimated this
model using random effects, as per the protocol.
Rankings from the NMA suggested that 44 µg of SC IFN-β-1a three times weekly was ranked best,
followed by 250 µg of SC IFN-β-1b every other day, 30 µg of IM IFN-β-1a once a week and 20 mg of SC
GA once daily (Table 6). Placebo was ranked last.
Study
0.5 1.0
Favours active drug Favours placebo
GA 20 mg SC daily vs. placebo 
PreCISe 2009174
Subtotal (I2 = .%, p = .)
IFN-β-1a 30 µg IM weekly vs. placebo
CHAMPS 2000176
Pakdaman 2007173
Subtotal (I2 = 0.0%, p = 0.718)
IFN-β-1a 44 µg SC thrice weekly vs. placebo
REFLEX 2012175
Subtotal (I2 = .%, p = .)
IFN-β-1b 250 µg SC every other day vs. placebo
BENEFIT 2006171
Subtotal (I2 = .%, p = .)
HR (95% CI)
0.55 (0.40 to 0.76)
0.55 (0.40 to 0.76)
0.49 (0.33 to 0.73)
0.54 (0.36 to 0.81)
0.52 (0.39 to 0.68)
0.48 (0.31 to 0.74)
0.48 (0.31 to 0.74)
0.50 (0.36 to 0.70)
0.50 (0.36 to 0.70)
2.00.1
FIGURE 3 Pairwise meta-analyses: time to CDMS.
ifn1a44
ifn1b250
placebo
ga20
ifn1a30
FIGURE 4 Network of studies: time to CDMS. ifn1a30, 30 µg of IM IFN-β-1a once a week; ifn1a44, 44 µg of SC
IFN-β-1a three times weekly; ifn1b250, 250 µg of SC IFN-β-1b every other day; ga20, 20mg of SC GA once daily.
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Findings for comparisons between active drugs and placebo were identical, as expected, to those in the
pairwise meta-analyses. Findings for indirect comparisons between drugs did not suggest the superiority of
any one drug over another.
Because the network was star shaped, we could not test for inconsistency.
Sensitivity analysis
We also re-estimated the network with effect sizes for time to conversion to McDonald MS for those
studies reporting it. Effectiveness estimates were robust to this change.
Meta-analyses: not possible for adverse events in clinically isolated syndrome
Of the four studies171,172,174,175 reporting discontinuations as a result of AEs, two reported discontinuations
over 36 months172,174 and two reported discontinuations over 24 months.171,175 As a result, we did not
estimate a NMA for discontinuations in CIS. Estimates can be found in Table 7.
TABLE 6 Network meta-analysis: time to CDMSa
Drug SUCRA
44 µg of
SC IFN-β-1a
three times
weekly
250 µg of SC
IFN-β-1b
every other
day
30 µg of IM
IFN-β-1a
weekly
20mg of SC
GA daily Placebo
44 µg of SC IFN-β-1a
three times weekly
0.70 0.96
(0.56 to 1.65)
0.93
(0.56 to 1.55)
0.87
(0.51 to 1.50)
0.48
(0.31 to 0.74)
250 µg of SC IFN-β-1b
every other day
0.68 0.97
(0.63 to 1.50)
0.91
(0.57 to 1.45)
0.50
(0.36 to 0.70)
30 µg of IM IFN-β-1a
weekly
0.62 0.94
(0.61 to 1.45)
0.52
(0.39 to 0.68)
20 mg of SC GA daily 0.5 0.55
(0.40 to 0.76)
Placebo 0
a Findings are expressed as HR (95% CI).
TABLE 7 Discontinuation as a result of AEs in CIS studies
Study Comparison
Follow-up
(months)
Treatment
arm events
Treatment
group (n)
Treatment
events
proportion
(%)
Placebo
arm
events
Placebo
group
(n)
Placebo
events
proportion
(%)
PreCISe
2009174
GA 20mg daily vs.
placebo
36 14 243 5.8 4 238 1.7
REFLEX
2012175
IFN-β-1a 44 µg SC
three times weekly
vs. placebo
24 5 171 2.9 6 171 3.5
CHAMPS
2000172
IFN-β-1a 30 µg IM
weekly vs. placebo
36 1 193 0.5 7 190 3.7
BENEFIT
2006171
IFN-β-1b 250 µg
SC every other day
vs. placebo
24 24 292 8.2 1 176 0.6
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Summary: clinically isolated syndrome
Comparisons for included drugs all relied on one or two trials, but each comparison suggested that IFN
or GA delayed time to CDMS over a 2- to 3-year follow-up. This finding appeared to be robust to the
diagnostic criteria used to establish a definitive MS diagnosis. The NMA did not suggest the superiority
of one drug over another. The rate of AEs tended to be higher in trial arms receiving the active drugs,
although, when mortality was reported, it was not significantly higher in patients receiving the study drug.
Findings on additional outcomes (MS symptoms, HRQoL) were infrequently reported.
Clinical effectiveness: relapsing–remitting multiple sclerosis
Our analysis was informed by 27 trials.170,181–221,226,229–231 Of these 27 trials, one evaluated HRQoL measures
alone181 and one evaluated AEs alone.182 In addition, two trials reported on mixed populations.183,184
The REMAIN (REbif compared with no treatment in the therapy of relapsing Multiple sclerosis After
mItoxaNtrone) trial,183 which followed up 30 participants over 96 weeks, included a mixed RRMS (n = 13)
and SPMS (n = 17) population. Because of the size of this open-label trial, because data were not stratified
by type of MS and because treatment switching was allowed, we decided to include this trial in narrative
synthesis but not in meta-analyses. In contrast, the BECOME (Betaseron vs. Copaxone in Multiple Sclerosis
with Triple-Dose Gadolinium and 3-Tesla MRI Endpoints) trial,184 which followed up 75 participants over
2 years, included 14 patients diagnosed with CIS before the revision of the McDonald criteria. Because we
judged it likely that many of the 14 patients originally diagnosed as having CIS would have been classed as
having RRMS under the most recent criteria, we analysed this trial alongside other RRMS-only trials. Thus,
24 relevant trials reported key clinical outcomes.
Several characteristics of the ‘epidemiology’ of the trial network bear discussing first: the design of included
multiarm trials, two-arm trials comparing active drugs against each other and trials with mixed populations.
Of the 24 trials reporting clinical outcomes, four trials had three relevant treatment arms:
1. Both Etemadifar et al.185 and Mokhber et al.186,187 evaluated 44 µg of SC IFN-β-1a three times a week
against 30 µg of IM IFN-β-1a once a week against 250 µg of SC IFN-β-1b every other day.
2. Calabrese et al.188 evaluated 44 µg of SC IFN-β-1a three times a week against 30 µg of IM IFN-β-1a
once a week against 20 mg of SC GA once daily.
3. The PRISMS (Prevention of Relapses and Disability by Interferon Beta-1a Subcutaneously in Multiple
Sclerosis) trial189 compared 44 µg of SC IFN-β-1a three times a week against 22 µg of SC IFN-β-1a three
times a week against placebo.
An additional seven two-arm trials compared active drugs against each other:
l Two trials184,190 compared 250 µg of SC IFN-β-1b every other day against 20 mg of SC GA once daily.
l The CombiRx (Combination Therapy in Patients with Relapsing–Remitting Multiple Sclerosis) trial.191
compared 30 µg of IM IFN-β-1a once a week against 20 mg of SC GA once daily.
l The REGARD (REbif vs. Glatiramer Acetate in Relapsing MS Disease) trial192 compared 44 µg of SC
TFN-β-1a three times a week against 20 mg of SC GA once daily.
l The EVIDENCE (Evidence of Interferon Dose–Response: European North American Comparative Efficacy)
trial193–195 compared 44 µg of SC IFN-β-1a three times a week against 30 µg of IM IFN-β-1a once
a week.
l The INCOMIN (Independent Comparison of Interferon) trial196 compared 250 µg of SC IFN-β-1b every
other day against 30 µg of IM IFN-β-1a once a week.
l The REFORMS (Rebif New Formulation versus Betaseron Tolerability Study) trial197 compared 44 µg of
SC IFN-β-1a three times a week against 250 µg of SC IFN-β-1b every other day.
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30 µg of interferon beta-1a intramuscularly once a week (Avonex) compared
with placebo
Our analysis was informed by three trials comparing 30 µg of IM IFN-β-1a once a week against
placebo.198–200 The BRAVO (Benefit–Risk Assessment of AVonex and LaquinimOd) trial198 compared oral
laquinimod against 30 µg of IM IFN-β-1a once a week and oral placebo, whereas Kappos et al.199
compared intravenous ocrelizumab against 30 µg of IM IFN-β-1a once a week and intravenous placebo.
The Multiple Sclerosis Collaborative Research Group (MSCRG) trial200 compared 30 µg of IM IFN-β-1a once
a week against an IM placebo.
An additional six trials compared 30 µg of IM IFN-β-1a once a week against other drugs: three multiarm
trials185–188 and three two-arm trials.191,193–196
Relapse outcomes
Findings for relapse outcomes relied on three trials with different follow-up times,198–200 including two of
the largest trials in this review.198,200 All three studies suggested a beneficial effect of 30 µg of IM IFN-β-1a
once a week in terms of reducing the rate of relapses. The BRAVO trial,198 which followed 887 patients in
the relevant trial arms for 24 months, found that patients receiving 30 µg of IM IFN-β-1a once a week had
a 26% reduction in the ARR (RR 0.74, 95% CI 0.60 to 0.92). In the study by Kappos et al.,199 108 patients
were followed up over 24 weeks and, although the ARR was lower in patients receiving 30 µg of IM
IFN-β-1a once a week (ARR 0.36, 95% CI 0.22 to 0.60) than in patients receiving placebo (ARR 0.64,
95% CI 0.43 to 0.94), this difference was only marginally significant (p = 0.07). Finally, in the MSCRG trial,200
301 patients were followed up for up to 3 years, although the study was stopped early for efficacy and thus
patients had variable times to follow-up. In analyses including all patients, the ARR for patients receiving the
study drug was significantly less than the ARR for patients receiving placebo (0.67 vs. 0.82; p = 0.04).
Only the MSCRG trial200 reported time to first relapse. This was not presented with a HR estimate, but a
log-rank test suggested that 30 µg of IM IFN-β-1a once a week did not significantly delay time to first
exacerbation compared with placebo (IFN-β-1a vs. placebo: median 47.3 vs. 36.1 weeks; p = 0.34).
Finally, all three studies reported the proportion of patients who were relapse free, although the findings
were somewhat heterogeneous and comparability is limited by the differential follow-up. The BRAVO
trial198 found that 69% of patients receiving 30 µg of IM IFN-β-1a once a week were relapse free
compared with 61% of patients receiving placebo (p = 0.023). This difference was narrower in the study
by Kappos et al.199 (30 µg of IM IFN-β-1a once a week 78% vs. placebo 76%), with a RR for experiencing
any relapses of 0.92 (95% CI 0.46 to 1.84). The MSCRG trial200 reported proportions only for those
patients who completed the intended 104 weeks of study, excluding those who were enrolled but who
did not complete the 104 weeks before the study was stopped. For the 85 patients included who received
30 µg IM of IFN-β-1a once a week, 38% were free of relapses, compared with 26% of the 87 patients
receiving placebo. A significance test was not presented.
Relapse severity
We could not locate any relevant comparisons between 30 µg of IM IFN-β-1a once a week and placebo for
outcomes relating to moderate or severe relapses or steroid-treated relapses.
Disability progression
Only the BRAVO trial198 estimated time to disability progression confirmed at 3 months. Patients receiving
30 µg of IM IFN-β-1a once a week and placebo were delayed, but not significantly so, in time to
progression (HR 0.74, 95% CI 0.51 to 1.09). The results for disability progression confirmed at 6 months
were similar (HR 0.73, 95% CI 0.47 to 1.14). The MSCRG trial200 also reported time to progression
confirmed at 6 months. Based on a Kaplan–Meier analysis, the predicted probability of progression at
2 years was 21.9% in patients receiving 30 µg of IM IFN-β-1a once a week compared with 34.9% in
patients receiving placebo (log-rank p = 0.02), indicating a slowing of time to progression.200,201 In a
separate publication, the reduction in hazard was reported as 43.0% (i.e. HR 0.570; p = 0.03).202
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Empirical proportions of patients with progression confirmed at 3 months were also reported in the BRAVO
trial198 (30 µg of IM IFN-β-1a once a week 11% vs. placebo 13%). The proportions with progression at
6 months were similarly low (30 µg of IM IFN-β-1a once a week 8% vs. placebo 10%). In the MSCRG trial,
empirical proportions of patients with progression confirmed at 6 months were reported for the full sample
in a separate publication from the main study report.202 Patients receiving 30 µg of IM IFN-β-1a once a week
had a lower probability of progression than patients receiving placebo (15% vs. 25%), although follow-up
was variable. Significance tests were not presented for these proportions per se (i.e. not as part of survival
analysis, discussed in the previous paragraph) in any of the three trials.
The magnitude of change from baseline in EDSS score was presented only for the MSCRG trial.200 Among
patients completing 104 weeks on the study, those receiving 30 µg of IM IFN-β-1a once a week had a
smaller increase in EDSS score than those receiving placebo (0.25 vs. 0.74; p = 0.02). This finding was
similar in patients examined to week 130 (0.02 vs. 0.61; p = 0.02), with the lower of the scores at week
104 or week 130 taken as a measure of ‘sustained’ change. In the BRAVO trial,198 patients receiving 30 µg
of IM IFN-β-1a once a week had a smaller decrease in the Multiple Sclerosis Functional Composite score at
24 months, but this difference was not significant (z-scores –0.045 vs. –0.14; p = 0.21).
Freedom from disease activity
We could not locate any relevant comparisons between 30 µg of IM IFN-β-1a once a week and placebo for
the combined clinical–MRI measures of freedom from disease activity.
Multiple sclerosis symptoms and health-related quality of life
The MSCRG trial203 reported performance on both the Comprehensive and Brief Neuropsychological
Batteries by examining change from baseline to 2 years and estimated models with both no covariates and
with baseline performance as a covariate. Although exact effect sizes were not provided, the study found
that, in patients completing 104 weeks on the study, compared with placebo, 30 µg of IM IFN-β-1a once a
week improved information processing and memory (p = 0.036 unadjusted, p = 0.011 adjusted for baseline
performance) and visuospatial abilities and executive functions (p = 0.005 unadjusted, p = 0.085 adjusted),
but not verbal abilities and attention span (p = 0.603 unadjusted, p = 0.917 adjusted). Findings were similar
for the Brief Neuropsychological Battery (p = 0.020 for both unadjusted and adjusted), although 30 µg of
IM IFN-β-1a once a week did not significantly delay time to onset of deterioration confirmed at 6 months
(log-rank p = 0.094). Analyses of PASAT scores indicated that, although the difference in magnitude of
change did not rise to significance (p = 0.119 unadjusted, p = 0.090 adjusted), patients receiving 30 µg of
IM IFN-β-1a once a week did delay time to sustained deterioration (log-rank p = 0.023).
Additionally, patients receiving 30 µg of IM IFN-β-1a once a week had a decreased hazard of sustained
worsening in the timed 25-foot walk (HR 0.401; p = 0.04). However, this decreased hazard was not
evidenced in the nine-hole peg test with the dominant hand (HR 0.514; p = 0.07) or the non-dominant
hand (HR 0.494; p = 0.10) or the box and block test with the dominant hand (HR 0.581; p = 0.45) or
the non-dominant hand (HR 0.835; p = 0.75).202 A variety of combinations of these end points was also
tested. In a separate publication, use of an instrument to examine functional independence showed that
change over 104 weeks in cognitive aspects of functional independence was not significant.204 This was
the case when considered as a difference in both means (p = 0.08) and time to sustained worsening
(log-rank p = 0.188), with similar findings for difference in means for motor aspects of functional
independence (p = 0.10, log-rank p = 0.368). Total changes in functional independence were significant
at 104 weeks (p = 0.03).
Finally, the MSCRG trial reported on the effects of 30 µg of IM IFN-β-1a once a week on the Sickness Impact
Profile as a measure of QoL.205 In the study population as a whole, there were no differences between
placebo and the study drug on the overall measure, nor on its physical or psychosocial components.
However, when considering patients with low HRQoL at baseline (defined as a score of ≥ 10 on the
measure), patients receiving the study drug had a greater improvement on physical aspects of the measure
than those receiving placebo (–3.78 vs. 3.57; p < 0.05).
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Adverse events and mortality
We stratified the comparison of AEs by type of placebo, as local AEs (e.g. injection site reactions) would
not apply in studies with oral or intravenous placebos. Full results are available on request.
Mortality was not different between groups for either type of placebo. However, only one death occurred
in the MSCRG trial200 (in the study drug arm), no deaths occurred in the study by Kappos et al.199 and only
one death occurred in the BRAVO trial198 (in the study drug arm).
Summary of the narrative synthesis: 30 µg of interferon beta-1a intramuscularly once a
week (Avonex) compared with placebo
Findings from three trials198–200 suggested that, relative to placebo, 30 µg of IM IFN-β-1a once a week
reduces relapse rates, although findings were less clear for other relapse-related outcomes. Findings from
two trials198,200 suggested that 30 µg of IM IFN-β-1a once a week also has a beneficial effect in terms of
delaying disability progression, although only the MSRCG trial200 presented significant results. Findings
from the MSCRG trial200–204 with regard to MS symptoms were inconsistent across tests. We were unable
to find any relevant comparisons for relapse severity, defined as moderate/severe or steroid-treated
relapses, or the combined clinical–MRI measures of freedom from disease activity. Mortality was rare and
not significantly different between groups.
30 µg of interferon beta-1a intramuscularly once a week (Avonex) compared
with 44 µg of interferon beta-1a subcutaneously three times a week (Rebif)
Four trials compared 30 µg of IM IFN-β-1a once a week against 44 µg of SC IFN-β-1a three times
a week.185–188,193–195
Relapse outcomes
Findings for relapse outcomes relied on three trials, of which the EVIDENCE trial193–195 was the largest by
far. Calabrese et al.188 analysed 141 patients randomised to either 30 µg of IM IFN-β-1a once a week
(n = 47), 44 µg of SC IFN-β-1a three times a week (n = 46) or 20 mg of SC GA once daily (n = 48) over
2 years, with complete follow-up for analysed patients. Relapses were apparently analysed using a normal
distribution, although formal significance tests were not presented. At 2 years, patients receiving 30 µg of
IM IFN-β-1a once a week had an average ARR of 0.5 [standard deviation (SD) 0.6], whereas patients
receiving 44 µg of SC IFN-β-1a three times a week had an average ARR of 0.4 (SD 0.6). We estimated a
RR of 1.25 (95% CI 0.81 to 1.92). Etemadifar et al.185 analysed 90 patients randomised 1 : 1 : 1 to either
30 µg of IM IFN-β-1a once a week, 44 µg of SC IFN-β-1a three times a week or 250 µg of SC IFN-β-1b
every other day. Because relapses were analysed using a repeated measures ANOVA method with normal
distributions, we re-estimated RRs based on the number of relapses in each arm. Based on a total of 57
relapses in patients receiving 30 µg of IM IFN-β-1a once a week and 66 relapses in patients receiving 44 µg
of SC IFN-β-1a three times a week, we estimated a RR of 0.86 (95% 0.61 to 1.23). Finally, the EVIDENCE
trial194,195 randomised 677 patients and followed them up for an intended period of at least 48 weeks,
with a median follow-up of 64 weeks. Patients receiving 30 µg of IM IFN-β-1a once a week had a higher
ARR (0.65) than patients receiving 44 µg of SC IFN-β-1a three times a week (0.54); this difference was
statistically significant (RR 1.20; p = 0.033).
Only the EVIDENCE trial194,195 presented data for time to first relapse. The 40th percentile of patients
receiving 30 µg of IM IFN-β-1a once a week had their first relapse at 6.7 months whereas the 40th
percentile of patients receiving 44 µg of SC IFN-β-1a three times a week had their first relapse at
13.5 months. Relative to patients receiving 30 µg of IM IFN-β-1a once a week, patients receiving 44 µg of
SC IFN-β-1a three times a week had a decreased hazard of first relapse (HR 0.70, 95% CI 0.56 to 0.88).
Both studies presenting data on the proportions of patients free of relapse were in agreement on the
direction of effect. In the study by Etemadifar et al.,185 patients receiving 30 µg of IM IFN-β-1a once a week
were less likely to be free of relapses than patients receiving 44 µg of SC IFN-β-1a three times a week
(20.0% vs. 56.7%), but a pairwise significance test was not presented. In the EVIDENCE trial,194,195 patients
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receiving 30 µg of IM IFN-β-1a once a week were less likely to be relapse free (48%) than patients receiving
44 µg of SC IFN-β-1a three times a week (56%), that is, the OR for being relapse free at the end of the study
favoured patients receiving 44 µg of SC IFN-β-1a three times a week (OR 1.5, 95% CI 1.1 to 2.0).
Relapse severity
Only the EVIDENCE trial194,195 reported outcomes related to relapse severity, in this case ARRs for
steroid-treated relapses. Patients receiving 30 µg of IM IFN-β-1a once a week had an ARR of 0.28 for
steroid-treated relapses, whereas patients receiving 44 µg of SC IFN-β-1a three times a week had an
ARR of 0.19 for steroid-treated relapses. Thus, the RR for steroid-treated relapses is 1.47 (p = 0.009).
Disability progression
The EVIDENCE trial193 was the only trial that reported time to disability progression and the proportions
of patients progressing. Drawing from interim data on all patients at 48 weeks of follow-up, patients
receiving 30 µg of IM IFN-β-1a once a week appeared to progress faster than patients receiving 44 µg of
SC IFN-β-1a three times a week. However, this finding was not significant for either progression confirmed
at 3 months (44 µg SC vs. 30 µg IM: HR 0.87, 95% CI 0.58 to 1.31) or progression confirmed at 6 months
(HR 0.70, 95% CI 0.39 to 1.25). At the end of the study, there was no statistically significant difference in
the proportion of patients with disability progression confirmed at 3 months between those receiving
30 µg of IM IFN-β-1a once a week and those receiving 44 µg of SC IFN-β-1a three times a week (17% vs.
16%; p = 0.710).
In the study by Calabrese et al.,188 the magnitude of change in EDSS score did not appear to be
numerically different between 30 µg of IM IFN-β-1a once a week [0.2 (SD 0.4)] and 44 µg of SC IFN-β-1a
three times a week [0.2 (SD 0.5)], but formal significance testing was not reported. However, in the study
by Etemadifar et al.,185 patients receiving 30 µg of IM IFN-β-1a once a week had a reduction in EDSS score
of 0.1 (95% CI –0.2 to 0.5), a numerically smaller decrease than that seen for patients receiving 44 µg of
SC IFN-β-1a three times a week (0.3, 95% CI 0.03 to 0.5). Again, formal significance testing was not
reported. Finally, Mokhber et al.186,187 found no difference in EDSS score between baseline and 12 months’
follow-up for 30 µg of IM IFN-β-1a once a week (0.0, n = 20; p = 0.548), whereas a test for change was
significant for 44 µg of SC IFN-β-1a SC three times a week (–1.0, n = 21; p = 0.001). Pairwise testing was
not performed but an overall test was not significant.
Freedom from disease activity
We could not locate any relevant comparisons between 30 µg of IM IFN-β-1a once a week and 44 µg of
SC IFN-β-1a three times a week for the combined clinical–MRI measures of freedom from disease activity.
Multiple sclerosis symptoms and health-related quality of life
Mokhber et al.186 presented tests of cognitive function, although without pairwise comparisons. Except for
the symbol digit modalities test, for all tests presented (selective reminding test, spatial recall test, symbol
digit modalities test, PASAT and word list generation), comparisons across all three treatment groups were
not statistically significant. Post hoc tests found evidence that patients receiving 30 µg of IM IFN-β-1a once
a week did not improve as much as patients receiving 44 µg of SC IFN-β-1a three times a week on the
word list generation and PASAT-easy tests.
Additionally, Mokhber et al.187 disaggregated the Multiple Sclerosis Quality of Life-54 scale into its
subcomponents, including mental health (five components) and physical health (eight components). There
were few significant within-group differences in this small trial and pairwise significance tests, as well as
estimates of change from baseline, were not presented in a standard format, permitting only discussion of
direction and significance of differences. Patients receiving 30 µg of IM IFN-β-1a once a week significantly
worsened in terms of energy and fatigue compared with patients receiving 44 µg of SC IFN-β-1a three
times a week, who improved. However, patients receiving 30 µg of IM IFN-β-1a once a week significantly
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improved in terms of physical role limitations compared with patients receiving 44 µg of SC IFN-β-1a three
times a week, who also improved. Patients receiving 30 µg of IM IFN-β-1a once a week also significantly
improved in terms of both emotional role limitations and cognitive function compared with patients receiving
44 µg of SC IFN-β-1a three times a week. Differences were not significant for physical function, health
perceptions, pain, sexual function, social function, health distress, overall QoL or emotional well-being.
Adverse events and mortality
The EVIDENCE trial206 was the only trial that reported AEs. No studies reported mortality. Full results are
available on request.
Summary of the narrative synthesis: 30 µg of interferon beta-1a intramuscularly once
a week (Avonex) compared with 44 µg of interferon beta-1a subcutaneously three
times a week (Rebif)
Findings from three trials, of which one was considerably larger than the others, suggested that 30 µg
of IM IFN-β-1a once a week was less effective than 44 µg of SC IFN-β-1a three times a week in terms
of reducing and delaying relapses. Findings from the EVIDENCE trial194,195 suggested that 30 µg of IM
IFN-β-1a once a week was also less effective than 44 µg of SC IFN-β-1a three times a week at reducing
steroid-treated relapses. Across disability progression outcomes, the findings did not show a clear pattern,
and the largest trial193 did not find a significant difference in terms of disability progression outcomes.
Findings on MS symptoms and HRQoL were poorly reported and inconsistent and relied on one small trial.
We were unable to locate any comparisons for combined clinical–MRI measures of freedom from disease
activity and the included studies did not report mortality.
30 µg of interferon beta-1a intramuscularly once a week (Avonex) compared with
250 µg of interferon beta-1b subcutaneously every other day (Betaferon/Extavia)
Three trials compared 30 µg of IM IFN-β-1a once a week against 250 µg of SC IFN-β-1b every
other day.185–187,196
Relapse outcomes
Findings for relapse outcomes relied on two trials, both with 24 months of follow-up. In the study by
Etemadifar et al.,185 patients receiving 30 µg of IM IFN-β-1a once a week had fewer relapses over 2 years
of follow-up than patients receiving 250 µg of SC IFN-β-1b every other day (57 vs. 65; n = 30 in both
groups). We estimated this as a RR of 0.88 (95% CI 0.61 to 1.25). However, in the INCOMIN trial,196 which
followed up 188 patients over 24 months, patients receiving 30 µg of IM IFN-β-1a once a week had a
higher ARR (0.7) than patients receiving 250 µg of SC IFN-β-1b SC every other day (0.5). Because the
authors presented the effect size estimate as a standardised mean difference, we re-estimated the RR as
1.4 (95% CI 1.07 to 1.83).
Both trials suggested that the proportion of patients who were relapse free was comparatively higher in
the group receiving 250 µg of SC IFN-β-1b every other day. The proportions of patients experiencing
relapses were significantly different between the relevant arms in the study by Etemadifar et al.,185 with
patients receiving 30 µg of IM IFN-β-1a once a week less likely to be free of relapse (20% vs. 43.3%,
p = 0.049). In the INCOMIN trial,196 patients receiving 30 µg of IM IFN-β-1a once a week were also less
likely to be free of relapse than patients receiving 250 µg of SC IFN-β-1b every other day (36% vs. 51%;
risk ratio 0.76, 95% CI 0.59 to 0.99).
Relapse severity
Only the INCOMIN trial196 presented findings for relapse severity, specifically ARRs for steroid-treated
relapses. Although patients receiving 30 µg of IM IFN-β-1a once a week were more likely to have
steroid-treated relapses than those receiving 250 µg of SC IFN-β-1b every other day (0.5 vs. 0.38), this
difference was not significant (estimated RR 1.32, 95% CI 0.96 to 1.80).
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Disability progression
Only the INCOMIN trial196 presented differences in time to disability progression confirmed at 6 months
and proportions with disability progression. More patients receiving 30 µg of IM IFN-β-1a once a week
progressed than patients receiving 250 µg of SC IFN-β-1b every other day (30% vs. 13%), with patients
in the 250 µg of SC IFN-β-1b every other day group having a reduction in risk of progression of 56%
(p = 0.005). In combination with a log-rank test reported as p < 0.01, this gives an estimated HR of 2.24
(95% CI 1.21 to 4.13).
Findings from all three trials suggested that 30 µg of IM IFN-β-1a once a week did not have as beneficial
an effect on the magnitude of change in EDSS score as 250 µg of SC IFN-β-1b every other day. In the
study by Etemadifar et al.,185 patients receiving 30 µg of IM IFN-β-1a once a week had a reduction in EDSS
score of 0.1 (95% CI –0.2 to 0.5), a numerically smaller decrease than that seen in patients receiving
250 µg of SC IFN-β-1b every other day (0.7, 95% CI 0.5 to 0.9). Again, formal pairwise significance testing
was not reported. Moreover, in a comparatively small trial, Mokhber et al.186,187 found no evidence of a
significant difference in EDSS score between baseline and 12 months’ follow-up for 30 µg of IM IFN-β-1a
once a week (0.0, n = 20; p = 0.548), whereas a test for change was significant for 250 µg of SC IFN-β-1b
every other day (–0.6, n = 19; p = 0.028). Pairwise testing was not performed but an overall test was not
significant. Finally, using ANCOVA-adjusted estimates, the INCOMIN trial196 found that patients receiving
30 µg of IM IFN-β-1a once a week had a higher EDSS score at the end of the trial than patients receiving
250 µg of SC IFN-β-1b every other day (2.5 vs. 2.1; p = 0.004).
Multiple sclerosis symptoms and health-related quality of life
Mokhber et al.186 presented tests of cognitive function, although without pairwise comparisons. It should
be reiterated that this trial was a small trial, with 39 patients analysed in total for the relevant comparisons.
Except for the symbol digit modalities test, for all tests presented (selective reminding test, spatial recall
test, symbol digit modalities test, PASAT and word list generation), comparisons across all three treatment
groups were not statistically significant. Post hoc tests found evidence that patients receiving 30 µg of IM
IFN-β-1a once a week did not improve as much as patients receiving 250 µg of SC IFN-β-1b every other
day on the symbol digit modalities and PASAT-easy tests.
Additionally, Mokhber et al.187 disaggregated the Multiple Sclerosis Quality of Life-54 scale into its
subcomponents, including mental health (five components) and physical health (eight components).
There were few significant within-group differences in this small trial and pairwise significance tests, as
well as estimates of change from baseline, were not presented in a standard format, permitting only
discussion of direction and significance of differences. Patients receiving 30 µg of IM IFN-β-1a once a week
significantly improved in terms of health perceptions and pain compared with patients receiving 250 µg of
SC IFN-β-1b every other day, who declined on both measures. However, patients receiving 250 µg of SC
IFN-β-1b every other day improved more on overall QoL, overall mental health aspects of QoL and
emotional well-being than patients receiving 30 µg of IM IFN-β-1a once a week. Differences were not
significant for overall physical health aspects of QoL, physical function, energy/fatigue, physical role
limitations, sexual function, social function, health distress, emotional role limitations or cognitive function.
Adverse events and mortality
Only the INCOMIN trial196 reported AEs. No studies reported mortality. Full results are available on request.
Summary of the narrative synthesis: 30 µg of interferon beta-1a intramuscularly once
a week (Avonex) compared with 250 µg of interferon beta-1b subcutaneously every
other day (Betaferon/Extavia)
Although the included trials were in conflict with regard to the relative effect of the drugs on relapse rates,
the INCOMIN trial196 suggested that 30 µg of IM IFN-β-1a once a week was less effective than 250 µg of
SC IFN-β-1b every other day in reducing relapse rates and both studies found that the proportion of
patients free of relapses was lower in the group receiving 30 µg of IM IFN-β-1a once a week. The
INCOMIN trial196 did not find a difference between groups with regard to relapse severity, measured as
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steroid-treated relapses, but both studies agreed that 30 µg of IM IFN-β-1a once a week was less effective
than 250 µg of SC IFN-β-1b every other day for disability progression. Findings on MS symptoms and
HRQoL relied on one small trial with inconsistent effects and poor reporting. No studies reported mortality.
30 µg of interferon beta-1a intramuscularly once a week (Avonex) compared with 20 mg
of glatiramer acetate subcutaneously once daily (Copaxone)
Two trials compared 30 µg of IM IFN-β-1a once a week against 20 mg of SC GA once daily.188,191
Relapse outcomes
Findings for relapse outcomes relied on both trials, with substantial follow-up; one trial, the CombiRx
trial,191 was considerably larger than the other. In the trial by Calabrese et al.,188 patients receiving 30 µg of
IM IFN-β-1a once a week (n = 47) did not appear to have a numerically different ARR [0.5 (SD 0.6) vs. 0.5
(SD 0.4)] after 2 years’ follow-up than patients receiving 20 mg of SC GA once daily (n = 48). A formal
significance test was not reported, but we re-estimated the RR as 1.00 (95% CI 0.67 to 1.50). However,
in the larger CombiRx trial,191 with 36 months’ follow-up, patients receiving 30 µg of IM IFN-β-1a once a
week (n = 250) had a higher ARR than patients receiving 20 mg of SC GA once daily (0.16 vs. 0.11). This
difference was tested using a Cox proportional hazards model with correction for repeated events, which
found statistically significant evidence of a shorter time between relapses for 30 µg of IM IFN-β-1a once a
week than for 20 mg of SC GA once daily (HR 1.43, 95% CI 1.04 to 1.95). This finding was robust to a
sensitivity analysis including non-protocol-defined relapses.
However, the CombiRx trial191 did not find a significant difference between groups in time to first relapse
(p = 0.19). Additional information was not reported. The CombiRx trial191 also did not find a significant
difference between groups in the proportion with protocol-defined relapses at 36 months (74.0% vs.
79.5%; p = 0.14).
Relapse severity
We were unable to locate any relevant comparisons between 30 µg of IM IFN-β-1a once a week and
20 mg of SC GA once daily on outcomes relating to moderate or severe relapses or steroid-treated relapses.
Disability progression
The CombiRx trial191 reported the proportions of patients with EDSS progression at 6 months. Fewer
patients receiving 30 µg of IM IFN-β-1a once a week progressed than patients receiving 20 mg of SC GA
once daily (21.6% vs. 24.8%), but this difference was reported as not statistically significant.
In the trial by Calabrese et al.,188 patients receiving 30 µg of IM IFN-β-1a once a week had a numerically
lower increase in EDSS score at 2 years [0.2 (SD 0.4)] than patients receiving 20 mg of SC GA once daily
[0.3 (SD 0.5)], but formal significance testing was not reported.
Freedom from disease activity
Only the CombiRx trial191 reported freedom from disease activity outcomes for this comparison. In this
trial, the proportion with freedom from disease activity (defined as the absence of exacerbation, EDSS
progression or combined unique lesion activity, that is, no new enhanced lesions, unenhanced T2 lesions
or enlarged unenhanced T2 lesions) was not different between patients receiving 30 µg of IM IFN-β-1a
once a week and patients receiving 20 mg of SC GA once daily (21.2% vs. 19.4%; p = 0.62). This finding
was robust to the inclusion of non-protocol-defined exacerbations (17.1% vs. 16.1%; p = 0.762).
Multiple sclerosis symptoms and health-related quality of life
In the CombiRx trial,191 change from baseline to 36 months was measured for the Multiple Sclerosis
Functional Composite and several of its components, but none of the differences between groups was
statistically significant. Overall, the Multiple Sclerosis Functional Composite score improved slightly in both
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the 30 µg of IM IFN-β-1a once a week group [mean 0.1 (SD 0.5)] and the 20 mg of SC GA once-daily
group [mean 0.2 (SD 0.5)]. Time in seconds to complete the timed 25-foot walk increased slightly in both
groups [0.2 (SD 1.1) vs. 0.2 (SD 1.7)] but time in seconds to complete the nine-hole peg test decreased
slightly [–0.4 (SD 3.8) vs. –0.1 (SD 4.1)]. In addition, both groups improved in terms of the number of
questions answered correctly on the PASAT [3.5 (SD 8.1) vs. 4.3 (SD 7.4)].
Adverse events and mortality
Only the CombiRx trial191 reported AEs or mortality. Full results are available on request. One death
occurred in each of the relevant arms of the CombiRx trial and thus differences were not significant.
Summary of the narrative synthesis: 30 µg of interferon beta-1a intramuscularly once a
week (Avonex) compared with 20 mg of glatiramer acetate subcutaneously once
daily (Copaxone)
Findings from the two studies were mixed with regard to relapse outcomes, but the results of the larger of
the two trials suggested that 30 µg of IM IFN-β-1a once a week was less effective than 20 mg of SC GA
once daily at reducing relapses. Findings for disability progression, combined clinical–MRI measures of
freedom from disease activity and MS symptoms did not suggest a difference between the two drugs.
We were unable to locate any evidence for relapse severity, defined as moderate or severe relapses or
steroid-treated relapses. Mortality was rare and not different between treatments in the CombiRx trial.191
44 µg and 22 µg of interferon beta-1a subcutaneously three times a week (Rebif)
compared with placebo
Our analysis was informed by three trials comparing 44 µg of SC IFN-β-1a three times a week against no
treatment.183,189,207 The REMAIN trial183 used BSC alone as a comparator, whereas the other two trials used
placebo. As noted earlier, the REMAIN trial is of limited interest but is included here for completeness.
The PRISMS trial189 also compared 22 µg of SC IFN-β-1a three times a week against no treatment.
An additional six trials compared 44 µg of SC IFN-β-1a three times a week against other drugs: three
multiarm trials185–188 and three two-arm trials.192–195,197 Comparisons in the EVIDENCE trial193–195 were
discussed earlier.
Relapse outcomes
Both key studies reported relapse outcomes. The PRISMS trial,189 which tested both doses of SC IFN-β-1a
three times a week, followed up 560 patients (n = 184 in the 44-µg arm, n = 189 in the 22-µg arm,
n = 187 in the placebo arm) over 2 years. Relative to placebo, both the 44-µg dose (RR 0.67, 95% CI 0.56
to 0.79) and the 22-µg dose (RR 0.73, 95% CI 0.61 to 0.86) reduced the rate of relapses. The IMPROVE
(Investigating MRI Parameters with Rebif imprOVEd formulation) trial,207 a comparatively short trial that
followed up 180 patients over 16 weeks (n = 120 in the 44-µg arm, n = 60 in the placebo arm), also
showed a substantial decrease in the rate of relapses in those receiving the study drug (RR 0.43, 95% CI
0.23 to 0.82). Time to first relapse outcomes were cursorily presented in the PRISMS trial.189 Both the
44-µg dose and the 22-µg dose delayed time to first relapse, by 5 months and 3 months respectively,
although a significance test was not presented. However, (confidential information has been removed).
Finally, the PRISMS trial189 reported the proportions of patients who were free of relapse. Higher proportions
of patients were relapse free in both treatment groups than in the placebo group at 2 years of follow-up: in
the placebo arm 16% of patients were free of relapses, patients receiving 44 µg of SC IFN-β-1a three times
a week had a 32% chance of being free of relapses (OR 2.57, 95% CI 1.56 to 4.25) and patients receiving
22 µg of SC IFN-β-1a three times a week had a 27% chance of being free of relapses (OR 2.01, 95% CI
1.21 to 3.35).
The REMAIN trial,183 which followed up 30 patients with either RRMS or SPMS for 96 weeks, did not find a
significant difference between arms in time to first relapse or the proportion of patients relapse free.
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Relapse severity
The PRISMS trial189 presented data for both moderate or severe relapses and steroid-treated relapses. Patients
receiving placebo had, on average, more moderate or severe relapses over the course of the study (0.99) than
patients receiving 44 µg of SC IFN-β-1a three times a week (0.62) or patients receiving 22 µg of SC IFN-β-1a
three times a week (0.71). We re-estimated the corresponding RR for 44 µg of SC IFN-β-1a three times a
week as 0.64 (95% CI 0.53 to 0.74) and for 22 µg of SC IFN-β-1a three times a week as 0.72 (95% CI 0.61
to 0.84). Correspondingly, patients receiving 44 µg of SC IFN-β-1a three times a week were more likely to be
free of any moderate or severe relapses (OR 2.32, 95% CI 1.47 to 3.37). Findings were similar for the 22 µg
of SC IFN-β-1a three times a week compared with placebo (OR 2.13, 95% CI 1.41 to 3.21).
The pattern of findings in the PRISMS trial189 for steroid treatment was similar. Patients receiving placebo had,
on average, more courses of steroids for MS relapses over the course of the study (1.39) than patients receiving
44 µg (0.75) or 22 µg (0.97) of SC IFN-β-1a three times a week. We re-estimated the corresponding RR for
44 µg of SC IFN-β-1a three times a week compared with placebo as 0.54 (95% CI 0.46 to 0.63) and for 22 µg
of SC IFN-β-1a three times a week compared with placebo as 0.70 (95% CI 0.61 to 0.80). Correspondingly,
patients receiving 44 µg of SC IFN-β-1a three times a week were more likely to be free of any steroid-treated
relapses (OR 1.99, 95% CI 1.32 to 3.02), as were patients receiving 22 µg of SC IFN-β-1a three times a week
(OR 1.71, 95% CI 1.14 to 2.57).
Disability progression
In the PRISMS trial,189 time to disability progression confirmed at 3 months was slowed by both doses of
SC IFN-β-1a three times a week compared with placebo. The 25th percentile of the distribution of time
to progression was 21.3 months for patients receiving 44 µg of SC IFN-β-1a three times a week and
18.5 months for patients receiving 22 µg of SC IFN-β-1a three times a week, compared with 11.9 months
for patients receiving placebo. Corresponding HRs showed evidence of a statistically significant delay in
progression (44 µg: HR 0.62, 95% CI 0.43 to 0.91; 22 µg: HR 0.68, 95% CI 0.48 to 0.98).
Both the PRISMS trial189 and the IMPROVE trial207 reported the magnitude of change in EDSS score. In the
PRISMS trial,189 compared with placebo, both 44 µg and 22 µg of SC IFN-β-1a three times a week resulted
in a smaller increase in EDSS score, with a difference of 0.25 EDSS points (both p < 0.05). The IMPROVE
trial207 did not report a standard significance test, although the median change in EDSS score in both the
44-µg arm and the placebo arm was 0.
In the REMAIN trial,183 the magnitude of change in EDSS score, time to progression and proportions of
patients with progression were not significantly different between arms.
Freedom from disease activity
We were unable to locate any relevant comparisons between 44 µg or 22 µg of SC IFN-β-1a three times a
week and placebo for the combined clinical–MRI measures of freedom from disease activity.
Multiple sclerosis symptoms and health-related quality of life
The PRISMS trial reported the effects of 44 µg and 22 µg of SC IFN-β-1a three times a week on various MS
symptoms.189,208 As noted in the original trial report,189 patients receiving the 44-µg dose were less likely to
have a sustained worsening in ambulation than those receiving placebo (7% vs. 13%; p < 0.05); however,
the corresponding value for those receiving the 22-µg dose (12%) was not significantly different from that
for placebo. Subsequently, Gold et al.231 reported that, although patients in all three groups increased
their scores from baseline on the Center for Epidemiologic Studies Depression Rating Scale, these changes
were not significantly different between the groups (44 µg: 0.2, 22 µg: 1.8, placebo: 0.9; p = 0.60).
Similarly, the risk of exceeding the cut-off score for depression on this scale was not significantly different
between either the 44-µg arm (RR 0.7, 95% CI 0.3 to 1.6) or the 22-µg arm (RR 0.8, 95% CI 0.3 to 1.8)
and the placebo arm and the proportions of patients exceeding the cut-off on the Beck Hopelessness Scale
were not significantly different between the placebo arm (6.9%) and either the 44-µg arm (6.9%; p = 1.0)
or the 22-µg arm (10.5%; p = 0.55). Finally, data were not presented numerically, but it was reported that
there was no difference between the groups in scores on the General Health Questionnaire or its subscales.
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Adverse events and mortality
All studies presented AEs. Full results are available on request. None of the studies reported deaths related
to the study drugs.
Summary of the narrative synthesis: 44 µg and 22 µg of interferon beta-1a subcutaneously
three times a week (Rebif) compared with placebo
Findings from two trials suggested a beneficial effect of 44 µg of SC IFN-β-1a three times a week
compared with placebo for relapse outcomes. Additionally, findings from the PRISMS trial189 suggested a
beneficial effect of 44 µg of SC IFN-β-1a three times a week on relapse severity (both moderate/severe
relapses and steroid-treated relapses) and on delaying disability progression. Findings from the PRISMS
trial189,208 also suggested a beneficial effect of 44 µg of SC IFN-β-1a three times a week on ambulation, but
not mental health. Findings for the 22-µg dose in the PRISMS trial189,208 were similar except for ambulation.
Mortality was not reported.
44 µg of interferon beta-1a subcutaneously three times a week (Rebif) compared with
250 µg of interferon beta-1b subcutaneously every other day (Betaferon/Extavia)
Three trials compared 44 µg of SC IFN-β-1a three times a week against 250 µg of SC IFN-β-1b every other
day.185–187,197 An additional trial182 compared these drugs with regard to AEs.
Relapse outcomes
Assessment of relapse outcomes for this comparison relied on two small studies with very different follow-up
times. In the study by Etemadifar et al.,185 over 2 years of follow-up, patients receiving 44 µg of SC IFN-β-1a
three times a week had 66 relapses whereas patients receiving 250 µg of SC IFN-β-1b every other day had
65 relapses (n = 30 in both groups). We estimated this as a RR of 1.02 (95% CI 0.72 to 1.43). In the
REFORMS trial,197 patients receiving 44 µg of SC IFN-β-1a three times a week had an ARR of 0.15 whereas
patients receiving 250 µg of SC IFN-β-1b every other day had an ARR of 0.11. This difference was statistically
significant (p < 0.001), although this was a relatively small trial (n = 129), patients were followed up for only
12 weeks and patient relapses were self-reported rather than assessed by a neurologist.
In the study by Etemadifar et al.,185 the proportion of patients without relapses at 2 years was numerically
higher in the group receiving 44 µg of SC IFN-β-1a three times a week than in the group receiving 250 µg
of SC IFN-β-1b every other day (56.7% vs. 43.3%), but no pairwise significance testing was performed.
Relapse severity
We were unable to find any comparisons between 44 µg of SC IFN-β-1a three times a week and 250 µg of
SC IFN-β-1b every other day for outcomes relating to moderate or severe relapses or steroid-treated relapses.
Disability progression
Analysis of disability progression in both trials was by magnitude of EDSS score change, although both
trials reported inadequate details of the analysis. In the study by Etemadifar et al.,185 patients receiving
44 µg of SC IFN-β-1a three times a week had a decrease in EDSS score of 0.3 (95% CI 0.03 to 0.5),
whereas patients receiving 250 µg of SC IFN-β-1b every other day had a decrease in EDSS score of 0.7
(95% CI 0.5 to 0.9). A pairwise significance test was not performed. Patients in the study by Mokhber
et al.186,187 in both treatment groups also showed a decrease in EDSS score, but in the opposite direction
(44 µg: –1.0, p = 0.001; 250 µg: –0.6, p = 0.028). Again, a pairwise significance test was not performed.
Freedom from disease activity
We were unable to find any comparisons between 44 µg of SC IFN-β-1a three times a week and 250 µg of
SC IFN-β-1b every other day for combined clinical–MRI measures of freedom from disease activity.
Multiple sclerosis symptoms and health-related quality of life
As noted previously, analyses in the study by Mokhber et al.186 for cognitive function found no significant
differences between the groups, except for the symbol digit modalities test. Post hoc analyses indicated
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that patients receiving 44 µg of SC IFN-β-1a three times a week improved more than those receiving
250 µg of SC IFN-β-1b every other day on the symbol digit modalities test and the PASAT-easy.
Across the QoL domains tested in the study by Mokhber et al.,187 44 µg of SC IFN-β-1a three times a week was
not significantly different from 250 µg of SC IFN-β-1b every other day except for overall mental health aspects
of HRQoL, with patients receiving 250 µg of SC IFN-β-1b every other day improving significantly more.
Adverse events and mortality
Adverse events were reported only in the AVANTAGE trial182 and the REFORMS trial.197 Only the AVANTAGE
trial182 reported mortality, with no events occurring in either study arm. Full results are available on request.
Summary of the narrative synthesis: 44 µg of interferon beta-1a subcutaneously three
times a week (Rebif) compared with 250 µg of interferon beta-1b subcutaneously every
other day (Betaferon/Extavia)
Findings were derived from three small trials and should thus be treated with caution. The two trials
reporting relapse outcomes disagreed on the comparative effectiveness of these two drugs, although there
was some evidence from the REFORMS trial197 that patients receiving 44 µg of SC IFN-β-1a three times a
week had a higher ARR. Findings for disability progression, MS symptoms and HRQoL were inconsistent
and poorly reported. We were unable to find comparisons for relapse severity or combined clinical–MRI
measures of freedom from disease activity. No deaths were reported.
44 µg of interferon beta-1a subcutaneously three times a week (Rebif) compared with
20 mg of glatiramer acetate subcutaneously once daily (Copaxone)
Two trials compared 44 µg of SC IFN-β-1a three times a week against 20 mg of SC GA once daily.188,192
Relapse outcomes
In the study by Calabrese et al.,188 patients receiving 44 µg of SC IFN-β-1a three times a week had a
numerically lower ARR than patients receiving 20 mg of SC GA once daily after 2 years of follow-up
[0.4 (SD 0.6) vs. 0.5 (SD 0.4)], but formal significance testing was not reported and relapses were analysed
using a normal distribution. We re-estimated this as a RR of 0.80 (95% CI 0.52 to 1.23). In the larger
REGARD trial,192 764 patients were followed up for 96 weeks. The ARR was not significantly different
between patients receiving 44 µg of SC IFN-β-1a three times a week and patients receiving 20 mg of SC
GA once daily (0.30 vs. 0.29; p = 0.828).
The REGARD trial192 did not find a significant difference in time to first relapse between patients receiving
44 µg of SC IFN-β-1a three times a week and those receiving 20 mg of SC GA once daily (HR 0.94, 95% CI
0.74 to 1.21); there was also no significant difference between the groups in the proportion of patients
who were free of relapses at 96 weeks (62% vs. 62%; p = 0.96).
Relapse severity
In the REGARD trial,192 the ARR for steroid-treated relapses was not significantly different between patients
receiving 44 µg of SC IFN-β-1a three times a week and those receiving 20 mg of SC GA once daily
(0.19 vs. 0.17; p = 0.386).
Disability progression
The REGARD trial192 reported the proportions of patients with disability progression confirmed at 6 months.
The proportions were not significantly different between patients receiving 44 µg of SC IFN-β-1a three
times a week (11.7%) and those receiving 20 mg of SC GA once daily (8.7%) (p = 0.117).
In the study by Calabrese et al.,188 patients receiving 44 µg of SC IFN-β-1a three times a week had a
numerically lower increase in EDSS score at 2 years [0.2 (SD 0.5)] than patients receiving 20 mg of SC GA
once daily [0.3 (SD 0.5)], but formal significance testing was not reported.
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Freedom from disease activity
We were unable to locate any comparisons between 44 µg of SC IFN-β-1a three times a week and 20 mg
of SC GA once daily for combined clinical–MRI measures of freedom from disease activity.
Multiple sclerosis symptoms and health-related quality of life
We were unable to locate any comparisons between 44 µg of SC IFN-β-1a three times a week and 20 mg
of SC GA once daily for MS symptoms or HRQoL.
Adverse events and mortality
Adverse events and mortality were reported in the REGARD trial.192 Only one death occurred, in the IFN arm,
and thus mortality was not significantly different between groups. Full results are available on request.
Summary of the narrative synthesis: 44 µg of interferon beta-1a subcutaneously three
times a week (Rebif) compared with 20 mg of glatiramer acetate subcutaneously once
daily (Copaxone)
Findings from two trials did not suggest a difference between the two drugs for relapse outcomes, relapse
severity or disability progression. We could not locate comparisons relating to combined clinical–MRI
measures of freedom from disease activity or MS symptoms or HRQoL. There was no difference in
mortality between the groups.
250 µg of interferon beta-1b subcutaneously every other day (Betaferon/Extavia)
compared with placebo
We included two trials comparing 250 µg of SC IFN-β-1b every other day with placebo.209–211 Schwartz
et al.181 examined QoL outcomes only and used BSC as the comparator instead of placebo.
An additional six trials compared 250 µg of SC IFN-β-1b every other day against other drugs: two multiarm
trials185–187 and four two-arm trials.184,190,196,197 Comparisons from the trials by Etemadifar et al.185 and
Mokhber et al.186,187 and the INCOMIN trial196 and REFORMS trial197 have been discussed in previous sections.
Relapse outcomes
Both studies reporting ARRs suggested a beneficial effect of 250 µg of SC IFN-β-1b every other day,
although only the trial by the IFNB Multiple Sclerosis Study Group (IFNB MSSG)209,210 may have been
powered to detect a difference between the groups. In the IFNB MSSG trial,209,210 247 patients in the
relevant arms were followed up for variable amounts of time, with the initial 2-year study phase continuing
into a blinded extension; thus, some patients were followed for up to 5.5 years, with a median follow-up
of 46.0 months in the placebo arm and 48.0 months in the relevant study drug arm. At the end of the
study, patients receiving 250 µg of SC IFN-β-1b every other day had a lower ARR than patients receiving
placebo (0.78, 95% CI 0.70 to 0.88 vs. 1.12, 95% CI 1.02 to 1.23; p = 0.0006). In a comparatively small
trial, Knobler et al.211 followed up 30 patients over 3 years, including a 6-month dose-finding period at the
start of the study. The 24 patients receiving 250 µg of SC IFN-β-1b every other day had an ARR of 0.7
whereas the six patients receiving placebo had an ARR of 0.9. This difference was not significant (p = 0.33).
Both studies also reported information on time to first relapse. Knobler et al.211 reported that the median
time to first relapse was delayed, but not significantly so, in patients receiving 250 µg of SC IFN-β-1b every
other day compared with patients receiving placebo (14 months vs. 2 months; log-rank p = 0.07). The
comparatively larger IFNB MSSG trial209 reported a similar finding at the 3-year follow-up, albeit of a
smaller magnitude and rising to statistical significance. The median time to first exacerbation was delayed
in patients receiving 250 µg of SC IFN-β-1b every other day compared with placebo (264 days vs. 147 days;
log-rank p = 0.028).
The proportions of patients who were free of relapse were also available only at the 3-year follow-up for
the IFNB MSSG trial.209 The proportions free of relapse were not significantly different between the groups
(250 µg of SC IFN-β-1b every other day 21.8% vs. placebo 13.8%; p = 0.097). Three-year results from
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the study by Knobler et al.211 showed a similar trend (42% vs. 17%), with these findings also not
significant (p = 0.37).
Relapse severity
Relapse severity was reported based on both 2-year and final data from the IFNB MSSG trial,209,210 but
only the 2-year data were usable. At 2 years of follow-up, patients receiving 250 µg of SC IFN-β-1b every
other day had a lower ARR for moderate or severe relapses than those receiving placebo (0.23 vs. 0.45;
p = 0.002). Similar findings based on final data were reported, but only a p-value (p = 0.012) for a
relationship in the same direction was provided. Knobler et al.211 did not find a significant relationship for
‘attack severity’, although the findings were reported only as a non-significant p-value (p = 0.67) and
relapse severity was not defined.
Disability progression
The IFNB MSSG trial210 reported that 250 µg of SC IFN-β-1b every other day delayed disability progression
confirmed at 3 months, but not significantly so, with a median time to progression of 4.79 years, compared
with 4.18 years in the placebo group (log-rank p = 0.096). The proportions of patients with confirmed
progression showed a similar trend (35% vs. 46%). We re-estimated this as a HR of 0.71 (95% CI 0.48 to
1.06). Knobler et al.211 examined change in EDSS score from baseline between the groups but noted only
that the difference between the groups was not statistically significant (p = 0.42).
Freedom from disease activity
We were unable to locate any relevant comparisons between 250 µg of SC IFN-β-1b every other day and
placebo for combined clinical–MRI measures of freedom from disease activity.
Multiple sclerosis symptoms and health-related quality of life
In the study by Schwartz et al.,181 34 patients receiving 250 µg of SC IFN-β-1b every other day were compared
with 45 patients receiving BSC. Over the course of a year, there was no difference between the groups in
quality-adjusted time without symptoms and toxicity, measured in months (10.6 vs. 10.4; p = 0.50).
Adverse events and mortality
Adverse events were reported in the IFNB MSSG trial210 and the study by Knobler et al.211 None of the
studies reported mortality. Full results are available on request.
Summary of the narrative synthesis: 250 µg of interferon beta-1b subcutaneously every
other day (Betaferon/Extavia) compared with placebo
Findings from two studies suggested a beneficial effect of 250 µg of SC IFN-β-1b every other day on
relapse outcomes compared with placebo (although not on the proportions of patients who were relapse
free). Findings from the IFNB MSSG trial209,210 suggested a reduction in the rate of moderate or severe
relapses in the group receiving 250 µg of SC IFN-β-1b every other day, but findings from the study by
Knobler et al.211 were uninterpretable. Neither study found evidence of a delay in time to disability
progression. One small study comparing 250 µg of SC IFN-β-1b every other day against BSC did not find
differences in HRQoL over a year. We were unable to find any comparisons for combined clinical–MRI
measures of freedom from disease activity. None of the studies reported mortality.
250 µg of interferon beta-1b subcutaneously every other day (Betaferon/Extavia)
compared with 20 mg of glatiramer acetate subcutaneously once daily (Copaxone)
Two trials compared 250 µg of SC IFN-β-1b every other day against 20 mg of SC GA once daily.184,190
Relapse outcomes
Both the BECOME trial184 and the larger BEYOND (Betaferon Efficacy Yielding Outcomes of a New Dose)
trial190 reported ARRs. In the BECOME trial,184 75 patients were followed up for up to 2 years. Patients
receiving 250 µg of SC IFN-β-1b every other day did not have a significantly different ARR from patients
receiving 20 mg of SC GA once daily (0.37 vs. 0.33; p = 0.68). Findings from the BEYOND trial,190 in which
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1345 patients from the relevant trial arms were followed up for at least 2 and up to 3.5 years, suggested a
similar trend (ARR 0.36 vs. 0.34; one-tailed p = 0.79). This was expressed using a Cox proportional hazards
model with modification for repeated events (HR 1.06, 95% CI 0.89 to 1.26).
Time to first relapse was also not significantly different between arms in either study. In the BECOME
trial,184 of patients who had relapses, the median time to first relapse for those receiving 250 µg of SC
IFN-β-1b every other day (123 days) was not very different from the median time to first relapse for those
receiving 20 mg of SC GA once daily (121 days), with a non-significant log-rank test on the whole sample
(p = 0.12). In the BEYOND trial,190 there was no substantial difference in days to first relapse for patients
at the 25th percentile (250 µg of SC IFN-β-1b every other day 283 days vs. 20 mg of SC GA once daily
271 days; one-sided log-rank p = 0.75). This was supported by the proportions of patients who were
relapse free at 2 years, estimated from a Kaplan–Meier model, which were very similar (59% vs. 58%).
Finally, only the BECOME trial184 reported the empirical proportions of patients relapsing. Fewer patients
receiving 250 µg of SC IFN-β-1b every other day were relapse free than patients receiving 20 mg of SC GA
once daily, but this difference was not significant (53% vs. 72%; p = 0.10).
Relapse severity
Only the BEYOND trial190 reported ARRs for severity of relapse. ARRs for major relapse were not
significantly different between patients receiving 250 µg of SC IFN-β-1b every other day and those
receiving 20 mg of SC GA once daily (0.19 vs. 0.18; one-sided p = 0.36). Time to first major relapse was
also not significantly different between the arms, with both arms having proportions with a relapse at
2 years of 27%, as predicted by a Kaplan–Meier model (log-rank p = 0.56).
Both studies reported the empirical proportions of patients receiving steroid treatment for MS. In the
BECOME trial,184 more patients receiving 250 µg of SC IFN-β-1b every other day (44%) required steroid
treatment for relapses than patients receiving 20 mg of SC GA once daily (23%), but this difference was
only of marginal significance (p = 0.09). In contrast, the proportions of patients requiring steroid treatment
for relapses were not significantly different in the BEYOND trial190 (34% vs. 32%; p = 0.43).
Disability progression
The BEYOND trial190 reported time to disability progression confirmed at 3 months. Because median time
to progression was not reached, the time to progression at the 10th percentile was reported. The 10th
percentile of patients receiving 250 µg of SC IFN-β-1b every other day progressed after 274 days, whereas
patients receiving 20 mg of SC GA once daily progressed after 268 days (log-rank p = 0.35). Alternative
estimates were provided based on Kaplan–Meier models, in which the probability of progression at the
end of 2 years was 21% in those receiving 250 µg of SC IFN-β-1b every other day and 20% in those
receiving 20 mg of SC GA once daily (log-rank p = 0.68). We estimated a HR of 1.06 (95% CI 0.81 to
1.37) from these statistics.
In a separate publication to the main trial report, the BECOME trial212 reported time to disability
progression confirmed at 6 months. The empirical proportions of patients progressing in each arm were
dissimilar (250 µg of SC IFN-β-1b every other day 12.1% vs. 20 mg of SC GA once daily 17.6%), but the
log-rank test was non-significant (p = 0.51). Based on these statistics, we estimated a HR of 0.66 (95% CI
0.19 to 2.28). The BECOME trial212 also reported progression based on the Multiple Sclerosis Functional
Composite, in which an increase of 0.2 SDs confirmed at 6 months constitutes evidence of progression.
The same trend was apparent (5.7% vs. 10.3%, log-rank p = 0.39).
Freedom from disease activity
We were unable to locate any relevant comparisons between 250 µg of SC IFN-β-1b every other day and
20 mg of SC GA once daily for combined clinical–MRI measures of freedom from disease activity.
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Multiple sclerosis symptoms and health-related quality of life
We were unable to locate any relevant comparisons between 250 µg of SC IFN-β-1b every other day and
20 mg of SC GA once daily for MS symptoms or HRQoL. However, the BECOME trial212 did present results
for the Multiple Sclerosis Functional Composite, discussed earlier in Disability progression.
Adverse events and mortality
Both studies reported AEs, but only the BEYOND trial190 reported mortality. The difference between the
groups was not significant for mortality, although only one death occurred, in the GA arm. Full results are
available on request.
Summary of the narrative synthesis: 250 µg of interferon beta-1b subcutaneously every
other day (Betaferon/Extavia) compared with 20 mg of glatiramer acetate subcutaneously
once daily (Copaxone)
Findings from two trials – one small and one large – did not suggest a difference between the two drugs
in terms of relapse outcomes, relapse severity or disability progression. We were unable to locate any
comparisons for combined clinical–MRI measures of freedom from disease activity. The differences
between the groups was not significant for mortality.
125 µg of pegylated interferon beta-1a subcutaneously every 2 weeks (Plegridy)
compared with placebo
We included one trial comparing 125 µg of SC pegylated IFN-β-1a every 2 weeks against placebo.213 We
were unable to locate any trials including comparisons between 125 µg of SC pegylated IFN-β-1a every
2 weeks and other drugs. In its placebo-controlled phase, the ADVANCE trial213 compared 125 µg of SC
pegylated IFN-β-1a every 2 weeks and every 4 weeks with placebo for 48 weeks. In total, 1012 patients in
the relevant arms were analysed.
Relapse outcomes
Participants receiving 125 µg of SC pegylated IFN-β-1a every 2 weeks showed a decrease in ARR (RR 0.644,
95% CI 0.500 to 0.831).213 Time to first relapse was also delayed in patients receiving the active drug (HR
0.61, 95% CI 0.47 to 0.80).
Relapse severity
Publications arising from this study did not report relapse severity.
Disability progression
Participants receiving 125 µg of SC pegylated IFN-β-1a every 2 weeks experienced a delay in time to
disability progression confirmed at 3 months (HR 0.62, 95% CI 0.40 to 0.97).213 As reported in the
Summary of Product Characteristics filed by the European Medicines Agency,234 the time to disability
progression confirmed at 6 months was longer in patients receiving the study drug than in patients
receiving placebo (HR 0.46, 95% CI 0.26 to 0.81).
Freedom from disease activity
In the ADVANCE trial, measures of freedom from disease activity included mixed clinical and MRI,
clinical-only and MRI-only definitions and were reported in a separate publication214 to the main study
report. As stated in the methods, we report here the mixed clinical and MRI definition, which included
both the absence of relapses and the absence of onset of disability progression confirmed at 3 months, as
well as no gadolinium-enhancing lesions and no new or newly enlarging T2 hyperintense lesions. Between
baseline and week 48 of the trial, 33.9% of patients (n = 466 in this analysis) receiving the study drug had
no evidence of disease activity, whereas 15.1% of patients (n = 484 in this analysis) receiving placebo had
no evidence of disease activity (OR 2.89, 95% CI 2.11 to 3.95). This finding was robust to sensitivity
analysis of data missingness.
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Multiple sclerosis symptoms and health-related quality of life
In the ADVANCE trial,215 patients receiving 125 µg of SC pegylated IFN-β-1a every 2 weeks did not
significantly worsen over 48 weeks on the Multiple Sclerosis Impact Scale (MSIS-29) physical subscale
(mean change 0.08, 95% CI –1.10 to 1.27), whereas placebo patients did (mean change 1.24, 95% CI
0.05 to 2.44). Both groups improved on the MSIS-29 psychological subscale, with no statistically significant
difference between the groups (pegylated IFN-β-1a: –2.06, 95% CI –3.58 to –0.53; placebo: –2.17, 95% CI
–3.63 to –0.70). Participants also completed the Short Form questionnaire-12 items (both the physical
component summary and the mental component summary), EQ-5D and EQ-5D visual analogue scale. None
of the differences between groups or within groups was statistically significant (the authors did not present
specific data), but patients receiving 125 µg of SC pegylated IFN-β-1a every 2 weeks did show a significant
improvement on the visual analogue scale (mean change 2.06, 95% CI 0.58 to 3.54).
Adverse events and mortality
The ADVANCE trial213 reported AEs and mortality. Full results are available on request. Differences between
groups for mortality were not significant, with one event occurring in the study drug arm and two events
occurring in the placebo arm.
Summary of the narrative synthesis: 125 µg of pegylated interferon beta-1a subcutaneously
every 2 weeks (Plegridy) compared with placebo
Findings from one study included in this comparison suggested a beneficial effect of 125 µg of SC
pegylated IFN-β-1a every 2 weeks compared with placebo for relapse outcomes, disability progression and
freedom from disease activity. For HRQoL measures, 125 µg of SC pegylated IFN-β-1a every 2 weeks was
not different from placebo. Relapse severity outcomes were not reported. Groups were not significantly
different with respect to mortality.
20 mg of glatiramer acetate subcutaneously once daily and 40 mg of glatiramer acetate
subcutaneously three times a week (Copaxone) compared with placebo
We included five trials comparing 20 mg of SC GA once daily against placebo.170,216–220 One trial221 tested
40 mg of SC GA three times a week against placebo.
Additionally, one multiarm trial188 and four two-arm trials184,190–192 compared 20 mg of SC GA once daily
against other drugs. These comparisons have been discussed in the previous sections.
Relapse outcomes
All five trials comparing 20 mg of SC GA once daily against placebo reported relapse rates, as did the trial
comparing 40 mg of SC GA three times a week against placebo. The study by Bornstein et al.170 followed
up 48 patients over 2 years. There were 16 relapses over 2 years in the 25 patients receiving 20 mg of SC
GA once daily and 62 relapses in the 23 patients receiving placebo, which gives an estimated RR of 0.25
(95% CI 0.14 to 0.43). In another early trial by the Copolymer 1 Multiple Sclerosis Study Group (Cop1
MSSG),217,218 251 patients were followed up over at least 2 years, with an extension of up to 11 months.
At 2 years, the ARR in patients receiving 20 mg of SC GA once daily was 0.59, whereas the ARR in
patients receiving placebo was 0.84.217 This difference was statistically significant (p = 0.007). Subsequent
studies found similar reductions in ARR in the treatment arms. In a trial by the European/Canadian
Glatiramer Acetate Study Group (ECGASG),219 which followed up 239 patients over 9 months, the ARR in
the study drug group was 0.81 whereas the ARR in the placebo group was 1.21 (RR 0.67; p = 0.012). The
CONFIRM (Comparator and an Oral Fumarate in Relapsing–Remitting Multiple Sclerosis) trial216 followed up
713 patients in the relevant study arms for 2 years and also found a significant difference in ARRs between
the groups (20 mg of SC GA once daily 0.29 vs. placebo 0.40; RR 0.71, 95% CI 0.55 to 0.93). However, in
a trial following up 357 patients receiving branded GA and 84 patients receiving placebo for 9 months,220
the ARRs were not substantially different between groups (20 mg of SC GA once daily 0.40, 95% CI 0.26
to 0.62 vs. placebo 0.38, 95% CI 0.22 to 0.66), although a standard significance test was not presented.
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The GALA (Glatiramer Acetate Low-Frequency Administration) trial221 compared 40 mg of SC GA three
times a week against placebo (40 mg of SC GA three times a week, n = 943 vs. placebo, n = 461) over
12 months. Patients receiving the study drug had a significantly lower ARR than patients receiving placebo
(40 mg of SC GA three times a week 0.33, 95% CI 0.28 to 0.39 vs. placebo 0.51, 95% CI 0.42 to 0.61),
with an associated significant RR (0.66, 95% CI 0.54 to 0.80).
Two studies reported time to relapse. Including the extension phase, patients receiving 20 mg of SC GA
once daily in the Cop1 MSSG trial218 had a delayed time to first relapse compared with patients receiving
placebo, but this difference was not significant (median days to first relapse 287 vs. 198; p = 0.057).
However, in the larger CONFIRM trial,216 patients receiving 20 mg of SC GA once daily did have a significant
delay in time to relapse (HR 0.71, 95% CI 0.55 to 0.92). In the GALA trial,221 patients receiving 40 mg of SC
GA three times a week also had a longer median time to first relapse (393 days vs. 377 days), with a HR of
0.61 (95% CI 0.49 to 0.74).
Finally, greater empirical proportions of patients receiving 20 mg of SC GA once daily tended to be free
of relapse than patients receiving placebo, but this trend was not completely consistent. In the study by
Bornstein et al.,170 56% of patients receiving the study drug were relapse free at 2 years compared with
26% of patients receiving placebo (adjusted OR 4.6; p = 0.036). Similarly, the Cop1 MSSG trial218 found
that, over the whole trial, patients receiving the study drug were more likely to be free of relapses than
those receiving placebo (33.6% vs. 24.6%; p = 0.002). In the ECGASG trial219 this trend did not rise to
significance (55.5% vs. 49.2%; OR 1.47, 95% CI 0.84 to 2.56) and in the GATE (Glatiramer Acetate
Clinical Trial to Assess Equivalence with Copaxone) trial220 the proportions who were relapse free were
not substantially different between the groups (73.9% vs. 73.8%), although a significance test was not
provided. In the GALA trial,221 patients receiving 40 mg of SC GA three times a week were more likely to
be free of relapses than patients receiving placebo (77.0% vs. 65.5%; OR 1.93, 95% CI 1.49 to 2.49).
Relapse severity
In the ECGASG trial,219 patients receiving 20 mg of SC GA once daily had fewer steroid-treated relapses
than those receiving placebo (54 vs. 84). We estimated this as a RR for steroid-treated relapses of 0.65
(95% CI 0.46 to 0.91). The proportion of patients with steroid-treated relapses was correspondingly lower
in the study drug arm (33.6% vs. 39.2%), but this was not tested for significance. In the GALA trial,221
patients receiving 40 mg of SC GA three times weekly had a lower ARR (0.30, 95% CI 0.25 to 0.36) for
‘severe’ relapses, defined as steroid-treated or hospitalised relapses, than patients receiving placebo
(ARR 0.47, 95% CI 0.38 to 0.57). This translated into a RR of 0.64 (95% CI 0.53 to 0.79).
Disability progression
Three studies170,216,218 presented data on time to disability progression confirmed at 3 months, whereas only
the CONFIRM trial216 presented data on time to progression confirmed at 6 months. Studies suggested a
beneficial, but generally not significant, impact of 20 mg of SC GA once daily on confirmed disability
progression. In the study by Bornstein et al.,170 the median time to progression confirmed at 3 months was
not reached for patients receiving 20 mg of SC GA once daily, but was 18 months for patients receiving
placebo. This difference was significant (log-rank p = 0.05). Together with the proportions of patients with
progression of 20% in the study drug arm and 48% in the placebo arm, we estimated the HR of progression
as 0.37 (95% CI 0.14 to 1.00). In the Cop1 MSSG trial,218 the probability of non-progression was 76.8%
in the 20 mg of SC GA once-daily arm and 70.6% in the placebo arm. Using the value from a related
significance test (p = 0.199), we estimated the HR as 0.76 (95% CI 0.50 to 1.16). Finally, the CONFIRM
trial216 did not find that 20 mg of SC GA once daily slowed time to progression confirmed at 3 months
(HR 0.93, 95% CI 0.63 to 1.37). This finding was similar when disability progression was confirmed at
6 months (HR 0.87, 95% CI 0.55 to 1.38).
Only two studies presented data on the proportions of patients with confirmed disability progression
in comparisons between 20 mg of SC GA once daily and placebo. As noted above, in the study by
Bornstein et al.,170 20% of patients receiving 20 mg of SC GA once daily progressed over 2 years, whereas
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48% of patients receiving placebo progressed. In univariate analyses, this finding was not significant
(p = 0.064), but multivariate analyses found a significant effect on the probability of progression
(p = 0.033). In the Cop1 MSSG trial,218 the proportion with progression confirmed at 3 months was 23.2%
in patients receiving 20 mg of SC GA once daily and 29.4% in patients receiving placebo over the whole
trial. In the GALA trial,221 which compared 40 mg of SC GA three times weekly against placebo, 95.5% of
patients receiving the study drug were free of confirmed progression compared with 96.3% of patients
receiving placebo, but a formal significance test was not presented.
Finally, the magnitude of change in EDSS score was reported by most studies, with changes small across
studies. In the study by Bornstein et al.,170 the findings were presented as the proportions improving or
worsening by magnitude of improvement/worsening. We estimated that patients receiving 20 mg of SC
GA once daily improved by 0.12 EDSS points and patients receiving placebo worsened by 0.74 EDSS
points, with a significant difference between groups (p < 0.05). In the Cop1 MSSG trial,218 patients
receiving 20 mg of SC GA once daily did not show a significant improvement in EDSS score (–0.11, 95%
CI –0.31 to 0.10) whereas patients receiving placebo showed a significant worsening (0.34, 95% CI 0.13
to 0.54). This difference was statistically significant (p = 0.006). In the ECGASC trial,219 mean EDSS change
from baseline was not significantly different between groups (20 mg of SC GA once daily 0.02 vs. placebo
0.05), but a p-value or CIs were not presented. In the GATE trial,220 neither patients receiving the study
drug (–0.08, 95% CI –0.19 to 0.03) nor patients receiving placebo (–0.02, 95% CI –0.17 to 0.14) showed
a significant improvement in EDSS score. Change in the GALA trial221 was also negligible [40 mg of SC GA
three times weekly 0.0 (SD 0.6) vs. placebo 0.1 (SD 0.6)].
Freedom from disease activity
The GATE trial220 was the only study that reported combined clinical–MRI findings for freedom from
disease activity. The proportion free from disease activity was slightly greater in the arm receiving 20 mg of
SC GA once daily than in the placebo arm (9.2% vs. 7.1%), with similar findings once proportions were
adjusted for stratification variables (8.5% vs. 6.6%). A formal significance test was not presented.
Multiple sclerosis symptoms and health-related quality of life
The CONFIRM trial230 presented data for HRQoL disaggregated by subscale of the Short Form
questionnaire-36 items (SF-36). Compared with placebo, which showed a negative trend, change from
baseline in the 20 mg of SC GA once-daily group was positive for the whole scale and the two groups
were significantly different on the physical component summary (p = 0.0259). However, the groups were
not significantly different on the mental component summary. The group receiving 20 mg of SC GA once
daily significantly improved (p < 0.05) compared with the group receiving placebo with regard to physical
functioning (0.3 vs. –2.2), bodily pain (2.3 vs. –1.3) and general health (1.9 vs. –0.6), but not physical
(0.3 vs. –2.2) or emotional (1.4 vs. –3.3) aspects of role limitation, vitality (1.1 vs. 0.4), social functioning
(–0.6 vs. –0.1) or mental health (0.3 vs. 0.6). Changes in EQ-5D scores were not presented, but scores
were stated to be stable in all groups over the course of the study. Compared with patients receiving
placebo, patients receiving 20 mg of SC GA once daily were not more likely to have been stable or
improved in either the physical component (OR 1.24, 95% CI 0.83 to 1.85) or the mental component
(1.22, 95% CI 0.82 to 1.83) of the SF-36.
In the Cop1 MSSG trial,217 at 2 years the mean ambulation index scores were similar between patients
receiving 20 mg of SC GA once daily (0.27) and patients receiving placebo (0.28).
Adverse events and mortality
We stratified comparisons by type of placebo. All studies reported AEs but only the GALA,221 GATE220
and CONFIRM216 trials reported deaths. Only one death occurred in trials with matched placebos, in the
placebo arm of the GALA trial;221 in the CONFIRM trial,216 one death occurred in each arm. Full results are
available on request.
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Summary of the narrative synthesis: 20 mg of glatiramer acetate subcutaneously once
daily and 40 mg of glatiramer acetate subcutaneously three times a week (Copaxone)
compared with placebo
Taken together, findings from the five trials testing 20 mg of SC GA once daily and the one trial testing
40 mg of SC GA three times a week suggested a beneficial effect on relapse outcomes. Both trials (20 mg
of GA;219 40 mg of GA221) reporting relapse severity outcomes also found that the study drug decreased
the rate of steroid-treated relapses. Findings for disability progression were less convincing and studies
generally did not present significant results. Only one study presented combined clinical–MRI measures of
freedom from disease activity and this study did not show a large difference between groups, although
significance testing was not undertaken. One study showed some effects of 20 mg of SC GA once daily on
HRQoL measures. Groups were not significantly different with regard to mortality.
Meta-analyses: relapse rate
Pairwise meta-analyses
Direct evidence from comparisons against placebo is shown in Figure 5. All drugs had a statistically
significant beneficial effect on relapse rate compared with placebo. Findings for 125 µg of SC pegylated
IFN-β-1a every 2 weeks, 40 mg of SC GA three times weekly and 22 µg of SC IFN-β-1a three times weekly
Study
0.5 1.0
Favours active drug Favours placebo
GA 20 mg SC daily vs. placebo
Bornstein 1987170
CONFIRM 2012216
Cop1 MSSG 1995217
ECGASG 2001219
GATE 2015220
Subtotal (I2 = 72.9%, p = 0.005)
IFN-β-1a 22 µg SC thrice weekly vs. placebo 
PRISMS 1998189
Subtotal (I2 = .%, p = .)
GA 40 mg SC thrice weekly vs. placebo
GALA 2013221
Subtotal (I2 = .%, p = .)
IFN-β-1a 30 µg IM weekly vs. placebo
BRAVO 2014198
Kappos 2011199
MSCRG 1996200
Subtotal (I2 = 0.0%, p = 0.479)
IFN-β-1a 44 µg SC thrice weekly vs. placebo
IMPROVE 2012207
PRISMS 1998189
Subtotal (I2 = 42.6%, p = 0.187)
IFN-β-1a pegylated 125 µg SC every 2 weeks vs. placebo
ADVANCE 2014213
Subtotal (I2 = .%, p = .)
IFN-β-1b 250 µg SC every other day vs. placebo
IFNB MSSG 1995209
Knobler 1993211
Subtotal (I2 = 0.0%, p = 0.681)
Note: weights are from random-effects analysis
0.25 (0.14 to 0.43) 
0.71 (0.55 to 0.93) 
0.70 (0.57 to 0.86) 
0.67 (0.49 to 0.92) 
1.05 (0.52 to 2.12) 
0.62 (0.46 to 0.84)
0.66 (0.54 to 0.80) 
0.66 (0.54 to 0.80) 
0.73 (0.61 to 0.87) 
0.73 (0.61 to 0.87) 
0.74 (0.60 to 0.92) 
0.56 (0.30 to 1.05) 
0.82 (0.67 to 0.99) 
0.77 (0.67 to 0.88) 
0.43 (0.23 to 0.81) 
0.67 (0.56 to 0.80) 
0.60 (0.41 to 0.87) 
0.64 (0.50 to 0.83) 
0.64 (0.50 to 0.83) 
0.70 (0.60 to 0.81) 
0.78 (0.47 to 1.29) 
0.70 (0.61 to 0.81) 
RR (95% CI)
14.91
24.48
26.54
22.75
11.32
100.00
100.00
100.00
100.00
100.00
42.61
5.02
52.36
100.00
25.22
74.78
100.00
100.00
100.00
92.13
7.87
100.00
% weight
2.00.1
FIGURE 5 Pairwise meta-analyses: ARRs for active drug vs. placebo trials in RRMS.
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all relied on one study. Comparisons that relied on multiple studies were diverse in terms of heterogeneity:
heterogeneity ranged from an I2 of 0% (250 µg of SC IFN-β-1b every other day, 30 µg of IM IFN-β-1a once
a week) to an I2 of 43% (44 µg of SC IFN-β-1a three times weekly) and 73% (20 mg of SC GA once daily).
However, there were too few studies in each comparison to enable exploration of heterogeneity.
Direct evidence from comparisons between active drugs is shown in Figure 6. None of the pooled
comparisons showed evidence of a statistically significant effect favouring one drug over another.
Although several analyses had high I2 values each comparison had too few studies to permit exploration
of heterogeneity.
Network meta-analyses
The set of studies reporting ratios of relapse rates formed a connected network (Figure 7). In the network,
all drugs were compared against placebo, but 40 mg of SC GA three times weekly and 125 µg of SC
pegylated IFN-β-1a every 2 weeks were not compared against other active drugs in the network; 22 µg of
SC IFN-β-1a three times weekly was connected to the network because of its inclusion in the PRISMS
trial,189 which also tested the 44-µg dose.
Random-effects NMA generated estimates for each drug compared with placebo and with every other
drug (Table 8). Ranking of the drugs suggested that the drug with the highest cumulative probability
SUCRA of being the best was 20 mg of SC GA once daily, followed by 125 µg of SC pegylated IFN-β-1a
every 2 weeks and 40 mg of SC GA three times weekly, with 30 µg of IM IFN-β-1a once a week ranked
second to last and placebo ranked last.
Findings derived from the NMA for comparisons between each drug and placebo substantially mirrored
those of the pairwise comparisons and reflected statistically significant reductions in relapse rates in
patients receiving active drugs. Pairwise comparisons between drugs mostly revealed little evidence of
superiority of one drug over another, although 20 mg of SC GA once daily (RR 0.82, 95% CI 0.73 to
0.92), 44 µg of SC IFN-β-1a three times weekly (RR 0.85, 95% CI 0.76 to 0.95) and 250 µg of SC IFN-β-1b
every other day (RR 0.86, 95% CI 0.76 to 0.97) all produced significant reductions in the relapse rate
compared with 30 µg of IM IFN-β-1a once a week. These findings from the pairwise comparisons in the
NMA, which all included direct (i.e. head-to-head) evidence, were similar in magnitude of effect to findings
from the pairwise meta-analyses, but may have benefited from a ‘stabilised’ heterogeneity parameter
because of the assumption of equal between-studies variance.
Tests of inconsistency in the network did not suggest disagreement between direct and indirect evidence.
A Wald test for overall inconsistency derived from a design*treatment interaction model was not
statistically significant (p = 0.38) and comparisons between the direct and the indirect evidence derived
from the side-splitting model did not show any statistically significant differences.
Sensitivity analyses
Several characteristics of the trials included in this network suggested that additional analyses would
confirm the robustness of our findings. All of these analyses were post hoc. First, we excluded the
REFORMS trial197 from the analysis, as it was the only study in which relapses were self-reported by
subjects instead of documented by an examining neurologist. Effect estimates remained essentially
unchanged for all pairwise comparisons.
Second, we compared findings from studies with ‘true’, blinded placebos with findings from studies
that did not use blinded placebos, that is, studies that did not deliver placebos using the same route of
administration as for the study drugs. Specifically, the BRAVO,198 CONFIRM216 and Kappos et al.199 trials did
not administer placebo by the same route as the relevant IFN or GA arm in each trial. We found that the
effects of these drugs compared with placebo were robust to inclusion of a covariate in the model for trials
without a blinded placebo.
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Third, we noticed that the study by Bornstein et al.170 was an outlier in the comparison between 20 mg of
SC GA once daily and placebo. When we excluded this trial from the pairwise meta-analysis, the pooled
RR for relapses still suggested a reduction in ARR compared with placebo (RR 0.71, 95% CI 0.62 to 0.82),
with an I2 of 0%. Re-estimation of the NMA yielded a change in the SUCRA-based rankings, with 20 mg
of SC GA once daily now ranked third, but point estimates and CIs were not substantially different in the
new model (Table 9).
Meta-analyses: relapse severity – moderate or severe relapses
Pairwise meta-analyses
Direct evidence from pairwise comparisons is shown in Figure 8. Each comparison was informed by one
study. All drugs compared with placebo had a statistically significant beneficial effect in terms of reducing
the rate of moderate or severe relapses. In comparisons based on active drugs, there was no evidence that
one dose of SC IFN-β-1a three times weekly was statistically better than the other (44 µg vs. 22 µg) or that
250 µg of SC IFN-β-1b every other day was different from 20 mg of SC GA once daily. The active drugs
40 mg of SC GA three times weekly, 30 µg of IM IFN-β-1a once a week and 125 µg of SC pegylated
IFN-β-1a every 2 weeks were not represented in this analysis.
Network meta-analyses
The set of studies reporting ratios of relapse rates for moderate and severe relapses formed a connected
network (Figure 9). In the network, direct evidence for 20 mg of SC GA once daily was only available for
the comparison with 250 µg of SC IFN-β-1b every other day.
Because of the shape of the network, in which there was no opportunity for inconsistency and in which
no direct comparison was informed by more than one trial, the model was estimated using fixed effects
instead of random effects, as in the protocol. Ranking of drugs suggested that 20 mg of SC GA once daily
was best, followed by 250 µg of SC IFN-β-1b every other day and 44 µg and 22 µg of SC IFN-β-1a three
times weekly, with placebo ranked last (Table 10).
ga20
ifn1a30
placebo
peg
ga40
ifn1b250
ifn1a44
ifn1a22
FIGURE 7 Network of studies: ARRs in RRMS. ga20, 20mg of SC GA once daily; ga40, 40mg of SC GA once daily;
ifn1a22, 22 µg of SC IFN-β-1a three times weekly; ifn1a30, 30 µg of IM IFN-β-1a once a week; ifn1a44, 44 µg of SC
IFN-β-1a three times weekly; ifn1b250, 250 µg of SC IFN-β-1b every other day; peg, 125 µg of SC pegylated IFN-β-1a
every 2 weeks.
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Findings derived from the NMA for comparisons between each drug and placebo were similar to findings
from comparisons between each drug and placebo from the direct evidence, as would be expected. In an
indirect comparison, 20 mg of SC GA once daily reduced the rate of moderate and severe relapses
compared with placebo (RR 0.48, 95% CI 0.31 to 0.76). Pairwise comparisons between active drugs did
not yield evidence of the superiority of any one drug over another.
Because there was no possibility of inconsistency in the network, we did not test for it.
Study
0.50 1.00
Favours first treatment Favours placebo or second 
treatment
IFN-β-1a 22 µg SC thrice weekly vs. placebo
PRISMS 1998189
Subtotal 
IFN-β-1a 44 µg SC thrice weekly vs. placebo
PRISMS 1998189
Subtotal 
IFN-β-1b 250 µg SC every other day vs. placebo
IFNB MSSG 1995209
Subtotal 
IFN-β-1a 44 µg SC thrice weekly vs. IFN-β-1a 22 µg SC thrice weekly
PRISMS 1998189
Subtotal 
IFN-β-1b 250 µg SC every other day vs. GA 20 mg SC daily
BEYOND 2009190
Subtotal 
RR (95% CI)
0.72 (0.61 to 0.84)
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0.63 (0.53 to 0.74)
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0.87 (0.74 to 1.03)
0.87 (0.74 to 1.03)
1.06 (0.79 to 1.42)
1.06 (0.79 to 1.42)
1.500.25
FIGURE 8 Pairwise estimates: ARRs for moderate or severe relapses in RRMS.
ifn1a44
ifn1a22
placebo
ifn1b250
ga20
FIGURE 9 Network of studies: ARRs for moderate or severe relapses in RRMS. ga20, 20mg of SC GA once daily;
ifn1a22, 22 µg of SC IFN-β-1a three times weekly; ifn1a44, 44 µg of SC IFN-β-1a three times weekly; ifn1b250, 250 µg
of SC IFN-β-1b every other day.
RESULTS OF THE ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
74
Meta-analyses: relapse severity – steroid-treated relapses
Pairwise meta-analysis
Direct evidence from comparisons against placebo is shown in Figure 10. Each comparison was informed
by one study. All drugs that were compared with placebo had a significant effect in terms of reducing the
rate of steroid-treated relapses. In head-to-head comparisons between active drugs, 44 µg of SC IFN-β-1a
three times weekly produced a greater reduction in steroid-treated relapses than the 22-µg dose of the
same drug (RR 0.77, 95% CI 0.67 to 0.89) and 30 µg of IM IFN-β-1a once a week (RR 0.68, 95% CI 0.51
to 0.91). Pairwise comparisons between 30 µg of IM IFN-β-1a once a week and 250 µg of SC IFN-β-1b
every other day and between 44 µg of SC IFN-β-1a three times weekly and 20 mg of SC GA once daily did
not show statistical evidence of superiority. The active drug 125 µg of SC pegylated IFN-β-1a every 2 weeks
was not included in this analysis.
Network meta-analyses
The set of studies reporting ratios of steroid-treated relapse rates formed a connected network (Figure 11).
In the network, each comparison was informed by one study, but there were closed loops between
studies, suggesting the possibility of inconsistency. Because in this parameterisation of the model
inconsistency is regarded as a source of heterogeneity, even though there is no potential for heterogeneity
in any of the comparisons informed by direct evidence, we estimated the model as both a fixed-effects and
a random-effects model.
Numerical estimates of intervention effectiveness were not meaningfully different between the random-
effects model and the fixed-effects model (Table 11). However, the random-effects model did not support
a significant reduction in the rate of steroid-treated relapses with 250 µg of SC IFN-β-1b every other day
(fixed-effects RR 0.62, 95% CI 0.40 to 0.98; random-effects RR 0.64, 95% CI 0.36 to 1.14). The random-
effects model also did not support the superiority of any one drug over another, except for 44 µg of SC
IFN-β-1a three times weekly over 30 µg of IM IFN-β-1a once a week (RR 0.68, 95% CI 0.48 to 0.97).
However, in the fixed-effects model, 44 µg of SC IFN-β-1a three times weekly was superior to both 30 µg
of IM IFN-β-1a once a week (RR 0.68, 95% CI 0.51 to 0.91) and 22 µg of SC IFN-β-1a three times weekly
(RR 0.79, 95% CI 0.68 to 0.91), both of which comparisons were informed by direct evidence; 20 mg of
SC GA once daily was also superior to both 30 µg of IM IFN-β-1a once a week (RR 0.67, 95% CI 0.47 to
0.95) and 22 µg of SC IFN-β-1a three times weekly (RR 0.77, 95% CI 0.61 to 0.98), although neither
comparison was informed by direct evidence.
TABLE 10 Network meta-analysis: ARRs for moderate or severe relapses in RRMSa
Drug SUCRA
GA 20mg SC
once daily
IFN-β-1b
250 µg SC
every other
day
IFN-β-1a
44 µg SC
three times
weekly
IFN-β-1a
22 µg SC
three times
weekly Placebo
GA 20mg SC once
daily
0.85 0.95
(0.70 to 1.27)
0.77
(0.48 to 1.24)
0.68
(0.42 to 1.08)
0.48
(0.31 to 0.76)
IFN-β-1b 250 µg SC
every other day
0.80 0.82
(0.56 to 1.19)
0.71
(0.49 to 1.03)
0.51
(0.37 to 0.71)
IFN-β-1a 44 µg SC
three times weekly
0.57 0.87
(0.74 to 1.03)
0.63
(0.53 to 0.74)
IFN-β-1a 22 µg SC
three times weekly
0.28 0.72
(0.61 to 0.84)
Placebo 0.00
a Findings are expressed as RR (95% CI).
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Subtotal 
GA 40 mg SC thrice weekly vs. placebo
GALA 2013221
Subtotal 
RR (95% CI)
0.65 (0.46 to 0.91)
0.65 (0.46 to 0.91)
0.70 (0.61 to 0.80)
0.70 (0.61 to 0.80)
0.54 (0.46 to 0.63)
0.54 (0.46 to 0.63)
1.32 (0.96 to 1.80)
1.32 (0.96 to 1.80)
1.12 (0.87 to 1.44)
1.12 (0.87 to 1.44)
0.77 (0.67 to 0.89)
0.77 (0.67 to 0.89)
0.68 (0.51 to 0.91)
0.68 (0.51 to 0.91)
0.64 (0.53 to 0.79)
0.64 (0.53 to 0.79)
1.500.25
FIGURE 10 Pairwise estimates: ARRs for steroid-treated relapses in RRMS.
ifn1a44
ifn1a22
ga40
placebo
ga20
ifn1b250
ifn1a30
FIGURE 11 Network of studies: ARR for steroid-treated relapses in RRMS. ga20, 20mg of SC GA once daily; ga40,
40mg of SC GA three times weekly; ifn1a22, 22 µg of SC IFN-β-1a three times weekly; ifn1a30, 30 µg of IM IFN-β-1a
once a week; ifn1a44, 44 µg of SC IFN-β-1a three times weekly; ifn1b250, 250 µg of SC IFN-β-1b every other day.
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Because the overall Wald test for inconsistency did not provide evidence of a difference between direct
and indirect evidence (p = 0.20), the fixed-effects model may be preferable.
Meta-analyses: time to disability progression confirmed at 3 months
Pairwise meta-analyses
Direct evidence from comparisons is shown in Figure 12. Only one comparison, 20 mg of SC GA once daily
compared with placebo, included more than one study and 40 mg of SC GA three times weekly was not
represented in this analysis.
Comparison of drugs against placebo showed a mixed pattern of results. The active drugs 20 mg of SC GA
once daily (HR 0.79, 95% CI 0.60 to 1.05), 30 µg of IM IFN-β-1a once a week (HR 0.74, 95% CI 0.51 to
1.08) and 250 µg of SC IFN-β-1b every other day (HR 0.71, 95% CI 0.48 to 1.06) did not show evidence of
delaying disability progression. However, both 44 µg of SC IFN-β-1a three times weekly (HR 0.62, 95% CI
0.43 to 0.90) and 22 µg of SC IFN-β-1a three times weekly (HR 0.68, 95% CI 0.48 to 0.97) and 125 µg of
SC pegylated IFN-β-1a every 2 weeks (HR 0.62, 95% CI 0.40 to 0.97) did show evidence of delaying
disability progression. None of the three direct comparisons between active drugs suggested a benefit of
one over another.
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FIGURE 12 Pairwise meta-analyses: time to disability progression confirmed at 3 months in RRMS.
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Network meta-analyses
The set of studies reporting HRs for time to disability progression confirmed at 3 months formed a
connected network (Figure 13). In the network, all active drugs were compared against placebo and three
comparisons between active drugs were present as well.
The NMA, which was estimated with random effects as per the protocol, generated HR estimates for each
drug compared with placebo and with every other drug (Table 12). Ranking of the drugs suggested that
the drug with the highest cumulative probability of being the best was 44 µg of SC IFN-β-1a three times
weekly, followed by 125 µg of SC pegylated IFN-β-1a every 2 weeks and 22 µg of SC IFN-β-1a three times
weekly, with 250 µg of SC IFN-β-1b every other day ranked second to last and placebo ranked last.
Comparisons of active drugs with placebo were similar between the NMA and the pairwise meta-analyses.
Notably, additional information from indirect comparisons yielded a more precise estimate of effectiveness
for both 30 µg of IM IFN-β-1a once a week compared with placebo (HR 0.73, 95% CI 0.53 to 1.00;
p = 0.0499) and 20 mg of SC GA once daily compared with placebo (HR 0.76, 95% CI 0.60 to 0.97).
Comparisons between active drugs in the NMA did not indicate that any one drug was statistically better
than any other, as all pairwise comparisons were not statistically significant.
Tests of inconsistency in the network did not suggest any disagreement between direct and indirect
evidence. An overall Wald test derived from a design*treatment interaction model returned a
non-significant result (p = 0.84) and comparisons between the direct evidence and the indirect evidence
derived from the side-splitting model did not show any statistically significant differences.
Meta-analyses: time to disability progression confirmed at 6 months
Pairwise meta-analyses
Direct evidence from comparisons is shown in Figure 14. All comparisons were based on a single study,
except for 30 µg of IM IFN-β-1a once a week compared with placebo. The active drug 40 mg of SC GA
three times weekly was not represented in this analysis.
ifn1a22
ifn1a44
ifn1a30
peg
ga20
ifn1b250
placebo
FIGURE 13 Network of studies: time to disability progression confirmed at 3 months in RRMS. ga20, 20mg of SC
GA once daily; ifn1a22, 22 µg of SC IFN-β-1a three times weekly; ifn1a30, 30 µg of IM IFN-β-1a once a week;
ifn1a44, 44 µg of SC IFN-β-1a three times weekly; ifn1b250, 250 µg of SC IFN-β-1b every other day; peg, 125 µg of
SC pegylated IFN-β-1a every 2 weeks.
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Three drugs were compared against placebo: 20 mg of SC GA once daily did not delay confirmed disability
progression compared with placebo, but 30 µg of IM IFN-β-1a once weekly (HR 0.66, 95% CI 0.47 to
0.92) and 125 µg of SC pegylated IFN-β-1a every 2 weeks (HR 0.46, 95% CI 0.26 to 0.81) did. Of the
three comparisons between active drugs, only 30 µg of IM IFN-β-1a once a week yielded a significant
difference, when compared with 250 µg of SC IFN-β-1b every other day.
Network meta-analyses
The set of studies reporting HRs for time to disability progression confirmed at 6 months formed a
connected network (Figure 15). In the network, 250 µg of SC IFN-β-1b every other day and 44 µg of SC
IFN-β-1a three times weekly are not compared with placebo, but only with other active drugs.
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FIGURE 14 Pairwise meta-analyses: time to disability progression confirmed at 6 months in RRMS.
ifn1a30
ifn1a44
placebopeg
ga20
ifn1b250
FIGURE 15 Network of studies: time to disability progression confirmed at 6 months in RRMS. ga20, 20mg of SC
GA once daily; ifn1a30, 30 µg of IM IFN-β-1a once a week; ifn1a44, 44 µg of SC IFN-β-1a three times weekly;
ifn1b250, 250 µg of SC IFN-β-1b every other day; peg, 125 µg of SC pegylated IFN-β-1a every 2 weeks.
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The NMA, which was estimated with random effects as per the protocol, generated HR estimates for each
drug compared with placebo and with every other drug (Table 13). Ranking of the drugs suggested that
the drug with the highest cumulative probability of being the best was 250 µg of SC IFN-β-1b every other
day, followed by 125 µg of SC pegylated IFN-β-1a every 2 weeks, 44 µg of SC IFN-β-1a three times weekly
and 30 µg of IM IFN-β-1a once a week; 20 mg of SC GA once daily was ranked second to last and placebo
was ranked last.
When compared with placebo in the NMA, 20 mg of SC GA once daily had a similar estimate of
effectiveness (HR 0.82, 95% CI 0.53 to 1.26) as in the direct evidence, as did 30 µg of IM IFN-β-1a once a
week (HR 0.68, 95% CI 0.49 to 0.94) and 125 µg of SC pegylated IFN-β-1a every 2 weeks (HR 0.46,
95% CI 0.26 to 0.81). Both 44 µg of SC IFN-β-1a three times weekly (HR 0.47, 95% CI 0.24 to 0.93) and
250 µg of SC IFN-β-1b every other day (HR 0.34, 95% CI 0.18 to 0.63) showed evidence of delaying
disability progression compared with placebo. However, both of these estimates are based solely on
indirect evidence and findings from the INCOMIN trial,196 which informed the comparison between 250 µg
of SC IFN-β-1b every other day and 30 µg of IM IFN-β-1a once a week and relied on a HR estimated from
summary statistics.
Comparisons between active drugs in from the NMA suggested that 250 µg of SC IFN-β-1b every other
day is superior to both 30 µg of IM IFN-β-1a once a week (HR 0.50, 95% CI 0.29 to 0.87) and 20 mg of
SC GA once daily (HR 0.41, 95% CI 0.21 to 0.83). In particular, the result of the comparison between
250 µg of SC IFN-β-1b every other day and 20 mg of SC GA once daily was greater in magnitude than the
direct evidence suggested. No other comparisons between active drugs yielded statistically significant
evidence of superiority of one drug over any other.
TABLE 13 Network meta-analysis: time to disability progression confirmed at 6 months in RRMSa
Drug SUCRA
IFN-β-1b
250 µg SC
every
other day
Pegylated
IFN-β-1a
125 µg SC
every
2 weeks
IFN-β-1a
44 µg SC
three times
weekly
IFN-β-1a
30 µg IM
weekly
GA 20mg
SC once
daily Placebo
IFN-β-1b 250 µg
SC every other
day
0.90 0.74
(0.32 to 1.71)
0.71
(0.32 to 1.60)
0.50
(0.29 to 0.87)
0.42
(0.21 to 0.83)
0.34
(0.18 to 0.63)
Pegylated
IFN-β-1a 125 µg
SC every
2 weeks
0.71 0.97
(0.40 to 2.33)
0.68
(0.35 to 1.31)
0.56
(0.28 to 1.15)
0.46
(0.26 to 0.81)
IFN-β-1a 44 µg
SC three times
weekly
0.70 0.70
(0.39 to 1.25)
0.58
(0.27 to 1.27)
0.47
(0.24 to 0.93)
IFN-β-1a 30 µg
IM weekly
0.40 0.83
(0.49 to 1.41)
0.68
(0.49 to 0.94)
GA 20mg SC
once daily
0.25 0.82
(0.53 to 1.26)
Placebo 0.05
Wald test for
inconsistency
(χ2, df, p-value)
0.77, 1,
0.38
df, degrees of freedom.
a Findings are presented as HR (95% CI).
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Tests of inconsistency in the network did not suggest that direct and indirect evidence disagreed to a
statistically significant level; however, the network was sparse and only one comparison included more than
one study. An overall Wald test for inconsistency returned a statistically non-significant result (p = 0.38).
Meta-analyses: adverse events
Summary of the adverse events meta-analyses
Full results for pairwise meta-analyses of AEs are available on request. Although the diversity and
heterogeneity of AEs precluded detailed examination of each, several trends were apparent across
pairwise comparisons:
l comparing 30 µg of IFN-β-1a (Avonex) with equivalent placebo, 30 µg of IFN-β-1a was associated with
more chills, flu-like symptoms, NABs and myalgia
l comparing 30 µg of IFN-β-1a (Avonex) with 44 µg of SC IFN-β-1a (Rebif), 44 µg of IFN-β-1a was
associated with more injection site reactions, liver disorders, NABs and white blood cell abnormalities,
whereas 30 µg of IFN-β-1a was associated with more fatigue
l comparing 30 µg of IFN-β-1a (Avonex) with IFN-β-1b (Betaferon/Extavia), IFN-β-1b was associated with
more injection site reactions and NABs
l comparing 30 µg of IFN-β-1a (Avonex) with GA (Copaxone), there were no significant differences
in AEs
l comparing 44 µg of IFN-β-1a (Rebif) with placebo, 44 µg of IFN-β-1a was associated with more
injection site reactions, flu-like symptoms, liver disorders, granulocytopenia, leucopenia, lymphopenia
and NABs
l comparing 44 µg of IFN-β-1a (Rebif) with IFN-β-1b (Betaferon/Extavia), 44 µg of IFN-β-1a was associated
with more alanine aminotransferase disorders and IFN-β-1b was associated with more injection site pain
l comparing 44 µg of IFN-β-1a (Rebif) with GA (Copaxone), 44 µg of IFN-β-1a was associated with more
liver enzyme disorders, NABs, headache, flu-like symptoms and myalgia and GA was associated with
more injection site reactions, immediate post-injection reactions and binding antibodies
l comparing IFN-β-1b (Betaferon/Extavia) with placebo, IFN-β-1b was associated with more injection site
inflammation and NABs
l comparing IFN-β-1b (Betaferon/Extavia) with GA (Copaxone), IFN-β-1b was associated with more
flu-like symptoms, insomnia and disordered liver enzymes and GA was associated with more injection
site reactions, itching, pain, inflammation and induration and immediate post-injection reactions
l comparing GA (Copaxone) with equivalent placebo, GA was associated with more injection site
induration, itching, injection site mass, erythema, pain, inflammation and reactions and more
immediate post-injection systemic reactions
l comparing pegIFN-β-1a (Plegridy) with placebo, pegylated IFN-β-1a was associated with more injection
site erythema, pain, itching, chills and/or fever, headache, flu-like symptoms, myalgia, pyrexia, any AE
possibly related to the drug, patients who discontinued the study because of AEs and severe AEs.
Discontinuation because of adverse events: modal follow-up
Pairwise meta-analyses
Pairwise meta-analyses for discontinuation because of AEs, combined across studies at the modal follow-up,
are presented in Figure 16. The modal follow-up was approximately 24 months and thus we included
studies with an intended follow-up period around this point. We included 12 estimates in these meta-
analyses. There was no visual evidence of a systematic difference between the groups based on the strict
definition of the outcome. In every pairwise meta-analysis, CIs were wide, as would be expected. Three
pooled estimates relied on multiple studies: 20 mg of SC GA once daily compared with placebo, 30 µg of
IM IFN-β-1a once a week compared with placebo and 250 µg of SC IFN-β-1b every other day compared
with 20 mg of SC GA once daily. There was no evidence in this analysis for 40 mg of SC GA three times
weekly or 125 µg of SC pegylated IFN-β-1a every 2 weeks.
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Direction of effect in pooled estimates and single studies generally suggested that discontinuation because
of AEs was more likely in study arms testing active drugs than in study arms testing placebo, but these
findings were generally not statistically significant. The one exception was the IFNB MSSG trial,210 from
which we used 24-month data. In this study, which compared 250 µg of SC IFN-β-1b every other day with
placebo, patients receiving the study drug were more likely to withdraw from the study because of an AE
(risk ratio 9.92, 95% CI 1.29 to 76.32).
Network meta-analyses
The set of studies included in the NMA formed a connected network (Figure 17). All drugs were compared
with placebo; 40 mg of SC GA three times weekly and 125 µg of SC pegylated IFN-β-1a every 2 weeks
were not included in this analysis.
The NMA, which was estimated with random effects, generated estimates for each drug compared with
placebo and with every other drug (Table 14). Because CIs were wide in pairwise, direct meta-analyses, CIs
were wide in the NMA, and estimates compared with placebo were often numerically different. The NMA
did not offer statistical evidence that any one drug was more likely to result in discontinuation because of
AEs than any other drug. Based on SUCRAs, 250 µg of SC IFN-β-1b every other day was ranked highest for
discontinuation because of AEs, followed by 44 µg of SC IFN-β-1a three times weekly. Placebo was ranked last.
In comparison with the direct evidence from the IFNB MSSG trial,210 the risk ratio for discontinuation
because of AEs for 250 µg of SC IFN-β-1b every other day compared with placebo was lower but remained
statistically significant (risk ratio 4.41, 95% CI 1.07 to 18.29). The risk ratio for 44 µg of SC IFN-β-1a three
times weekly compared with placebo was lower in the NMA (risk ratio 3.85, 95% CI 0.81 to 18.29) than
the pairwise estimate derived from the PRISMS trial189 (risk ratio 7.11, 95% CI 0.88 to 57.25), as was the
risk ratio for 22 µg of SC IFN-β-1a three times weekly compared with placebo (NMA: risk ratio 1.86, 95%
CI 0.21 to 16.83; PRISMS trial:189 risk ratio 2.97, 95% CI 0.31 to 28.28). However, the risk ratio for 20 mg
of SC GA once daily compared with placebo was higher in the NMA (risk ratio 2.60, 95% CI 0.88 to 7.64)
than in the pairwise meta-analysis (risk ratio 1.69, 0.51 to 5.58).
An overall test for inconsistency across the network did not suggest the presence of inconsistency
(p = 0.50). However, a side-splitting test did find that direct and indirect evidence were in conflict for the
comparison between 20 mg of SC GA once daily and placebo, with a suggestion that the risk of
discontinuation because of AEs in the indirect evidence was higher than that presented in the direct
evidence (p = 0.037). Thus, there is some evidence of inconsistency in this network.
ifn1a44
ga20 ifn1b250
ifn1a30
placebo
ifn1a22
FIGURE 17 Network of studies: discontinuation because of AEs at 24 months in RRMS. ga20, 20mg of SC GA once
daily; ifn1a22, 22 µg of SC IFN-β-1a three times weekly; ifn1a30, 30 µg of IM IFN-β-1a once a week; ifn1a44, 44 µg
of SC IFN-β-1a three times weekly; ifn1b250, 250 µg of SC IFN-β-1b every other day.
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Discontinuation because of adverse events: all follow-up times
Pairwise meta-analyses
Pairwise meta-analyses for discontinuation because of AEs across all time points are shown in Figure 18.
There was no visual evidence of a systematic difference between the groups based on the strict definition
of the outcome. In every pairwise meta-analysis, CIs were wide, as would be expected. Five pooled
estimates relied on multiple studies: 20 mg of SC GA once daily compared with placebo, 30 µg of IM
IFN-β-1a once a week compared with placebo and 250 µg of SC IFN-β-1b every other day compared with
each placebo, 20 mg of SC GA once daily and 44 µg of SC IFN-β-1a three times weekly.
Despite visual evidence suggesting that discontinuation because of AEs was more likely in study arms
testing active drugs than in study arms testing placebo, almost all individual study estimates and pooled
estimates did not suggest that discontinuation was more likely in trial arms corresponding to one drug
over another to a statistically significant level. The one exception was 125 µg of SC pegylated IFN-β-1a
every 2 weeks compared with placebo, in which patients receiving the study drug were more likely to
discontinue the study because of AEs (risk ratio 3.49, 95% CI 1.52 to 7.99). Estimates for 40 mg of SC GA
three times weekly compared with placebo were marginally non-significant (risk ratio 2.36, 95% CI 0.99 to
5.65). Again, both estimates were based on one study. Of note is that comparisons between 20 mg of SC
GA once daily and placebo, which included five studies, did not suggest a substantial relationship between
the study drug and discontinuation (risk ratio 1.07, 95% CI 0.64 to 1.79), but this was driven (at least in
part) by the null finding from the CONFIRM trial216 (risk ratio 0.95, 95% CI 0.62 to 1.47).
TABLE 14 Network meta-analysis: discontinuation because of AEs at 24 months in RRMSa
Drug SUCRA
IFN-β-1b
250 µg SC
every
other day
IFN-β-1a
44 µg SC
three times
weekly
GA 20mg
SC once
daily
IFN-β-1a
22 µg SC
three times
weekly
IFN-β-1a
30 µg IM
weekly Placebo
IFN-β-1b
250 µg SC
every other
day
0.79 1.15
(0.20 to 6.56)
1.70
(0.50 to 5.81)
2.37
(0.22 to 25.84)
2.74
(0.56 to 13.38)
4.41
(1.07 to 18.29)
IFN-β-1a
44 µg SC
three times
weekly
0.76 1.48
(0.39 to 5.57)
2.07
(0.32 to 13.44)
2.39
(0.38 to 15.22)
3.85
(0.81 to 18.29)
GA 20mg SC
once daily
0.57 1.40
(0.17 to 11.76)
1.61
(0.38 to 6.91)
2.60
(0.88 to 7.64)
IFN-β-1a
22 µg SC
three times
weekly
0.41 1.15
(0.10 to 13.09)
1.86
(0.21 to 16.83)
IFN-β-1a
30 µg IM
weekly
0.35 1.61
(0.52 to 5.02)
Placebo 0.12
Wald test for
inconsistency
(χ2, df,
p-value)
2.38,
3, 0.50
a Findings are presented as risk ratio (95% CI).
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Network meta-analyses
The studies included in this analysis formed a connected network (Figure 19). All drugs were compared
with placebo and all drugs were included in this analysis.
The NMA, which was estimated with random effects as per the protocol, generated estimates for each
drug compared with placebo and with every other drug (Table 15). The NMA did not offer statistical
evidence that any one drug was more likely to result in discontinuation because of AEs than any other
drug. Based on SUCRAs, 125 µg of SC pegylated IFN-β-1a every 2 weeks was ranked highest for risk of
discontinuation because of AEs (i.e. greatest risk of discontinuation), followed by 44 µg of SC IFN-β-1a
three times weekly. Placebo was ranked last.
Study Outcome definition
0.10 1.00
Favours first treatment Favours placebo or second treatment
GA 20 mg SC daily vs. placebo
Bornstein 1987170
CONFIRM 2012216
Cop1 MSSG 1995217
ECGASC 2001219
GATE 2015220
Subtotal (I2 = 7.1%, p = 0.366)
Discontinued study drug because of AEs
Discontinued study drug because of AEs
Discontinued study because of AEs
Discontinued study because of AEs
Discontinued study drug because of AEs
GA 40 mg SC thrice weekly vs. placebo
GALA 2013221
Subtotal (I2 = .%, p = .)
Discontinued study drug because of AEs
IFN-β-1a 22 µg SC thrice weekly vs. placebo
PRISMS 1998189
Subtotal (I2 = .%, p = .)
Discontinued study drug because of AEs
IFN-β-1a 30 µg IM weekly vs. placebo
BRAVO 2014198
Kappos 2011199
MSCRG 1996200
Subtotal (I2 = 0.0%, p = 0.564)
Discontinued study because of AEs
Discontinued study because of AEs
Discontinued study drug because of AEs
IFN-β-1a 44 µg SC thrice weekly vs. placebo
PRISMS 1998189
Subtotal (I2 = .%, p = .)
Discontinued study drug because of AEs
IFN-β-1a pegylated 125 µg SC every 2 weeks vs. placebo
ADVANCE 2014213
Subtotal (I2 = .%, p = .)
Discontinued study because of AEs
IFN-β-1b 250 µg SC every other day vs. placebo
IFNB MSSG 1995209
Knobler 1993211
Subtotal (I2 = 16.8%, p = 0.273)
Withdrawal from study because of AEs
Withdrawal from study because of AEs
IFN-β-1a 30 µg IM weekly vs. GA 20 mg SC daily
CombiRx 2013191
Subtotal (I2 = .%, p = .)
Discontinued study because of AEs
IFN-β-1a 30 µg IM weekly vs. IFN-β-1a 44 µg thrice weekly
EVIDENCE 2007195
Subtotal (I2 = .%, p = .)
Discontinued study because of AEs
IFN-β-1a 44 µg SC thrice weekly vs. GA 20 mg SC daily
REGARD 2008192
Subtotal (I2 = .%, p = .)
Discontinued study drug because of AEs
IFN-β-1b 250 µg SC every other day vs. GA 20 mg SC daily
BECOME 2009184
BEYOND 2009190
Subtotal (I2 = 0.0%, p = 0.408)
Discontinued study drug because of AEs
Withdrawal from study because of AEs
IFN-β-1b 250 µg SC every other day vs. IFN-β-1a 30 µg IM weekly
INCOMIN 2002196
Subtotal (I2 = .%, p = .)
Discontinued study drug because of AEs
IFN-β-1b 250 µg SC every other day vs. IFN-β-1a 44 µg SC thrice weekly
AVANTAGE 2014182
REFORMS 2012197
Subtotal (I2 = 26.2%, p = 0.244)
Note: weights are from random-effects analysis
Withdrawal from study because of AEs
Discontinued study drug because of AEs
4.62 (0.23 to 91.34)
0.95 (0.62 to 1.47)
5.04 (0.60 to 42.53)
1.51 (0.26 to 8.89)
0.47 (0.09 to 2.53)
1.07 (0.64 to 1.79)
2.94
74.40
5.66
8.08
8.92
100.00
2.36 (0.99 to 5.65)
2.36 (0.99 to 5.65)
100.00
100.00
2.97 (0.31 to 28.28)
2.97 (0.31 to 28.28)
100.00
100.00
1.38 (0.77 to 2.45)
3.00 (0.12 to 72.05)
3.17 (0.67 to 15.00)
1.55 (0.91 to 2.65)
85.43
2.81
11.76
100.00
7.11 (0.88 to 57.25)
7.11 (0.88 to 57.25)
100.00
100.00
3.49 (1.52 to 7.99)
3.49 (1.52 to 7.99)
100.00
100.00
0.69 (0.20 to 2.42)
0.69 (0.20 to 2.42)
100.00
100.00
9.92 (1.29 to 76.32)
1.40 (0.08 to 25.92)
4.93 (0.76 to 32.00)
64.28
35.72
100.00
0.95 (0.51 to 1.78)
0.95 (0.51 to 1.78)
100.00
100.00
1.19 (0.66 to 2.14)
1.19 (0.66 to 2.14)
100.00
100.00
3.24 (0.14 to 77.15)
0.81 (0.34 to 1.94)
0.89 (0.39 to 2.08)
7.06
92.94
100.00
4.79 (0.57 to 40.24)
4.79 (0.57 to 40.24)
100.00
100.00
0.43 (0.13 to 1.45)
0.08 (0.00 to 1.36)
0.29 (0.06 to 1.34)
75.73
24.27
100.00
RR (95% CI) % weight
0.01 10.00 100.00
 
FIGURE 18 Pairwise meta-analyses: discontinuation because of AEs at all time points in RRMS. RR, risk ratio.
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Because CIs were frequently wide in pairwise, direct meta-analyses, CIs were wide in the NMAs, and
estimates compared with placebo were often numerically different. Compared with direct estimates from
the PRISMS trial,189 evidence from the NMA suggested a numerically lower risk of discontinuation because
of AEs for 44 µg of SC IFN-β-1a three times weekly compared with placebo (NMA: risk ratio 2.49, 95% CI
0.89 to 6.95; PRISMS trial:189 risk ratio 7.11, 95% CI 0.88 to 57.25), that is, the magnitude of the risk of
discontinuation compared with placebo was smaller in the NMA than in the one trial informing the direct
comparison. The same applied for 22 µg of SC IFN-β-1a three times weekly (NMA: risk ratio 1.24, 95% CI
0.21 to 7.26; PRISMS trial:189 risk ratio 2.97, 95% CI 0.31 to 28.28). Similarly, estimates for discontinuation
because of AEs for 250 µg of SC IFN-β-1b every other day compared with placebo were lower in the NMA
than in the pairwise meta-analysis (NMA: risk ratio 1.75, 95% CI 0.63 to 4.89; pairwise meta-analysis: risk
ratio 4.93, 95% CI 0.76 to 32.00). Estimates of discontinuation because of AEs were higher in the NMA
for 20 mg of SC GA once daily compared with placebo (NMA: risk ratio 1.56, 95% CI 0.77 to 3.14;
pairwise meta-analysis: risk ratio 1.07, 95% CI 0.64 to 1.79).
An overall Wald test for inconsistency in the network did not reach significance, but suggested some
conflict between direct and indirect evidence (p = 0.09). Examination of the specific design effects from the
design*treatment interaction model suggested that direct estimates of discontinuation because of AEs for
250 µg of SC IFN-β-1b every other day compared with placebo could be driving this result (design effect
p = 0.075). However, a side-splitting test did not suggest an obvious source of conflict between direct and
indirect evidence. Thus, although there is no statistically significant evidence of inconsistency in this
network, the findings should be viewed with caution.
Comparison of network meta-analyses: modal follow-up compared with all time points
Neither NMA found evidence that one drug was superior to any other.
However, estimates for discontinuation because of AEs for active drugs compared with placebo tended to be
lower in the network including all time points, possibly because the majority of studies included in this analysis
that were set aside in the modal follow-up analysis included shorter follow-up periods (generally of ≤ 1 year).
Estimates were essentially unchanged for 30 µg of IM IFN-β-1a once a week compared with placebo (modal
follow-up: risk ratio 1.61, 95% CI 0.52 to 5.02; all time points: risk ratio 1.62, 95% CI 0.82 to 3.23).
ifn1a30
placebo
peg
ga40
ifn1a22
ifn1a44
ifn1b250
ga20
FIGURE 19 Network of studies: discontinuation because of AEs at all time points in RRMS. ga20, 20mg of SC GA
once daily; ga40, 40mg of SC GA three times weekly; ifn1a22, 22 µg of SC IFN-β-1a three times weekly; ifn1a30,
30 µg of IM IFN-β-1a once a week; ifn1a44, 44 µg of SC IFN-β-1a three times weekly; ifn1b250, 250 µg of SC IFN-β-1b
every other day; peg, 125 µg of SC pegylated IFN-β-1a every 2 weeks.
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Supplementary analyses: pooled effectiveness of disease-modifying therapies used in
the risk-sharing scheme
In preparation for the cost-effectiveness analyses, we undertook a post hoc, supplementary, pairwise
meta-analysis of all trials comparing DMTs in the RSS with placebo (i.e. excluding trials of pegylated IFN
and 40 mg of GA, as well as head-to-head-only trials). We used a random-effects model and estimated
outcomes for ARR and time to disability progression confirmed at 3 months. Based on 12 relevant trials
examining the ARR, on-scheme DMTs reduced the relapse rate (RR 0.65, 95% CI 0.56 to 0.76). Across six
relevant trials examining time to disability progression confirmed at 3 months, on-scheme DMTs delayed
disability progression (HR 0.70, 95% CI 0.55 to 0.87).
Summary: relapsing–remitting multiple sclerosis
The studies suggested, and meta-analyses confirmed, that IFNs and GA reduce the relapse rate, reduce
the rate of severe relapses (both measured using neurological rating scales and steroid treatment) and
generally delay disability progression in RRMS. However, the findings were clearer for disability progression
confirmed at 3 months than disability progression confirmed at 6 months. There was little evidence that
any one drug was superior to any other, except for disability progression confirmed at 6 months, but
networks were especially sparse. Findings for disability progression confirmed at 3 months did not match
the findings for disability progression confirmed at 6 months. Freedom from disease activity, MS symptoms
and HRQoL were infrequently reported and evidence for MS symptoms and HRQoL also suffered from
poor reporting. Findings for discontinuations because of AEs, which were intended to be indicative, did not
suggest that one drug was more likely to result in discontinuation than any other or, with few exceptions,
than placebo. However, findings for discontinuations relied on networks with some limited evidence
of inconsistency.
In Table 16 we summarise the main clinical effectiveness and safety outcome results from the NMAs for
each DMT compared with placebo.
Clinical effectiveness: secondary progressive multiple sclerosis
This analysis was informed by three trials.222–224 It should be noted that, although all studies included both
relapsing and non-relapsing patients, only the SPECTRIMS (Secondary Progressive Efficacy Clinical Trial
of Recombinant Interferon-Beta-1a in MS) trial224 presented subgroup analyses by history of previous
relapses in SPMS.
44 µg and 22 µg of interferon beta-1a subcutaneously three times a week (Rebif)
compared with placebo
One trial evaluated both the 44-µg dose and the 22-µg dose of SC IFN-β-1a three times a week compared
with placebo.224
Relapse outcomes
In the SPECTRIMS trial,224 618 patients were followed up for 3 years. RRs based on ARRs were numerically
identical for both active arms compared with placebo (44 µg: RR 0.69, 95% CI 0.56 to 0.85; 22 µg: RR
0.69, 95% CI 0.56 to 0.84).
Subgroup analyses stratifying by whether patients had a history of relapse showed a pattern of significant
results for those previously relapsing and non-significant results for those not previously relapsing.224 For
those previously relapsing, ARRs for the 44-µg dose (0.67; p < 0.001) and the 22-µg dose (0.57; p < 0.001)
were significantly different from the ARR in the placebo arm (1.08). For those not previously relapsing,
ARRs for both dosages (44 µg: 0.43, p > 0.05; 22 µg: 0.36, not significant) were not significantly different
from the ARR in the placebo arm (0.39).
Both active arms also showed a similar delay in time to first relapse, although only the 44-µg dose had a
significant effect compared with placebo (HR 0.77, 95% CI 0.61 to 0.98), corresponding to a median time
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to first relapse of 494 days in the 44-µg dose group compared with 281 days in the placebo group.224
Although the results for the 22-µg dose group compared with the placebo group were similar (476 days
compared with 281 days), this did not translate into a significant effect (HR 0.87, 95% CI 0.69 to 1.10).
The difference between the two active arms was not calculated in this trial, although the HR for the 44-µg
dose compared with the 22-µg dose can be approximated as 0.77/0.87 = 0.89, which is not statistically
different from unity.
Relapse severity
Both active arms in the SPECTRIMS trial224 showed a similar reduction in the annualised rate of moderate
or severe relapses (44 µg: RR 0.68, 95% CI 0.44 to 0.81; 22 µg: RR 0.66, 95% CI 0.51 to 0.86).224 The
findings were similar for annualised rates of steroid courses used to treat relapses (44 µg: RR 0.66, 95% CI
0.49 to 0.89; 22 µg: RR 0.59, 95% CI 0.44 to 0.81).
Disability progression
In the SPECTRIMS trial,224 disability progression was confirmed at 3 months. Neither active drug was
associated with a significant decrease in hazard for time to confirmed disability progression in the main
analysis (44 µg: HR 0.83, 95% CI 0.65 to 1.07; 22 µg: 0.88, p = 0.305), nor were the active arms
substantially different. However, an analysis controlling for disease characteristics found a significant
difference in the 44-µg arm (HR 0.78, 95% CI 0.60 to 1.00) compared with the control arm.
Subgroup analyses combined the two active drug dosages into one arm and stratified models by whether
patients had a history of relapse.224 The HR for time to confirmed disability progression suggested a
positive, although non-significant, effect in previously relapsing patients (0.74; p = 0.055), whereas the HR
approached unity in non-relapsing patients (1.01; p = 0.934). However, among previously relapsing
patients, the proportion of patients with confirmed disability progression was significantly different
between those receiving 44/22 µg of the active drug and those receiving placebo (OR 0.52, 95% CI 0.29
to 0.93), whereas among those not previously relapsing, the proportion of patients with confirmed
disability progression was not significantly different between those receiving 44/22 µg of the active drug
and those receiving placebo (OR 1.07, 95% CI 0.64 to 1.78).
Freedom from disease activity
We were unable to locate any relevant comparisons between 44 µg or 22 µg of SC IFN-β-1a three times a
week and placebo for combined clinical–MRI measures of freedom from disease activity.
Multiple sclerosis symptoms and health-related quality of life
We were unable to locate any relevant comparisons between 44 µg or 22 µg of SC IFN-β-1a three times a
week and placebo for MS symptoms and HRQoL.
Adverse events and mortality
The SPECTRIMS trial224 reported AEs and mortality. Full results are available on request. Mortality was not
significantly different between the groups: one patient died in the placebo arm whereas two patients died
in the 44-µg arm and one patient died in the 22-µg arm.
250 µg of interferon beta-1b subcutaneously every other day (Betaferon/Extavia)
compared with placebo
Two trials evaluated 250 µg of SC IFN-β-1b every other day.222,223,225 The North American Study Group on
Interferon beta-1b in Secondary Progressive MS (NASG) trial223 included a dosage of IFN-β-1b that is not
recommended and thus this arm was not included in the analysis.
Relapse outcomes
In the European Study Group on Interferon β-1b in Secondary Progressive MS (ESG) trial,222,225 718 patients
were followed for up to 2 years. Patients receiving the study drug had a significantly lower ARR than those
in the placebo arm (0.42 vs. 0.57; p = 0.003). We approximated this as a RR of 0.74 (95% CI 0.65 to
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0.83). Similarly, for the 623 patients enrolled in the relevant study arms in the NASG trial223 and followed
for up to 3 years before early study termination, patients receiving the study drug had a significantly lower
ARR than placebo patients (0.16 vs. 0.28; p = 0.009). We approximated this as a RR of 0.57 (95% CI 0.43
to 0.75).
Both studies also demonstrated a statistically significant delay in time to first relapse in the active drug arm.
In interim data from the ESG trial,222 the median time to first relapse was 644 days in the study drug arm
compared with 403 days in the placebo arm (log-rank p = 0.003). In the NASG trial,223 end-of-study data
demonstrated a time to relapse at the 30th percentile of 1051 days in the study drug arm compared with
487 days in the placebo arm (log-rank p = 0.01). However, in the ESG trial222 the proportions relapsing
were not significantly different between the groups (57.5% in the study drug arm vs. 62.0% in placebo,
p = 0.083), whereas in the NASG trial there was a significant difference between the groups (29% vs.
38%; p = 0.018).
Relapse severity
Both studies showed a significant difference between the study drug arm and the placebo arm in the
proportion of patients experiencing moderate or severe relapses (ESG trial interim data:222 43.6% vs.
53.1%, p = 0.0083; NASG trial:223 21% vs. 30%, p = 0.012). In the NASG trial,223 the annualised rate of
moderate or severe relapses was significantly lower in the study drug arm than in the placebo arm (0.10
vs. 0.19; p = 0.022). However, it should be noted that outcome tables for the NASG trial presented two
markedly different estimates of relapse severity. Under the second set of estimates, neither the proportion
of patients with moderate or severe relapses (3% vs. 6%; p = 0.056) or the annualised rate of moderate or
severe relapses (0.01 vs. 0.02; p = 0.052) was significantly different between the arms. Contact with the
study investigators did not yield clarification.
In both studies, the percentage of patients treated with steroids also decreased significantly in the study
drug arm compared with the placebo arm (ESG trial interim data:222 53.6% vs. 67.9%, p < 0.0001; NASG
trial:223 37% vs. 46%, p = 0.023).
Disability progression
In the ESG trial,225 progression was measured using a variety of criteria, including progression of at least
1.0 EDSS points confirmed at 3 months and at 6 months and progression of 2.0 EDSS points confirmed at
3 months. Each of these measures was estimated both excluding data collected during relapses (the
default) and including relapse data, but proportions were similar in all cases between measures including
and measures excluding data collected during relapses and thus only the default measures are discussed
here. The proportion of patients progressing at least 1.0 EDSS point confirmed at 3 months was
significantly lower in the study drug arm than in the placebo arm (45.3% vs. 53.9%; p = 0.031).
Combined with estimated probabilities from a life table model (estimated non-progression at 33 months
53% vs. 44%) and a log-rank p-value of 0.003, this yielded an approximate HR of 0.75 (95% CI 0.61 to
0.92). The proportions with confirmed progression of at least 1.0 EDSS point at 6 months (40.8% vs.
48.6%; p = 0.049) and with confirmed progression of at least 2.0 EDSS points at 3 months (16.4% vs.
22.6%; p = 0.032) showed similar trends. However, in the NASG trial,223 disability progression was
confirmed at 6 months and did not show a significant difference in terms of time to progression (study
drug 32% vs. placebo 34%; log-rank p = 0.61).
Similarly, although patients in the ESG trial225 showed a significant difference between arms in the average
EDSS progression score (0.47 vs. 0.69 points; p = 0.003), patients in the NASG trial223 did not (0.53 vs.
0.62 points; p = 0.634).
Freedom from disease activity
We were unable to locate any relevant comparisons between 250 µg of SC IFN-β-1b every other day and
placebo for combined clinical–MRI measures of freedom from disease activity.
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Multiple sclerosis symptoms and health-related quality of life
In the NASG trial,223 change from baseline was not significantly different between patients in the study
drug arm and patients in the placebo arm for fatigue (Environmental Status Scale score change 1.7 vs. 1.2;
p = 0.125), cognition (composite neuropsychological score change –0.28 vs. –0.32; p = 0.42) or depression
(Beck Depression Inventory score change –0.5 vs. –1.0; p = 0.652; percentage newly treated with
antidepressants 29% vs. 29%; p = 0.987). Changes in overall Multiple Sclerosis Quality of Life Inventory
scores were also not significantly different (p = 0.502).
Adverse events and mortality
Both studies reported AEs and mortality. Full results are available on request. Studies were not significantly
different with regard to mortality: there were seven deaths in the combined 250 µg of SC IFN-β-1b every
other day arms of the two trials and two deaths in the combined placebo arms.
Meta-analyses: relapse rate
Pairwise meta-analyses
Direct evidence from comparisons is shown in Figure 20. The SPECTRIMS trial224 compared 44 µg of SC
IFN-β-1a three times weekly, 22 µg of SC IFN-β-1a three times weekly and placebo, whereas the other two
included trials compared 250 µg of SC IFN-β-1b every other day with placebo. The pooled effect of 250 µg
of SC IFN-β-1b every other day compared with placebo suggested that the drug reduces the rate of relapse
(RR 0.71, 95% CI 0.63 to 0.79).
Network meta-analyses
Ranking of the drugs in the resultant network suggested that 250 µg of SC IFN-β-1b every other day was
superior to the equally ranked 44 µg of SC IFN-β-1a three times weekly and 22 µg of SC IFN-β-1a three
times weekly (Table 17). Placebo was ranked last. Findings for comparisons between active drugs and
placebo were, as would be expected, essentially the same as in the direct evidence. Comparisons between
250 µg of SC IFN-β-1b every other day and both 44 µg of SC IFN-β-1a three times weekly and 22 µg of SC
IFN-β-1a three times weekly did not suggest a statistically significant difference between the drugs in terms
of effectiveness (44 µg: HR 0.97, 95% CI 0.63 to 1.50; 22 µg: HR 0.97, 95% CI 0.63 to 1.49). Because
there was no possibility of inconsistency in the network, we did not test for it.
Study
0.5 1.0
Favours first treatment Favours placebo or second 
treatment
IFN-β-1b 250 µg SC every other day vs. placebo
ESG 1998222
NASG 2004223
Subtotal (I2 = 63.5%, p = 0.098)
RR (95% CI)
0.74 (0.65 to 0.83)
0.57 (0.43 to 0.75)
0.71 (0.63 to 0.79)
IFN-β-1a 44 µg SC thrice weekly vs. placebo
SPECTRIMS 2001224
Subtotal (I2 = .%, p = .)
0.69 (0.56 to 0.85)
0.69 (0.56 to 0.85)
IFN-β-1a 22 µg SC thrice weekly vs. placebo
SPECTRIMS 2001224
Subtotal (I2 = .%, p = .)
0.69 (0.56 to 0.85)
0.69 (0.56 to 0.85)
IFN-β-1a 44 µg SC thrice weekly vs. IFN-β-1a 22 µg SC thrice weekly
SPECTRIMS 2001224
Subtotal (I2 = .%, p = .) 
1.00 (0.81 to 1.23)
1.00 (0.81 to 1.23)
2.00.1
FIGURE 20 Pairwise meta-analyses: ARRs in SPMS.
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Meta-analyses: relapse severity
We did not undertake meta-analyses for relapse severity in SPMS because of the quality and scarcity of the data.
Meta-analyses: time to disability progression confirmed at 3 months
Pairwise meta-analyses
Direct evidence from comparisons is shown in Figure 21. Comparisons included two trials.222,224,225
The findings are the same as for the individual trials.
Network meta-analyses
Because of the shape of the network, in which there was no opportunity for inconsistency and in which no
direct comparison was informed by more than one trial, the model was estimated using fixed effects
instead of random effects, as in the protocol. Ranking of drugs in the resultant network suggested that
250 µg of SC IFN-β-1b every other day was superior to 44 µg of SC IFN-β-1a three times weekly and 22 µg
of SC IFN-β-1a three times weekly (Table 18). Placebo was ranked last. Findings for comparisons between
active drugs and placebo were, as would be expected, essentially the same as in the direct evidence.
Comparisons between 250 µg of SC IFN-β-1b every other day and both 44 µg of SC IFN-β-1a three times
weekly and 22 µg of SC IFN-β-1a three times weekly did not suggest a statistically significant difference
between the drugs in terms of effectiveness (44 µg: HR 0.91, 95% CI 0.65 to 1.25; 22 µg: HR 0.85, 95%
CI 0.62 to 1.18). Because there was no possibility for inconsistency in the network, we did not test for it.
TABLE 17 Network meta-analysis: ARRs in SPMSa
Drug SUCRA
IFN-β-1b 250 µg
SC every other
day
IFN-β-1a 44 µg SC
three times
weekly
IFN-β-1a 22 µg SC
three times
weekly Placebo
IFN-β-1b 250 µg SC
every other day
0.71 0.97 (0.63 to 1.50) 0.97 (0.63 to 1.49) 0.67 (0.52 to 0.86)
IFN-β-1a 44 µg SC
three times weekly
0.64 1.00 (0.71 to 1.42) 0.69 (0.49 to 0.98)
IFN-β-1a 22 µg SC
three times weekly
0.64 0.69 (0.49 to 0.98)
Placebo 0.01
a Findings are expressed as HR (95% CI).
Study
0.5 1.0
Favours first treatment Favours placebo or second 
treatment
IFN-β-1a 22 µg SC thrice weekly vs. placebo
SPECTRIMS 2001224
Subtotal
HR (95% CI)
0.88 (0.69 to 1.12)
0.88 (0.69 to 1.12)
IFN-β-1a 44 µg SC thrice weekly vs. IFN-β-1a 22 µg SC thrice weekly
SPECTRIMS 2001224
Subtotal
0.94 (0.74 to 1.21)
0.94 (0.74 to 1.21)
IFN-β-1a 44 µg SC thrice weekly vs. placebo
SPECTRIMS 2001224
Subtotal
0.83 (0.65 to 1.06)
0.83 (0.65 to 1.06)
IFN-β-1b 250 µg SC every other day vs. placebo
ESG 1998222
Subtotal
0.75 (0.61 to 0.92)
0.75 (0.61 to 0.92)
2.00.1
FIGURE 21 Pairwise comparisons: time to disability progression confirmed at 3 months in SPMS.
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Meta-analyses: time to disability progression confirmed at 6 months
Only one trial223 reported an effect size for time to disability progression confirmed at 6 months. In the
comparison between 250 µg of SC IFN-β-1b every other day and placebo, there was no statistically significant
effect of the study drug on time to disability progression. We imputed this HR as 0.93 (95% CI 0.71 to 1.22).
Meta-analyses: adverse events
Summary of adverse events meta-analyses
Full results for pairwise meta-analyses of AEs are available on request. Although the diversity and
heterogeneity of AEs precluded detailed examination of each, several trends were apparent across pairwise
comparisons. SC IFN-β-1a three times weekly was associated with more application site disorders, more
cases of necrosis, higher levels of alanine aminotransferase and aspartate aminotransferase, more cases of
leucopenia and lymphopenia, higher levels of NABs and a higher number of patients who discontinued
study treatment because of AEs than placebo. Comparing 250 µg of SC IFN-β-1b every other day with
placebo, IFN-β-1b was associated with more injection site inflammation, more cases of necrosis, pain,
injection site reactions, chest pain, chills only, chills and fever, fever only, flu syndrome, hypertonia,
leucopenia, lymphadenopathy, lymphopenia, higher levels of NABs, rash and a higher number of patients
who discontinued study treatment because of AEs.
Meta-analyses: discontinuation because of adverse events
Pairwise meta-analyses
All three studies presented data for discontinuation of the study drug because of AEs and all studies
included follow-up of 36 months. Pairwise estimates are provided in Figure 22. Compared with placebo,
all drugs were associated with a significant increase in the risk of discontinuation because of AEs.
Network meta-analyses
Studies formed a star-shaped network. Examination of SUCRAs in the resultant network suggested that
44 µg of SC IFN-β-1a three times weekly was ranked highest for discontinuation of the study drug because
of AEs (i.e. associated with the greatest risk), followed by 22 µg of SC IFN-β-1a three times weekly and
250 µg of SC IFN-β-1b every other day (Table 19). Placebo was ranked last.
As would be expected, estimates from comparisons with placebo were unchanged in the NMA compared
with the pairwise meta-analysis. There was no evidence from the NMA that any one drug was more likely
to result in discontinuations because of AEs than any other drug.
Because there was no opportunity for inconsistency in the network, we did not test for it.
TABLE 18 Network meta-analysis: time to disability progression confirmed at 3 months in SPMSa
Drug SUCRA
IFN-β-1b 250 µg
SC every other
day
IFN-β-1a 44 µg SC
three times weekly
IFN-β-1a 22 µg SC
three times weekly Placebo
IFN-β-1b 250 µg SC
every other day
0.85 0.91 (0.65 to 1.25) 0.85 (0.62 to 1.18) 0.75 (0.61 to 0.92)
IFN-β-1a 44 µg SC
three times weekly
0.64 0.94 (0.74 to 1.21) 0.83 (0.65 to 1.06)
IFN-β-1a 22 µg SC
three times weekly
0.44 0.88 (0.69 to 1.12)
Placebo 0.07
a Findings are expressed as HR (95% CI).
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Summary: secondary progressive multiple sclerosis
Findings for SPMS patients with a recent history of relapses were not reported consistently by studies;
thus, the findings should be regarded with caution. Taken together, the three studies suggested that the
included drugs reduced the relapse rate and relapse severity relative to placebo, although we were unable
to clarify issues related to relapse severity data from one trial. Findings for disability progression were mixed.
We were unable to locate any relevant comparisons for combined clinical–MRI measures of freedom from
disease activity. One study reported MS symptom data and did not find evidence of differences between the
study drug and placebo. There were no significant differences between the study drugs and placebo in
terms of mortality. Each drug was associated with an increased risk of discontinuation because of AEs.
Network meta-analyses of ARR and time to disability progression confirmed at 3 months did not suggest
superiority of one drug over another, nor did NMAs of discontinuation because of AEs suggest that one
drug was more likely to result in discontinuation than any other. We did not undertake meta-analyses for
relapse severity because of unresolved questions about one of the three included studies and because only
one study reported time to disability progression confirmed at 6 months.
Study
0.10 1.00
Favours first treatment Favours placebo or second treatment
IFN-β-1b 250 µg SC every other day vs. placebo
ESG 1998222
NASG 2004223
Subtotal (I2 = 0.0%, p = 0.640)
IFN-β-1a 22 µg SC thrice weekly vs. placebo
SPECTRIMS 2001224
Subtotal (I2 = .%, p = .)
IFN-β-1a 44 µg SC thrice weekly vs. placebo 
SPECTRIMS 2001224
Subtotal (I2 = .%, p = .)
Note: weights are from random-effects analysis
2.98 (1.69 to 5.25)
2.43 (1.27 to 4.66)
2.73 (1.78 to 4.19)
2.94 (1.09 to 7.95)
2.94 (1.09 to 7.95)
3.62 (1.37 to 9.56)
3.62 (1.37 to 9.56)
RR (95% CI)
56.96
43.04
100.00
100.00
100.00
100.00
100.00
% weight
100.0010.000.01
FIGURE 22 Pairwise meta-analyses: discontinuation because of AEs in SPMS. RR, risk ratio.
TABLE 19 Network meta-analysis: discontinuation because of AEs in SPMSa
Drug SUCRA
IFN-β-1a 44 µg SC
three times weekly
IFN-β-1a 22 µg SC
three times weekly
IFN-β-1b 250 µg SC
every other day Placebo
IFN-β-1a 44 µg
SC three times
weekly
0.81 1.23 (0.64 to 2.37) 1.32 (0.46 to 3.83) 3.62 (1.37 to 9.56)
IFN-β-1a 22 µg
SC three times
weekly
0.60 1.08 (0.37 to 3.18) 2.94 (1.09 to 7.95)
IFN-β-1b 250 µg
SC every other
day
0.58 2.73 (1.78 to 4.19)
Placebo 0.01
a Findings are expressed as risk ratio (95% CI).
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Overall summary of clinical effectiveness findings
In CIS, each included drug showed evidence of delaying time to CDMS. The NMA did not show evidence
of the superiority of one drug over another, although the network was sparse and only one drug was
represented by more than one trial. In RRMS, drugs showed good evidence of reducing the relapse rate,
including the rate of moderate or severe relapses and, in most cases, the rate of steroid-treated relapses.
There was little evidence of the superiority of one drug over another in reducing the relapse rate. Some
drugs, but not all, delayed time to disability progression confirmed at 3 months, although there was no
evidence of the superiority of one drug over any other. The NMA for time to disability progression
confirmed at 6 months indicated that most drugs showed improvement over placebo in delaying time to
progression, but this analysis was sparse and several comparisons against placebo relied solely on indirect
evidence. Finally, in SPMS, all drugs reduced the relapse rate, although the network was sparse and relied
on three studies. Time to confirmed disability progression at 3 months was measured in only two studies,
which showed variable effects across treatments. Analyses of discontinuation because of AEs in RRMS and
SPMS were indicative, but again did not point to one drug being more likely than any other to result in
discontinuation because of an AE.
We were unable to undertake meta-analyses for additional outcomes – MS symptoms, HRQoL and
freedom from disease activity – because of heterogeneity and sparsity of data and poor reporting for these
outcomes. Additionally, no studies reported discontinuation because of loss of effect attributed to NABs.
The conclusions are tempered by several considerations. Analyses did not show a clear ‘winner’ across
outcomes and, again, comparisons between drugs as part of NMA models were in the main inconclusive.
Although the main model for ARR was the best-populated model, analyses for relapse severity were sparse.
Analyses for time to disability progression confirmed at 6 months were especially sparse. In particular, several
comparisons of drugs with placebo as part of this last model relied exclusively on indirect evidence. Moreover,
analyses for time to progression confirmed at 3 and 6 months did not show a consistent pattern, except that
all drugs were beneficial in delaying disability progression. This is particularly concerning, as progression
confirmed at 6 months is considered to be a ‘stronger’ outcome than progression confirmed at 3 months.
NMA models also had an imbalanced risk of bias across the networks of studies. For example, most active
drug compared with active drug trials were open-label trials. Finally, trials relied on short follow-up times of
mostly < 2 years in duration.
We used the drug-specific estimates for ARR, disability progression sustained at 3 months and disability
progression sustained at 6 months derived from our NMAs in the economic modelling presented in
Chapter 12. Our NMAs informed key clinical parameters in sensitivity analyses for our base-case model.
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Chapter 6 Manufacturers’ submissions:
clinical effectiveness
Three submissions were received from:
1. Merck for 44 µg and 22 µg of IM IFN-β-1a three times weekly (Rebif)
2. Teva Pharmaceutical Industries for 20 mg of SC GA daily or 40 mg of SC GA three times
weekly (Copaxone)
3. Biogen Idec Ltd for 125 µg of SC pegIFN-β-1a every 2 weeks (Plegridy) and 30 µg of IM IFN-β-1a
weekly (Avonex).
44 µg and 22 µg of interferon beta-1a intramuscularly three times
weekly (Rebif): summary of the Merck submission
The clinical effectiveness section of the submission presented an overview of the relevant trials sponsored
by the manufacturer, including the following clinical effectiveness data.
Clinical effectiveness of Rebif in relapsing–remitting multiple sclerosis
The manufacturer’s submission stated that, in patients with RRMS, Rebif demonstrated short-term and
long-term efficacy in reducing relapses and delaying disease progression compared with BSC. The
submission included findings from the PRISMS trial,189 including its long-term and observational extensions,
to support this claim. The manufacturer’s submission also presented findings from head-to-head trials,
including the EVIDENCE,195 IMPROVE207 and REGARD192 trials.
Clinical effectiveness of Rebif in clinically isolated syndrome
The manufacturer’s submission stated that, in patients with CIS, Rebif demonstrated a reduction in the
number of patients who progressed to a diagnosis of MS over the short and long term compared with
BSC. The submission included findings from the REFLEX trial,175 including its long-term and observational
extension, to support this claim.
Clinical effectiveness of Rebif in secondary progressive multiple sclerosis
The manufacturer’s submission stated that, in trials including subsets of patients with SPMS with relapses,
Rebif has some, but not a significant, effect in terms of reducing the time to disability progression and a
significant effect in terms of reducing the relapse rate. The submission included findings from the
SPECTRIMS trial224 to support this claim.
Risk sharing scheme findings on the clinical effectiveness of Rebif
The year 10 RSS analysis and data for Rebif were included in the manufacturer’s submission. The
submission stated that the HRs estimated from the RSS for disability progression for Rebif compared with
BSC (confidential information has been removed) were within the 10% range for the target HR needed to
result in clinical effectiveness. The manufacturer’s submission also noted that the RSS yielded an estimate
of effectiveness for Rebif that was similar to estimates from the PRISMS trial.
Our assessment of the Merck submission
Our AMSTAR assessment of the manufacturer’s submission is provided in Table 20.
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Review of the network meta-analyses methods
Model type
Network meta-analyses models were estimated in the Bayesian framework. Both fixed-effects and random-
effects models were assessed according to the relative treatment-specific effect. The fit of the fixed-effects
and random-effects models was compared using the deviance information criterion (DIC). A lower DIC is
indicative of better fit. The best-fitting model was identified for each analysis. When the fit was similar
between the fixed-effect model and the random-effects model, the random-effects model was adopted as
a conservative approach. Moreover, the NMA included a comparison of the posterior distribution of
between-study SDs with the prior distributions to assess whether it was updated by the available evidence
(i.e. the additional information had had an effect). Consistency was assessed using node-splitting analyses.
(Confidential information has been removed.)
TABLE 20 The AMSTAR appraisal of the Merck submission
AMSTAR checklist Manufacturer’s submission
1. Was an ‘a priori’ design provided? Yes – the systematic review protocol was described in the
submission appendix
2. Was there duplicate study selection and data
extraction?
Yes – all abstracts were reviewed by two experienced systematic
reviewers according to the eligibility criteria; any differences in
opinion regarding eligibility were resolved through discussion with
a third reviewer. The same process was applied to the subsequent
review of full papers
3. Was a comprehensive literature search performed? Yes – searches were performed in the following electronic
databases: MEDLINE and MEDLINE In-Process & Other Non-Indexed
Citations (via Ovid SP); EMBASE (via Ovid SP); CENTRAL; and PubMed
(for e-publications ahead of print). Abstracts from the following key
international conferences were searched: Americas Committee for
Treatment and Research in Multiple Sclerosis (ACTRIMS) Annual
Meeting (2015); European Committee for Treatment and Research
in Multiple Sclerosis (ECTRIMS) Annual Congress (2015); ACTRIMS
and ECTRIMS joint meeting (2014); American Academy of Neurology
(AAN) Annual Meeting (2015); and American Neurological
Association (ANA) Annual Meeting (2014 and 2015). Searches were
run on 5 October 2015
4. Was the status of publication (i.e. grey literature)
used as an inclusion criterion?
No inclusion of grey literature
5. Was a list of studies (included and excluded)
provided?
Included studies were listed; excluded studies were not listed in
the main submission but those excluded from the NMA were
listed in the NMA document
6. Were the characteristics of the included studies
provided?
Interventions, doses, regimens, numbers of participants and the
data arising from the review that was used to inform the NMA
are shown in the appendix. Comparison tables of patient baseline
characteristics and for the outcomes of ARR and sustained
disability progression in the identified RCTs are available on request
7. Was the scientific quality of the included studies
assessed and documented?
Quality appraisal tables are available on request; not supplied
because of the number of pages
8. Was the scientific quality of the included studies
used appropriately in formulating conclusions?
Not stated that quality of studies used in formulating conclusions;
no mention of sensitivity analyses by study quality
9. Were the methods used to combine the findings
of studies appropriate?
Methods appear appropriate
10. Was the likelihood of publication bias assessed? Not stated
11. Was the conflict of interest included? Manufacturer’s submission
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Prior distributions and estimation
The models were fitted using the OpenBUGS software package version 3.2.2 (Free Software Foundation,
Inc., Boston, MA, USA). Models used 100,000 burn-in simulations with 150,000 simulations used. Flat
priors were used in all cases for the treatment-specific, study-specific and between-study variance terms.
Interventions
The NMA included all trials testing licensed drugs with dosages at or below the recommended dose.
Interventions and comparators of interest were immunosuppressives or immunomodulators: alemtuzumab
(Lemtrada), dimethyl fumarate (Tecfidera), fingolimod (Gilenya), GA (Copaxone), IFN-β-1a (Avonex),
IFN-β-1b (Betaferon/Extavia), pegylated IFN-β-1a, natalizumab (Tysabri) and teriflunomide (Aubagio).
Outcomes and data preparation
The NMA included analyses for ARR and disability progression. Models for disability progression included
progression confirmed at 6 months, with additional data from confirmation at 3 months when 6-month
data were not available, and the converse, that is, disability progression confirmed at 3 months, with
additional data from confirmation at 6 months when 3-month data were not available. One potential issue
with this method is that analyses are not strictly interpretable and rely on an assumption that progression
estimates from 3 months and 6 months are exchangeable, but this is unclear and may be questionable.
Authors used an optimisation algorithm to estimate person-years and number of relapses to be used with
an exact Poisson likelihood. Authors also used summary HRs in estimating disability progression models.
One strength of the reporting in this NMA was the transparency about included effect sizes for
each model.
Participants
The NMA included all patients with a diagnosis of RRMS or progressive relapsing MS (PRMS). The NMA
included an informal assessment of the similarity of baseline characteristics across trials. The authors did
not undertake meta-regression or subgroup analyses.
Included trials
Unlike the assessment group’s NMA, the NMA in the manufacturer’s submission included trials with
comparators outside the NICE scope.141 However, even though the NMA in the manufacturer’s submission did
not set explicit restrictions on the duration of follow-up, several trials appeared to be missing, including the
BRAVO trial,198 IMPROVE trial,207 trial by Knobler et al.,211 trial by Kappos et al.199 and the GATE trial.220 Although
some of these trials may have been published after the last search, it is not clear why they were excluded.
Findings from the network meta-analyses presented in the manufacturer’s submission
Annualised relapse rate findings
A lower ARR is indicative of a better response. Although the submitted NMA covered a variety of doses and
drugs, we summarise here only those results relating to licensed doses of the drugs under consideration.
(Confidential information has been removed.)
Sustained disability progression findings
(Confidential information has been removed.)
Results compared with the results of the assessment group’s network meta-analyses
For ARR, the results for 22 µg of IFN-β-1a three times weekly and 44 µg of IFN-β-1a three times weekly
compared with placebo were similar in the manufacturer’s NMA and in the assessment group’s NMA.
(Confidential information has been removed.) This was also the case in the assessment group’s NMA.
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The ‘blending’ method used in the manufacturer’s NMA for analyses of sustained disability progression
at 3 months and 6 months means that its analyses are not strictly commensurate with the assessment group’s
NMAs. Over both analyses, the assessment group’s NMAs suggested a significant effect of 22 µg of IFN-β-1a
three times weekly and 44 µg of IFN-β-1a three times weekly. (Confidential information has been removed.)
Summary of the Merck submission
The quality of the submitted systematic review and NMA was reasonable and appropriate and the findings
matched in magnitude and direction, although not always in significance, the corresponding findings from
the assessment group’s NMAs. The assessment group did note challenges with the interpretation of the
combined disability progression models and observed that several ostensibly relevant trials were not
included in the NMA. Additionally, the submission included trials of patients with PRMS, which was
outside the NICE scope141 for this submission. NMAs were not presented for CIS or SPMS.
20mg of glatiramer acetate subcutaneously daily or 40mg of glatiramer
acetate subcutaneously three times weekly (Copaxone): summary of the
Teva Pharmaceutical Industries submission
Clinical effectiveness of Copaxone in relapsing–remitting multiple sclerosis and clinically
isolated syndrome
The manufacturer’s submission stated that GA in both doses (20 mg SC daily and 40 mg SC three times
weekly) reduces the ARR and disability progression. It cited the trial by Bornstein et al.,170 the Cop1 MSSG
trial,217 the ECGASG trial,219 the trial by Calabrese et al.,188 the CONFIRM trial216 and the GALA trial221 in
support of this claim. It further noted that GA in its 20-mg SC daily dose delays progression to CDMS,
citing the PreCISe trial174 and its extension.235
Risk sharing scheme findings on the clinical effectiveness of Copaxone
The manufacturer’s submission stated that, based on the year 10 RSS analysis, 20 mg of SC GA once daily
reduced EDSS disability progression at 10 years (confidential information has been removed), with no
evidence of a treatment waning effect at 10 years compared with the updated 6-year analysis. Based on
the year 6 data, the manufacturer’s submission stated that, compared with the total IFN-β cohort together,
the Copaxone cohort (confidential information has been removed).
Our assessment of the Teva Pharmaceutical Industries submission
Our assessment of the systematic review contained in the Teva submission is provided in Table 21.
Review of the network meta-analyses methods
Model type
Models were estimated in the Bayesian framework. Both fixed-effects and random-effects models were
estimated and then compared on fit. The authors also estimated pairwise meta-analyses and
heterogeneity statistics.
Prior distributions and estimation
The authors used non-informative prior distributions. The authors used WinBUGS version 1.4.3 software
(MRC Biostatistics Unit, Cambridge, UK) in all NMAs. In each model, two parallel chains were run, with a
50,000 iteration burn-in period. A total of 20,000 iterations against a thinning fact of 10 were sampled
from each of the two chains. Convergence was assessed using Brooks–Gelman–Rubin diagnostics.
Interventions
All licensed drugs were included. Dosages were not specified, which poses significant ambiguity about whether
all dosages in the literature were considered or only those that correspond to the marketing authorisation.
It appears that both dosages of GA were pooled into one node in the analysis, but this was not clear.
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Outcomes and data preparation
For disability progression, the authors estimated the number of events and the person-years of follow-up in
each study and analysed data using a binomial likelihood with a complementary log-log link. Analyses used a
model in which disability progression confirmed at 6 months was preferred, with 3-month data used when
6-month data were not available. Analyses of ARR used an arm-level data approach with a Poisson likelihood.
Although the authors presented relevant arm-level data for trials including GA in the text of the submission,
it was not clear what the NMA inputs were. No forest plots for individual study estimates were presented.
Participants
Only participants with RRMS were included in the NMA.
Included trials
Unlike the assessment group’s NMA, the NMA in the manufacturer’s submission included trials with
comparators outside the NICE scope.141 However, the authors also excluded studies with a follow-up of
< 6 months. Within these restrictions, it appears that the authors captured all relevant trials, although the
trial by Knobler et al.211 was not included.
TABLE 21 The AMSTAR appraisal of the Teva submission
AMSTAR checklist Manufacturer’s submission
1. Was an ‘a priori’ design provided? Yes – protocol in the submission appendix
2. Was there duplicate study selection and data
extraction?
Not stated
3. Was a comprehensive literature search performed? Yes – searches were performed in PubMed, EMBASE and The
Cochrane Library
4. Was the status of publication (i.e. grey literature)
used as an inclusion criterion?
No mention of grey literature
5. Was a list of studies (included and excluded)
provided?
Included studies were listed in the appendix; a list of excluded
studies was not provided
6. Were the characteristics of the included studies
provided?
Yes – in the appendix
7. Was the scientific quality of the included studies
assessed and documented?
Yes – in the appendix
8. Was the scientific quality of the included studies
used appropriately in formulating conclusions?
An analysis of heterogeneity in the included studies was carried
out and a number of potential sources of heterogeneity were
identified. The main sources of heterogeneity and their impacts
were investigated further through sensitivity analyses. The
following sensitivity analyses were conducted: exclusion of studies
with < 2 years’ follow-up; exclusion of studies with < 50 patients
per treatment arm; and a separate analysis of 3-month and
6-month confirmed disability progression. However, it does not
appear that sensitivity analyses were carried out using overall
quality scores. The results of RCTs were shown separately from
the results of non-randomised studies
9. Were the methods used to combine the findings
of studies appropriate?
Results were tabulated but not combined in forest plots
10. Was the likelihood of publication bias assessed? Not stated
11. Was the conflict of interest included? Manufacturer’s submission
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Findings from the network meta-analyses presented in the manufacturer’s submission
Annualised relapse rate findings
(Confidential information has been removed.)
Sustained disability progression findings
(Confidential information has been removed.)
Results compared with the results of the assessment group’s network meta-analyses
(Confidential information has been removed.) HRs for disability progression at 3 months and 6 months
were blended and pooled across Copaxone doses in the manufacturer’s submission, but were analysed
separately in the assessment group’s NMA; thus, the findings are not strictly commensurate. (Confidential
information has been removed) in the assessment group’s NMA the HR for disease progression for GA
compared with placebo was significantly better at 3 months (HR 0.76, 95% CI 0.60 to 0.97) only and not
at 6 months (HR 0.82, 95% CI 0.53 to 1.26). Point estimates for disability progression were similar.
Summary of the Teva Pharmaceutical Industries submission
The quality of the submitted systematic review and NMA was reasonable and appropriate and the findings
matched in magnitude and direction, although not always in significance, the corresponding findings from
the assessment group’s NMAs. The assessment group did note challenges with the interpretation of the
combined disability progression models, but found that the inclusion of trials was reasonable and clear.
However, there was a considerable lack of transparency about the inputs that were used for each NMA
model and no forest plots were presented. Additionally, it was not clear how dosages were used in the
included models. NMAs were not presented for CIS.
30 µg of interferon beta-1a intramuscularly weekly (Avonex) and
125 µg of pegylated interferon beta-1a subcutaneously every 2 weeks
(Plegridy): summary of the Biogen Idec Ltd submission
Clinical effectiveness of Avonex in relapsing–remitting multiple sclerosis and
clinically isolated syndrome
The manufacturer’s submission stated that 30 µg of IM IFN-β-1a weekly is effective in reducing the relapse
rate and disability progression compared with placebo, citing the MSCRG trial200 and its observational
extension236 as evidence. The submission further stated that 30 µg of IM IFN-β-1a weekly is effective in
delaying CDMS in patients with CIS, citing the CHAMPS trial172 and its open-label extension237 in support
of this.
Risk sharing scheme findings on the clinical effectiveness of Avonex
The clinical effectiveness of Avonex in the RSS showed that, in the year 10 analysis, (confidential
information has been removed).
Clinical effectiveness of Plegridy in relapsing–remitting multiple sclerosis
The manufacturer’s submission stated that 125 µg of SC pegylated IFN-β-1a every 2 weeks is effective in
reducing the relapse rate and disability progression compared with placebo, citing the ADVANCE trial213
as well as its extension238 in support of this. Plegridy was not included in the RSS.
Our assessment of the Biogen Idec Ltd submission
Our assessment of the systematic review contained in the Biogen Idec Ltd submission is provided
in Table 22.
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TABLE 22 The AMSTAR appraisal of the Biogen Idec Ltd submission
AMSTAR checklist Manufacturer’s submission
1. Was an ‘a priori’ design provided? Yes – Table 37
2. Was there duplicate study selection and
data extraction?
Yes – the literature searches for this review were conducted as part of a
wider programme of research on treatments for MS. Search strategies
included terms designed to identify studies of all European Union
(EU)-approved treatments or treatments expected to be approved in
the near future in CIS, RRMS or SPMS patients. Identified studies were
independently assessed by a reviewer to ascertain whether they met
the predefined inclusion and exclusion criteria [based on population,
interventions, comparators and outcomes (PICOS)], with any uncertainties
resolved by discussion with a second reviewer. Data were extracted from
eligible publications into a predefined table by a reviewer. All studies
meeting the inclusion criteria described in Table 37 were initially included
in the systematic review. These studies were then screened by two
reviewers against the PICOS criteria of the NICE MTA of IFN-β and GA
(NICE scope141) for treating MS to identify relevant studies for inclusion in
meta-analyses and narrative syntheses
3. Was a comprehensive literature search
performed?
Yes – searches were conducted in October 2014 and updated on
9 November 2015 in MEDLINE (including MEDLINE In-Process & Other
Non-Indexed Citations and MEDLINE Daily Update), EMBASE, CENTRAL
and Science Citation Index, with no restrictions on date. Using Boolean
operators, the searches combined terms [including medical subject
headings (MeSH) as appropriate] for the condition, the treatments and
the outcomes of interest. A rapid appraisal was also conducted to
identify relevant systematic reviews, TAs, guidelines and guidance in the
following databases: Cochrane Database of Systematic Reviews, DARE,
HTA database, NICE, National Institute for Health Research (NIHR),
Canadian Agency for Drugs and Technologies in Health (CADTH) and
PROSPERO. In addition, searches were conducted in the following clinical
trial registers to identify data from ongoing or unpublished clinical trials:
ClinicalTrials.gov, Current Controlled Trials, WHO ICTRP, PharmNet.Bund
and EU Clinical Trials Register (EUCTR). The full search strategies were
provided in appendix E. Hand searching of reference lists from included
studies and relevant systematic reviews was also conducted
4. Was the status of publication (i.e. grey
literature) used as an inclusion criterion?
Unpublished trials were sought
5. Was a list of studies (included and excluded)
provided?
A summary of the 16 studies included in the multiple treatment
comparison was provided in appendix G (Table 55). Details of studies
included in the systematic review but excluded from the multiple
treatment comparison were provided in appendix F (Table 54), along
with the rationale for their exclusion. Excluded studies were listed in
appendix 3
6. Were the characteristics of the included
studies provided?
Yes – appendix G
7. Was the scientific quality of the included
studies assessed and documented?
Yes – Table 57 and appendix G
8. Was the scientific quality of the included
studies used appropriately in formulating
conclusions?
Not stated
9. Were the methods used to combine the
findings of studies appropriate?
Yes – sensitivity analyses took into account heterogeneity
10. Was the likelihood of publication bias
assessed?
As stated in the submission, ‘Publication bias would have been assessed
using funnel plots (e.g. SE (log [RR]) vs. RR) where at least ten studies
were included in an analysis; however, there were no head-to-head
comparisons that included enough studies to produce a funnel plot’
(p. 205)
11. Was the conflict of interest included? Manufacturer’s submission
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Review of the network meta-analyses methods
Model type
Random-effects and fixed-effects models were both estimated and compared on the DIC, with random-
effects models preferred throughout. Further iterations were captured if convergence was in question.
Prior distributions and estimation
Network meta-analyses were estimated in the Bayesian framework using gemtc in the R environment
(The R Foundation for Statistical Computing, Vienna, Austria). After 50,000 burn-in iterations, a further
50,000 iterations were captured. Convergence was assessed using the Brooks–Gelman–Rubin diagnostic.
Prior distributions were non-informative.
Interventions
All studies testing comparisons of the drugs in the NICE scope141 and at the dosages contained in the
marketing authorisations were included. Thus, dosages were clearly specified.
Outcomes and data preparation
Analyses included ARR for studies with follow-up of at least 12 months; HRs for disability progression
confirmed at 3 months and, separately, at 6 months, with follow-up data at 12 or 24 months; and ORs
for either any AE or serious AE. Data were analysed as log RRs, log HRs or log ORs with corresponding
standard errors. The authors did not provide a justification for models that were intended to be estimated
at either 12 or 24 months’ follow-up or why they chose to stratify estimates in this way. There was a lack
of clarity regarding study inputs and no forest plots for individual study estimates were presented.
Participants
Although the searches included patients with RRMS, CIS and SPMS, it appears that only RRMS trials were
meta-analysed.
Included trials
Studies excluded from the NMA and reasons for exclusion were, overall, clearly documented. However,
the Biogen Idec Ltd NMA excluded several studies on what would appear to be the basis of short-term
follow-up. This was not made explicit.
Findings from the network meta-analyses presented in the manufacturer’s submission
The NMA found that 30 µg of IM IFN-β-1a weekly significantly reduced the ARR relative to placebo,
but not relative to other treatments. In fact, in the manufacturer’s NMA, 20 mg of SC GA once daily was
more effective at reducing the ARR than 30 µg of IM IFN-β-1a weekly. Findings for disability progression
confirmed at 3 or 6 months were not significant relative to other treatments or placebo.
The NMA found that, for ARR, no significant treatment effects were observed in the comparisons between
125 µg of SC pegylated IFN-β-1a every 2 weeks and other treatments or between 125 µg of SC pegylated
IFN-β-1a every 2 weeks and placebo, although the last finding was marginally non-significant (RR 0.64,
95% CI 0.41 to 1.04). For disability progression sustained at 3 or 6 months, no statistically significant
differences were observed between 125 µg of SC pegylated IFN-β-1a every 2 weeks and other treatments
or placebo.
Analyses for AEs were conducted only for 30 µg of IFN-β-1a weekly. No differences were found relative to
placebo or other treatments.
The authors carried out a wide variety of sensitivity analyses, which were summarised in appendix H.
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Results compared with the results of the assessment group’s network meta-analyses
Biogen Idec Ltd’s NMA on the whole did not identify a statistically significant benefit of 125 µg of
pegylated IFN-β-1a every 2 weeks or 30 µg of IFN-β-1a weekly with regard to the key outcomes – ARR
and disability progression confirmed at 3 months and 6 months. However, both drugs demonstrated
statistically significant effectiveness for these three outcomes in the assessment group’s NMA. Point
estimates were generally similar between the NMA for ARR and the NMA for time to disability progression
confirmed at 3 months. This discrepancy may result from the choice of prior distribution for between-trial
variance in the base case of the manufacturer’s NMA, as well as the apparent exclusion of studies with
short-term follow-up. Notably, the assessment group considered several more drugs in the analysis of
disability progression confirmed at 6 months than it would appear were included in the manufacturer’s
NMA for this outcome.
Summary of the Biogen Idec Ltd submission
The quality of the submitted systematic review was both reasonable and appropriate. Although a strength
of the models was the explicit approach to dosages of comparators included, inputs in the NMA models
were opaque and no study-level forest plots were presented with specific estimates. Moreover, the initial
decision to stratify estimates by 12 or 24 months was not clearly explained and apparent exclusions based
on follow-up were not explicitly declared.
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Chapter 7 Methods for the assessment of
cost-effectiveness studies
Identification of studies: clinically isolated syndrome
Introduction
The purpose of this systematic review was to identify existing cost-effectiveness model designs in CIS and
to identify parameter values (e.g. health state utilities and costs) suitable for use in a decision-analytic
model. We did not identify a suitable systematic review in CIS in the overview of systematic reviews (see
Appendix 5) and scoping searches did not find many existing models. Therefore, our searches were broad
and not limited by date.
Search strategy
The following electronic databases were searched: MEDLINE (via Ovid); MEDLINE In-Process & Other
Non-Indexed Citations and MEDLINE Daily Update (via Ovid); EMBASE (via Ovid); The Cochrane Library
(via Wiley Online Library), including the NHS EED and HTA database; Science Citation Index (Web of
Knowledge); Research Papers in Economics (RePEc) and the Cost-effectiveness Analysis (CEA) Registry. The
database searches were designed to be broad in nature, with search terms for CIS combined with terms
for economic/HRQoL generic measures (based on recognised search filters239–242) when appropriate. A full
record of the searches carried out is provided in Appendix 6. The searches were not limited by publication
date. All bibliographic records identified through the electronic searches were collected in a managed
reference database. The reference lists of included studies were also checked. Grey literature searches were
undertaken concurrently for both clinical effectiveness and cost-effectiveness evidence using the online
resources of various regulatory bodies, health service research agencies, professional societies and patient
organisations. For a record of these searches, see Appendix 1.
We undertook several additional searches. We checked the reference lists of primary studies identified
through database searches for studies on the natural history of people with CIS and CIS patient registries.
We also undertook targeted database searches to identify any additional CIS patient registries including
data from before 1995 (see Appendix 7). We searched studies citing included studies to identify more
recent literature.
Inclusion and exclusion criteria
Studies meeting the following criteria were included in the review:
l population – adults (aged ≥ 18 years) diagnosed with CIS, defined as people who had experienced a
single demyelinating event in one or several areas of the CNS within the previous 2 months
l interventions – DMTs (IFN-β-1a, IFN-β-1b and GA) licensed for the treatment of CIS
l comparators – BSC without DMTs or another DMT (IFN-β-1a, IFN-β-1b or GA) licensed for the
treatment of CIS
l outcomes – cost per QALY gained, cost per life-year gained and cost per case of MS delayed
l study design – economic analysis consisting of a decision-analytic model
l language – English and Spanish.
All publication types were included.
Other studies that contained information on parameter values (e.g. health state utilities, costs, natural
history outcomes) suitable for use in a decision-analytic model were identified at this stage and set aside
for later review.
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Studies in people diagnosed with RRMS, SPMS or PPMS were excluded.
Study selection
Studies were first reviewed on title and abstract by two reviewers working independently (Hendramoorthy
Maheswaran and Peter Auguste). Subsequently, full-text studies were accessed and checked against the
criteria for inclusion. As mentioned in the previous section, studies that presented information on costs and
outcomes related to the natural history of, or DMT for people with, CIS were also examined at this stage
and set aside for later review.
Data extraction
Data extraction was conducted by two reviewers (Hendramoorthy Maheswaran and Peter Auguste).
Information extracted by one reviewer was cross-checked by the other. Any disagreements were resolved
by discussion or by recourse to a third-party reviewer (Jason Madan). We extracted study details (title,
author and year of study), background characteristics (population, intervention, comparator and outcomes),
methods (study perspective, time horizon, discount rate, measure of effectiveness, assumptions and
analytical methods), results (study parameters, base-case and sensitivity analyses), discussion (study findings,
limitations of the models and generalisability) and ‘other’ details (source of funding and conflicts of
interests). The data extraction sheet is presented in Appendix 6.
Quality assessment
The studies were appraised using the Consolidated Health Economic Evaluation Reporting Standards
(CHEERS)243 and Philips et al.244 frameworks for best practice in economic evaluation and decision-analytic
modelling respectively. The CHEERS assessment tool243 consists of six dimensions: title and abstract,
introduction, methods, results, discussion and other. A series of questions is used to check whether these
dimensions/attributes have been satisfactorily reported (see Appendix 6). The Philips et al.244 tool consists of
two main dimensions: structure of the model and information used to parameterise the model. A series of
questions is used to check whether these have been satisfactorily conducted (see Appendix 6).
The quality assessment was undertaken by two reviewers (Hendramoorthy Maheswaran and Peter Auguste).
Study quality assessed by Hendramoorthy Maheswaran was cross-checked by Peter Auguste and vice versa.
Any disagreements were resolved by discussion or by recourse to a third-party reviewer (Jason Madan).
Data synthesis
Findings from the included studies were synthesised narratively with the goal of summarising current
modelling methods.
Identification of studies: relapsing–remitting multiple sclerosis
Introduction
The purpose of this systematic review was to identify existing cost-effectiveness model designs in RRMS
and to identify parameter values (e.g. health state utilities, costs) suitable for use in a decision-analytic
model. We identified several related systematic reviews of cost-effectiveness evaluations in RRMS in the
overview of systematic reviews.245–253 Therefore, we performed searches for primary cost-effectiveness
studies from the earliest search date found in these selected reviews (i.e. 2012) to April 2016. We
performed separate searches for relevant HRQoL studies, with no date limits applied. We used
well-established methods that are used for undertaking systematic reviews of clinical studies.166
Search strategy
The following electronic databases were searched separately for cost-effectiveness studies and HRQoL
studies: MEDLINE (via Ovid); MEDLINE In-Process & Other Non-Indexed Citation and MEDLINE Daily Update
(via Ovid); EMBASE (via Ovid); The Cochrane Library (via Wiley Online Library), including the NHS EED and
HTA database; Science Citation Index (Web of Knowledge); RePEc; and the CEA Registry. The database
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searches were kept broad, with search terms for MS combined with terms for economics/HRQoL generic
measures (based on recognised search filters239–242) when appropriate. A full record of the searches carried
out is provided in Appendix 7. The searches for primary cost-effectiveness studies were limited by
publication date from January 2012 to April 2016. HRQoL searches were not limited by publication date.
All bibliographic records identified through the electronic searches were collected in a managed reference
database. The reference lists of included studies were also checked. Grey literature searches were
undertaken using the online resources of various regulatory bodies, health service research agencies,
professional societies and patient organisations.
The following additional searches were undertaken. We checked the reference lists of primary studies
identified through the searches described in the paragraph above for studies on the natural history of
people with RRMS and RRMS patient registries. We also undertook targeted database searches to identify
any additional RRMS patient registries that included data from before 1995 (see Appendix 7). Citation
searches on the included studies were undertaken to identify more recent literature.
Inclusion and exclusion criteria
Studies meeting the following criteria were included in the review:
l population – adults (≥ 18 years) diagnosed with RRMS
l interventions – DMTs (IFN-β-1a, pegylated IFN-β-1a, IFN-β-1b or GA) licensed for the treatment
of RRMS
l comparators – BSC without DMTs or another DMT (IFN-β-1a, IFN-β-1b or GA) licensed for the
treatment of RRMS
l outcomes – cost per QALY gained, cost per life-year gained and cost per case of MS delayed
l study design – economic analysis consisting of a decision-analytic model.
Other studies that contained information on parameter values (e.g. health state utilities, costs, natural
history outcomes) suitable for use in a decision-analytic model were identified at this stage and set aside
for later review.
Studies were excluded if they included people diagnosed with CIS. Additionally, studies were excluded if
they were reported in the form of an abstract or conference proceeding or were not published in the
English language.
Study selection
Studies were first reviewed on title and abstract by two reviewers working independently (HM and PA).
Subsequently, full-text studies were accessed and checked against the criteria for inclusion. As mentioned
in the previous section, studies that presented information on costs and outcomes related to the natural
history of, or DMT for people with, RRMS were also examined at this stage and set aside for later review.
Data extraction
Data extraction was conducted by two reviewers (Hendramoorthy Maheswaran and Peter Auguste).
Information extracted by one reviewer was cross-checked by the other. Any disagreements were resolved by
discussion or by recourse to a third-party reviewer (Jason Madan). We extracted study details (title, author and
year of study), background characteristics (population, intervention, comparator and outcomes), methods
(study perspective, time horizon, discount rate, measure of effectiveness, assumptions and analytical methods),
results (study parameters, base-case and sensitivity analyses), discussion (study findings, limitations of the
models and generalisability) and ‘other’ details (source of funding and conflicts of interests). The data
extraction sheet is presented in Appendix 7.
Quality assessment
The studies were appraised against the CHEERS243 and Philips et al.244 frameworks for best practice in
economic evaluation and decision-analytic modelling respectively. The CHEERS assessment tool consists
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of six dimensions: title and abstract, introduction, methods, results, discussion and other. A series of
questions is used to check whether these have been satisfactorily reported (see Appendix 7). The Philips
et al.244 tool consists of two main dimensions: structure of the model and information used to parameterise
the model. A series of questions is used to check whether these have been satisfactorily reported (see
Appendix 7).
The quality assessment was undertaken by two reviewers (Hendramoorthy Maheswaran and Peter Auguste).
Study quality assessed by one reviewer was cross-checked by the other. Any disagreements were resolved
by discussion or by recourse to a third-party reviewer (Jason Madan).
Data synthesis
Information extracted from the included studies was summarised in a table. The findings from these
studies have been compared narratively to show the current modelling methods used and our
recommendations for future modelling of RRMS are discussed.
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Chapter 8 Results of the systematic review of the
cost-effectiveness literature
Results of the searches for clinically isolated syndrome studies
The electronic database searches identified 614 records (Figure 23). After removing duplicates, 452 records
were screened for inclusion. On the basis of title and abstract, 435 records were excluded and the
remaining 17 records were included for full-text screening. A further eight articles were excluded at the
full-text stage, with the reasons for exclusion provided in Appendix 6, leaving nine studies254–262 that
included a decision-analytic model, which were used to estimate the cost-effectiveness of DMTs for
treating people with CIS.
Description of the included studies
Summary of economic studies comparing disease-modifying therapies for people with
clinically isolated syndrome
Fredrikson et al.254
Fredrikson et al.254 used a Markov model structure to assess the cost-effectiveness of 44 µg SC IFN-β-1a
three times weekly compared with no treatment for people who had experienced a single demyelinating
event in one or several areas of the CNS within the previous 2 months. The model simulated the pathway
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FIGURE 23 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart: economic
studies relating to CIS.
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for people with CIS who received DMTs compared with no treatment and cost-effectiveness was estimated
over the model’s time horizon. The model started with a hypothetical cohort with a mean age of 31 years,
which reflected the participants in the REFLEX trial,175 and continued with participants occupying/
progressing to one of the following health states: CIS and on treatment, CIS no treatment or RRMS
defined by the McDonald 2005 criteria.66 Fredrikson et al.254 made a number of simplifying assumptions:
once people converted to RRMS they could progress in single-step increments; the treatment effect was
assumed to continue over the model time horizon, based on clinical judgement; a maximum duration of
25 years for treatment was applied; the probability of discontinuation of DMTs was derived based on the
3-year rate from the REFLEXION (REbif FLEXible dosing in early MS extensION) trial263 (this probability was
applied from year 3 for the remainder of the model duration); 95% of people with CIS would convert to
MS using the McDonald criteria; and people with MS who progressed to EDSS 7 or who converted to
SPMS would discontinue treatment.
Information required to populate the model was obtained from the REFLEX175 and REFLEXION263 trials as
well as resource use and costs from published sources. Information was required for utility values associated
with CIS and MS (by EDSS state), the conversion rate from CIS to CDMS according to McDonald MRI
criteria, the annual average dropout rate over 25 years and the market share of DMTs prescribed for MS.
Resource use and costs included those related to informal care, services, investments (house and car
modifications, walking aides, wheelchairs), symptom management medication, tests (MRI scans of the brain
and spinal cord in the first year of diagnosis and a brain MRI scan every year), ambulatory care, inpatient
care, loss of productivity because of early retirement and short-term absence. The analysis was conducted
from a societal perspective and the results were presented in terms of costs per progression-free life-years
and costs per QALY gained over a 40-year time horizon. All costs were reported in 2012 Swedish kronors
and converted to euros using a historical average exchange rate from 2005. All costs and outcomes were
discounted at 3% per annum. Along with the cost-effectiveness analysis, Fredrikson et al.254 conducted
univariate and probabilistic sensitivity analyses.
The results showed that there was an incremental gain of 1.63 progression-free life-years for people who
received a DMT compared with no treatment. Additionally, there was a 0.53 incremental QALY gain for
people who received treatment. From a societal perspective, the base-case results showed a cost saving of
approximately SEK 270,260.
Kobelt et al.255
Kobelt et al.255 used a Markov structure to assess the cost-effectiveness of 250 µg of SC IFN-β-1b every
other day compared with no treatment for people with CIS. The model simulated disease progression for a
hypothetical cohort of people being treated for CIS and cost-effectiveness was estimated over a 20-year time
horizon. The model started with a cohort of people who received either 250 µg of SC IFN-β-1b every other
day or no treatment and continued with them remaining in the CIS health state or progressing to mild,
moderate or severe MS disability. An illustrative Markov structure was not presented as this was an abstract.
The authors did not elaborate on the sources of information used to populate the model. All costs were
reported in 2006 euros. The primary outcome measure of effectiveness was QALYs gained over the
20-year time horizon; however, the authors did not elaborate on the descriptive tools used to value these
health states. All costs and benefits were discounted at 3% per annum. The analysis was conducted from
a societal perspective and the results were presented in terms of incremental cost-effectiveness ratios
(ICERs) expressed as the cost per QALY gained. Kobelt et al.255 conducted sensitivity analyses by changing
key model input parameters to determine the impact on the deterministic results. Additionally, a
probabilistic sensitivity analysis was undertaken.
The base-case results showed that IFN-β-1b dominated the no-treatment arm. In sensitivity analyses the
base-case results were robust to changes in model input parameters. The results from the probabilistic
sensitivity analysis showed that IFN-β-1b was the preferred option, with a > 50% probability of being
cost-effective compared with no treatment at a willingness-to-pay threshold of €50,000 per QALY.
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Lazzaro et al.256
Lazzaro et al.256 developed an epidemiological/survival model to estimate the cost-effectiveness of 250 µg
of SC IFN-β-1b every other day for people with a monofocal or multifocal CIS diagnosis compared with
postponing disease-modifying disease treatment until subsequent conversion to CDMS.
Information required to populate the model was obtained from published sources. Information on the
incidence of CIS, the utility value of CIS, the conversion rate from CIS to CDMS according to McDonald
MRI criteria and the annual average dropout rate over 25 years was obtained. All resource use and
costs (for disease-modifying drugs and other drugs, outpatient diagnostic procedures, consultations and
laboratory tests, hospitalisation, physical therapy, walking aids, transport, working days lost by patients and
their caregivers and informal care) were obtained from published sources and were presented in 2006 euros.
The results were presented as ICERs, expressed as cost per QALY gained over the 25-year time horizon.
The measurement and valuation of preference-based outcomes were not reported. The base-case analysis
was undertaken from the Italian National Health Service (INHS) perspective and all costs and benefits were
discounted at 3% per annum. To have a workable model, a number of simplifying assumptions were made.
The authors undertook a number of one-way (annual consumption of and average annual compliance rate
for 250 µg of SC IFN-β-1b every other day; replacement of IFN-β-1b with 44 µg of SC IFN-β-1a three days a
week; CDMS-related patient utility values) and multiway (annual conversion rates to CDMS during year 1
and 2) sensitivity analyses and also conducted a probabilistic sensitivity analysis.
From the INHS perspective, the base-case results showed that the mean incremental cost for people
who received early treatment compared with delayed treatment was approximately €894. The mean
incremental gain for people who received early treatment compared with delayed treatment was 0.35,
which equated to an ICER of approximately €2575 per QALY. From the societal viewpoint, early treatment
dominated delayed treatment, meaning that early treatment was cheaper than delayed treatment and
more effective. The results from the one-way and multiway sensitivity analyses showed that the base-case
results were sensitive to change in the DMT and the lower-limit 95% CI CDMS conversion rates during
years 1 and 2 of the epidemiological model. The results from the probabilistic sensitivity analysis showed
that, at a willingness-to-pay for an incremental QALY of €5500, early treatment was likely to be
cost-effective, with a probability of 100%.
Iskedjian et al.257
Iskedjian et al.257 used two Markov model structures to assess the cost-effectiveness of 30 µg of IM IFN-β-1a
once weekly compared with current treatment (four intravenous injections of 1 g of methylprednisolone for
3 days followed by 14 days of 1 mg of oral steroids twice daily) for people who had experienced a single,
clinically diagnosed, demyelinating event. The model simulated the pathway for people with CIS who received
DMTs compared with symptom management and cost-effectiveness was estimated over a 12-year time
horizon. The first model started with a hypothetical cohort of people receiving one of the two treatments and
captured the costs and outcomes associated with progression to CDMS and the second model estimated
the long-term costs and outcomes of progression through various EDSS states [mild (EDSS score of ≤ 3.5),
moderate (EDSS score of 4–5.5) and severe (EDSS score of ≥ 6)]. Iskedjian et al.257 made a number of simplifying
assumptions, for example that people who progressed to CDMS received no treatment benefit but accrued
costs associated with their EDSS health states and people in both arms of the model received 30 µg of IM
IFN-β-1a once weekly once diagnosed with CDMS. Relapse rates were fixed to one every 2 years, relapses were
assumed to last for 2 months and people did not discontinue treatment (i.e. 100% compliance was assumed).
Information on transition probabilities, resource use and costs was obtained from the literature. The
analysis was conducted from the Canadian Ministry of Health and societal perspectives and the results
were presented in terms of costs per mono-symptomatic life-years (MLYs) gained and QALYs gained over a
12-year time horizon. Utility values were derived based on the Health Utilities Index (HUI) questionnaire,
which was administered to Canadian MS patients. A separate analysis was undertaken that used utility
values derived from the EQ-5D questionnaire. All costs were reported in 2001 Canadian dollars and all
costs and outcomes were discounted by 5% per annum. Along with the cost-effectiveness analysis,
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Iskedjian et al.257 conducted univariate (20- and 30-year time horizons, using utility values based on the
EQ-5D questionnaire and varying the discount rate) and probabilistic sensitivity analyses.
Results from the Canadian Ministry of Health perspective showed that, over the 12-year time horizon,
mean costs were CA$173,000 and CA$108,000 for the Avonex arm and current treatment arm respectively.
Expected mean MLYs gained were 4.69 and 3.48 for the Avonex and current treatment arms, respectively,
which equated to an ICER of CA$53,110 per MLY gained. Results from the societal perspective showed that,
over the 12-year time horizon, mean costs were CA$317,000 and CA$262,000 for the Avonex and current
treatment arms respectively. Expected mean MLYs gained were 4.69 and 3.48 for the Avonex and current
treatment arms, respectively, which equated to an ICER of approximately CA$44,800 per MLY gained. The
ICERs per QALY gained were approximately CA$227,600 and CA$189,300 from the Canadian Ministry of
Health and societal perspectives respectively. Using utilities derived from the EQ-5D, the ICERs per QALY
gained were approximately CA$116,100 and CA$91,200 from the Canadian Ministry of Health and societal
perspectives respectively. The sensitivity analysis demonstrated that, in the progression to CDMS model, the
results were sensitive to the time horizon and the rate of progression to CDMS. Using a 6-year time horizon
resulted in an incremental cost per MLY gained of CA$85,100 and CA$79,300 for the Canadian Ministry of
Health and societal perspectives respectively. Increasing the probability of progressing to CDMS reduced the
incremental cost per MLY gained to CA$44,700 and CA$35,600 for the Canadian Ministry of Health and
societal perspectives respectively. Decreasing the probability of progression to CDMS resulted in an increase
in the incremental cost per MLY gained to CA$67,800 and CA$60,200 for the Canadian Ministry of Health
and societal perspectives respectively.
Arbizu et al.258
The study by Arbizu et al.258 was presented in abstract form. Arbizu et al.258 undertook a cost–utility
analysis comparing the costs and consequences of providing supportive care with those of treatment with
IFN-β-1b in Spanish patients with incident CIS. Costs were estimated from a societal perspective and
adjusted to 2008 euros. A 3% discount rate was applied to future costs and health benefits. A Markov
model was used and EDSS scores defined initial health states. In the analyses it was assumed that those
who progressed to RRMS would start IFN-β-1b and would remain on treatment until the EDSS score
worsened to 6.5. The BENEFIT trial171 findings were used to model EDSS progression over time and
transitions from CIS to MS. Costs and utility scores were predominantly obtained from published sources.
Their main findings suggested that, when the model was run over a 50-year time horizon, the ICER for
IFN-β-1b compared with no treatment was €20,500 per QALY gained. The findings were sensitive to the
time horizon, the cost of IFN-β-1b and the risk of disease progression on treatment.
Caloyeras et al.260
The study by Caloyeras et al.260 was presented in abstract form. Caloyeras et al.260 undertook a cost–utility
analysis comparing the costs and consequences of providing supportive care with those of treatment with
IFN-β-1b in Australian patients with incident CIS. The authors used findings from the BENEFIT trial171 to
determine initial EDSS scores for those with CIS, the subsequent risk of progression in EDSS score and the
risk of progressing to RRMS. Costs were estimated from a societal perspective and adjusted to 2007
Australian dollars. A discount rate of 5% was applied to future costs and health benefits, in accordance
with Australian policy guidelines. A Markov model was used and EDSS scores defined initial health states
for CIS and RRMS. The costs and utilities attached to treatment health states for CIS and RRMS were
identical and dependent on the EDSS score. It was assumed that DMTs were discontinued when disability
worsened to an EDSS score of 6.5. Published sources were used to estimate costs and utility weights for
health states.
When the model was run over a 25-year time horizon the ICER for IFN-β-1b compared with supportive
care was AU$20,000 (US$14,000) per QALY gained.
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Caloyeras et al.259
The study by Caloyeras et al.259 was presented in abstract form, with the poster presentation retrieved for
appraisal. Caloyeras et al.259 undertook a cost–utility analysis comparing the costs and consequences of
providing supportive care with those of treatment with IFN-β-1b in Australian patients with incident CIS.
The authors used findings from the BENEFIT trial171 to determine initial EDSS scores for those with CIS, the
subsequent risk of progression in EDSS scores and the risk of progressing to RRMS. Costs were estimated
from a societal perspective and adjusted to 2007 Australian dollars. A discount rate of 5% was applied to
future costs and health benefits, in accordance with Australian policy guidelines. A Markov model was
used and EDSS scores defined initial health states for CIS and RRMS. The costs and utilities attached to
treatment health states for CIS and MS were the same and dependent on EDSS score. It was assumed that
DMTs were not discontinued unless disability worsened to an EDSS score of 6.5. Patients were limited to
one AE per annum.
The main findings suggested that, when the model was run over a 25-year time horizon, the ICER for
IFN-β-1b compared with no treatment was AU$68,000 per QALY gained.
It is of note that these findings are presented by the same group as the study by Caloyeras et al.260
A different cost per QALY was derived, even though it appears that the same setting/perspective, time
horizon, model structure and underlying data from the BENEFIT trial171 were used.
Caloyeras et al.261
Caloyeras et al.261 used a Markov model structure to assess the cost-effectiveness of 250 µg of IFN-β-1b
once daily compared with BSC for people with their first clinical event suggestive of MS. The model
simulated the pathway for people with CIS who received DMTs compared with BSC and cost-effectiveness
was estimated over the model’s time horizon. The model started with a hypothetical cohort of people
aged 30 years who were diagnosed with CIS and who had an EDSS score of 0–5.5 and continued with
people occupying/progressing to one of the following seven health states: EDSS 0.0, EDSS 1.0–1.5, EDSS
2.0–2.5, EDSS 3.0–3.5, EDSS 6.0–7.5 non-relapse, EDSS 8.0–9.5 non-relapse and EDSS 10 (MS-related
death). Caloyeras et al.261 made a number of assumptions: progression in EDSS levels was modelled
independently of progression to MS; two types of relapses were modelled – relapse resulting in
progression from CIS to MS and relapse after progression to MS; all-cause mortality was estimated using
life tables; MS-specific mortality occurred only when the EDSS score was 10 and people who discontinued
treatment did not restart DMTs.
Clinical information (e.g. HRs for DMTs compared with placebo) required to populate the model was
obtained from the BENEFIT trial.171 Information on utilities associated with EDSS levels was obtained from
published sources. Resource use and costs included those for hospital inpatient care, ambulatory care,
tests, drugs (DMTs and other drugs), services, adaptations/investments and informal care. Costs associated
with relapses were estimated from a cross-sectional web-based survey. The analysis was conducted from a
Swedish societal perspective and the results were presented in terms of costs per QALY gained over a
50-year time horizon. All costs were reported in 2009 Swedish kronor and all costs and outcomes were
discounted at 3% per annum. Along with the cost-effectiveness analysis, Caloyeras et al.261 undertook
one-way sensitivity analysis (acquisition costs, EDSS threshold for discontinuation, time horizon of the
model, EDSS progression probability and discount rates) and probabilistic sensitivity analysis (drug
acquisition costs, direct and indirect costs, utilities, EDSS progression probabilities, treatment
discontinuation rate, relapse rate) using a uniform distribution and varying model parameters by ±2.5%.
The base-case results showed that treatment with IFN-β-1b dominated BSC arm (commencing treatment
when people progressed to RRMS). People who started on early treatment accumulated slightly higher
direct medical costs per patient but lower direct non-medical costs. The sensitivity analyses demonstrated
that the base-case results were robust to changes made to model parameters. However, the model
findings were sensitive to changes made to the time horizon of the analysis. Undertaking the analysis over
a shorter 5-year time horizon found that early treatment was not cost-effective (ICER SEK 1.32M).
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Zarco et al.262
Zarco et al.262 used a decision tree structure to assess the cost-effectiveness of IFN-β-1a or IFN-β-1b
compared with BSC for people diagnosed with CIS. The model started with a hypothetical cohort of people
with CIS and continued with a proportion of people having a relapse or not having a relapse at a 1-year time
horizon. At the 2-year time horizon, the model considered the proportion of people progressing to CDMS
and those remaining in a CIS health state. The report was unclear on the assumptions made in the model.
Information on progression from CIS to CDMS in an untreated population was obtained from the BENEFIT
trial.171 Information on the treatment efficacy of DMTs was obtained from clinical trials. Resource use
and costs were estimated from a hospital-level microcosting study and treatment costs were estimated
from national health insurance data. The analysis was conducted from the Colombian societal perspective
and the results were presented in terms of costs per QALY and costs per disability-adjusted life-year
over a 2-year time horizon. All costs were reported in 2011 US dollars and all costs and outcomes
were discounted in the second year by 3%. The authors undertook univariate and probabilistic
sensitivity analyses.
In terms of costs per QALY, the base-case results showed that interferons were not cost-effective
compared with BSC for treating people with CIS.
Characteristics of the included studies
The characteristics of the studies included in this review are presented in Table 23. All of the studies
included an economic model to estimate the cost-effectiveness of DMTs for treating people with CIS.
The economic evaluations were conducted in Sweden,254,255,261 Australia,259,260 Italy,256 Colombia,262 Spain258
and Canada.257
Studies mainly compared DMT with no treatment.254–256,258–261 Treatment included SC IFN-β-1a three times
weekly254 and SC IFN-β-1b.255,256,258–261 One study262 compared IFN-β-1a with IFN-β-1b and one study257
compared DMTs (30 µg of IM IFN-β-1a once weekly) with current treatment (four intravenous injections of
1 g of methylprednisolone for 3 days followed by 14 days of 1 mg of oral steroids twice daily).
Seven studies254,255,257,258–261 used a cohort Markov model structure and one study262 used a decision tree
structure and the remaining study256 used an epidemiological/survival model and affixed costs and benefits
accrued over time for occupying health states. One study258 used a decision tree structure and, in the
remaining study,262 it was unclear what model structure was used. Model cycle lengths ranged from
6 months261 to 1 year and time horizons ranged from 2 years257 up to 50 years.261 Most studies254,255,257,259–261
included longer-term progression through to RRMS and estimated cost-effectiveness.
Five studies254,255,259,261,262 analysed cost-effectiveness from the societal perspective, whereas two studies256,257
analysed cost-effectiveness from both the health service perspective and the societal perspective. Two
studies258,260 were unclear on the perspective of the analysis. Six studies254–256,258,261,262 used a discount rate of
3% per annum for costs and outcomes, whereas three studies257,259,260 applied an annual 5% discount rate
for costs and outcomes. Six studies255,256,258–261 presented the results in terms of cost per QALY alone, one
study used progression-free survival in addition to cost per QALY,254 one study used MLYs gained in addition
to cost per QALY257 and one study used disability-adjusted life-years and QALYs.262
Definition of clinically isolated syndrome
The definitions used to characterise people with CIS were consistent. The majority of the studies defined
their hypothetical cohort as adults who had experienced a single demyelinating event suggestive of MS.
Two studies254,256 elaborated on this definition and suggested that their cohorts consisted of adults who
had experienced a single demyelinating event in one or several areas of the CNS. To our knowledge, no
studies included in this systematic review defined their population based on the McDonald 2010 criteria.62
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Characteristics of clinically isolated syndrome models
Four studies254,255,257,261 modelled the longer-term impact of treating CIS with DMTs, incorporating
progression to RRMS. No studies modelled conversion from RRMS to SPMS. All studies except that
conducted by Iskedjian et al.257 considered progression until death in the analysis; there was no justification
for omitting this health state in the analysis by Iskedjian et al.257 Disease progression in the RRMS health
states was stratified by severity (mild, moderate and severe)255,257 or by predicting changes in EDSS
scores.254,256,258–261 In the majority of the studies the risk of death was obtained from country-specific
lifetime tables for the general population. In one study,254 mortality rates were adjusted to reflect the
increased risk of mortality associated with MS. Here, background mortality was multiplied by EDSS-specific
adjustment factors to reflect MS-specific mortality. All other studies accounted for death by assuming that
people died on progression to EDSS 10. Adjusting the background mortality and including progression to
EDSS 10 leads to double counting of people who may die from MS-related causes.
Treatment effect of disease-modifying therapies in the clinically isolated syndrome
health state
Three studies254,256,261 clearly stated that treatment discontinuation was considered in the analysis. One
study257 assumed that people did not discontinue treatment. The remaining studies255,258–260 were unclear
on whether treatment discontinuation was included in the analysis. Treatment discontinuation was assumed
to be a result of AEs from drug utilisation and/or progression to an EDSS score of ≥ 6. Discontinuation
rates ranged from 6% every 2 years254 to 17.7% annually.256 It appeared that the study by Fredrikson et al.254
assumed a constant hazard over time for discontinuation of treatment in the first 2 years and, in subsequent
years, used information from a follow-on trial. In the analysis undertaken by Caloyeras et al.,261 a Weibull
parametric model was fitted to Swedish registry data to derive time-dependent transition probabilities for
people discontinuing treatment. Here, discontinuation of treatment was assumed to be the same for both
early and delayed treatment (waiting until people developed MS).
Quality assessment of the modelling methods in clinically isolated syndrome studies
In this section we present a summary of the reporting quality of the studies included in the current review
against the Philips et al.244 checklist, which is presented in Appendix 6.
Model structures
Models presented in full publications were generally of good quality. The studies clearly stated their
decision problem, the perspective of the analysis and the objectives of the analysis, all of which were
consistent with the decision problem and disease progression. However, analyses were often limited in
scope. Most studies compared one DMT with BSC and thus did not include and analyse all treatment
options available for people with CIS. All studies clearly stated the time horizon of their analysis, but
studies with shorter time horizons may not have been able to capture all of the costs and consequences of
treating or not treating CIS with DMTs.
Information required for models
In general, methods used in the published studies to identify relevant information to populate the models
were satisfactory.254,256,257,261,262 As expected, less information was available from published abstracts.255,258–260
All studies provided references for their model inputs, but authors were not clear on how the evidence was
synthesised (e.g. search strategy, quality assessment). In all studies, information was required on the effect
of DMTs on disease progression, resource use and costs, outcomes and mortality. The effect of DMTs
on delaying progression from CIS to RRMS was modelled using HRs. The relative reduction in progression
that was associated with DMTs was then applied to the predicted baseline cohort of people with CIS.
All studies except that by Zarco et al.262 derived a HR directly from a trial. In contrast, the study by Zarco
et al.262 obtained this HR by combining the treatment effects from a number of studies. However, the
authors of this study did not elaborate on the quality assessment of these RCTs or on how information on
treatment effects was meta-analysed. The effect of DMTs can be applied to a baseline cohort of people
to show the treatment effect on conversion to RRMS. Baseline information can be obtained from CIS
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registries, a natural history cohort or a placebo arm of a clinical trial. In all studies, information on disease
progression in a baseline cohort was obtained from RCTs. Most studies undertook analyses based on a
long time horizon, which is in line with the NICE reference case.156 However, only two studies254,261
elaborated on the techniques used to extrapolate treatment effects beyond the time horizon of the RCTs.
These studies provided information on the parametric models chosen and justified their choice of
survival model.
Most studies254,256,257,261,262 justified and referenced the costs used in their analyses. Costs required for the
models were mainly obtained from published sources and these were inflated to current prices using the
appropriate indices. In some studies256,261 the authors provided detailed information on resource use. All
authors stated the perspective of the analyses and the resource use and costs reflected the viewpoint/
perspective of the analyses. All authors discounted costs and benefits using the appropriate rates.
In the studies that reported the model results in terms of QALYs, the authors provided the references used
to obtain the utility weights. However, the majority of the studies did not elaborate on the descriptive
tools/measures used to value these health states in these populations or did not elaborate on the quality
assessment or choices made between sources. Additionally, authors did not elaborate on whether or not
the sources of utility information used were relevant to their population of interest. To our knowledge,
utility weights were obtained primarily from studies undertaken in a RRMS population.
Uncertainty
All studies addressed parameter uncertainty in the analyses, but none attempted to address all types
(methodological, structural, parameter and generalisability) of uncertainty. All studies made changes to key
model input parameters to explore the impact on the results. Two studies255,257 ran their analyses over
shorter time horizons to explore the impact on the ICER estimates. However, it was unclear whether these
studies also assumed that the duration of the treatment effect had been reduced.
Summary of the clinically isolated syndrome cost-effectiveness evidence
The evidence base offers insight into the decision-analytic models used to estimate the cost-effectiveness
of DMTs for reducing conversion of CIS to MS. We identified nine studies, which included six full-text
articles254–257,261,262 and three abstracts.258–260
In general, the modelling methodology appeared to draw on current approaches to evaluating
cost-effectiveness of DMTs in RRMS. The authors used EDSS levels to define health states for CIS, with
DMTs impacting on progression from CIS to RRMS. Once individuals progressed to RRMS, their disease
progression was modelled using increasing EDSS scores and progression to SPMS. This seems a reasonable
approach as EDSS levels were commonly used to describe populations recruited in clinical trials evaluating
DMTs in CIS. In addition, it enables cost and utility data for RRMS patients to be utilised in the CIS model.
For example, utility weights for EDSS levels among CIS patients could be assumed to be equivalent to
utility weights for comparable EDSS levels among RRMS patients.
The shorter time horizons that some studies used to evaluate costs and consequences were of concern. As
CIS patients progress to RRMS, and DMTs reduce this progression, it would seem important to incorporate
the long-term costs and consequences of RRMS (either treatment with DMTs or BSC) in a cost-effectiveness
analysis of treatment strategies for patients with CIS.
We appraised studies against the CHEERS243 and Philips et al.244 checklists for best practice for reporting
economic evaluation and economic modelling studies. Based on our appraisal, the majority of the full-text
articles scored well in terms of defining the decision problem, outlining the study perspective, listing the
intervention and comparators, presenting an illustrative model structure and providing a clear outline of
the assumptions. Abstracts were limited in the amount of information that could be provided. From our
review, we have raised some limitations/concerns that mainly relate to the information required to
populate the economic models. First, it was unclear how authors made choices between data sources,
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especially utility values. It was unclear whether utility values had been obtained by undertaking a
systematic review. The majority of the studies reporting their results in terms of QALYs provided references
for these utility values. However, authors did not provide details on the descriptive tools/measures used to
measure HRQoL and also insufficient information was provided on who (CIS/MS patient or public) valued
these health states. Second, the study undertaken by Zarco et al.262 estimated the treatment effect on
conversion to MS from a number of trials. However, little information was provided on how a point
estimate for the treatment effect was derived. Third, only two studies254,261 provided sufficient information
on extrapolating the treatment effect beyond the trial time horizon. Finally, it was unclear whether studies
accounted for the uncertainty around extrapolating beyond the trail time horizon.
In Chapter 12, we have used information from this review to develop a de novo model structure, which
we used to estimate the cost-effectiveness of DMTs for treating people with CIS.
Results of the searches for relapsing–remitting multiple sclerosis studies
The electronic database searches identified 2451 records (Figure 24). After removing duplicates, 1393
records were screened for inclusion. On the basis of title and abstract, 1168 records were excluded and
the remaining 225 records were included for full-text screening. A further 213 articles were excluded at
the full-text stage (see Appendix 7 for a list of excluded studies with reasons), leaving 10 studies154,264–272
that included a decision-analytic model used to estimate the cost-effectiveness of DMTs for treating
people with RRMS.
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FIGURE 24 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart: economic
studies relating to RRMS.
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Description of the included studies
Summary of economic studies comparing disease-modifying therapies for people with
relapsing–remitting multiple sclerosis
Sanchez-de la Rosa et al.264
Sanchez-de la Rosa et al.264 used a Markov model structure to assess the cost-effectiveness of IM IFN-β-1a,
SC IFN-β-1a, SC IFN-β-1b and SC GA compared with symptomatic treatment for people in Spain diagnosed
with RRMS. The model simulated the pathway for people with RRMS who received DMTs compared with
symptomatic treatment and cost-effectiveness was estimated over the model’s time horizon. The model
started with a hypothetical cohort of adults diagnosed with RRMS and continued with people occupying/
progressing to one of the following health states: EDSS 0.0–2.5, relapse EDSS 0.0–2.5, EDSS 3.0–5.5,
relapse EDSS 3.0–5.5, EDSS 6.0–7.5, EDSS 8.0–9.5 and dead). The authors made a number of simplifying
assumptions: people could die from natural causes in all health states except for EDSS 8.0–9.5, all people
in the model received symptomatic treatment for MS, people who discontinued treatment were assumed
to receive symptom management alone, treatment reduced the amount of sick leave and people were
always working regardless of EDSS level.
The model required information on the starting distribution by EDSS level, probability of progression,
incidence of NABs, resource use and costs and utility values by EDSS level. Information on utilities
associated with RRMS was obtained from an observational study that was undertaken in Spain, which
included a sample of people with MS who responded to the EQ-5D questionnaire. Resource use and costs,
stratified by EDSS level, were obtained from published sources. Costs included pharmacological, MS
management and loss of productivity costs. The analysis was conducted from the Spanish societal
perspective and the results were presented in terms of costs per life-year gained and costs per QALY
gained over a 10-year time horizon. All costs were reported in 2010 euros and all costs and outcomes
were discounted at 3% per annum. The authors undertook one-way sensitivity analysis (applied 0% and
5% discount rates; varied the time horizon to 2, 4, 6 and 8 years; and changed the incidence of NABs and
loss of productivity costs).
The base-case results in terms of costs per QALY showed that IM IFN-β-1a was dominant compared with
SC IFN-β-1b. However, treatment with IM IFN-β-1a was not cost-effective compared with SC GA at a
willingness-to-pay threshold of €30,000 per QALY. The sensitivity analyses demonstrated that the
base-case results were robust and stable to changes made to model parameters.
Nikfar et al.265
Nikfar et al.265 estimated the cost-effectiveness of using symptom management in combination with IM
IFN-β-1a, SC IFN-β-1a or SC IFN-β-1b compared with symptom management alone for the treatment of
RRMS. The authors developed a Markov structure to demonstrate the clinical pathway (RRMS defined by
EDSS levels and transitioning to SPMS) that people would undergo for the treatment of RRMS. The model
started with a hypothetical cohort of adults (aged 30 years) who received one of four treatment strategies.
One of the simplifying assumptions was that people started in EDSS 1–3.5. People could transition from
RRMS to SPMS from the third cycle (approximately 5 years after diagnosis of RRMS, with an assumption
that this took place between EDSS 4–6 and EDSS 6–9.5). In the case of withdrawal from IFN-β treatment in
cycles 4–15, patients were allocated to the transition probabilities for relapse and disease progression used
in the symptom management arm. Information required to populate the model (probabilities of clinical
events and probabilities of switching to other IFN-β treatment or symptomatic treatments and relapse
rates) was obtained from published sources through a literature review. Information on utility values,
resource use and costs was obtained from a cross-sectional study undertaken by the authors. Briefly,
200 MS patients were recruited randomly from three referral hospitals in two cities, three private offices
of MS specialists and members of the MS Iranian Society. The authors elicited utility values directly from
participants using a visual analogue scale and the EQ-5D and HUI-3 validated questionnaires. Information
on resource use and costs was obtained using a retrospective approach, in which information was
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collected at a single time point and covered the 1-year period before inclusion in the study. All prices were
extracted from official tariffs and were reported in 2012 US dollars. The analysis was conducted from the
Iranian societal perspective and the base-case results were expressed as ICERs based on the outcome of
cost per QALY gained. All costs and outcomes were discounted at 7.2% and 3% per annum respectively.
The base-case results showed that, when using the World Health Organization’s recommendation for
willingness-to-pay thresholds (for developing countries, an ICER of less than three times the national gross
domestic product is considered cost-effective), all interventions except IM IFN-β-1a were cost-effective
compared with symptom management alone. However, using utility values based on the EQ-5D, IM IFN-β-1a
was shown to be cost-effective. The sensitivity analyses showed that these results were robust except when
changes were made to the use of copied biopharmaceuticals and biosimilars, when these interventions were
shown to be dominant.
Agashivala and Kim266
Agashivala and Kim266 undertook a cost-effectiveness analysis using a decision tree. The authors simulated
the costs and benefits of using fingolimod in both the first and second years as compared to using IFN-β
in the first year and then using fingolimod in the second year, as in the extension to the TRANSFORMS
(TRial Assessing injectable interferoN vS. FTY720 Oral in RRMS) trial.273 They did not provide a description or
diagrammatic representation of their model. The authors estimated the costs of providing treatments over
the model time horizon and compared these with the observed rates of relapse from the TRANSFORMS trial
and thereby estimated the additional costs per relapse avoided. Their definition of relapse, which was based
on the definition used in the TRANSFORMS trial, was new, worsening or recurrent neurological symptoms
occurring 30 days from the onset of a preceding relapse and lasting for at least 24 hours, without fever or
infection. Relapses were confirmed if they were accompanied by an increase of at least half a point on the
EDSS, 1 point on two different functional systems of the EDSS or 2 points on one of the functional systems
(bowel, bladder or cerebral functional systems were excluded). Resource use data were extracted from the
literature and unit costs were obtained from the 2010 Physicians’ Fee and Coding Guide.274 Costs were
estimated from a US private payer perspective (health insurance) and included drug acquisition costs and the
costs of monitoring and relapses. The analysis was undertaken over a time horizon of 2 years. Costs were
adjusted to 2011 US dollars and future costs and outcomes were not discounted. The authors undertook
one-way sensitivity analysis by varying input parameters by ± 10%.
The main finding was that it is more cost-effective to start fingolimod than to start IFN-β and then
switch to fingolimod after 1 year of treatment. The estimated cost per relapse avoided was lower when
fingolimod was started as first-line treatment than when it was started in the second year, with a cost per
relapse avoided of US$20,499 more in the delayed fingolimod group than in the early fingolimod group.
The findings are limited by the scope of the analysis undertaken. The analysis did not take into account
(or did not describe) potential differences between the two treatments in terms of long-term health
and cost impacts, the impact on disability/QoL or the consequences of adverse reactions to treatment.
In addition, the parameter for risk of relapse was derived from a single clinical trial with inclusion and
exclusion criteria that may limit generalisability to the general population.
Palace et al.154
Palace et al.154 developed a Markov model to simulate the long-term experiences of people with RRMS.
To model the natural history of RRMS, information from a baseline cohort was obtained from the British
Columbia Multiple Sclerosis (BCMS) database. The clinical course of RRMS was modelled using health states
that captured the long-term disability progression. Health states in RRMS were defined by EDSS levels 0–10.
People who progressed to an EDSS score of ≥ 6 were assumed to have converted to SPMS. In all health
states people were subjected to the risk of all-cause mortality or MS-related mortality. The treatment effect
of DMTs (IFN-β or GA) on disability progression and relapse rates was obtained from the RSS year 6 analysis.
Transitions for both the treated and the untreated cohorts occurred annually. In each model cycle, people
incurred costs and accrued benefits based on the health state that they occupied. Costs incurred were
related to drug acquisition costs, costs of management by EDSS level and the cost of relapse. Benefits
accrued were measured in terms of HRQoL and this information was obtained from published sources.
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Palace et al.154 projected the cost-effectiveness of DMTs included in the RSS over a 20-year time horizon.
The analysis was conducted from the UK NHS and PSS perspective and the results were presented in
terms of ICERs, expressed as costs per QALY gained. All costs were reported in 2014 UK pounds and all
costs and benefits were discounted at 3.5% per annum. The authors undertook a sensitivity analysis
to determine whether the base-case results were sensitive to the choice of the natural history cohort.
Pan et al.267
Pan et al.267 used a Markov model and estimated the cost-effectiveness of 250 µg of IFN-β-1b compared with
no treatment for people with RRMS. The model simulated the pathway for two cohorts (intervention vs. no
treatment) and cost-effectiveness was estimated over a 70-year time horizon. The model started with a
hypothetical cohort of people who were aged ≥ 18 years and who had been diagnosed with CDMS or
laboratory-supported definite MS for > 1 year and who were ambulatory with an EDSS score of ≥ 5.5,
with at least two acute relapses during the previous 2 years. In the Markov model structure, the authors
considered seven health states: EDSS 0.0–1.5, EDSS 2.0–2.5, EDSS 3–3.5, EDSS 4–5.5, EDSS 6–7.5, EDSS
8–9.5 and dead. In the model, people remained or progressed to more severe RRMS health states over
6-monthly cycles. To have a workable model structure, the following assumptions were made: people who
received mixed treatments during the post-trial period were assumed to have the same treatment efficacy as
those who received IFN-β-1b during the trial period, a utility decrement of 0.0235 was applied to people
who relapsed and this was assumed to last for 6 months, the model assumed no backward/regressive
transitions, that is, MS was seen as a progressive disease, the effectiveness of treatment was assumed to last
for the duration of treatment, people who discontinued treatment were assumed to progress at the same
rate as people in a natural history cohort, the model assumed that people with RRMS (EDSS score of < 6.0)
received treatment and people who discontinued treatment were assumed not to reinitiate treatment.
Data required to populate the model were obtained from published sources. Clinical information on the risk
of EDSS progression and relapse rates was based on a meta-analysis undertaken by the authors. Information
on utility values was obtained from a published source and these values were based on the EQ-5D. Utility
values were allocated according to EDSS health state. Utility decrements were applied to people who
relapsed, independent of EDSS state. No disutilities for carers were included in the analysis. Resource use and
costs stratified by EDSS level were obtained from published sources. Costs included drug treatment costs,
health state costs stratified by EDSS state, informal care costs and indirect (loss of productivity) costs. The
authors applied a 10% discount to drug prices for IFN-β-1b and mixed DMTs. The analysis was conducted
from a US societal perspective and the results were presented in terms of ICERs, expressed as costs per QALY
gained. All costs were reported in 2011 US dollars and all costs and outcomes were discounted at 3% per
annum. Pan et al.267 undertook one-way sensitivity analyses on key model input parameters (changing the
time horizon, exclusion of productivity losses as a result of premature death and changing the discount rate
and starting EDSS distribution) but did not undertake probabilistic sensitivity analysis.
The base-case results in terms of life-years gained showed that the discounted mean incremental cost of
IFN-β-1b was approximately US$86,200, with a reduction in life-years lost of 2.8 years, which equated to
an ICER of approximately US$31,000 per life-years gained compared with no treatment. The results in
terms of QALYs gained showed that the discounted mean incremental gain was approximately US$86,200,
with a 1.9-year increase in QALYs, which equated to an ICER of approximately US$46,400 per QALY
gained. Changes made to the treatment discontinuation rate together with discounting on DMT drug costs
resulted in moderate changes to the ICER. However, changes made to the time horizon (from 70 years
to 20 years) resulted in the ICER (approximately US$163,600) becoming less cost-effective. Additionally,
changing the starting distribution to 50% in EDSS 0.0–1.5 and 50% in EDSS 2.0–2.5 resulted in a more
cost-effective ICER of approximately US$19,600.
Darbà et al.268
Darbà et al.268 undertook a cost-effectiveness analysis and compared the costs and consequences of treating
RRMS with GA, IM IFN-β-1b and combination therapy with GA and IM IFN-β-1b. The analysis used a Spanish
payer perspective, future costs and outcomes were discounted and costs were adjusted to 2013 euros.
RESULTS OF THE SYSTEMATIC REVIEW OF THE COST-EFFECTIVENESS LITERATURE
NIHR Journals Library www.journalslibrary.nihr.ac.uk
128
The authors built a Markov model with five health states relating to outcomes observed in the CombiRx
trial191 and estimated the incremental costs per relapses avoided. The model was run over 10 years with a
1-year cycle length. Transition probabilities were derived from the CombiRx trial,191 whereas health-care
resource use was obtained from other published sources. The authors assumed that the risk of exacerbation/
relapses decreased over time (for the years after the end of the trial). One-way and probabilistic sensitivity
analyses were carried out.
The main finding was that treatment with GA monotherapy dominated (was less costly and resulted in
fewer relapses) the other treatment options. The authors did not take into account the costs associated with
AEs and it is unclear exactly what the health state ‘information lost’ represents (likely to be dropouts from
the main trial). These two issues may impact on the findings. The findings have limited generalisability as no
other DMTs were considered and disability and QoL were not included in the model.
Imani and Golestani269
Imani and Golestani269 undertook a cost-effectiveness analysis to estimate the incremental costs and
benefits of four DMTs in comparison to BSC in Iran. They used a Markov model structure and estimated
costs and consequences over a lifetime horizon and from the Iranian societal perspective. Costs were
estimated in 2011 US dollars and discount rates used reflected Iranian policy. Direct health provider costs
included the costs of treatment, monthly costs associated with EDSS states and the costs of relapses. It was
unclear whether other medical costs were included, for example the costs of adverse drug events. Indirect
costs included the costs of loss of productivity from absenteeism. In the model, nearly 75% of those
modelled started with some degree of disability (EDSS score of > 2.5). Fewer health states, defined by
EDSS score, were used to model disability progression and to assign costs/utilities to and no diagrammatic
representation of the model was provided.
The authors found that, of the DMTs, treatment with IFN-β-1a was the most cost-effective option.
However, the ICER for IFN-β-1a in comparison to BSC was US$607,397 per QALY gained at the societal
level. One-way sensitivity analysis found that the ICER was higher when the analysis was undertaken over
a shorter time horizon. The findings have limited generalisability because of the analysis setting, as
resource use reflected care and costs in Iran.
Dembek et al.270
Dembek et al.270 undertook a cost-effectiveness analysis to estimate the incremental costs and benefits of
injectable DMTs in comparison with BSC in Spain. They compared three different regimens of IFN and GA.
They used a Markov model structure and estimated costs and consequences over a 30-year time horizon
and from the Spanish societal perspective. Costs were estimated in 2010 euros. Direct health provider
costs included the costs of treatment, monitoring, AEs and relapses. Indirect costs included the costs of
loss of productivity from absenteeism and early retirement. Other non-medical costs were also included
(e.g. costs of walking aids, informal care and transportation). In the model, the authors assumed that most
MS patients start DMTs early, at the point of minimal or no disability, and stop once the EDSS score
progresses to 6.0. In addition, they used fewer health states by EDSS score to model disability progression
and to assign costs/utilities to and assumed that there was no additional mortality risk from MS.
The authors found that, of the DMTs, treatment with IM IFN-β-1a was more cost-effective than treatment
with SC IFN-β-1a, IFN-β-1b or GA. The probabilistic sensitivity analysis showed that IM IFN-β-1a was the
most cost-effective treatment in 79–97% of simulations. However, the ICER for IM IFN-β-1a in comparison
with BSC was €168,629 per QALY gained at the societal level. One-way sensitivity analysis found that the
findings were sensitive to DMT costs, cycle utilities and disutility weights assigned to relapse events. The
authors discussed their findings in relation to previous economic analyses but did not discuss the policy
implications of the high ICER for DMT in comparison with BSC. The study is also limited by the fact that
the findings were not presented from the health payer perspective as well.
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Chevalier et al.271
Chevalier et al.271 undertook a cost-effectiveness analysis to estimate the incremental costs and benefits of
other DMTs in comparison to delayed-release dimethyl fumarate. They compared dimethyl fumarate with
three different dosing regimens of IFN and three other DMTs. They used the same model structure as in a
previous NICE HTA of DMTs in MS119 and estimated the cost-effectiveness from the French societal and
payer perspectives. The model was run over 30 years with a 1-year cycle length and followed French
guidelines for discounting. Costs were estimated in 2013 euros, although the costs of drugs were in 2015
prices. Direct health provider costs included the costs of drugs, monitoring, AEs and management
associated with EDSS health states and relapses. Indirect costs included the costs of loss of productivity as
a result of absenteeism and early retirement.
The authors found that GA, 30 µg of IFN-β-1a, 250 µg of IFN-β-1b, fingolimod and teriflunomide were
dominated (i.e. had higher costs and fewer QALYs) by 44 µg of IFN-β-1a and dimethyl fumarate at both
the societal and the health payer level. The ICER for 44 µg of IFN-β-1a in comparison to dimethyl fumarate
was €29,047 per QALY and €13,110 per QALY from the health payer and societal perspectives respectively.
The probabilistic sensitivity analysis found that, at a willingness-to-pay threshold of €30,000, the probability
that dimethyl fumarate was the most cost-effective option was 0.65. The one-way sensitivity analysis
suggested that, under the majority of scenarios investigated, dimethyl fumarate continued to dominate
other DMTs, except 44 µg of IFN-β-1a. The ICER was most influenced by the dimethyl fumarate disability
progression rate, the dimethyl fumarate acquisition cost, the EDSS state cost and the dimethyl fumarate
relapse rate. The main finding was that dimethyl fumarate is the optimal choice of DMT.
Lee et al.272
Lee et al.272 undertook a cost-effectiveness analysis to estimate the incremental costs and benefits of
fingolimod in comparison to IM IFN-β-1a. They estimated the cost-effectiveness from the US societal
perspective. The model was run over 10 years, with a 1-year cycle length, and followed US guidelines
for discounting, with costs adjusted to 2011 US dollars. The model simulated costs and outcomes for
hypothetical MS patients aged 37 years with minimal or no disability (EDSS score of < 2.5). Health states in
the model reflected the current EDSS score and whether patients were on treatment. The authors assumed
that relapses lasted for only 1 month and graded the severity of relapses and assumed that treatment was
stopped once the EDSS score was > 5.5. The direct health provider costs included the costs of drugs,
monitoring and management associated with EDSS health states and relapses. Indirect costs included the
costs of loss of productivity as a result of absenteeism, but it was unclear whether these costs also included
the costs of early retirement. QoL weights were derived from US-based studies.
The authors found that, in comparison to 30 µg of IM IFN-β-1a once weekly, the ICER for fingolimod was
US$73,975 per QALY gained at the societal level. The ICER was higher from the health payer perspective
(US$81,794 per QALY). The probabilistic sensitivity analysis found that fingolimod was not cost-effective at
a willingness-to-pay threshold of US$50,000 per QALY, but would be cost-effective if the cost of the drug
were to drop.
Characteristics of the included studies
The characteristics of the studies included in this review are presented in Table 24. All of the studies
included an economic model to estimate the cost-effectiveness of DMTs for treating people with RRMS.
The economic evaluations were mainly conducted in the USA266,267,272 and Spain,264,268,270 with two studies
carried out in Iran265,269 and the remaining studies carried out in the UK154 and France.271 Studies mainly
compared IM IFN-β-1a once weekly, SC IFN-β-1a three times weekly, SC IFN-β-1b or SC GA with symptom
management.264,265,269,270 Two studies compared IM IFN-β-1a once weekly with GA,154,268 one study
compared SC IFN-β-1b with symptom management,267 two studies included IM IFN-β-1a once weekly in
their intervention compared with fingolimod266,272 and the remaining study included comparisons between
IFN-β-1a, IFN-β-1b or GA and dimethyl fumarate.271
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All studies except that by Agashivala and Kim266 used a Markov cohort model structure to determine the
cost-effectiveness of DMTs for RRMS. Agashivala and Kim266 used a decision tree structure. For those
studies using a Markov model structure, model cycle lengths were 1 month,264 6 months,267 annual154,268–272
or biennial265 and time horizons ranged from 2 years266 up to death.269 Five studies264,265,267,270,272 analysed
cost-effectiveness from a societal perspective alone, two studies154,268 analysed cost-effectiveness from a
NHS perspective, two studies269,271 analysed cost-effectiveness from both a NHS and a societal perspective
and one study266 analysed cost-effectiveness from a third-party provider perspective. Six studies264,267–270,272
used a discount rate of 3% per annum for costs and outcomes, one study271 applied an annual 4%
discount rate for costs and outcomes, one study154 applied a 3.5% annual discount rate, one study265 used
a discount rate of 7.2% for costs and 3% for outcomes and the final study266 did not explicitly state the
discounting approach. Additionally, two studies264,268 included a discount rate of 7.5% for the cost of
drugs. The results were mainly presented in terms of relapses avoided, life-years gained and QALYs gained.
Definition of relapsing–remitting multiple sclerosis
The definitions used to characterise people with RRMS were consistent across all studies. However, to our
knowledge no studies elaborated on the definitions used to define MS from the clinical studies that were
used to obtain treatment effects of DMTs.
Characteristics of relapsing–remitting multiple sclerosis
All studies considered disease progression based on the use of EDSS levels to capture disability progression
in people with RRMS. All models also captured the relapsing nature of MS. Nine studies264–272 grouped
EDSS health states (e.g. EDSS 1–3.5265) but authors did not provide justification for how these groupings
were derived. In contrast, Palace et al.154 modelled each EDSS level to show disease progression. One
study265 clearly presented definitions for each health state included in the model. Three studies154,265,272
included the conversion of RRMS to SPMS. Only one study154 allowed people to transition to less severe
health states. In studies that considered relapses in their models,154,265,272 authors assumed that relapses
occurred up to an EDSS level of 5.5. At this level, authors assumed that people discontinued treatment
and followed the same pathway as people who were at the same EDSS level but untreated.
In general the risk of death was obtained from country-specific lifetime tables for the general population.
Two studies264,272 assumed that people were at risk of MS-related death at EDSS 8–9.5. However, it was
unclear whether Sanchez-de la Rosa et al.264 varied the risk of death by age. Nikfar et al.265 used another
method to account for death. These authors assumed that MS increased the risk of death by threefold
across age- and sex-adjusted mortality rates. Pan et al.267 modelled mortality based on extrapolating
survival data from an observational study. These authors fitted a Weibull parametric model to the placebo
(no treatment) group to project survival over a lifetime, then mortality for IFN-β-1b was modified by
applying the HR derived from a comparison between the treatment group and the placebo group.
Evidence on other parametric model fits was not presented by the authors.
Treatment effect of disease-modifying therapy in relapsing–remitting multiple sclerosis
The effect of treatment on disability progression and the frequency of relapses was considered in all
studies by applying a HR/relative risk to a baseline cohort of people with RRMS. All studies drew on
evidence from RCTs. However, only one study264 was clear on the meta-analytical methods used to
estimate the treatment effect from clinical trials. These authors used log-linear regression to estimate the
treatment effect of DMTs on disease progression and relapse frequency.
It was unclear whether studies modelled the direct impact of DMTs in the conversion to SPMS. All studies
considered an indirect impact of DMTs on mortality by showing that DMTs delay disease progression.
It was not clear whether any studies accounted for the waning effect of DMTs. One study264 considered
the effect of NABs on the efficacy of DMTs.
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Discontinuation of treatment in relapsing–remitting multiple sclerosis
Discontinuation rates were considered in all studies except for that by Agashivala and Kim.266 Treatment
discontinuation was assumed to occur as a result of AEs from drug utilisation and/or progression to an
EDSS score of ≥ 6 or a perceived lack of efficacy.265 To our knowledge, no studies fitted a parametric
model to long-term data to derive time-dependent transition probabilities for people discontinuing
treatment. Studies used short-term information on discontinuation rates from trials and assumed a
constant hazard over time for the duration of the model.
Quality assessment
We present a summary of the reporting quality of the studies included in the current review assessed
against the CHEERS243 and Philips et al.244 criteria, which cover model structure, information required for
the model and uncertainty. Details of the quality assessment for each study are presented in Appendix 7.
Model structures
Structures of the models included in this review were generally of satisfactory quality. In accordance
with best practice for developing model structures, studies clearly stated the decision problem and the
viewpoint/perspective of the analysis and the objectives of the model, all of which were consistent with the
decision problem. Additionally, illustrative structures captured the relapsing nature of MS and followed
the pathway for people treated for RRMS. Although good reporting quality was noted in most studies,
some structural issues were noted. These related to the time horizon, the model structure, half-cycle
corrections and the generalisability of the results. In four studies154,264,266,272 the time horizon was possibly
too short to capture all of the costs and benefits of treatment with DMTs. Agashivala and Kim266 used a
decision tree structure and affixed probability estimates for progression at discrete/fixed time points. As a
result, this does not reflect the true nature of RRMS. A Markov model would have been more appropriate
because of the chronic nature of the disease and the long-term horizons for progressing to more severe
EDSS levels. Additionally, the health states included in the model structure were not clearly described.
One study264 used a 1-month cycle length in the model, but this does not reflect the routine follow-up for
people with RRMS; an annual cycle length would have been more appropriate. On the other hand, Nikfar
et al.265 used a model cycle over 2 years, although it was unclear whether a half-cycle correction was used.
In general, all studies154,264–272 stated the location of the analyses but not the setting, which prevents
assessment of the generalisability of the results.
Information required for models
The methods used to identify relevant information to populate the models were satisfactory in most
studies.264–266,268,270–272 All studies provided references for their model inputs but quality appraisal and
selection of relevant inputs were rarely made transparent. In all studies information was required on the
treatment effect of DMTs on progression and relapse rates, resource use and costs, outcomes and
mortality.154,264–272
The effects of treatment with DMTs on disease progression compared with no treatment were modelled
using HRs. The relative reduction in disability progression associated with DMTs was applied to the
predicted baseline cohort of people with RRMS. In some analyses, studies obtained this HR directly from a
trial or through reviewing the clinical effectiveness literature. However, studies that used the latter approach
did not elaborate on the quality assessment of these RCTs or provide sufficient detail on how the HR had
been derived. Information on a baseline cohort of people could be obtained from MS registries, a natural
history cohort or the placebo arm of a trial. In all studies, information on disease progression in a baseline
cohort was obtained from RCTs. All models considered the treatment effect on reduction in relapses. The
treatment effect on the average number of relapses experienced by EDSS level was obtained from published
sources. Most studies undertook analyses based on a long time horizon, which is in line with the NICE
reference case.156 However, authors did not elaborate on the techniques used to extrapolate the treatment
effects beyond the time horizon of the RCTs. Studies using a shorter time horizon, for example that by
Lee et al.,272 did not assume treatment benefit beyond the length of the follow-up study.
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Information on resource use and costs was obtained from published sources and these were well
documented in some studies. Resource use by EDSS level was well documented in the study undertaken
by Nikfar et al.265
Uncertainty
All studies included one-way sensitivity analysis, undertaken by changing key model inputs to determine
the robustness of the base-case results. Changes were made to discount rates, the time horizon, the initial
EDSS distribution of people in the starting cohort, the perspective of the analysis, the discontinuation rate
and utility values. To our knowledge, authors did not use information from a natural history cohort of
people to model disease progression as part of their sensitivity analyses or allow for waning treatment
effect over time.
Summary of the relapsing–remitting multiple sclerosis cost-effectiveness evidence
We identified 10 studies154,264–272 that used an economic model to estimate the cost-effectiveness of DMTs
for treating people with RRMS. The evidence offers insight into the modelling methodology, including
the illustrative structures to depict MS progression, key model inputs and assumptions made to assess
cost-effectiveness. These methods appeared to be feasible across all studies.
We appraised studies against the CHEERS243 and Philips et al.244 checklists for best practice for reporting
economic evaluation and economic modelling studies respectively. Studies performed well against these
checklists in terms of reporting sufficient information on the decision problem, outlining the study perspective,
listing the intervention and comparators, presenting an illustrative model structure and providing a clear
outline of the assumptions. Our review highlights some limitations of the studies; these are related to the
structure of the models and the information required to populate the models. In terms of the model structure,
the time horizon was short in some studies and the choice of model structure did not accurately reflect or
capture the disability progression associated with MS. Limitations associated with model information relate to
the lack of detail provided on the quality assessment of clinical effectiveness studies, the methods used to
meta-analyse information from clinical studies and extrapolating the treatment effect beyond the trial time
horizons. Additionally, we noted some limitations in the methods used to model mortality.
In Chapter 11 we draw on the information from this review in terms of model design and model inputs to
estimate the cost-effectiveness of DMTs for treating people with RRMS.
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Chapter 9 Risk-sharing scheme submission
Overview of the risk-sharing scheme model
In the RSS model, an economic analysis was conducted to assess the cost-effectiveness of the combined
treatment effect of 44 or 22 µg of SC IFN-β-1a three times weekly (Rebif), 20 mg of SC GA once daily
(Copaxone), 250 µg of SC IFN-β-1b every other day (Betaferon/Extavia) and 30 µg of IM IFN-β-1a once
weekly (Avonex) compared with BSC for people with RRMS.154
In the analysis, a Markov model was used to depict the natural history of people with RRMS, including
progression to SPMS. Information required on the natural history of people with RRMS was based on the
BCMS cohort. Two sets of transition probabilities were reported: transitions based on the age at onset of
RRMS below (subgroup 1) and above (subgroup 2) the median age. In both the natural history cohort
and the RSS cohort, disability progression was characterised using the EDSS, which ranges from 0 to 10
(death). In addition to progressing to more severe EDSS states, people were allowed to regress to less
severe EDSS states, which reflected the natural course of the disease. In the model, only those in EDSS
level 7–9 could progress to EDSS level 10 (death). Additionally, it was assumed that the SMR increased by
twofold, regardless of the age at onset or severity of MS.
In the treatment arm (RSS model), the model assumed a discontinuation rate of 5% per annum for
patients with an EDSS score of 0–6 and that all patients reaching an EDSS score of ≥ 7 would discontinue
treatment. It was assumed that people who discontinued treatment would remain off treatment for the
remainder of their life.
The analysis was undertaken from the UK NHS and PSS perspective in a secondary care setting. Health
outcomes were measured in QALYs and the analysis was undertaken over a 50-year time horizon.
Information on utilities by EDSS state was obtained by pooling utility estimates from the 2002 and 2005
MS Trust surveys, based on information collected on the EQ-5D, which were subsequently converted to an
EQ-5D index score. Information on resource use and unit costs was obtained from Tappenden et al.275 and
subsequently inflated to current prices. The results were presented as ICERs, expressed as cost per QALY
gained. Both costs and benefits were discounted at 3.5% per annum.
The base-case results showed that, for people in subgroup 1, the mean cost per person in the treatment
arm was approximately £357,100, with a mean of 7.987 QALYs gained per person. For BSC, the mean
cost per person was approximately £328,800, with a mean of 6.947 QALYs gained per person.
Consequently, the ICER was approximately £27,200 per QALY. In subgroup 2, the mean cost per person in
the treatment arm was approximately £379,300, with 8.022 QALYs gained per person, whereas the mean
cost per person in the BSC arm was approximately £355,500, with 7.028 QALYs gained per person. This
gave an ICER of approximately £23,900 per QALY. Overall, the mean incremental cost of DMTs compared
with BSC was approximately £25,600, with a corresponding 1.013 QALYs gained and an ICER of
approximately £25,300 per QALY.
A number of sensitivity analyses were undertaken:
1. excluding from the analyses those who switched to a non-scheme DMT
2. using imputation techniques to account for missing values in the multilevel model examining patient
trajectories in EDSS scores, with observations nested within people
3. changing the assumption made in the Markov model about the treatment effect of DMTs on
backward transitions
4. supplementing transition probabilities derived from the BCMS with imputed values.
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Sensitivity analysis 1 showed a marginal increase in the treatment effect for the ‘base run’. For sensitivity
analysis 2, slight differences were seen between treatment effects. No probabilistic sensitivity analyses were
undertaken. Table 25 gives a summary of the RSS model.
Evidence used to parameterise the risk-sharing scheme multiple sclerosis model
The model was populated with clinical information from the RSS and secondary sources. Information
required to parameterise the model included evidence on the natural history of people with RRMS, the
aggregate treatment effect of DMTs, AEs, resource use and costs, mortality and HRQoL.
Natural history of relapsing–remitting multiple sclerosis
The natural history of RRMS and SPMS was estimated using the BCMS database. Details of the BCMS
cohort have been published elsewhere.153 In brief, the BCMS database is a population-based database
established in the 1980s that captures about 80% of people with MS in British Columbia, Canada.154 EDSS
scores were recorded by a MS specialist after a face-to-face consultation with patients and this usually
occurred at the annual visit to the MS clinic. In the database, people who progressed to SPMS were not
censored. However, all patients were censored in 1996 as a result of the introduction of DMTs in British
Columbia. This database is considered to be large (by 2004 the BCMS database included > 5900
participants), with prospectively collected information (e.g. EDSS scores, relapses, AEs) and a long-term
follow-up (> 25,000 cumulative years), and the database covers a relatively recent time period.154
TABLE 25 Summary of the RSS model
Parameter RSS model
Natural history cohort BCMS cohort
Population People initially diagnosed with RRMS and those who progress to SPMS
Intervention DMTs available in the RSS: 30 µg of IM IFN-β-1a once a week (Avonex), 44 or
22 µg of SC IFN-β-1a three times per week (Rebif), 250 µg of SC IFN-β-1b every
other day (Betaferon/Extavia), 20 mg of SC GA daily (Copaxone)
Comparator BSC
Type of model Markov model
HR Targeted outcomes were agreed for each of the four DMTs included in the RSS,
expressed as HRs of disability progression for treated compared with no treatment
Resource use and costs DMT costs, health state/EDSS costs and cost of relapses
HRQoL Utility values were pooled from the 2002 and 2005 MS Trust surveys
Discontinuation of treatment Assumed that 5% of people would discontinue treatment every year, as seen in
the RSS
Relapse Weighted average of the frequency of relapses for people with RRMS and SPMS,
irrespective of EDSS level
AEs Utility decrement of 0.02 associated with AEs from DMTs. It was assumed that this
decrement would apply only to the first year of treatment
Mortality MS-related death for people in EDSS 7–9. For all states, a SMR was estimated and
multiplied by two to take account of MS-related and non-MS-related mortality
Time horizon 50 years
Base-case analysis results Using the ‘base run’ model, an ICER of approximately £25,300 per QALY was
derived. Using the ‘time-varying model’, an ICER of approximately £33,700 per
QALY was derived
Sensitivity analysis (and probabilistic
sensitivity analysis) results
No probabilistic sensitivity analysis was undertaken
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Expanded Disability Status Scale progression in the British Columbia Multiple
Sclerosis cohort
The method of Jackson et al.276 was used to depict the natural history of MS, based on the observation of
people with RRMS in the BCMS cohort. Transition matrices were derived for people whose age at onset
of MS was below and above the median age (Tables 26 and 27 respectively). Disability progression was
characterised using the EDSS. In addition to progressing to more severe EDSS states, people were allowed
to improve to less severe EDSS states, which reflects the natural course of the disease. From the transition
matrix, only people in EDSS 7–9 could progress to EDSS 10 (MS-related death).
TABLE 26 Natural history transition matrix based on information from the BCMS database: age at onset of MS
below the median (subgroup 1)
From EDSS
state
To EDSS state
0 1 2 3 4 5 6 7 8 9 10
0 0.6870 0.0612 0.0169 0.0062 0.0018 0.0005 0.0001 0.0000 0.0000 0.0000 0
1 0.2110 0.6787 0.1265 0.0522 0.0225 0.0056 0.0014 0.0002 0.0000 0.0000 0
2 0.0720 0.1664 0.5955 0.1165 0.0662 0.0291 0.0045 0.0005 0.0000 0.0000 0
3 0.0224 0.0646 0.1729 0.5439 0.1210 0.0594 0.0252 0.0026 0.0003 0.0000 0
4 0.0043 0.0170 0.0454 0.0945 0.4874 0.0915 0.0321 0.0073 0.0006 0.0000 0
5 0.0014 0.0047 0.0184 0.0573 0.1009 0.4727 0.0424 0.0042 0.0005 0.0000 0
6 0.0018 0.0067 0.0219 0.1148 0.1664 0.2810 0.7283 0.1220 0.0187 0.0014 0
7 0.0001 0.0005 0.0018 0.0107 0.0262 0.0396 0.1151 0.6814 0.0570 0.0045 0
8 0.0000 0.0001 0.0005 0.0037 0.0069 0.0191 0.0457 0.1628 0.8544 0.1301 0
9 0.0000 0.0000 0.0000 0.0004 0.0007 0.0014 0.0052 0.0189 0.0608 0.6252 0
10 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0001 0.0077 0.2387 1
TABLE 27 Natural history transition matrix based on information from the BCMS database: age at onset of MS
above the median (subgroup 2)
From EDSS
state
To EDSS state
0 1 2 3 4 5 6 7 8 9 10
0 0.6954 0.0583 0.0159 0.0059 0.0017 0.0005 0.0001 0.0000 0.0000 0.0000 0
1 0.2029 0.6950 0.1213 0.0496 0.0221 0.0053 0.0013 0.0001 0.0000 0.0000 0
2 0.0725 0.1578 0.6079 0.1201 0.0666 0.0294 0.0044 0.0005 0.0000 0.0000 0
3 0.0217 0.0609 0.1680 0.5442 0.1152 0.0587 0.0250 0.0025 0.0003 0.0000 0
4 0.0042 0.0164 0.0446 0.0911 0.4894 0.0874 0.0307 0.0073 0.0005 0.0000 0
5 0.0014 0.0046 0.0185 0.0584 0.1039 0.4869 0.0408 0.0038 0.0005 0.0000 0
6 0.0018 0.0064 0.0216 0.1165 0.1681 0.2731 0.7407 0.1168 0.0187 0.0013 0
7 0.0001 0.0005 0.0017 0.0103 0.0258 0.0388 0.1089 0.6926 0.0553 0.0043 0
8 0.0000 0.0001 0.0005 0.0036 0.0067 0.0188 0.0438 0.1606 0.8964 0.1326 0
9 0.0000 0.0000 0.0000 0.0003 0.0006 0.0010 0.0042 0.0156 0.0205 0.6230 0
10 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0001 0.0077 0.2387 1
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Types of multiple sclerosis
The model included people who commenced in a RRMS health state and who progressed to SPMS. People
with CIS, PPMS or benign disease were not included in the RSS as treatment options included in the
scheme were not licensed for these types of MS.275
Interventions
The RSS model analysed the combined treatment effects of IFN-β and GA compared with BSC for people
with RRMS. Table 28 shows the drugs and dose regimes included in the RSS with their licensed indications
in the UK. The year 10 analyses included people whose EDSS scores were recorded after they had
switched to non-scheme DMTs. The assessment group was not clear on the non-scheme DMTs included in
the RSS. Sensitivity analysis was conducted around the treatment effect, which involved censoring people
whose EDSS scores were recorded after switching treatment. Censoring these people resulted in an
increase in the combined treatment effect (HR 0.7666).
Population
The population included in the RSS model was similar to the population in the BCMS cohort. In the RSS,
the population was stratified by age at onset of RRMS and by EDSS score. The initial distribution of people
in each EDSS state is presented in Table 29.
TABLE 29 Baseline distribution of people in the RSS
EDSS level Age at onset below median, n Age at onset above median, n Total
0 61 74 135
1 295 394 689
2 411 677 1088
3 401 569 970
4 273 379 652
5 162 279 441
6 76 166 242
7 0 0 0
8 0 0 0
9 0 0 0
10 0 0 0
Total 1679 2538 4217
TABLE 28 Interventions included in the RSS
Trade name Drug Dose regime Route of administration Licensed indications
Avonex IFN-β-1a 30 µg once a week IM RRMS
Rebif IFN-β-1a 44 µg three times per week
(22 µg three times per week
for patients unable to
tolerate the higher dose)
SC RRMS, SPMS
Betaferon IFN-β-1b 250 µg every other day SC RRMS, SPMS
Copaxone GA 20mg once daily SC RRMS
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Mortality rate
Two types of mortality were included in the model, MS-related death (EDSS 10) and death from other
causes. General population mortality was obtained from the Office for National Statistics (ONS)277 and a
weighted average was taken to represent the distribution of men and women in the economic model.
People with RRMS and SPMS were assumed to have a higher mortality rate than those in the general
population. It was assumed that the SMR increased twofold, regardless of the age at onset or severity of
MS and EDSS level. The assessment group noted that the same transition probabilities from EDSS 7–9 to
MS-related death were used for both natural history subgroups and also for both active therapy subgroups.
The assessment group was concerned that MS-related mortality may have been overestimated, as individuals
in the model also died as a result of progression to EDSS 10 (death).
Resource use and costs
All resource use and costs included in the analysis were those directly related to the NHS and PSS
perspective and were reported in UK pounds in 2015/16 prices. The RSS model included the
following costs:
l DMT costs
l health state/EDSS costs
l cost of relapse.
Disease-modifying therapy costs
Table 28 shows the DMTs included in the RSS model. Drug prices were agreed as part of the RSS.
A weighted average cost of these treatments was taken, with a mean cost of £7300 per year derived for
people who received treatment. However, it was not clear how this weighted average cost was derived.
Health state/Expanded Disability Status Scale costs
Information on resource use and costs associated with treating MS from a UK perspective was obtained
from a cross-sectional observational study undertaken by Kobelt et al.108 This study obtained resource
use information to derive the costs of MS from a societal perspective (direct and indirect costs), but also
provided disaggregated information relating to the direct costs of MS (detection, treatment, rehabilitation
and long-term care). The direct costs included the costs of inpatient care, ambulatory care, social care,
drug treatment, investments made to the home and informal care (care provided in the absence of family).
The study reported that direct costs (including informal care) accounted for 54% of the total costs,
with the remaining 46% representing indirect costs. However, excluding informal care from the analysis,
direct costs accounted for 38% of the total costs per patient per year. The costs were estimated for each
individual patient in the study and an average cost per patient was reported with respect to the different
levels of disability (mild, moderate and severe). All costs were reported in UK pounds at 1999/2000 prices.
The previous report by the School of Health and Related Research (ScHARR), University of Sheffield,275
suggested that 244 out of the 622 records of resource use and costs for treating MS in the UK were
excluded because respondents had PPMS or benign MS or information on EDSS state was missing. Mean
direct costs by EDSS state and mean cost of a relapse reported in the economic model submitted by the
Department of Health were based on information supplied to the ScHARR team in confidence and the
assessment group did not have access to this information. Costs in the ScHARR submission were
subsequently inflated to current prices (2015/16) using the appropriate indices from the Hospital and
Community Health Services (HCHS) pay and price index 2015/16278 and the assessment group believes that
these have been appropriately derived. Table 30 shows the costs included in the model.
Despite these mean costs being correctly derived, the RSS model assumed that resource use and patient
management have not changed since 1990/2000. The assessment group believes that a systematic review
could have been conducted to obtain more recent information on resource use.
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The assessment group is unable to provide comment on:
l the resource use information valued to derive the mean unit costs per EDSS state
l the number of people reporting on resource use in each health state
l the percentage of people receiving each drug treatment
l the distribution of resource use and the techniques used to account for the skewness of costs,
if this existed
l the techniques used to account for missing data, if they existed
l ‘mapping’ from mild, moderate and severe disability onto the EDSS.
Cost of relapse
The cost of a relapse included in the RSS model was obtained from Tappenden et al.275 and subsequently
inflated to current prices using the HCHS pay and price index 2015/16.278 The cost represents an average
cost regardless of the severity of the relapse. The cost of a relapse was the same in the treatment and no
treatment arms of the model. As with health state costings, the assessment group noted that the original
cost year was 1999/2000 and assumptions were made that resource use and management have not
changed since the base year. Despite this assumption, the assessment group considers the cost of relapse
(£4263) to have been derived correctly. However, the assessment group is unclear on the components/
resources costed to derive this cost. Additionally, the assessment group believes that a review of the
literature could have been undertaken to obtain more recent information.
The costs included in the model were related to drug treatment, health state/EDSS and relapse costs.
The assessment group was not clear whether the costs of treating AEs, administering the drugs or monitoring
treatments were included in the analysis. For example, IFN-β-1a (Avonex) is administered intramuscularly and
would incur additional directs costs (e.g. training patients or carers to administer injections).
Health state utility values
The primary outcome measure used in the model was a ‘deviation score of the average observed loss of
utility’ (Department of Health, 10 January 2017, personal communication). Health outcomes were
measured in QALYs, with utility weights assigned to the health states in the model. The utilities used in the
RSS model were derived by first pooling values from two MS Trust surveys (2002 and 2005) and then
subtracting carers’ disutility. Utilities obtained from Boggild et al.,279 as used in Tappenden et al.,275 were
derived based on information from a two-stage survey of 1554 respondents from the MS Trust database.
TABLE 30 Mean unit costs included in the RSS model
EDSS state Unit costs (£), 1999/2000 prices Unit costs (£), 2015/16 prices
0 756 1164
1 756 1164
2 756 1164
3 1394 2147
4 1444 2225
5 5090 7840
6 5678 8746
7 17,327 26,688
8 26,903 41,439
9 34,201 52,679
10 0 0
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To our understanding, these three sets (data from the two MS Trust surveys and Boggild et al.279) formed
the three-pooled data set. Utility estimates, by EDSS, were derived based on information collected on
the EQ-5D questionnaire, which was subsequently converted to an EQ-5D index score. Alternative utility
values were derived based on pooled data sets from the ScHARR model275 and also from the UK MS Trust
surveys. Table 31 shows the utility values used in the RSS model.
Carers’ disutility
An analysis was undertaken that included carers’ disutility by EDSS state. Table 31 shows the disutility
values used in the model. Initially, the assessment group was unclear on the source of these disutilities.
However, on clarification the Department of Health suggested that these values were obtained from a
study by Acaster et al.280 The assessment group examined the literature to identify other potential sources
of disutilities associated with providing care for people with MS.
Treatment effect
The effect of treatment with DMTs was modelled for the relative reduction in the annual frequency of
relapses and the relative risk of disease progression between EDSS states. In the RSS model, both treatment
effects were estimated based on observed relapses and progressions in EDSS scores in people in the RSS.
Although not clear, it appeared that similar methods used to derive transition matrices for the BCMS cohort
were used to derive transition matrices for the RSS model. From the comparison between both cohorts, a
mean HR of 0.7913 for disability progression was derived, based on the RSS year 10 analyses. The model
assumed that the treatment effect reduced the instantaneous rate of forward transitions by this HR,
independent of EDSS level, and that there was no effect on backward transitions. The report suggested that
the HRs for backward transitions were similar to that for forward transitions; however, these ratios were not
reported. Additionally, in the model (base run) it was assumed that the HR remained the same over the
entire duration (50 years) of the model time horizon.
Relapse frequency
In the RSS model, a weighted average of the frequency of relapse for people with RRMS and SPMS, at the
same EDSS level, was derived based on information obtained from the 2002 survey by the MS Trust
(Table 32). However, because of the paucity of information reported on the aggregate treatment effect of
DMTs on reducing relapse frequencies, we are unable to provide further commentary on this estimate.
TABLE 31 Mean utility values used in the RSS model
EDSS state Boggild et al.279 data set Three-pooled data set Two-pooled data set Carers’ disutility
0 0.7850 0.8722 0.9248 –0.002
1 0.7480 0.7590 0.7614 –0.002
2 0.6900 0.6811 0.6741 –0.002
3 0.5827 0.5731 0.5643 –0.002
4 0.5827 0.5731 0.5643 –0.045
5 0.5790 0.5040 0.4906 –0.142
6 0.4740 0.4576 0.4453 –0.167
7 0.3650 0.2825 0.2686 –0.063
8 0.2640 0.0380 0.0076 –0.095
9 –0.1770 –0.2246 –0.2304 –0.095
10 0 0 0 0
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Treatment discontinuation
In the treatment arm of the economic model it was assumed that 5% of people discontinue treatment
every year as a result of AEs and that treatment would be discontinued among individuals progressing to
an EDSS score of ≥ 7. However, the reasons for this were unclear, for example people may discontinue
treatment because the therapy is no longer working.275
The assessment group noted that no sensitivity analysis or probabilistic sensitivity analysis was undertaken
around these key assumptions about discontinuation. The justification for these assumptions was based
on the proportion of people discontinuing treatment as seen in the RSS. However, published evidence
suggests that the proportion of people discontinuing treatment in clinical trials of the DMTs included in the
RSS may range from 0%197 to 10%.216 Additionally, it appears that people who discontinued treatment
continued to accrue treatment benefits without additional costs. When people progressed to EDSS 7–9,
the model used ‘on treatment’ transition probabilities. The assessment group would expect that people
who discontinued treatment would progress to more severe health states in a similar way to people in the
natural history cohort.
Analysis (cycle length, time horizon and perspective)
For the base-case analysis, a Markov model was developed and programmed to assess the cost-effectiveness
of the combined treatment effect of DMTs in the RSS compared with no treatment (BSC) for people with
RRMS. The model cycled yearly, with a starting age of 30 years, and estimated the mean costs and effects
associated with treatment compared with no treatment over a 50-year time horizon. The analysis was
conducted from the NHS and PSS perspective and the results were reported in terms of ICERs, expressed as
cost per QALY gained. Both costs and benefits were discounted at 3.5% per annum.
Time-varying model
The RSS submission also included a sensitivity analysis using a ‘time-varying model’ to take account of a
perceived lack of fit of the RSS in taking account of the trajectories of patients with higher EDSS levels
at baseline. The model had two sets of transition probabilities, one for years 0–2 and one for all
subsequent years.
TABLE 32 Relapse frequency by EDSS state
EDSS
Relapse frequency Mean frequency
RRMS SPMS % RRMS % SPMS Untreated Treated
0 0.8895 0.0000 1.000 0.000 0.8895 0.6405
1 0.7885 0.0000 0.861 0.139 0.6790 0.4888
2 0.6478 0.6049 0.861 0.139 0.6418 0.4621
3 0.6155 0.5154 0.806 0.194 0.5961 0.4292
4 0.5532 0.4867 0.545 0.455 0.5230 0.3765
5 0.5249 0.4226 0.343 0.657 0.4577 0.3295
6 0.5146 0.3595 0.270 0.730 0.4014 0.2890
7 0.4482 0.3025 0.053 0.947 0.3103 0.2234
8 0.3665 0.2510 0.000 1.000 0.2510 0.1807
9 0.2964 0.2172 0.000 1.000 0.2172 0.1564
10 0.0000 0.0000 0.000 0.000 0 0
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Summary of the critical appraisal of the risk-sharing model
In general, the assessment group considered the RSS model to be appropriate to estimate the
cost-effectiveness of DMTs compared with BSC. In most cases the model draws on the best available
evidence on progression through RRMS and SPMS by EDSS level, resource use and costs and utility values.
We have considered and provided a critique of the RSS model against the NICE reference case156 and of
the economic model inputs and we have checked the model used to estimate cost-effectiveness. However,
some uncertainties remain, which are presented below. Additionally, in Chapter 11, we describe alternative
analyses that address our concerns:
1. The model applied a constant rate of 5% for people discontinuing treatment. However, there is little
evidence to support this assumption.
2. The difference between combined DMTs and BSC in reducing the frequency of relapses was 0.72,
but it was unclear how this value was derived. The report suggested that a weighted average of the
frequency of relapses for people with RRMS and SPMS, irrespective of EDSS level, was used and that
this was derived from information obtained from the 2002 survey undertaken by the MS Trust.
3. The assessment group noted that there was an assumption of increased risk of mortality for people
with MS compared with the general population. This was in addition to transition probabilities to EDSS
10 (MS-related death). Using this assumption would lead to double counting of MS-related deaths in
the model.
4. The model considers the prices of drugs agreed between the companies and the Department of Health.
However, it was unclear to the assessment group how these prices were derived.
5. In the analysis, the model included carers’ disutilities. The assessment group agrees that people may
experience a loss in utility when caring for people with MS. However, this analysis used a NHS and
PSS perspective.
6. A probabilistic sensitivity analysis to incorporate uncertainty in the estimates for model parameters was
not undertaken.
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Chapter 10 Manufacturers’ submissions: economic
evidence
Biogen Idec Ltd
Background
This section focuses on the economic evidence submitted by Biogen Idec Ltd. This section is set out as follows:
first, we present an overview/summary and then we provide a critique of the economic model submitted,
which describes in detail the evidence (e.g. natural history information, effectiveness of interventions included
in the analysis, resource use and costs, mortality and HRQoL) used to parameterise the model. In the Biogen
Idec Ltd model, an economic analysis was conducted to assess the cost-effectiveness of 30 µg of IM IFN-β-1a
once weekly (Avonex), 44 or 22 µg of SC IFN-β-1a three times weekly (Rebif), 250 µg of SC IFN-β-1b every
other day (Betaferon/Extavia), 125 µg of SC pegIFN-β-1a every 2 weeks (Plegridy) and 20mg of SC GA daily or
40mg of SC GA three times weekly (Copaxone) compared with BSC for people with RRMS.
In the analysis, a Markov model was used to depict the natural history of people with RRMS through the
SPMS. Information required on the natural history of people with RRMS was based on extrapolating the
ADVANCE placebo arm data213 with the BCMS cohort data.
In the intervention arms it was assumed that treatment with DMTs was not discontinued after reaching
a particular EDSS level, which the authors suggested is in accordance with the current Association of
British Neurologists guidelines.281 It was assumed that people would discontinue treatment only having
progressed to the SPMS health state.
The analysis was undertaken from the payer perspective. The outcome measure used in the analysis was
QALYs gained, over a 50-year time horizon. Treatment effects were assumed to delay the progression
of the disease and reduce the frequency of relapses. Utilities for RRMS by EDSS level were based on
information from the ADVANCE trial213 and Orme et al.,101 which was derived from utility values from the
UK MS Trust survey. Utility values for SPMS by EDSS level were based on information from the UK MS
Trust survey, as cited in the manufacturer’s submission. Carers’ disutilities were based on information
obtained from the manufacturer’s submission to NICE for TA127.282 Disutility values for AEs associated
with each DMT were included in the economic analysis.
Information on resource use and unit costs was obtained from various sources. The results were presented
as ICERs and expressed as cost per life-year gained and cost per QALY gained. Both costs and benefits
were discounted at 3.5% per annum. The authors carried out a number of sensitivity analyses (considering
the societal perspective, patient baseline characteristics, transition probabilities, treatment efficacy, relapse
rates, discontinuation rates, utility values, mortality multipliers, patients’ out-of-pocket costs, carers’ costs,
loss of productivity for people with MS and AEs) and probabilistic sensitivity analysis to determine the
robustness of the base-case results.
The base-case results showed that treatment with 125 µg of SC pegylated IFN-β-1a every 2 weeks resulted
in the highest mean life-years gained (20.658) and mean QALYs gained (9.642) compared with all other
interventions included in the analysis. Compared with BSC, 125 µg of SC pegylated IFN-β-1a every 2 weeks
had a mean incremental cost of approximately £25,200, with corresponding incremental QALYs of 0.810,
which equated to an ICER of approximately £31,000 per QALY.
The results from the sensitivity analyses showed that the base-case results were robust to univariate
changes made to key input parameters, except for changes to the HR for confirmed disability progression,
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which had the greatest impact. The probabilistic sensitivity analysis suggested that, at a £30,000 per QALY
willingness-to-pay threshold, 125 µg of SC pegylated IFN-β-1a every 2 weeks had a < 0.4 probability of
being cost-effective compared with BSC.
Types of multiple sclerosis
The model included people who commenced in a RRMS health state and progressed to SPMS. People with
CIS, PPMS or benign disease were not included in the analysis.
Model structure
The illustrative Markov model structure submitted by the manufacturer was based on the original ScHARR
model,275 with developments to include other interventions. The manufacturer used a cohort-based
Markov model to depict the natural history of people with RRMS. The model simulated disability progression,
progression from RRMS to SPMS and the relapsing nature of the disease. People with RRMS were able to
occupy one of the EDSS health states, which ranged from 0 to 10 in increments of 0.5. The model allowed
for people to progress, regress or stay in the same EDSS health state or progress from RRMS to SPMS.
When people progressed to SPMS they either remained in the same EDSS state or progressed to more
severe EDSS states.
In the model, people incurred costs and accrued benefits depending on the EDSS state for RRMS and
SPMS. Benefits were measured using QALYs, whereby each model cycle a utility is assigned to people
occupying a specific health state.
The assessment group was uncertain whether a review of the economic literature was undertaken to
inform the model design and/or its inputs. Based on our review there appears to be some inconsistency
in the model structures used to estimate the cost-effectiveness of DMTs for people with RRMS. These
discrepancies may be a result of the complex nature of MS. In Biogen Idec Ltd’s model, people could
progress from health states of an EDSS score of ≥ 1 to SPMS. However, in some models identified in the
review people could progress only from health states of an EDSS score of ≥ 6 to SPMS.
Interventions
The interventions considered in the economic analyses were 30 µg of IM IFN-β-1a once weekly (Avonex),
44 or 22 µg of SC IFN-β-1a three times weekly (Rebif), 250 µg of SC IFN-β-1b every other day (Betaferon/
Extavia), 125 µg of SC pegIFN-β-1a every 2 weeks (Plegridy) and 20 mg of SC GA daily or 40 mg of SC GA
three times weekly (Copaxone). These comparisons are all in line with the NICE scope.141 The interventions
were compared against BSC for people with RRMS. The manufacturer suggested that BSC would not
currently be offered as a starting point to RRMS patients.
Population
The population included in the economic analysis was similar to the population included in the ADVANCE
trial213 (i.e. 71% female, RRMS with a starting age of 36 years). The initial distribution of people in each
EDSS state is presented in Table 33.
Transitions
To simulate how people transitioned between the health states in the model, information was required on
transitions between RRMS health states, progression from RRMS to SPMS and transitions between SPMS
health states for both the comparator arm and the intervention arm. In the comparator arm (natural
history receiving BSC), in the base case the transition probabilities were derived from information from the
ADVANCE trial,213 supplemented with information from the BCMS data set.153 Table 34 shows the annual
transition probabilities between RRMS health states used in the natural history arm. In sensitivity analysis,
the manufacturer derived other transition probabilities, using information from the ADVANCE trial213
extrapolated with information from the BCMS data set153 or the London Ontario data set.80 The transition
probabilities for RRMS to SPMS were based on information from the London Ontario data set.80 The
manufacturer suggested that these values were not available in the BCMS cohort but did not elaborate on
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how they were derived. Table 35 shows the transition probabilities for RRMS to SPMS by EDSS level.
Transition probabilities for people progressing within SPMS health states were estimated from the BCMS
cohort.153 These annual probabilities were derived using a multistate model. Table 36 shows the transitions
between SPMS states.
Treatment effects of 30 µg of interferon beta-1a intramuscularly once weekly (Avonex)
For disability progression the manufacturer derived a HR based on a Cox proportional hazard model as a
measure of relative risk. In the RSS model, the treatment effect of 30 µg of IM IFN-β-1a once weekly
(Avonex) was shown to be (confidential information has been removed). The year 10 implied HR of
(confidential information has been removed) for 30 µg of IM IFN-β-1a once weekly was used in the
TABLE 34 Natural history matrix of annual transition probabilities based on information from the ADVANCE trial213
and the BCMS data set:153 Biogen Idec Ltd’s model
From EDSS
state
To EDSS state
0 1 1.5–2 2.5–3 3.5–4 4.5–5 5.5–6 6.5–7 7.5–8 8.5–9.5 10
0 0.850 0.050 0.100 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0
1 0.024 0.830 0.114 0.024 0.000 0.000 0.006 0.001 0.001 0.000 0
1.5–2 0.014 0.152 0.670 0.104 0.048 0.000 0.010 0.001 0.001 0.000 0
2.5–3 0.000 0.008 0.125 0.693 0.084 0.017 0.064 0.005 0.004 0.000 0
3.5–4 0.000 0.022 0.000 0.216 0.519 0.086 0.141 0.009 0.007 0.000 0
4.5–5 0.000 0.000 0.000 0.000 0.041 0.532 0.375 0.028 0.023 0.000 0
5.5–6 0.000 0.000 0.000 0.000 0.000 0.000 0.894 0.049 0.056 0.001 0
6.5–7 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.807 0.189 0.004 0
7.5–8 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.995 0.006 0
8.5–9.5 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 1.000 0
10 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 1
TABLE 33 Baseline distribution of people by EDSS state: Biogen Idec Ltd’s model
EDSS state Distribution (%)
0 6
1 26
1.5–2 28
2.5–3 24
3.5–4 12
4.5–5 4
5.5–6 0
6.5–7 0
7.5–8 0
8.5–9.5 0
10 0
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manufacturer’s model. Assuming no waning, the transition matrices are presented in Tables 37 and 38 for
age at onset of < 28 years and age at onset of > 28 years respectively. The implied HR was applied to the
model to show the relative effect of treatment on disability progression.
Resource use and costs
All costs included in the analysis were those directly related to the NHS and PSS perspective. Costs were
reported in UK pounds in 2015/16 prices. The model included the following costs:
l drug acquisition costs
l administration costs
l monitoring costs
l health state/EDSS costs
l cost of relapse
l treatment-related AE costs.
TABLE 35 Annual transition probabilities for RRMS to SPMS based on information from the London Ontario data
set:80 Biogen Idec Ltd’s model
EDSS state Probability of transition to SPMS (one EDSS state higher)
1 0.003
1.5–2 0.032
2.5–3 0.117
3.5–4 0.210
4.5–5 0.299
5.5–6 0.237
6.5–7 0.254
7.5–8 0.153
8.5–9.5 1.000
TABLE 36 Annual transition probabilities between SPMS health states based on information from the BCMS data
set:153 Biogen Idec Ltd’s model
From EDSS
state
To EDSS state
0 1 1.5–2 2.5–3 3.5–4 4.5–5 5.5–6 6.5–7 7.5–8 8.5–9.5 10
0 0.695 0.203 0.073 0.022 0.004 0.001 0.002 0.000 0.000 0.000 0
1 0.058 0.695 0.158 0.061 0.016 0.005 0.006 0.000 0.000 0.000 0
1.5–2 0.016 0.121 0.608 0.168 0.045 0.018 0.022 0.002 0.001 0.000 0
2.5–3 0.006 0.050 0.120 0.544 0.091 0.058 0.116 0.010 0.004 0.000 0
3.5–4 0.002 0.022 0.067 0.115 0.489 0.104 0.168 0.026 0.007 0.001 0
4.5–5 0.001 0.005 0.029 0.059 0.087 0.487 0.273 0.039 0.019 0.001 0
5.5–6 0.000 0.001 0.004 0.025 0.031 0.041 0.741 0.109 0.044 0.004 0
6.5–7 0.000 0.000 0.001 0.002 0.007 0.004 0.117 0.693 0.161 0.016 0
7.5–8 0.000 0.000 0.000 0.000 0.001 0.001 0.019 0.056 0.903 0.021 0
8.5–9.5 0.000 0.000 0.000 0.000 0.000 0.000 0.002 0.006 0.174 0.818 0
10 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 1
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Drug acquisition costs
Treatment costs for the DMTs are presented in Table 39. Annual costs were presented for the list and net
price for each DMT available at the time of the RSS. From the Microsoft Excel® model submitted (2013;
Microsoft Corporation, Redmond, WA, USA), the annual cost of each drug was derived from the dosage
(per week and per year) and the price per packet. The assessment group considered these acquisition costs
to be correctly derived.
When no net prices for DMTs were available [SC pegIFN-β-1a (Plegridy), SC IFN-β-1b (Extavia) and GA
(Copaxone)], the list prices of these drugs were used in the analysis. The assessment group noted that the
annual drug acquisition cost for 250 µg of SC IFN-β-1b every other day (Betaferon/Extavia) was reported as
£7239 but the model used £7239.11 in the analysis.
Administration costs
Annual administration costs encompassed the costs associated with teaching people to self-administer the
drugs. The administration costs are presented in Table 40. The assessment group considered the resource
use and costs to be appropriate.
Monitoring costs
Annual monitoring costs for each treatment were presented in appendix K of the main report. The
manufacturer clearly outlined the resource use used to derive monitoring costs. Monitoring costs were
presented for year 1 and for subsequent years. The monitoring costs for all interventions are presented in
Table 41. These annual monitoring costs appeared to have been derived and used in the model correctly.
TABLE 39 Annual treatment costs: Biogen Idec Ltd’s model
Treatment Administration
Doses
per year
Annual acquisition cost (£, 2014/15 prices)
List price Net price
Year 1
Subsequent
years Year 1
Subsequent
years
IFN-β-1a IM (Avonex) 30 µg once
weekly
52.18 8502 8502 (Confidential
information has
been removed)
(Confidential
information has
been removed)
PegIFN-β-1a SC
(Plegridy)
125 µg every
2 weeks
26.1 8502 8502 8502 8502
IFN-β-1a SC (Rebif) 22 µg three
times weekly
156.18 7914 7976 (Confidential
information has
been removed)
(Confidential
information has
been removed)
IFN-β-1a SC (Rebif) 44 µg three
times weekly
156.18 10,311 10,572 (Confidential
information has
been removed)
(Confidential
information has
been removed)
IFN-β-1b SC
(Betaferon/Extavia)
250 µg every
other day
182.63 7239 7239 (Confidential
information has
been removed)
(Confidential
information has
been removed)
IFN-β-1b SC (Extavia) 250 µg every
other day
182.63 7239.11 7239.11 7239.11 7239.11
GA SC (Copaxone) 20mg once daily 365.25 6681 6681 (Confidential
information has
been removed)
(Confidential
information has
been removed)
GA SC (Copaxone) 40mg once daily 156.18 6681 6681 6681 6681
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Health state/Expanded Disability Status Scale costs
Health state costs (payer perspective) by EDSS level and MS type (RRMS/SPMS) are presented in Table 42.
These costs were related to MS management (expected/unexpected visits to health-care providers). The
manufacturer also identified and presented cost estimates from the study by Karampampa et al.283 and the
burden of illness (BOI) study. Costs obtained from Karampampa et al.283 were inflated using the HCHS
index and these seemed to have been correctly derived. These cost estimates were used in sensitivity
analyses. Costs were presented from the payer, government and societal perspectives in the sensitivity
analyses. It appears that the cost estimates by EDSS state varied between studies. There appears to be a
gradual increase in the management cost estimates derived in the submission and the BOI study from
EDSS 0 to 6, followed by larger increases beyond EDSS 6. However, in the Karampampa et al.283 study,
management costs seem to increase gradually from EDSS 0 to 10.
Cost of relapse
In the main report of the manufacturer’s submission, the cost of a relapse (£2697) was obtained from the
ScHARR model275 and subsequently inflated to current prices (£4265) using the HCHS pay and price index
2014/15.278 Using a cost from a dated source assumes that the management of and resource use for treating
relapses have not changed post 2001. The assessment group considered this to be a strong assumption.
TABLE 40 Administration costs for each intervention: Biogen Idec Ltd’s model
Treatment
Annual administration
cost for year 1
(£, 2014/15 prices) Resource use
Annual administration
cost for subsequent years
(£, 2014/15 prices)
Resource
use
IFN-β-1a 30 µg IM once
weekly (Avonex)
177.00 3 hours of nurse’s
time to teach
self-administration
0.00 None
IFN-β-1a 44 or 22 µg SC
three times weekly (Rebif)
177.00 3 hours of nurse’s
time to teach
self-administration
0.00 None
IFN-β-1b 250 µg SC every
other day (Betaferon/
Extavia)
177.00 3 hours of nurse’s
time to teach
self-administration
0.00 None
PegIFN-β-1a 125 µg SC
every 2 weeks (Plegridy)
177.00 3 hours of nurse’s
time to teach
self-administration
0.00 None
GA 20mg SC once daily or
40 mg SC three times
weekly (Copaxone)
177.00 3 hours of nurse’s
time to teach
self-administration
0.00 None
TABLE 41 Annual costs for monitoring of each treatment: Biogen Idec Ltd’s model
Treatment
Monitoring cost for (£, 2014/15 prices)
Year 1 Subsequent years
IFN-β-1a 30 µg IM once weekly (Avonex) 190.73 10.78
IFN-β-1a 44 or 22 µg SC three times weekly (Rebif) 203.25 10.78
IFN-β-1b 250 µg SC every other day (Betaferon/Extavia) 190.73 10.78
PegIFN-β-1a 125 µg SC every 2 weeks (Plegridy) 191.92 10.78
GA 20mg SC once daily or 40 mg SC three times weekly
(Copaxone)
175.75 10.78
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In critiquing the economic model submitted (and as stated in the appendices), the assessment group noted
that the cost of relapse used was obtained from the study by Hawton and Green107 and then subsequently
inflated to current prices using the HCHS pay and price index 2014/15.278 This cost represents an average
cost regardless of the severity of the relapse. Costs were derived for relapses not requiring hospitalisation
(£568) and for relapses requiring hospitalisation (£3651). The assessment group noted that these costs were
the same in all arms (intervention and comparator arms) of the model. These costs appear to have been
correctly derived. However, the manufacturer did not elaborate on the resource use estimates used to derive
the unit cost of a relapse. Resource use information in the Hawton and Green study107 was obtained from
information collected in the UK South West Impact of Multiple Sclerosis (SWIMS) project.284 The SWIMS
project is a prospective, longitudinal cohort study of people with MS in Devon and Cornwall, with follow up
every 6 months. In this study information was collected on type of MS, disease severity measured by the
EDSS, number of relapses in the previous 6 months, length of relapse, whether relapses led to hospital
admittance and treatment received for relapses. Additional information was collected on health or social
care use in the previous 6 months and the frequency of contact with a health-care professional. Resource
use was valued using the Personal Social Services Research Unit (PSSRU),278 NHS reference costs285 and the
BNF.21 All costs derived were reported in UK pounds in 2012 prices. The assessment group considered this
study to be methodologically robust. However, these costs represented people with various types of MS
(RRMS, PPMS, SPMS, benign, combination or not known) who experienced relapses over a 6-month period.
Resource use and costs were not reported by type of MS in the Hawton and Green study.107 The assessment
group considers that the costs used in the model were underestimates of the cost of a relapse.
Cost of adverse events
The model included the costs of AEs resulting from the use of DMTs. Estimates of resource use were
presented in appendix K of the manufacturer’s submission. Health-care resource use for each AE was
validated by a Delphi panel conducted by the manufacturer in December 2013. The manufacturer provided
the percentages of people who developed these AEs by DMT. Table 43 shows the annual cost of treatment
for AEs by DMT used in the model. These annual costs for the treatment of AEs appear to have been
correctly derived.
TABLE 42 Mean unit management costs in the model from a payer perspective: Biogen Idec Ltd’s model
EDSS state
RRMS (£, 2014/15 prices) SPMS (£, 2014/15 prices)
Biogen
Idec Ltd Karampampa et al.283 BOI study
Biogen
Idec Ltd Karampampa et al.283 BOI study
0 937 1179 4301 1263 1470 4301
1 974 1399 4783 1301 1745 4783
1.5–2 714 1674 8666 1040 2088 8666
2.5–3 3906 2006 7720 4232 2502 7720
3.5–4 1892 2393 7159 2218 2985 7159
4.5–5 3210 2837 9147 3537 3538 9147
5.5–6 4285 3337 12,830 4611 4161 12,830
6.5–7 11,279 3892 17,971 11,605 4854 17,971
7.5–8 27,472 4503 29,915 27,798 5616 29,915
8.5–9.5 21,982 5170 37,656 22,309 6449 37,656
10 0 0 0 0 0 0
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Health state utility values
Utilities were derived by EDSS level and MS type (RRMS and SPMS). In the base case these were derived by
combining information from the placebo arm of the ADVANCE trial213 (EDSS 0–5) with information from the
UK MS Trust survey (EDSS score of ≥ 6). Utility values for EDSS 6 were derived by adding the utility value for
EDSS 5 (taken from the ADVANCE trial213) to the difference in utility values between EDSS 6 and EDSS 5
from the UK MS Trust survey. The same method was used to derive utility values for EDSS scores from ≥ 7
to 9. Utility values used in the model are presented in Table 44. The manufacturer also included disutilities
associated with relapses experienced in a RRMS health state (–0.071) and in a SPMS health state (–0.045).
These disutilities were applied across all EDSS levels by MS type (RRMS and SPMS). Disutilities were obtained
from the study by Orme et al.101 An analysis was also undertaken that included carers’ disutility by EDSS
state. Table 44 shows the disutility values used in the model. Because of a lack of information, the burden
associated with caring for people with RRMS or SPMS was assumed to be the same.
Adverse event disutilities
The disutilities associated with AEs resulting from treatment with the DMTs are presented in Table 45.
TABLE 43 Annual cost of treatment for AEs by DMT: Biogen Idec Ltd’s model
Treatment Unit cost (£, 2014/15 prices)
IFN-β-1a 30 µg IM once weekly (Avonex) 154.97
PegIFN-β-1a 125 µg SC every 2 weeks (Plegridy) 76.95
IFN-β-1a 22 µg SC three times weekly (Rebif) 127.33
IFN-β-1a 44 µg SC three times weekly (Rebif) 140.89
IFN-β-1b 250 µg SC every other day (Betaferon) 104.12
IFN-β-1b 250 µg SC every other day (Extavia) 104.12
GA 20mg SC once daily (Copaxone) 74.78
GA 40mg SC three times weekly (Copaxone) 74.78
TABLE 44 Mean utility values used in the model: Biogen Idec Ltd’s model
EDSS state
Utility value Carers’ disutility
RRMS SPMS RRMS SPMS
0 0.879 0.834 0.000 0.000
1 0.866 0.821 –0.001 –0.001
1.5–2 0.771 0.726 –0.003 –0.003
2.5–3 0.662 0.617 –0.009 –0.009
3.5–4 0.573 0.528 –0.009 –0.009
4.5–5 0.549 0.504 –0.020 –0.020
5.5–6 0.491 0.446 –0.027 –0.027
6.5–7 0.328 0.283 –0.053 –0.053
7.5–8 –0.018 –0.063 –0.107 –0.107
8.5–9.5 –0.164 –0.209 –0.140 –0.140
Relapse disutility in the RRMS states –0.071
Relapse disutility in the SPMS states –0.045
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Mortality rate
Mortality was assumed to be equivalent between RRMS and SPMS and dependent on EDSS state. All
patients were modelled to be at risk of mortality from MS and other causes. This was modelled by first
estimating SMRs using data from the ONS,277 as cited in the Biogen Idec Ltd submission, and applying a
mortality multiplier to reflect both causes of death. Additionally, individuals in EDSS 7–9 could die from
MS-specific mortality from transition to EDSS 10 (death).
Relapse frequency
The ARRs were obtained from the ADVANCE trial213 up to EDSS 5.5 and were supplemented with rates
derived from the study by Patzold et al.,286 as cited in the manufacturer’s submission. Table 46 shows the
relapse rates by EDSS level used in the base case (ADVANCE trial placebo arm213) and other relapse rates
used in scenario analyses.
Relapse rates per person per year for EDSS levels > 5.5 were derived based on the relative increase in ARR
reported in the study by Patzold et al.286 Patzold et al.286 reported ARRs based on the year of diagnosis of
RRMS. ARRs by year were converted to ARRs by EDSS level by taking the mean number of relapses per
TABLE 45 Annual disutility values associated with the DMTs: Biogen Idec Ltd’s model
Treatment Annual disutility
IFN-β-1a 30 µg IM once weekly (Avonex) –0.024
PegIFN-β-1a 125 µg SC every 2 weeks (Plegridy) –0.016
IFN-β-1a 44 µg SC three times weekly (Rebif) –0.019
IFN-β-1b 250 µg SC every other day (Betaferon) –0.018
IFN-β-1b 250 µg SC every other day (Extavia) –0.018
GA 20mg SC once daily (Copaxone) –0.007
GA 40mg SC three times weekly (Copaxone) –0.007
TABLE 46 Relapse frequency by EDSS state and type of MS (RRMS and SPMS): Biogen Idec Ltd’s model
EDSS state
Study
ADVANCE trial213
placebo arm
Patzold et al.286 and UK MS
Trust survey
(TA254,120 TA320119 methods)
Patzold et al.286 and UK MS
Trust survey
(TA303,122 TA312118 methods)
RRMS SPMS RRMS SPMS RRMS SPMS
0 0.260 0.000 0.709 0.000 0.725 0.000
1 0.237 0.000 0.729 0.000 0.743 0.000
1.5–2 0.460 0.315 0.676 0.465 0.690 0.447
2.5–3 0.495 0.602 0.720 0.875 0.723 0.788
3.5–4 0.670 0.515 0.705 0.545 0.707 0.567
4.5–5 0.181 0.160 0.591 0.524 0.599 0.517
5.5–6 0.150 0.139 0.490 0.453 0.508 0.445
6.5–7 0.156 0.104 0.508 0.340 0.504 0.312
7.5–8 0.156 0.104 0.508 0.340 0.504 0.312
8.5–9.5 0.156 0.104 0.508 0.340 0.504 0.312
10 0 0 0 0 0 0
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year for each health state from the UK MS Trust survey and multiplying by the relative relapse rates per
person reported by Patzold et al.286
Treatment discontinuation
In the model, people who progressed to a SPMS health state discontinued treatment. However, treatment
was assumed not to be discontinued after reaching a particular EDSS level. This is in accordance with
current Association of British Neurologists guidelines.281 Annual discontinuation rates used in the model are
presented in Table 47.
Analysis (cycle length, time horizon and perspective)
The analysis was undertaken from a NHS and PSS perspective. The outcome measure used in the analysis
was QALYs gained, over a 50-year time horizon with an annual cycle length. The starting age of the
population was 36 years. The results were presented as ICERs, expressed as cost per QALY gained. Both
costs and benefits were discounted at 3.5% per annum.
Assumptions
To have a workable model, the manufacturer made the following assumptions:
l The probability of transitioning to a health state in the next cycle depends only on the health state in
the present cycle.
l Transition from RRMS to SPMS is accompanied by an increase in EDSS state of 1.0.
l The population at baseline in the ADVANCE trial213 is representative of the RRMS population in
clinical practice.
l Each year, the EDSS score can remain the same, increase or decrease.
l In the base case, treatments affect EDSS progression but not EDSS regression.
l Treatment effects on relapse and EDSS progression are independent.
l In the base case, treatments have the same effect on progression in each EDSS state.
l In the base case, treatment efficacy is constant over time.
l Treatments do not directly impact on transitions to SPMS but impact on patients’ EDSS state, which
influences the transition to SPMS.
l Treatment discontinuation is constant for all years.
l The mortality rate for age > 100 years is same as that for age 100 years.
l Annualised AE risks are applied every year – this may overestimate the incidence of AEs as patients
who have AEs may discontinue treatment in the initial years on treatment.
l RRMS patients in all EDSS states may receive treatments depending on the maximum EDSS limit.
l SPMS patients receive BSC only.
l Patient access schemes, when publicly available, are considered in the base case.
TABLE 47 Annual discontinuation rates by DMT: Biogen Idec Ltd’s model
Treatment Annual withdrawal (%)
IFN-β-1a 30 µg IM once weekly (Avonex) 7.9
PegIFN-β-1a 125 µg SC every 2 weeks (Plegridy) 10.4
IFN-β-1a 22 µg SC three times weekly (Rebif) 6.0
IFN-β-1a 44 µg SC three times weekly (Rebif) 12.3
IFN-β-1b 250 µg SC every other day (Betaferon) 5.7
IFN-β-1b 250 µg SC every other day (Extavia) 5.7
GA 20mg SC once daily (Copaxone) 7.2
GA 40mg SC three times weekly (Copaxone) 7.2
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Summary of the Biogen Idec Ltd submission results
The base-case results showed that treatment with 125 µg of SC pegIFN-β-1a every 2 weeks (Plegridy)
resulted in the highest mean life-years gained (20.658) and mean QALYs (9.642) compared with all other
interventions included in the analysis. Compared with BSC, 125 µg of SC pegylated IFN-β-1a every 2 weeks
had a mean incremental cost of approximately £25,200 with corresponding incremental QALYs of 0.810,
which equated to an ICER of approximately £31,000 per QALY.
The results from the sensitivity analyses showed that the base-case results were robust to univariate
changes made to key input parameters, except for changes to the HR for confirmed disability progression,
which had the greatest impact. The probabilistic sensitivity analysis suggested that, at a £30,000 per QALY
willingness-to-pay threshold, 125 µg of SC pegylated IFN-β-1a every 2 weeks had a < 0.4 probability of
being cost-effective compared with BSC.
Teva UK Limited
Background
This section focuses on the economic evidence on GA (Copaxone) submitted by Teva UK Ltd. This section
is set out as for the previous manufacturer’s submission: first, we present an overview/summary and
then we provide a critique of the economic model submitted by Teva. This section describes in detail the
evidence (e.g. natural history information, effectiveness of the interventions included in the analysis,
resource use and costs, mortality and HRQoL) used to parameterise the model.
The economic submission to NICE included:
l a description of the de novo economic model from Teva, which assessed the cost-effectiveness of
DMTs for the treatment of RRMS; this included details on the intervention and comparators, study
population, resource use and costs, the modelling methodology and assumptions made
l appendices with details of the evidence used to inform the model and a description of a NMA carried
out to generate alternative estimates of efficacy that were used in sensitivity analysis.
Overview
In the Teva model, an economic analysis was conducted to assess the cost-effectiveness of the DMTs 30 µg
of IM IFN-β-1a once weekly (Avonex), 44 or 22 µg of SC IFN-β-1a three times weekly (Rebif), 250 µg of SC
IFN-β-1b every other day (Betaferon/Extavia), 125 µg of SC pegIFN-β-1a every 2 weeks (Plegridy) and 20 mg
of SC GA daily or 40 mg of SC GA three times weekly (Copaxone), as well as fingolimod, natalizumab and
dimethyl fumarate, for use in second-line therapy, compared with BSC for people with RRMS.
In the analysis, a Markov model was used to depict the natural history of people with RRMS through
progression to SPMS. The model included 21 health states, defined by EDSS score and disease stage
(RRMS or SPMS). Only integer EDSS values were allowed, with fractional values rounded down. Disease
progression rates during RRMS on BSC were based on the BCMS database, as in the RSS model.153
Transition rates to SPMS were estimated using HRs observed in the London Ontario data set,80 following
assumptions made in the ScHARR model.275 The Teva model assumed that progression to SPMS increases
EDSS scores by 1. Progression between EDSS scores for SPMS was calculated using the same transition
probabilities as for RRMS. Treatment was assumed to continue until patients progressed to SPMS or
reached an EDSS score of ≥ 7 and was not reinitiated.
The analysis was undertaken from the payer perspective, although sensitivity analyses were included from
a societal perspective. The outcome measure used in the analysis was QALYs gained, over a 50-year
time horizon. Treatment effects were assumed to delay the progression of the disease and reduce the
frequency of relapses. The assumed HR (applied to all forward transitions) for GA compared with BSC was
(confidential information has been removed) in the base case, based on the subset of patients in the RSS
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who received this DMT. Utilities for RRMS by EDSS level were based on pooling data from the MS Trust
survey and Orme et al.,101 following the RSS.153 Utilities for SPMS by EDSS level were assumed to be the
same as for RRMS. Carers’ disutilities were based on information obtained from the manufacturer’s
submission to NICE for TA127.282 Disutility values for AEs associated with each DMT were taken from a
range of sources, including the NICE appraisal of alemtuzumab118 and the study by Maruszczak et al.287
Information on resource use and unit costs was obtained from various sources (BNF,21 PSSRU,278 NHS
reference costs285). The results were presented as ICERs and expressed as cost per life-year gained and cost
per QALY gained. Both costs and benefits were discounted at 3.5% per annum. The authors undertook
a number of sensitivity analyses (considering the societal perspective, patient baseline characteristics,
transition probabilities, treatment efficacy, relapse rates, discontinuation rates, utility values, mortality
multipliers, patients’ out-of-pocket costs, carers’ costs, loss of productivity for people with MS and AEs)
and probabilistic sensitivity analysis to determine the robustness of the base-case results. The base-case
results showed that treatment with GA resulted in a mean gain per patient of (confidential information has
been removed) life-years or (confidential information has been removed) QALYs, at a net discounted cost
of (confidential information has been removed), giving an ICER of (confidential information has been
removed) per QALY. The probability of the cost-effectiveness of GA relative to BSC was (confidential
information has been removed) at £20,000 per QALY and (confidential information has been removed) at
£30,000 per QALY. Results from deterministic sensitivity analyses showed that the base-case results were
robust to univariate changes made to key input parameters, except for changes to the HR for confirmed
disability progression, which had the greatest impact, and EDSS score-related costs, which influenced
whether GA was cost-effective relative to BSC.
Evidence used to parameterise the Teva model
Natural history of relapsing–remitting multiple sclerosis
Two key sources informed the analysis of natural history of RRMS: the London Ontario data set80 for
transition to SPMS and SPMS transitions and the BCMS data set153 for EDSS progression. Tables 48 and 49
show the natural history transition matrices from the BCMS data set for people with an age at onset
below the median age and an age at onset above the median age respectively.
Types of multiple sclerosis
The model included people who commenced in a RRMS health state and progressed to SPMS. People with
CIS, PPMS or benign disease were not included in the analysis.
Interventions
The interventions considered in the economic analyses are presented in Table 50. The interventions
included 30 µg of IM IFN-β-1a once weekly (Avonex), 44 or 22 µg of SC IFN-β-1a three times weekly
(Rebif), 250 µg of SC IFN-β-1b every other day (Betaferon/Extavia), 125 µg of SC pegIFN-β-1a every
2 weeks (Plegridy) and 20 mg of SC GA daily or 40 mg of SC GA three times weekly (Copaxone), as well
as fingolimod (Gilenya), natalizumab (Tysabri) and dimethyl fumarate (Tecfidera) as second-line therapies.
It was assumed that the split between these second-line therapies would be 50%, 30% and 20%,
respectively, based on expert opinion. The interventions were compared with BSC for people with RRMS.
Model structure
The illustrative Markov model structure submitted by the manufacturer was based on the original ScHARR
model275 with developments to include other interventions. The manufacturer used a cohort-based Markov
model to depict the natural history of people with RRMS. The model simulated disability progression,
progression from RRMS to SPMS and the relapsing nature of the disease. People with RRMS were able
to occupy one of the EDSS health states, which ranged from 0 to 10. The model allowed for people to
progress, regress or stay in the same EDSS health state or progress from EDSS to SPMS. When people
progressed to SPMS, they could progress, regress or remain in the same EDSS state.
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In the model, people incurred costs and accrued benefits depending on the EDSS state for RRMS and
SPMS. Benefits were measured using QALYs, with a utility being assigned to people occupying a specific
health state each model cycle.
Population
The population included in the economic analysis was similar to the population in the RSS data set
(confidential information has been removed). The initial distribution of people in each EDSS state is
presented in Table 51.
Resource use and costs
Costs included in the analysis were those directly related to the NHS and PSS perspective. Costs were
reported in UK pounds in 2015/16 prices. The model included the following costs:
l drug acquisition costs
l administration costs
l monitoring costs
TABLE 51 Baseline distribution of people by EDSS score:
Teva model
EDSS state Distribution (%)
0 3
1 16
2 26
3 23
4 16
5 10
6 6
7 0
8 0
9 0
10 0
TABLE 50 Interventions included in the economic analysis: Teva model
Trade name Drug Dose regime
Route of
administration
Licensed
indication
Avonex IFN-β-1a 30 µg once a week IM RRMS
Rebif IFN-β-1a 22 or 44 µg three times per week SC RRMS
Betaferon/Extavia IFN-β-1b 250 µg every other day SC RRMS
Plegridy PegIFN-β-1a 125 µg every 2 weeks SC RRMS
Copaxone GA 20mg once daily/40 mg three times weekly Oral RRMS
Gilenya Fingolimod 0.5 mg once daily Oral RRMS
Tysabri Natalizumab 300mg once every 4 weeks IVI RRMS
Tecfidera Dimethyl fumarate 240 mg twice daily Oral RRMS
IVI, Intravenous infusion.
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l health state/EDSS costs
l cost of relapse
l treatment-related AE costs.
Drug acquisition costs
Treatment costs for GA along with the other DMTs are presented in Table 52. Annual costs were
presented for the list and net price for each DMT that was available at the time of the RSS. From the
Microsoft Excel (2013) model submitted, the annual cost of each drug was based on the dosage (per week
and year) and the price per packet.
When no net prices for DMTs were available because of treatments not being included in the RSS
[fingolimod, natalizumab and 125 µg of SC pegIFN-β-1a every 2 weeks (Plegridy)], the list price of these
drugs were used in the analysis.
Administration costs
Annual administration costs encompassed the costs associated with teaching people to self-administer the
drugs. The administration costs are presented in Table 53.
Monitoring costs
Annual monitoring costs for each treatment were presented in appendix 6 of the main report. The
manufacturer clearly outlined the resource use used to derive monitoring costs. Monitoring costs were
presented for year 1 and for subsequent years. The annual monitoring costs for all interventions are
presented in Table 54. These annual monitoring costs appeared to be derived and used in the model correctly.
The monitoring costs for second-line therapies were not presented in appendix 6 of the submission.
Health state/Expanded Disability Status Scale costs
Health state costs (payer perspective) by EDSS level and MS type (RRMS/SPMS) are presented in Table 55.
These costs were related to MS management (expected/unexpected visits to health-care providers). The
costs were taken from the ScHARR model275 and inflated to 2015 prices. Sensitivity analyses were carried
out using health state costs sourced from Tyas et al.288 and Karampampa et al.283 The former set of costs
TABLE 52 Annual treatment costs: Teva model
Treatment
Annual acquisition cost (£, 2014/15 prices)
List price Net price
GA 20mg once daily or 40 mg SC three times
weekly (Copaxone)
6704.29 (Confidential information has
been removed)
IFN-β-1a 30 µg IM once weekly (Avonex) 8531.20 (Confidential information has
been removed)
IFN-β-1b 250 µg SC every other day
(Betaferon/Extavia)
7264.82 (Confidential information has
been removed)
IFN-β-1a 44 µg SC three times weekly (Rebif) 10,608.43 (Confidential information has
been removed)
IFN-β-1a 22 µg SC three times weekly (Rebif) 8003.67 (Confidential information has
been removed)
Fingolimod (Gilenya) 19,175.63 19,175.63
Natalizumab (Tysabri) 14,740.45 14,740.45
Dimethyl fumarate (Tecfidera) 17,910.29 (Confidential information has
been removed)
PegIFN-β-1a 125 µg SC every 2 weeks (Plegridy) 8531.20 8531.20
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TABLE 53 Administration costs for each intervention: Teva model
Treatment
Annual
administration
cost for year 1
(UK£, 2014/15
prices) Resource use
Annual
administration cost
for subsequent
years (UK£,
2014/15 prices) Resource use
GA 20 mg SC once daily/
40 mg SC three times
weekly (Copaxone)
174.00 3 hours of nurse’s
time to teach
self-administration
0.00 None
IFN-β-1a 30 µg IM once
weekly (Avonex)
174.00 3 hours of nurse’s
time to teach
self-administration
0.00 None
IFN-β-1b 250 µg SC every
other day (Betaferon/
Extavia)
174.00 3 hours of nurse’s
time to teach
self-administration
0.00 None
IFN-β-1a 44 µg SC three
times weekly (Rebif)
174.00 3 hours of nurse’s
time to teach
self-administration
0.00 None
IFN-β-1a 22 µg SC three
times weekly (Rebif)
174.00 3 hours of nurse’s
time to teach
self-administration
0.00 None
PegIFN-β-1a 125 µg SC
every 2 weeks (Plegridy)
174.00 3 hours of nurse’s
time to teach
self-administration
0.00 None
Fingolimod (Gilenya) 144.99 Continuous
electrocardiography
and blood pressure
monitoring for
6 hours following
the first dose
0.00 None
Natalizumab (Tysabri) 5199.02 Thirteen infusions
per year with 1 g of
methylprednisolone
per infusion
5199.02 Thirteen infusions
per year with 1 g of
methylprednisolone
per infusion
Dimethyl fumarate
(Tecfidera)
0 None 0 None
TABLE 54 Annual monitoring costs for each treatment: Teva model
Treatment
Monitoring costs for (£, 2014/15 prices)
Year 1 Subsequent years
GA 20 mg SC once daily/40 mg SC three times weekly (Copaxone) 414.00 414.00
IFN-β-1a 30 µg IM once weekly (Avonex) 521.08 512.54
IFN-β-1a 22 µg SC three times weekly (Rebif) 521.08 512.54
IFN-β-1a 44 µg SC three times weekly (Rebif) 521.08 512.54
PegIFN-β-1a 125 µg SC every 2 weeks (Plegridy) 521.08 512.54
IFN-β-1b 250 µg SC every other day (Betaferon/Extavia) 521.08 512.54
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involved lower costs for high EDSS scores leading to an increase in the ICER for GA to £29,000 per QALY.
The latter involved higher costs for high EDSS scores, which resulted in GA dominating BSC.
Cost of relapse
The cost of a mild relapse was estimated as £870 and the cost of a severe relapse requiring hospitalisation
was estimated as £5580. The submission stated that these costs were sourced from the manufacturer’s
submission for NICE TA312118 (alemtuzumab for treating RRMS), which took these costs from a budget
impact analysis in the Republic of Ireland.289 This raises questions about the robustness of the estimate and
its relevance to a UK setting. The assessment group for TA312 conducted its own sensitivity analysis in
which the cost of a severe relapse was assumed to be lower (£3039). A justification for this was not
presented in the report, but it implies that the assessment group at the time thought that the higher figure
might be an overestimate.
Cost of adverse events
The model included the costs of AEs resulting from the use of DMTs. Estimates of resource use were
presented in appendix 6 of the manufacturer’s submission. Unit costs of resources used to manage AEs
were sourced from the PSSRU,278 national reference costs285 and the manufacturer’s submission for
TA312,118 although insufficient detail is presented for the accuracy of the costs assumed for AEs to be fully
verified. Table 56 shows the annual cost of treatment for AEs by DMT used in the model.
TABLE 55 Mean unit costs from the payer perspective:
Teva model
EDSS state Cost (£)
0 1195
1 1195
2 1195
3 2204
4 2284
5 8049
6 8978
7 27,398
8 42,541
9 54,080
TABLE 56 Annual cost of treatment for AEs by DMT: Teva model
Treatment
Unit cost (£, 2014/15 prices)
Year 1 Year 2
GA (Copaxone) 44.61 44.61
IFN-β-1a 30 µg IM once weekly (Avonex) 32.81 32.81
IFN-β-1a 22 µg SC three times weekly (Rebif) 20.59 20.59
IFN-β-1a 44 µg SC three times weekly (Rebif) 26.90 26.90
PegIFN-β-1a 125 µg SC every 2 weeks (Plegridy) 13.64 22.66
IFN-β-1b 250 µg SC every other day (Betaferon/Extavia) 30.75 30.75
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Health state utility values
Utilities were derived by EDSS level and were assumed to be independent of MS type (RRMS and SPMS).
In the base case, these were derived from the same sources as in the RSS model.153 Utility values used in
the model are presented in Table 57.
Carers’ disutility
An analysis was undertaken that included carers’ disutility by EDSS state. Table 57 shows the disutility
values used in the model.
Mortality rate
Expanded Disability Status Scale-dependent mortality multipliers were used to estimate mortality from
UK general population rates (sourced from ONS data for 2012–14290). These multipliers (which were
themselves adapted from Pokorski et al.291) were taken from the manufacturer’s submission to NICE for
teriflunomide.292 This raises concerns around the robustness of the assumed mortality rates and raises
questions around whether a more up-to-date source could have been identified.
Adverse event disutilities
The assumed annual disutilities resulting from AEs are provided in Table 58. These were calculated from
AE rates derived from clinical trials of the treatments included in the submission. Disutilities for AEs
were obtained from the study by Maruszczak et al.,287 from the manufacturers’ submissions to NICE for
TABLE 57 Utility values by health state: Teva model
EDSS state Utility Carers’ disutility
0 0.925 0.002
1 0.761 0.002
2 0.674 0.002
3 0.564 0.002
4 0.564 0.045
5 0.491 0.142
6 0.445 0.167
7 0.269 0.063
8 0.008 0.095
9 –0.230 0.095
TABLE 58 Annual disutility values associated with the DMTs: Teva model
Treatment
Annual disutility
Year 1 Subsequent years
GA (Copaxone) –0.0043 –0.0043
IFN-β-1a 30 µg IM once weekly (Avonex) –0.0009 –0.0009
IFN-β-1a 22 µg SC three times weekly (Rebif) –0.0027 –0.0027
IFN-β-1a 44 µg SC three times weekly (Rebif) –0.0034 –0.0034
PegIFN-β-1a 125 µg SC every 2 weeks (Plegridy) –0.0043 –0.0037
IFN-β-1b 250 µg SC every other day (Betaferon/Extavia) –0.0028 –0.0028
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alemtuzumab,118 teriflunomide122 and dimethyl fumarate119 and from the Summary of Product
Characteristics for 44 µg of SC IFN-β-1a three times weekly (Rebif).293
Relapse
The disutility per relapse was assumed to be 0.058 if the relapse was severe and 0.009 otherwise. The
lower utility value was based on the study by Orme et al.101 The manufacturer was unable to identify a UK
source for estimating the disutility associated with severe relapse. An estimate for a US population was
identified, but the manufacturer argued that this was an overestimate for an equivalent UK population.
This utility value was therefore degraded by the ratio of UK to US disutilities for non-severe relapse
(0.071/0.091), which resulted in a reduction in the severe disutility from 0.302 to 0.236. This was
combined with an assumed duration of 90 days to provide the estimate of 0.058.
Treatment discontinuation
In the Teva model, people who progressed to a SPMS health state discontinued treatment. Accordingly,
treatment was assumed to discontinue at EDSS 7, in agreement with Association of British Neurologists
guidelines.281
Analysis (cycle length, time horizon and perspective)
The analysis was undertaken from a NHS and PSS perspective. The outcome measure used in the analysis
was QALYs gained, over a 50-year time horizon with an annual cycle length. The starting age of the
population was 30 years. The results were presented as ICERs and were expressed as cost per QALY
gained. Both costs and benefits were discounted at 3.5% per annum.
Summary of the model assumptions
In summary, the following assumptions were made in the Teva model:
l The probability of transitioning to a health state in the subsequent cycle depends only on the health
state in the present cycle.
l Transition from RRMS to SPMS is accompanied by an increase in EDSS state of 1.
l Each year, the EDSS score can remain the same, increase or decrease.
l In the base case, treatments affect EDSS progression but not EDSS regression.
l Treatment effects on relapse and EDSS progression are independent.
l In the base case, treatments have the same effect on progression in each EDSS state.
l In the base case, treatment efficacy is constant over time.
l Treatments do not directly impact on transitions to SPMS but impact on patients’ EDSS state, which
influences transition to SPMS.
l Treatment discontinuation is constant for all years.
l The annualised AE risks are applied every year – this may overestimate the incidence of AEs as patients
who undergo AEs may discontinue treatment in the initial years of treatment.
l Patients who discontinue treatment move on to one of three second-line treatments: Gilenya (50%),
Tysabri (30%) and Tecfidera (20%).
l SPMS patients receive BSC only.
l The list price of GA was considered in the base case.
Summary of the results
The base-case results showed that treatment with GA (Copaxone) resulted in a mean gain per patient of
(confidential information has been removed) life-years or (confidential information has been removed),
at a net discounted cost of (confidential information has been removed), giving an ICER of (confidential
information has been removed) per QALY. The probability of GA (Copaxone) being cost-effective relative
to BSC was (confidential information has been removed) at £20,000 per QALY and (confidential
information has been removed) at £30,000 per QALY.
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Merck Biopharma
Background
This section of the report focuses on the economic evidence submitted to NICE by Merck on 44 µg/22 µg
of SC IFN-β-1a three times weekly (Rebif). In this section we provide a summary of the economic analysis
presented by Merck and then critically appraise the analysis and findings. Merck’s economic model and
cost-effectiveness analysis considered 44 µg/22 µg of SC IFN-β-1a three times weekly compared with BSC
for the treatment of RRMS, SPMS and CIS. Details were provided of the intervention and comparators,
the study population, resource use and costs, the modelling methodology and assumptions made.
Merck initially conducted a systematic review of the cost-effectiveness literature relating to MS and
identified four studies that met its inclusion criteria; two of these studies examined DMTs in CIS.256,261
In addition, it reviewed cost-effectiveness analyses undertaken as part of HTAs for NICE (four
publications118–120,122) and the Canadian Agency for Drugs and Technologies in Health (CADTH) (one
publication294). It concluded that the majority of studies used a comparable approach to that used in the
ScHARR analysis,275 undertaken for TA32.24 In addition, it highlighted that it adopted a commonly used
approach to modelling mortality for MS patients, although it did not specify which studies from its review
used this approach.
Merck relapsing–remitting multiple sclerosis model
For the RRMS analysis, a Markov model was used to depict the natural history of people with RRMS. The
analysis was undertaken from the UK NHS and PSS perspective. The outcome measure used in the analysis
was QALYs. The model was run over a 50-year time horizon with 1-year cycles and a half-cycle correction
was applied. A 3.5% discount rate was applied to all future costs and health outcomes.
The model used EDSS scores, increasing in increments of 1, to model disability progression with and
without DMTs. The model did not have separate health states for SPMS and assumed that all patients
discontinued DMTs on reaching EDSS 7. The BCMS natural history model153 was used to model disease
progression in people with RRMS. For those not on treatment, disability could improve (backward
transition in EDSS states). The model included information from both doses of the drug; thus, Merck
estimated outcomes for patients given the different doses, based on numbers given the different doses in
the RSS cohort, and then pooled the outcomes. Of note, Merck used dose-specific parameters to populate
its models (e.g. costs, treatment effects).
In its analysis, the initial distribution of EDSS scores was based on what was observed in the RSS data set
for those treated with 44 µg/22 µg of SC IFN-β-1a three times weekly (Rebif). Treatment effects were
assumed to delay the progression of the disease and reduce the frequency of relapses. HRs from the
10-year RSS data provided by the Department of Health were used to model the impact of DMTs on
disability progression (worsening EDSS scores). The ‘waning effect’ of DMTs on disability progression
hazards was also incorporated. For relapse rates, Merck used findings from the PRISMS study.189 In its
base-case analysis, Merck modelled mortality in the same way as in the ScHARR model275 by applying a
SMR of 2.0 to life table mortality estimates, with an additional MS-specific mortality risk applied to those
whose EDSS score reached 6.
Health outcomes were measured in QALYs. Merck assigned utility weights to the EDSS health states and
included utility decrements for carers, relapses and adverse drug reactions. Utility estimates were derived
by pooling data from the UK MS Trust postal survey, as cited in the submission, and the Heron data set.101
The pooling of these data was undertaken by IMS Health on behalf of the UK MS Trust. Merck assumed
that the duration of the utility decrement from a relapse was 46 days and that approximately 5% per
annum would experience a utility decrement from an AE. Health-care resource use and cost estimates used
in the model were derived from the Department of Health/ScHARR estimates275 and adjusted accordingly.
The costs were assigned to EDSS health states and to relapses. The costs of DMTs were based on the
annual per-patient NHS acquisition costs.
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Merck undertook a number of sensitivity analyses to investigate the impact of discounting, shorter time
horizons, alternative approaches to deriving mortality rates and HRs, alternative sources of utilities and
costs and alternative assumptions regarding AEs and discontinuation rates. In addition, it undertook
probabilistic sensitivity analysis to determine the robustness of the base-case results.
In its base case analysis, Merck estimated that the treatment of RRMS with 44 µg/22 µg of SC IFN-β-1a
three times weekly (Rebif) would result in an additional (confidential information has been removed)
QALYs gained at an additional cost of (confidential information has been removed) over a 50-year time
horizon. The ICER was estimated to be (confidential information has been removed) per QALY gained.
The ICER estimated in the probabilistic sensitivity analysis was (confidential information has been removed)
per QALY gained. In sensitivity analyses, Merck found that the base-case results were robust to univariate
changes made to key input parameters. The majority of the sensitivity analyses resulted in lower ICERs.
The ICERs were higher when different approaches were used to estimate EDSS health state costs (provided
in appendix 17 of the submission).
Merck secondary progressive multiple sclerosis model
Merck also undertook an economic analysis of 44 µg/22 µg of SC IFN-β-1a three times weekly (Rebif) for
patients with SPMS. It used the same model structure and modelling techniques as before and populated
the model with patient characteristics and treatment effects for treatment with 44 µg/22 µg of SC IFN-β-1a
three times weekly (Rebif) in SPMS patients. As highlighted before, the model did not include separate
health states for SPMS and assumed that all patients discontinued DMTs on reaching EDSS 7. For the
characteristics of the population modelled Merck used observational data from the SPECTRIMS study224
(64% female, mean age 43 years and EDSS score 5 or 6 at baseline). Additional assumptions made
included the presence of a constant relapse rate independent of EDSS level.
In the base-case deterministic analysis, Merck estimated that treatment of SPMS with 44 µg/22 µg of SC
IFN-β-1a three times weekly (Rebif) would result in an additional (confidential information has been
removed) QALYs gained at an additional cost of (confidential information has been removed) over a
50-year time horizon. The ICER was estimated to be (confidential information has been removed) per
QALY gained. The ICER estimated from the probabilistic sensitivity analysis was (confidential information
has been removed) per QALY gained. In sensitivity analyses, Merck found that the base-case results were
robust to univariate changes made to key input parameters. The majority of the sensitivity analyses resulted
in comparable ICER estimates (provided in appendix 17 of the submission).
Merck clinically isolated syndrome model
Merck also undertook an economic analysis of treatment with 44 µg/22 µg of SC IFN-β-1a (Rebif) in
patients with CIS. It estimated the ICERs for starting DMTs in CIS patients, to providing BSC for CIS
patients with DMTs when patients progress to RRMS. Merck used the same model structure and modelling
techniques as before and populated the model with patient characteristics and treatment effects for
treatment with 44 µg/22 µg of SC IFN-β-1a (Rebif) in CIS patients. The characteristics of the population
modelled were based on participants in the REFLEX trial.175 The relative risks for conversion from CIS to
RRMS for the first and second year on DMTs and the relative risk of relapse were extracted from the
REFLEX trial.175 In addition, Merck assumed that there was no treatment effect of DMTs on risk of
progression to RRMS after 2 years. For delayed therapy we considered that the rates of conversion and
relapse were also based on the placebo arm of the REFLEX trial, although this is not clear from the
submission. Merck also assumed that for CIS patients EDSS scores remained constant until conversion to
RRMS, at which point the EDSS scores were based on EDSS scores while in the CIS state.
In the base-case deterministic analysis, Merck estimated that early treatment of CIS with 44 µg/22 µg of
SC IFN-β-1a three times weekly (Rebif) would result in an additional (confidential information has been
removed) QALYs gained at an additional cost of (confidential information has been removed) over a
50-year time horizon. The ICER was estimated to be (confidential information has been removed) per
QALY gained. The ICER estimated from the probabilistic sensitivity analysis was (confidential information
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has been removed) per QALY gained. In sensitivity analyses, Merck found that the base-case results were
robust to univariate changes made to key input parameters. The majority of the sensitivity analyses resulted
in comparable ICER estimates (provided in appendix 17 of the submission).
Evaluation of Merck’s submission
Types of multiple sclerosis
Merck undertook an economic analysis of 44 µg/22 µg of SC IFN-β-1a three times weekly (Rebif) for the
treatment of RRMS, SPMS and CIS. The base-case analysis examined costs and health outcomes for MS
patients aged < 30 years.
Model structure
The illustrative Markov model structure submitted by the manufacturer was based on the original ScHARR
model.275 The manufacturer used a cohort-based Markov model to depict the natural history of people
with RRMS. The model simulated disability progression, progression from RRMS to SPMS and the relapsing
nature of the disease. People with RRMS/SPMS were able to occupy one of the EDSS health states, which
ranged from 0 to 9, in increments of 1.0. The model allowed for people to progress, regress or stay in the
same EDSS health state or progress from RRMS to SPMS. For those on DMTs no backward transition in
EDSS states was permitted.
Merck used the same model structure for the economic analysis of DMTs for the treatment of SPMS and
parameterised the model with patient characteristics and treatment effects for treatment with 44 µg/22 µg
of SC IFN-β-1a three times weekly (Rebif) in SPMS patients. The CIS model had an additional five
on-treatment and five off-treatment health states defined by EDSS score (0–4, in increments of 1). In
addition, in the CIS model it was assumed that EDSS scores remained constant until conversion to RRMS,
at which point EDSS scores were based on EDSS scores while in the CIS state.
Interventions
The interventions considered in the economic analyses are presented in Table 59. For RRMS and SPMS
Merck compared 44 µg/22 µg of SC IFN-β-1a three times weekly (Rebif) with BSC and for CIS it compared
44 µg/22 µg of SC IFN-β-1a three times weekly (Rebif) with BSC, with DMTs started on progression to
RRMS. For all those started on DMTs, treatment was discontinued once the EDSS score was ≥ 7. In
addition, it was assumed that 5% per annum discontinued treatment as a result of AEs. For the DMT
treatment strategy, the model aggregated the observed RSS data across both doses of the drug.
Population
In the RRMS model, the population included in the economic analysis was similar to the population who
started IFN-β-1a (Rebif) in the RSS cohort.153 In the base-case RRMS analysis, Merck examined the costs
and health outcomes for MS patients aged < 30 years and MS patients aged ≥ 30 years. In the SPMS model,
the population included in the economic analysis was similar to the population included in the SPECTRIMS
study224 and, in the CIS model, the population included in the economic analysis was similar to the population
included in the REFLEX study.175 The initial distribution of people in each EDSS state is presented in Table 60.
Of note, the distribution of initial EDSS scores for the RRMS population was taken from the Microsoft Excel
(2013) file and is not the same as that presented in the manufacturer’s final written summary.
TABLE 59 Interventions included in the economic analysis: Merck model
Trade name Drug Dose Route of administration Type of MS
Rebif IFN-β-1a 44 or 22 µg SC RRMS
Rebif IFN-β-1a 44 or 22 µg SC SPMS
Rebif IFN-β-1a 44 or 22 µg SC CIS
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Mortality rate
In the base-case analysis, the manufacturer modelled mortality in the same way as in the ScHARR model275
by applying a SMR of 2.0 to life table mortality estimates, with an additional MS-specific mortality risk
applied to those whose EDSS score reached 6. In sensitivity analyses Merck used an alternative approach to
modelling mortality. Briefly, this approach resulted in lower mortality rates assigned to early EDSS health
states and higher mortality rates assigned to those with more advanced disability. Although this approach
may be valid, the data used to derive these values were published > 20 years ago, when BSC was likely to
have been less optimal than current provision, especially for those with more advanced disability.
Treatment effects of disease-modifying therapy
Merck followed the same approach used in the Department of Health RSS model analysis to model the
impact of DMTs on disability progression. The BCMS natural history model153 was used to model disease
progression in people with RRMS, allowing for improvements in disability (backward transition in
EDSS states).
In the RRMS model, the DMT strategy utilised the 44 µg/22 µg of SC IFN-β-1a three times weekly
(Rebif)-specific HRs supplied by the Department of Health from the year 10 RSS data. These HRs were applied
to the natural history model to model the on-treatment impact. Of note, Merck individually modelled the
treatment impact for the two different dosages of the drug and pooled the final costs and health outcomes
to estimate the ICERs. It also assumed that there would be no improvement in disability (backward transition
in EDSS states) for those on DMTs. In the models it assumed that 44 µg/22 µg of SC IFN-β-1a three times
weekly (Rebif) would be discontinued when disability progressed to an EDSS level of ≥ 7. In addition,
it assumed that 5% of patients stopped treatment for other reasons (i.e. dropouts) every year. It also
incorporated the ‘waning effect’ of DMTs on disability progression hazards. For relapse rates it used the
findings from the PRISMS study.189
In the CIS model, progression to RRMS in the delayed treatment strategy (DMTs once progressed to RRMS)
and the rates of conversion and relapse were based on the outcomes of the placebo arm of the REFLEX
trial.175 In the CIS DMT treatment strategy the relative risks for conversion from CIS to RRMS for the first
and second year on DMTs and the relative risk of relapse were extracted from the REFLEX trial.175 The
manufacturer assumed that there was no treatment effect of DMTs on risk of progression to RRMS after
2 years. It also assumed that for CIS patients EDSS scores remained constant until conversion to RRMS,
at which point the EDSS scores were based on the EDSS scores while in the CIS state.
Resource use and costs
All costs included in the analysis were those directly related to the NHS and PSS perspective. Costs were
reported in 2015 UK pounds, with future costs discounted at a rate of 3.5% per annum. The model
included the following costs:
l drug acquisition costs
l health state/EDSS costs
l cost of relapse
l AE costs.
Drug acquisition costs
In the model, the drug acquisition costs represent the annual per-patient NHS acquisition costs
(confidential information has been removed). The drug acquisition costs for the two dosages of SC
IFN-β-1a three times weekly (Rebif), 44 µg and 22 µg, were (confidential information has been removed)
and (confidential information has been removed) respectively. In the model Merck utilised the observed
numbers of patients on the two different dosages in the RSS cohort and assigned costs accordingly.
Hence, the true modelled cost of the drugs will be a RSS sample weighted average. The costs of
administering the drugs and monitoring response to treatment were not included.
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Health state/Expanded Disability Status Scale costs
Resource use/costs were assigned to each EDSS health state. In the base-case analysis Merck utilised the
same costs as in the ScHARR analysis,275 with adjustment to 2015 UK pounds. This is the same approach
used in the Department of Health RSS model analysis. In sensitivity analyses Merck used costs reported by
Tyas et al.288 and Karampampa et al.,283 again with adjustment to 2015 UK pounds.
Cost of relapse
In the base-case analysis the manufacturer utilised the same cost of relapse as in the ScHARR analysis,275
with adjustment to 2015 UK pounds. This is the same approach used in the Department of Health RSS
model analysis.
Adverse event costs
In the base-case analysis the manufacturer did not include costs incurred as a result of AEs, in accordance
with the Department of Health RSS model analysis. In a sensitivity analysis it incorporated costs incurred as
a result of AEs, using data on AEs reported in the PRISMS study.189
Health state utility values
Health outcomes were measured in QALYs and future health outcomes were discounted at a rate of 3.5%
per annum. Utility weights were assigned to the EDSS health states, including utility decrements for carers,
relapses and adverse drug reactions. Utility estimates were derived by pooling data from the UK MS Trust
postal survey and the Heron data set.101 The data were pooled using sample size-weighted averages, with
pooling undertaken by IMS Health on behalf of the MS Trust. Merck assumed that the duration of the
utility decrement from a relapse was 46 days and that approximately 5% per annum would experience a
utility decrement from an AE.
Table 61 shows the utility weights used in the base-case analysis. Of note, the pooled values do not take
into account differences between the two samples in terms of age, sex and other variables that may be
independently associated with HRQoL. The pooled utility values were used in the Department of Health
RSS model analysis, including the impact on carers. Merck stated that, as the pooled values were not
provided with standard errors for the probabilistic sensitivity analysis, it used the standard errors reported
TABLE 61 Utility values in the base-case analysis by health state: Merck model
EDSS state
Utility value, mean (standard error)
Patient health states Carer decrements
0 0.925 (0.045) –0.002 (0.053)
1 0.761 (0.048) –0.002 (0.053)
2 0.674 (0.048) –0.045 (0.057)
3 0.564 (0.052) –0.045 (0.057)
4 0.564 (0.048) –0.142 (0.062)
5 0.491 (0.047) –0.16 (0.055)
6 0.445 (0.047) –0.173 (0.054)
7 0.269 (0.049) –0.03 (0.038)
8 0.008 (0.050) –0.095 (0.075)
9 –0.23 (0.074) 0
Relapse –0.22 (0.089) for 46 (10) days
AE –0.321 (0.051) in 5.1% (8.6%) of patients
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in one of the two data sets that were pooled.101 For this the company extracted the standard errors from the
multivariable regression analysis and therefore these represent the standard errors for the adjusted coefficients.
In a sensitivity analysis Merck estimated the ICERs using utility values derived from an unpublished study by
Boggild et al. and using utility values derived from pooling all three data sets (unpublished data from the
UK MS Trust postal survey, the Heron data set101 and unpublished data from Boggild et al.). The utility
values assigned to health states in the sensitivity analysis were lower (poorer HRQoL).
Analysis (cycle length, time horizon and perspective)
The analysis was undertaken from the NHS and PSS perspective. The outcome measure used in the
analysis was QALYs gained, over a 50-year time horizon and with an annual cycle length. The results were
presented as ICERs and expressed as cost per QALY gained. Both costs and benefits were discounted at
3.5% per annum.
Assumptions
Merck made a range of assumptions in the model analysis. For the RRMS model it assumed that:
l The year 10 RSS data set reflects the future MS population characteristics, the initial EDSS level on
starting DMTs, the dosage of 44 µg/22 µg of SC IFN-β-1 three times weekly (Rebif) and the treatment
impact on disability progression.
l Age at MS diagnosis was 30 years.
l The natural history progression of MS, resource use, HRQoL, waning effect of DMTs and mortality rates
were the same as those used by the UK Department of Health in its RSS model analysis.
l Uncertainty around the HRs characterising the treatment impact of DMTs was assumed to have an
upper limit of 1.0 in the probabilistic sensitivity analysis.
l DMTs were discontinued once the EDSS score was ≥ 7.
l Five per cent of patients discontinued DMTs for other reasons (dropouts).
The model included additional assumptions relating to SPMS:
l A starting EDSS level of 5 and 6 (50% each) was assumed.
l An untreated relapse rate of 1.08 per patient-year was assumed.
l HRs for progression and relative risks for relapse were assumed to be as for the SPECTRIMS trial224
relapsing population.
Finally, the model included several assumptions relating to CIS:
l Patients’ baseline EDSS scores were assumed to be as in the REFLEX trial.175
l Conversion from CIS was assumed to be as in the REFLEX trial175 for delayed treatment, with relative
risks for years 1 and 2 calculated from the REFLEX trial.175
l No treatment effect was applied beyond year 2, although patients with CIS were assumed to remain
on treatment for up to 5 years.
l Patients were assumed to remain in the starting EDSS state during and on conversion to MS diagnosed
by the McDonald criteria.62
Summary of results
In the base-case analysis, Merck estimated that treatment of RRMS with 44 µg/22 µg of SC IFN-β-1a three
times weekly (Rebif) would result in an additional (confidential information has been removed) QALYs
gained at an additional cost of (confidential information has been removed) over a 50-year time horizon.
The ICER was estimated to be (confidential information has been removed) QALY gained. The ICER
estimated from the probabilistic sensitivity analysis was (confidential information has been removed) per
QALY gained.
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Summary and critique of the manufacturers’ submissions
Overview of the manufacturers’ submissions
This section provides an overview of the economic evidence submitted by the three companies: (1) Biogen
Idec, (2) Teva UK Ltd and (3) Merck Biopharma. We provide a summary of the manufacturers’ submissions
and an assessment of how they compare with the NICE reference case156 and how they differ from each
other and from the Department of Health RSS model analysis.
The economic evaluations are summarised in Table 62. Biogen Idec Ltd undertook an economic analysis
to assess the cost-effectiveness of its DMTs, 30 µg of IM IFN-β-1a once weekly (Avonex) and 125 µg
of SC pegIFN-β-1a every 2 weeks (Plegridy), and other DMTs on the market, including 44 or 22 µg of
SC IFN-β-1a three times weekly (Rebif), 250 µg of SC IFN-β-1b every other day (Betaferon/Extavia) and
20 mg of SC GA daily or 40 mg of SC GA three times weekly (Copaxone). Teva undertook a comparable
economic analysis of its DMT, 20 mg of SC GA daily or 40 mg of SC GA three times weekly (Copaxone),
and others on the market, including 30 µg of IM IFN-β-1a once weekly (Avonex), 125 µg of SC pegIFN-β-1a
every 2 weeks (Plegridy), 44 or 22 µg of SC IFN-β-1a three times weekly (Rebif), 250 µg of SC IFN-β-1b
every other day (Betaferon/Extavia), fingolimod (Gilenya), natalizumab (Tysabri) and dimethyl fumarate
(Tecfidera), whereas Merck undertook an economic analysis of only its DMT, 44 or 22 µg of SC IFN-β-1a
three times weekly (Rebif).
TABLE 62 Summary of economic evaluations undertaken by companies
Parameter
Company
Biogen Idec Ltd: IFN-β-1a
30 µg IM once weekly
(Avonex), pegIFN-β-1a 125 µg
SC every 2 weeks (Plegridy)
Merck: IFN-β-1a 44 or 22 µg
SC three times weekly (Rebif)
Teva: GA 20mg SC once daily
or 40mg SC three times
weekly (Copaxone)
Natural history
cohort
Natural history cohort based on
extrapolating data from the
ADVANCE trial placebo arm213
with information from the
BCMS data set153
Natural history cohort based on
the BCMS natural history model
Natural history cohort based on
the BCMS natural history data
set for RRMS states153 and the
London Ontario natural history
cohort for transitions from
RRMS to SPMS and SPMS
transitions80
Population Adults (≥ 18 years) with RRMS RRMS: adults, mean age
30 years, (confidential
information has been removed)
female (based on RSS data153);
SPMS: adults, mean age
43 years, 64% female (based
on the SPECTRIMS trial224); CIS:
adults, mean age 31 years,
67% female (based on the
REFLEX trial175)
Adults (≥ 18 years) with RRMS
Interventions IFN-β-1a 30 µg IM once weekly
(Avonex), pegIFN-β-1a 125 µg
SC every 2 weeks (Plegridy),
IFN-β-1a 44 µg SC three times
weekly (Rebif), IFN-β-1b 250 µg
SC every other day (Betaferon),
IFN-β-1b 250 µg SC every other
day (Extavia), GA 20mg SC
three times weakly (Copaxone),
GA 40mg SC three times
weekly (Copaxone)
IFN-β-1a 44 or 22 µg SC
three times weekly (Rebif)
GA 20mg SC once daily
(Copaxone), IFN-β-1a 30 µg
IM once weekly (Avonex),
pegIFN-β-1a 125 µg SC every
2 weeks (Plegridy), IFN-β-1a
22 µg SC three times weekly
(Rebif), IFN-β-1a 44 µg SC three
times weekly (Rebif), IFN-β-1b
250 µg SC every other day
(Betaferon), fingolimod 0.5 mg
once daily (Gilenya), natalizumab
300mg once every 4 weeks
(Tysabri), dimethyl fumarate
240mg twice daily (Tecfidera)
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TABLE 62 Summary of economic evaluations undertaken by companies (continued )
Parameter
Company
Biogen Idec Ltd: IFN-β-1a
30 µg IM once weekly
(Avonex), pegIFN-β-1a 125 µg
SC every 2 weeks (Plegridy)
Merck: IFN-β-1a 44 or 22 µg
SC three times weekly (Rebif)
Teva: GA 20mg SC once daily
or 40mg SC three times
weekly (Copaxone)
Comparator BSC CIS: BSC for CIS and DMTs for
RRMS; RRMS: BSC; SPMS: BSC
BSC
Type of model
and health
states
Cohort-based Markov model
with 21 health states (10 for
RRMS, 10 for SPMS and one for
the dead state) characterised by
EDSS levels, which ranged from
0–10 in increments of 0.5
CIS: cohort-based Markov
model with an additional
five on-treatment and five
off-treatment health states for
CIS defined by EDSS score (0–4,
in increments of 1) (otherwise
includes the same health
states as for the RRMS model);
RRMS and SPMS: cohort-based
Markov model with 21 health
states: 10 EDSS not-on-
treatment states, 10 EDSS
on-treatment states and
absorbing death state (EDSS
health states 0–9, in increments
of 1.0)
Cohort-based Markov model
with 21 health states (10 for
RRMS, 10 for SPMS and one for
the dead state) characterised by
EDSS levels, which ranged from
0 to10 in increments of 1
HRs HRs based on confirmed
disability progression. The year
10 implied HR of (confidential
information has been removed)
for 30 µg of IM IFN-β-1a was
used in the manufacturer’s
model
CIS: conversion rate for CIS to
RRMS based on the REFLEX
trial;175 RRMS: HRs for sustained
disability progression supplied to
Merck by the Department of
Health based on analysis of year
10 RSS data: progression –
(confidential information has
been removed), relapse –
HR (44 µg) 0.67, HR (22 µg)
0.71; SPMS: relapse rate for
SPMS not on treatment based
on the placebo arm of the
SPECTRIMS trial,224 HR for SPMS
on treatment with 44-µg dosage
derived from the SPECTRIMS
trial:224 progression – HR (44 µg)
(confidential information has
been removed), relapse – HR
(44 µg) 0.62, HR (22 µg) 0.53
HRs for GA of (confidential
information has been removed)
for disability progression and
(confidential information has
been removed) derived from
Teva’s NMA. Additional
sensitivity analysis of Teva’s
NMA assuming (confidential
information has been removed)
HR for progression compared
with BSC was used in scenario
analyses in the model
Resource use
and costs
Drug acquisition costs,
monitoring costs, administration
costs, relapse costs (including
a percentage requiring
hospitalisation as a proxy for
severity), health state costs,
treatment-related AE costs
RRMS: based on Department
of Health/ScHARR275 resource
use and costs, adjusted to
2015 UK pounds, with costs
including drug acquisition costs,
monitoring costs, administration
costs, relapse costs, health state
costs and treatment-related AE
costs; SPMS and CIS: based on
the RRMS model approach
Drug acquisition costs,
monitoring costs, administration
costs, relapse costs (including
a percentage requiring
hospitalisation as a proxy for
severity), health state costs and
treatment-related AE costs
continued
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TABLE 62 Summary of economic evaluations undertaken by companies (continued )
Parameter
Company
Biogen Idec Ltd: IFN-β-1a
30 µg IM once weekly
(Avonex), pegIFN-β-1a 125 µg
SC every 2 weeks (Plegridy)
Merck: IFN-β-1a 44 or 22 µg
SC three times weekly (Rebif)
Teva: GA 20mg SC once daily
or 40mg SC three times
weekly (Copaxone)
HRQoL Utility values by EDSS level were
based on information from the
ADVANCE trial213 and Orme
et al.,101 which was derived from
utility values from the UK MS
Trust survey. Carers’ disutilities
were derived based on
information obtained from the
manufacturer’s submission to
NICE for TA127121
Utility values by EDSS score
were derived by pooling data
from a UK MS Trust postal
survey and the Heron data
set.101 Data were pooled using
sample size-weighted averages,
with pooling undertaken by IMS
Health on behalf of the MS
Trust
Utility values by EDSS level were
based on information from
Orme et al.,101 which was
derived from utility values
from the UK MS Trust survey.
A sensitivity analysis was
performed using smoothed
data from three RSS data sets.
Carers’ disutilities were derived
based on information obtained
from the manufacturer’s
submission to NICE for TA127121
Discontinuation
of treatment
Only people who progressed to
SPMS discontinued DMTs
Treatment was stopped when
the EDSS score was ≥ 7. In
addition, 5% discontinued
treatment irrespective of EDSS
level (derived from the observed
dropout rate from the 8-year
RSS data)
Withdrawal rate of 5% per year
as per the RSS model. Treatment
was also discontinued for those
with an EDSS score of ≥ 7
Relapse Relative risks of a relapse per
person in the RRMS health
states were estimated from the
ADVANCE trial213 for EDSS levels
up to 5.5. ARRs for EDSS levels
> 5.5 were based on the relative
increases in ARR reported in the
study by Patzold et al.286
RRMS: relapse rates were
assigned to each EDSS health
state. These estimates were
based on the MS Trust survey
in 2001. For those receiving
treatment it was assumed that
patients would benefit from a
risk reduction for relapse. The
relative risk reduction of relapse
was taken from data presented
in the 2002 ScHARR model.275
The original source of these
estimates is the PRISM study.189
RRMS: IFN-β-1a 44 µg: RR 0.67
(95% CI 0.67 to 1.00), IFN-β-1a
22 µg: RR 0.71 (95% CI 0.60 to
0.84); SPMS: IFN-β-1a 44 µg:
RR 0.62 (95% CI 0.52 to 0.74),
IFN-β-1a 22 µg: RR 0.53
(95% CI 0.44 to 0.64)
Relative risks of relapse were
estimated from Teva’s NMA. A
distinction was made between
moderate and severe relapse.
The ARR was applied to the
proportion of relapses that
were severe. For GA this was
0.796.219 For other DMTs this
ranged from 0.495 (pegylated
IFN-β-1a) to 1.282 (Tecfidera)
AEs Annualised risks for AEs were
considered for all treatments.
AEs for people in the BSC
arm were not considered.
Annualised risks for each
treatment were qualitatively
analysed. AEs reported in the
ADVANCE trial (> 5% for any
DMT or > 3% for all treatments)
were included in the economic
analysis
5.1% experienced AEs every
year on DMTs. AEs were
associated with a utility
decrement of 0.02
The nature and rate of AEs were
derived from pooled clinical trial
data. The assumed probability
of an AE on GA was 0.481
(first and second year). For other
DMTs probabilities ranged
from 0.32 (Tecfidera) to 0.752
(pegylated IFN-β-1a). The
disutility of an AE was 0.004
QALYs for GA and ranged
from 0.000 QALYs (Gilenya,
Tecfidera) to 0.004 QALYs
(Copaxone, pegylated IFN-β-1a)
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In the primary analysis all three companies undertook an economic analysis of DMTs compared with BSC
for people with RRMS. The three companies clearly stated their decision problem, which was consistent
with NICE’s scope141 for the appraisal.
Types of multiple sclerosis
Biogen Idec Ltd and Teva undertook a cost-effectiveness analysis of DMTs for those with RRMS only.
Merck also evaluated the cost-effectiveness of its DMT in patients presenting with SPMS and CIS.
Analysis (cycle length, time horizon and perspective)
All three manufacturers followed the same approach with regard to the model analysis, perspectives,
outcome measures and time horizon for analysis. They all undertook a cost–utility analysis from the NHS
and PSS perspective, in accordance with the NICE reference case.156 The outcome measure used in the
analysis was QALYs gained, over a 50-year time horizon with an annual cycle length, with a starting age
for the population modelled of ≥ 30 years. The time horizon used should be sufficiently long to reflect
differences in costs and outcomes. The results were presented as ICERs, expressed as cost per QALY
gained. Both costs and benefits were discounted at 3.5% per annum.
TABLE 62 Summary of economic evaluations undertaken by companies (continued )
Parameter
Company
Biogen Idec Ltd: IFN-β-1a
30 µg IM once weekly
(Avonex), pegIFN-β-1a 125 µg
SC every 2 weeks (Plegridy)
Merck: IFN-β-1a 44 or 22 µg
SC three times weekly (Rebif)
Teva: GA 20mg SC once daily
or 40mg SC three times
weekly (Copaxone)
Mortality Mortality was assumed to be
equivalent between RRMS and
SPMS and dependent on the
EDSS level
Utilised the Department of
Health/RSS approach to
mortality in the base-case
analysis. This involved applying
a SMR of 2.0 to life table
estimates and a MS-specific
mortality rate for those with a
EDSS score of ≥ 6
An EDSS-dependent mortality
multiplier was used to estimate
mortality from UK general
population rates (sourced from
ONS data for 2012–14290).
These multipliers (which were
adapted from Pokorski et al.291)
were taken from the
manufacturer’s submission on
teriflunomide to NICE122
Time horizon 50 years 50 years 50 years
Base-case
analysis results
Pegylated IFN-β-1a 125 µg SC
every 2 weeks had an ICER of
approximately £31,000 per
QALY compared with BSC
CIS: ICER: (confidential
information has been removed)
gained; RRMS: ICER:
(confidential information has
been removed) gained; SPMS:
ICER: (confidential information
has been removed) gained
GA had an ICER of (confidential
information has been removed)
per QALY compared with
BSC (confidential information
has been removed) when
excluding support for nursing/
infrastructure cost) in the
Department of Health-agreed
analysis. In the de novo model
(confidential information has
been removed) per QALY for
GA compared with BSC. GA
was (confidential information
has been removed)
Sensitivity
analysis (and
probabilistic
sensitivity
analysis) results
All base-case results except for
the HR for confirmed disability
progression were robust to
sensitivity analysis. At the
willingness-to-pay threshold for
a QALY, 125 µg of SC pegylated
IFN-β-1a every 2 weeks had a
< 0.4 probability of being
cost-effective compared with BSC
CIS: ICER: (confidential
information has been removed)
gained; RRMS: ICER:
(confidential information has
been removed) gained; SPMS:
ICER: (confidential information
has been removed) gained
(Confidential information
has been removed) of
cost-effectiveness at £20,000
compared with BSC. The
cost-effective results were
most sensitive to the choice of
data informing the HR for
progression
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Model structure
All three submissions utilised a Markov cohort model, based on the original ScHARR model,275 to undertake
their cost-effectiveness analysis. Broadly, all of the submissions used EDSS scores to define RRMS and SPMS
health states, with 10 mutually exclusive EDSS-defined health states. In all of the models, people with RRMS
could progress, regress or stay in the same EDSS health state or progress from RRMS to SPMS. People could
not move from SPMS to RRMS and, once progressed to SPMS, individuals’ EDSS scores could not improve.
There were some differences between the manufacturers’ submissions with regard to when DMTs were
stopped in the model analysis. In the Biogen Idec Ltd model it was assumed that DMTs were discontinued
once patients progressed to SPMS. In the Teva model DMTs were discontinued once the EDSS score was
≥ 7 or when patients had progressed to SPMS. In the Merck model DMTs were discontinued once the
EDSS score was ≥ 7, irrespective of whether patients had progressed to SPMS. In all three submissions,
DMTs were stopped if patients experienced adverse drug reactions. When DMTs are stopped is likely to
impact on the modelled lifetime costs and therefore the ICER estimates.
Interventions evaluated
All three manufacturers compared treatment with DMTs with BSC in patients with RRMS. For SPMS Merck
compared 44 or 22 µg of SC IFN-β-1a three times weekly (Rebif) with BSC and for CIS it compared 44 or
22 µg of SC IFN-β-1a three times weekly (Rebif) with BSC followed by DMTs on progression to RRMS.
Population modelled
There were differences between the three manufacturer submissions in how they determined the population
to be modelled. Teva and Merck used the population characteristics (age; sex distribution; starting EDSS
scores) observed in the RSS cohort data,153 whereas Biogen Idec Ltd used the baseline characteristics observed
in the ADVANCE trial.213 A major difference between the two approaches is the mean age at onset of
RRMS used. In the Biogen Idec Ltd model this was 36 years whereas in the Teva and Merck models this was
30 years. Also, in the Biogen Idec Ltd model approximately 32% of the cohort modelled started with an EDSS
score of ≤ 1, whereas in the Teva and Merck models between 19% and 23% of the cohort modelled started
with an EDSS score of ≤ 1. The age of the population is likely to impact on modelled lifetime costs and
lifetime QALYs. For example, modelling cost-effectiveness of DMTs in an older population will likely result in
lower total lifetime costs and lower total lifetime QALYs, but how this impacts on the ICER estimate may be
complex. In addition, the initial distribution of EDSS scores in the population modelled will also have an
impact on lifetime costs and QALYs, especially as higher EDSS health states are associated with higher costs
and poorer utility weights than lower EDSS health states. Again, how this impacts on the ICER is complex.
The assessment group considers that the age, sex and EDSS scores among those in the RSS data set better
reflect the UK RRMS population than participants recruited into a clinical trial.
Transition probabilities: disease progression, relapse and mortality
The manufacturers’ submissions used different approaches to model disease progression for those on BSC.
Biogen Idec Ltd derived transition probabilities using disability progression observed in the placebo arm of
the ADVANCE trial,213 supplemented with information from the BCMS data set.153 Teva used the London
Ontario data80 to derive the majority of its transition probabilities to model progression, whereas Merck
used the BCMS data set.153 The data sources used to model disease progression for the BSC strategy are
likely to impact on the ICER. Although it may be difficult to argue which of the London Ontario or BCMS
data sets provides the optimal representation of disease progression in MS patients not receiving DMTs, it
would seem unorthodox to use patients recruited into the placebo arm of a clinical trial to represent this.
For relapse rates (ARRs) there were some differences in the data used by each manufacturer. All three
manufacturers applied EDSS health state-specific relapse rates. Biogen Idec Ltd estimated relapse rates
using data obtained from the ADVANCE trial213 up to an EDSS score of 5.5 and supplemented this with
rates derived from the study by Patzold et al.286 Teva and Merck both followed the Department of Health
RSS model approach and used the same relapse rates as in the previous ScHARR model.275 The relapse
rates (for BSC) used by Biogen Idec Ltd tended to be lower, translating into fewer episodes and lower
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modelled lifetime costs and higher lifetime QALYs. How this impacts on the ICER estimate will also depend
on the relapse rates assigned to the DMT strategy.
All three manufacturers used comparable approaches to modelling mortality. As with the RSS model,
background all-cause mortality was derived from age- and sex-specific mortality rates. In addition, an
MS-specific mortality rate was included through a mortality multiplier assigned to each EDSS health state.
Transition probabilities: treatment effect
All three manufacturers followed comparable approaches to modelling the treatment effect of DMTs;
however, there were some differences in the data sources used. Treatment effects included the impact
of DMTs on disease progression and on relapses. A HR was applied to the natural history progression
matrices to determine disease progression for those on DMTs. Biogen Idec Ltd and Teva stated that they
undertook a NMA to estimate the HRs for disability progression. Of note, implied HRs for 125 µg of SC
pegIFN-β-1a every 2 weeks (Plegridy) are not available from the year 10 RSS data set. However, Merck
stated that it used the implied HR for disability progression from the 10-year RSS data provided by the
Department of Health. Of note, the implied HRs from the RSS data sets tended to be higher than those
obtained from the NMA. A higher HR for disability progression will result in higher ICER estimates.
For relapse rates on DMTs, Biogen Idec Ltd and Teva undertook a NMA whereas Merck extracted the value
from the previous ScHARR model.275 As previously mentioned Biogen Idec Ltd used a different data source
from the other two manufacturers for relapse rates for BSC, with the relapse rates that it used for BSC being
lower. The relapse rates on DMTs obtained from NMA s tended to be lower than those obtained from the
10-year RSS data sets. Untangling the impact on the final ICER is complex, especially in the case of Biogen Idec
Ltd’s model. However, a greater effect of DMTs on reducing relapse rates will lead to smaller ICER estimates.
There were minor differences in how treatment discontinuation was modelled in the three manufacturer
submissions. Biogen Idec Ltd reported that it used the discontinuation rates observed in clinical trials of the
DMTs. Teva and Merck followed the Department of Health RSS model and assumed that 5% of patients
would discontinue treatment per annum. The discontinuation rates used by Biogen Idec Ltd were generally
higher than 5% per annum for the DMTs that it evaluated. A higher discontinuation rate will lead to lower
lifetime costs but also fewer QALYs for treatment with DMTs. This may potentially impact on ICER estimates.
There were significant differences in how the treatment waning effect was modelled in the three
manufacturer submissions. Biogen Idec Ltd assumed that there would be no treatment waning effect in its
base-case analysis and that the efficacy of DMTs would be maintained. Teva and Merck followed the
approach taken in the RSS model and assumed that, after 10 years on DMTs, efficacy would be lower. Not
including a waning effect will not impact on lifetime costs on DMTs but will increase QALYs on DMTs and
will likely result in lower ICER estimates.
Although the NICE reference case156 highlights that systematic reviews should be undertaken to obtain
evidence on outcomes, the RSS cohort long-term outcome data may be a more valid data source.
Resource use and costs
In all three manufacturer submissions, costs included in the analysis were those directly related to the NHS
and PSS perspective, with costs inflated to 2015 UK pounds. There were some differences in the costs
included by the three manufacturers. All three manufacturers included:
l drug acquisition costs
l administration costs
l monitoring costs
l health state/EDSS costs
l cost of relapse
l treatment-related AE costs.
DOI: 10.3310/hta21520 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 52
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Melendez-Torres et al. under the terms of a commissioning contract issued by the Secretary of State
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
183
There were some differences in how the cost of providing DMTs (acquisition, administration and monitoring)
was estimated and/or described. Biogen Idec Ltd and Teva provided a detailed breakdown of the costs
included by drug acquisition, administration and monitoring. Merck provided a single total cost for treatment
with DMTs. It is unclear whether this estimate included the cost of administering and/or monitoring of
treatment with DMTs. Additionally, the estimate used in the model analysis was classified as commercial-in-
confidence material and may not represent the list price for the drug. The total cost involved in providing
DMTs to patients will be an important driver of cost-effectiveness. It does not appear that any of the three
manufacturers included infrastructure costs (e.g. nursing infrastructure) in the drug treatment costs.
Teva and Merck used resource use data reported in the ScHARR analysis275 to determine the costs to assign
to EDSS-defined health states. The costs assigned by Teva and Merck, adjusted to 2015 UK pounds, were
approximately the same. Biogen Idec Ltd reported that it used cost data reported in the UK MS Trust
survey and assigned different costs depending on both EDSS state and whether patients had RRMS or
SPMS. The costs assigned to the EDSS states in Biogen Idec Ltd’s submission tended to be lower than
those used by Teva and Merck. This is likely to result in lower lifetime costs but will affect both the DMT
strategy and the BSC strategy.
For the cost of relapse, the three manufacturers followed the same approach. A proportion of those
experiencing relapses would experience mild relapses (not requiring hospitalisation) whereas the others
would experience severe relapses (requiring hospitalisation). The costs of each type of relapse differed and
so an average cost of relapse was estimated (based on the proportions). The sources of the data differed,
with Biogen Idec Ltd using data from the study by Hawton and Green107 and Teva and Merck inflating the
costs reported in the ScHARR model.275 The cost estimates used in Biogen Idec Ltd’s model were lower
than those used in the Teva and Merck models.
Merck did not include the cost of treatment-related AEs in the primary analysis but included this cost in
sensitivity analysis. Biogen Idec Ltd and Teva included the cost of AEs. Biogen Idec Ltd undertook its own
study with specialists (a Delphi panel) to estimate resource use for AEs and consequently the unit costs.
Teva derived the unit costs for AEs using a combination of information from the PSSRU,278 national
reference costs285 and the manufacturer’s submission for TA312.118
Health state utility values
There were some differences between the manufacturers’ submissions with regard to the sources of health
state utility weights and how these were assigned to the health states. In the submissions by Teva and
Merck, health state utilities for EDSS health states were derived by pooling data from the MS Trust and the
Heron data sets.101 Both assumed that the current EDSS score determined the utility scores for both the
RRMS and the SPMS health states. This was the approach used in the RSS model. Biogen Idec Ltd derived
utility weights differently in its model analysis. It used a combination of utility data from the ADVANCE
trial213 and the UK MS Trust survey and its approach to pooling the data was driven by data availability
and not by standard methodological approaches to pooling data. In addition, Biogen Idec Ltd assigned
different utility weights to the EDSS health states according to whether or not a patient had RRMS or
SPMS. As the EDSS state provides an assessment of disability, it may not be appropriate to apply a lower
utility weight to the same EDSS state if patients had SPMS.
All three manufacturers used different approaches to quantify the disutility from relapses. Teva and Merck
assigned a disutility weight for a relapse and assumed that the disutility from a relapse would last for
between 46 and 90 days, with Teva further stratifying relapse disutility by the severity of the relapse (mild
vs. severe). Although not clear, it appears that Biogen Idec Ltd assumed that the disutility from a relapse
would persist and assigned an additional disutility to all EDSS health states (by subtracting the relapse
disutility from the EDSS utility) for those who had a relapse.
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The above two issues highlight major differences in the utility weights assigned to the EDSS health states
between Biogen Idec Ltd and Teva/Merck. The way that this impacts on the ICER estimates is multifactorial and
complex. There is a potential that this may lead to more favourable ICERs (greater QALY gain from DMTs) in
the Biogen Idec Ltd model as one of the benefits of DMTs is to reduce relapses and delay progression to SPMS.
There were also some minor differences in the manufacturers’ submissions in the data sources used to
quantify carers’ disutility. Teva and Merck followed the approach used in the RSS model, using data
reported by Acaster et al.,280 whereas Biogen Idec Ltd used data from the study by Orme et al.101 Overall,
this translated to Biogen Idec Ltd assigning predominantly lower disutility weights to the lower EDSS health
states and higher disutility weights to the two highest EDSS health states.
There were some minor differences in how disutilities from adverse drug reactions were modelled. All
three manufacturers assigned an average disutility, as in the RSS model. The average disutility was based
on the proportion experiencing AEs and the disutility weights attached to adverse drug reactions. Overall,
the values were not too dissimilar and are unlikely to impact on ICER estimates.
Summary
The assessment group reviewed the three manufacturer submissions from Biogen Idec Ltd, Teva and Merck.
Overall, the methodological approaches used by the three companies were in accordance with the NICE
reference case156 (Table 63). However, there were significant differences in the modelling approach and
data sources used by the three manufacturers and this is likely to explain the differences in the estimated
TABLE 63 Manufacturers’ analyses compared with the NICE reference case156
Element of HTA
Company
Reference case156
Biogen
Idec Ltd Teva Merck
Defining the decision problem ✓ ✓ ✓ The scope developed by NICE141
Comparator(s) ✓ ✓ ✓ As listed in the scope developed by NICE141
Perspective on outcomes ✓ ✓ ✓ All direct health effects, whether for patients or,
when relevant, carers
Perspective on costs ✓ ✓ ✓ NHS and PSS
Type of economic evaluation ✓ ✓ ✓ Cost–utility analysis with fully incremental analysis
Time horizon ✓ ✓ ✓ Long enough to reflect all important differences in
costs or outcomes between the technologies being
compared
Synthesis of evidence on health
effects
✓ ✓ ✓ Based on a systematic review
Measuring and valuing health effects ✓ ✓ ✓ Health effects should be expressed in QALYs. The
EQ-5D is the preferred measure of HRQoL in adults
Source of data for measurement of
HRQoL
✓ ✓ ✓ Reported directly by patients and/or carers
Source of preference data for
valuation of changes in HRQoL
✓ ✓ ✓ Representative sample of the UK population
Equity considerations ✓ ✓ ✓ An additional QALY has the same weight regardless
of the other characteristics of the individuals
receiving the health benefit
Evidence on resource use and costs ✓ ✓ ✓ Costs should relate to NHS and PSS resources and
should be valued using the prices relevant to the
NHS and PSS
Discounting ✓ ✓ ✓ The same annual rate for both costs and health
effects (currently 3.5%)
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ICERs. Importantly, there were significant differences between the approaches used by the manufacturers
and the approach used in the Department of Health RSS model analysis. Biogen Idec Ltd’s submission
differed the most from the Department of Health RSS model analysis and Merck’s submission differed
the least.
Impact on the results of the assumptions made by the manufacturers
To understand the consequences of the assumptions made by the manufacturers, we calculated the results
using the manufacturer-submitted treatment effects and list prices but otherwise mainly used the RSS
model assumptions.
In these analyses we retained the majority of the assumptions made in the RSS model but made the
following changes:
l we excluded carers’ disutilities
l we used the HRs for disability progression submitted by each manufacturer
l we used the list prices for the DMTs.
Using the RSS base run and time-varying models, we estimated the cost-effectiveness of the DMTs [30 µg
of IM IFN-β-1a weekly (Avonex), 44 µg of SC IFN-β-1a three times weekly (Rebif) and 20 mg of SC GA daily
(Copaxone)] included in the RSS model and manufacturer submissions compared with BSC for people with
RRMS. We present the results in terms of total mean costs and total mean QALYs and ICERs based on the
cost per QALY gained. We report the results based on pairwise comparisons (each DMT compared with
BSC) and on an incremental analysis. In the incremental analysis the strategies are ranked in ascending
order according to mean cost. We eliminated strategies that were dominated, that is, strategies that were
more expensive and less effective. If there was a linear combination of two other strategies that were more
costly and less effective (extended dominance), these were eliminated. For the remaining strategies we
derived an incremental cost per QALY gained.
Results in terms of quality-adjusted life-years gained
Over a 50-year time horizon, the results from the base-run model showed that the BSC arm had expected
mean costs of approximately £344,900 and mean QALYs of 8.451. Mean costs for 30 µg of IM IFN-β-1a
weekly (Avonex) were approximately (confidential information has been removed) and corresponding
mean QALYs were (confidential information has been removed). Mean costs for 44 µg of SC IFN-β-1a
three times weekly (Rebif) and 20 mg of SC GA daily (Copaxone) were approximately (confidential
information has been removed), with corresponding mean QALYs of (confidential information has been
TABLE 64 Results based on the RSS model with individual manufacturer submission HRs (incremental analysis)
Strategy
Cost (£) QALYs
ICER (£)Mean Incremental Mean Incremental
BSC 344,900 – 8.451 – –
GA 20mg SC once daily
(Copaxone)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
IFN-β-1a 30 µg IM once
weekly (Avonex)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
IFN-β-1a 44 µg SC three
times weekly (Rebif)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
(Confidential
information has
been removed)
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removed) respectively. Results from the incremental analysis (Table 64) showed that (confidential
information has been removed). Excluding strategies that were dominated resulted in the comparison
between BSC and (confidential information has been removed). Our pairwise analysis (Table 65) showed
that ICERs for each drug compared with BSC were different between the manufacturers’ analyses and our
estimates from the RSS model.
Discussion and conclusion
In this analysis we compared DMTs with BSC and reported the incremental costs and QALYs for each
manufacturer and those derived using the RSS model. Of note, we had concerns about the total QALYs
estimated in the manufacturers’ submissions. The RSS model and our own cost-effectiveness model
analysis estimated mean QALYs of 8.5 for BSC in the base-case analysis, whereas Teva’s model estimated
approximately (confidential information has been removed) QALYs and Merck’s model estimated
approximately (confidential information has been removed) QALYs. When we adapted the RSS model to
use disability progression from the Teva and Merck submissions, the mean QALYs approximated to 8.5.
We looked at a range of parameters that might affect estimated mean QALYs: natural history cohort,
utility values, mortality rates and starting EDSS distributions. Teva used the London Ontario data set80 to
model disease progression and this may explain why its estimate was different. We could not explain the
difference between the findings from the RSS model and the findings in Merck’s submission. All other
aforementioned parameters were comparable between the models.
TABLE 65 Comparison between incremental costs and QALYs submitted by each manufacturer and those derived
using the RSS model (pairwise analysis)
DMT and
manufacturer
Manufacturer’s
incremental
costs (£)
Incremental
costs based
on RSS
model (£)
Manufacturer’s
incremental
QALYs
Incremental
QALYs
based on
RSS model
Manufacturer’s
ICER (£)
ICER (£)
based on
RSS model
IFN-β-1a 30 µg
IM once weekly
(Avonex) (Biogen
Idec Ltd)
(Confidential
information
has been
removed)
(Confidential
information
has been
removed)
(Confidential
information
has been
removed)
(Confidential
information
has been
removed)
(Confidential
information
has been
removed)
(Confidential
information
has been
removed)
IFN-β-1a 44 µg
SC three times
weekly (Rebif)
(Merck)
(Confidential
information
has been
removed)
(Confidential
information
has been
removed)
(Confidential
information
has been
removed)
(Confidential
information
has been
removed)
(Confidential
information
has been
removed)
(Confidential
information
has been
removed)
GA 20mg SC
once daily
(Copaxone)
(Teva)
(Confidential
information
has been
removed)
(Confidential
information
has been
removed)
(Confidential
information
has been
removed)
(Confidential
information
has been
removed)
(Confidential
information
has been
removed)
(Confidential
information
has been
removed)
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Chapter 11 Health economic assessment:
relapsing–remitting multiple sclerosis
Objectives and methods
Objective
In Chapter 9, the assessment group outlined some limitations of the RSS model. We undertook several
sensitivity analyses to address these concerns, using alternative information sources and assumptions.
The additional analyses undertaken by the assessment group are presented in this chapter.
To assess the impact of DMTs used to treat people diagnosed with RRMS, we developed a decision-analytic
modelling framework that used longitudinal data from natural history cohorts to provide information on the
progression of RRMS. The objective of the model was to estimate the cost-effectiveness of DMTs within
their marketing authorisation for treating people diagnosed with RRMS. In the model, health outcomes
were measured in QALYs and we present the results in terms of incremental cost per QALY gained. In the
UK, an ICER of < £20,000–30,000 per QALY is considered cost-effective by decision-makers.156
Developing the model structure
To estimate the cost-effectiveness of DMTs for treating people with RRMS, we used, and developed the
model structure for the RSS scheme submitted by the Department of Health. Details of the RSS model are
outlined elsewhere in this report (see Chapter 9). Briefly, the RSS model is a cohort-based Markov model.
The model cycled yearly, with a starting age of 30 years, and estimated the mean costs and effects
associated with treatment compared with no treatment (BSC) over a 50-year time horizon. The analysis
was conducted from the NHS and PSS perspective and the results were reported in terms of ICERs,
expressed as the cost per QALY gained. Both costs and benefits were discounted at 3.5% per annum.
Health states for people with RRMS or SPMS were characterised by EDSS levels ranging from 0 to 10. In
the model, transition matrices are applied to show how people move through the model. People are able
to progress to more severe EDSS levels or regress to less severe EDSS levels or there is a probability of
dying from MS-related or other causes.
Changes made in our analyses to the model assumptions and characteristics from the
risk-sharing scheme model
The assessment group assessed the impact of the following changes to the RSS model:
l use of discontinuation rates obtained from our clinical effectiveness review
l use of alternative estimates of treatment effectiveness (ARRs and HRs for disability progression) derived
from our clinical effectiveness review
l changes to mortality assumptions
l use of list prices for DMTs
l exclusion of carers’ disutilities
l impact of varying key model input parameters
l implementation of probabilistic sensitivity analysis.
Discontinuation rates
In the treatment arm of the RSS model it was assumed that every year 5% of people discontinued treatment
as a result of AEs. However, it was unclear whether this assumption was based on empirical evidence.
We undertook further analyses to derive a combined discontinuation rate based on all of the drugs used
in the RSS model and discontinuation rates based on each individual drug used in the RSS model.
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These proportions were derived from the RRMS studies included in our clinical review. Studies reported the
instantaneous rates of people who discontinued treatment as a result of DMTs. We converted these rates to
annual probabilities using the equation [probability = 1 – exp(–rt)], where r is rate and t is time.
Table 66 shows the annual discontinuation rates for each DMT, as well as the annual discontinuation rate
for all DMTs combined. Our combined annual probability of 2.29% is lower than the discontinuation
rate assumed in the RSS model. Using this value in the model would lead to more people remaining on
treatment. Discontinuation rates reported by each manufacturer tended to be higher than those derived
from our clinical review.
Treatment effectiveness: annualised relapse rates
In the RSS model the ARR for those treated with DMTs compared with those not treated was 0.72. We
undertook further analyses to derive the ARR based on the studies identified in our clinical effectiveness
review to see how this compared with the value reported in the RSS model and with the values reported in
the manufacturers’ submissions. From our meta-analysis we derived a combined ARR of 0.6494 (95% CI
0.5572 to 0.7567). Our ARR is lower than the ARR presented in the RSS model. The combined treatment
effect from our NMA of the published studies suggests that there is a discrepancy in the assessment of the
effectiveness of DMTs depending on the data source used. RCT evidence appears to show that DMTs are
more effective than is suggested by the RSS model (Table 67). In addition, we compared the ARRs for each
individual DMT derived from our NMA with the ARRs reported by each manufacturer. These ARRs appear
to be very similar.
Treatment effectiveness: time to disability progression
We used both pooled and DMT-specific estimates of disability progression relative to BSC from our NMAs
and compared them with other relevant inputs.
First, we estimated a combined treatment effect of DMTs by pooling relevant active versus placebo trials
for on-scheme DMTs. The results showed a reduced hazard of sustained confirmed disability progression
for people treated with DMT compared with BSC (HR 0.6955, 95% CI 0.5530 to 0.8747). In contrast,
the RSS model reported a HR of 0.7913 (95% CI 0.7705 to 0.8122).
TABLE 66 Annual proportions of people discontinuing treatment following AEs
Treatment
Reported in
RSS model
Derived from
assessment group
clinical review
Reported
by each
manufacturer
Derived from
assessment group
clinical review
IFN-β-1a 30 µg IM once a week (Avonex) 0.0500 0.0229 0.0790 0.0150
PegIFN-β-1a 125 µg SC every 2 weeks
(Plegridy)
0.0500 0.0229 0.1040 0.0150a
IFN-β-1a 44/22 µg SC three times per
week (Rebif)
0.0500 0.0229 0.0500 0.0263
IFN-β-1b 250 µg SC every other day
(Betaferon/Extavia)
0.0500 0.0229 Not submitted 0.0219
GA 20mg SC once daily or 40 mg SC
three times a week (Copaxone)
0.0500 0.0229 0.0500 0.0263
a We assumed that the discontinuation was the same as for 30 µg of IM IFN-β-1a once a week (Avonex).
HEALTH ECONOMIC ASSESSMENT: RELAPSING–REMITTING MULTIPLE SCLEROSIS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
190
Second, we compared the estimates for disease progression reported by each manufacturer with the
estimates derived from our analysis. Again, our results demonstrate a discrepancy between the effect sizes
generated by the different sources of data (the RSS model, the pooled RCT evidence, the effects reported
by the manufacturers and the DMT-specific effects estimated in our NMAs). Table 68 shows the treatment
effects on disability progression from the assessment group and manufacturer estimates. Assessment
group values are for disability progression confirmed at 3 months. We additionally considered disability
progression confirmed at 6 months (Table 69).
TABLE 67 Annualised relapse rates by DMT
Treatment
Reported by RSS
(95% CI)
Derived from
assessment
group clinical
review (95% CI)
Reported by each
manufacturer
(95% CI)
Derived from
assessment
group clinical
review (95% CI)
IFN-β-1a 30 µg IM once a week
(Avonex)
0.7200
(0.6118 to 0.8309)
0.6494
(0.5572 to 0.7567)
(Confidential
information has
been removed)
0.80 (0.72 to 0.88)
PegIFN-β-1a 125 µg SC every
2 weeks (Plegridy)
0.7200
(0.6118 to 0.8309)
0.6494
(0.5572 to 0.7567)
0.6420
(0.4070 to 1.0380)
0.64 (0.50 to 0.83)
IFN-β-1a 44/22 µg SC three
times per week (Rebif)
0.7200
(0.6118 to 0.8309)
0.6494
(0.5572 to 0.7567)
0.670 (0.57 to 0.79) 0.68 (0.61 to 0.76)
IFN-β-1b 250 µg SC every other
day (Betaferon/Extavia)
0.7200
(0.6118 to 0.8309)
0.6494
(0.5572 to 0.7567)
Not submitted 0.69 (0.62 to 0.76)
GA 40mg SC three times a
week (Copaxone)
0.7200
(0.6118 to 0.8309)
0.6494
(0.5572 to 0.7567)
(Confidential
information has
been removed)
0.66 (0.54 to 0.80)
GA 20mg SC once daily
(Copaxone)
0.7200
(0.6118 to 0.8309)
0.6494
(0.5572 to 0.7567)
(Confidential
information has
been removed)
0.66 (0.59 to 0.72)
TABLE 68 Treatment effects on disability progression confirmed at 3 months
Treatment
Reported by the
RSS model, HRa
(95% CI)
Derived from the
assessment group
clinical review,
HR (95% CI)
Reported by each
manufacturer, HR
(95% CI)
Derived from the
assessment group
clinical review, HR
(95% CI)
IFN-β-1a 30 µg IM once a week
(Avonex)
0.7913
(0.7705 to 0.8122)
0.6955
(0.5530 to 0.8747)
(Confidential
information has
been removed)
0.7300
(0.5300 to 1.0000)
PegIFN-β-1a 125 µg SC every
2 weeks (Plegridy)
0.620
(0.2090 to 1.8150)
0.6200
(0.4000 to 0.9700)
IFN-β-1a 44/22 µg SC three
times per week (Rebif)
(Confidential
information has
been removed)
0.6300
(0.4600 to 0.8600)
IFN-β-1b 250 µg SC every other
day (Betaferon/Extavia)
Not submitted 0.7800
(0.5900 to 1.0200)
GA 40mg SC three times a
week (Copaxone)
(Confidential
information has
been removed)
Not derived
GA 20mg SC once daily
(Copaxone)
0.7600
(0.6000 to 0.9700)
a The RSS estimate is an ‘implied’ HR.
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Mortality
The assessment group previously highlighted concerns regarding overestimation of MS-related mortality.
In the RSS model we noted that individuals were subject to MS-related mortality (modelled as twice the
standardised mortality rate from other causes) in addition to mortality from transition to EDSS 10
(MS-related death). We highlighted that this would theoretically lead to double counting of MS-related
deaths in the model and that the results would therefore show a reduction in life-years and QALYs gained.
Hence, we changed the risk of MS-related death to be the same as that for the general population, as the
risk of MS-related death is already captured in the transition matrices. An alternative approach that we did
not explore in these analyses would have been to consider using mortality multipliers for lower EDSS levels
to capture the increased risk of mortality for those with MS compared with the general population.
Resource use and costs
The costs of DMTs were obtained from the BNF.21 The annual cost of £8502 for treatment with IFN-β-1a
(Avonex) was derived based on the recommended dosage of 30 µg once a week. The annual cost of
£10,572 for treatment with IFN-β-1a (Rebif) was derived based on a dosage of 44 µg three times per
week. We derived annual costs of £7264 and £6681 (£6704) for treatment with IFN-β-1b 250 µg every
other day (Betaferon/Extavia) and GA (Copaxone) 40 mg SC three times weekly (20 mg SC once daily)
respectively. Table 70 presents the costs for each DMT. Of note, we did not specifically take into account
that those on 44 µg of IFN-β-1a (Rebif) three times per week may subsequently have their dosage reduced
to 22 µg three times per week.
Utility values including carers’ disutilities
The assessment group considered the utility values used in the RSS analyses to be appropriate. However,
we identified through literature searching other sources of utility estimates. In sensitivity analyses we
explored the impact of using these other sources of utility values.
TABLE 69 Treatment effects on disability progression confirmed at 6 months
Treatment
Derived from the assessment
group clinical review, HR (95% CI)
IFN-β-1a 30 µg IM once a week (Avonex) 0.68 (0.49 to 0.94)
PegIFN-β-1a 125 µg SC every 2 weeks (Plegridy) 0.46 (0.26 to 0.81)
IFN-β-1a 44/22 µg SC three times per week (Rebif) 0.47 (0.24 to 0.93)
IFN-β-1b 250 µg SC every other day (Betaferon/Extavia) 0.34 (0.18 to 0.63)
GA 40mg SC three times a week (Copaxone) Not reported
GA 20mg SC once daily (Copaxone) 0.82 (0.53 to 1.26)
TABLE 70 Costs of DMTs
Treatment Cost (£, 2015 prices) Source
IFN-β-1a 30 µg IM once a week (Avonex) 8502 BNF21
PegIFN-β-1a 125 µg SC every 2 weeks (Plegridy) 8502
IFN-β-1a 44 µg SC three times per week (Rebif) 10,572
IFN-β-1b 250 µg SC every other day (Betaferon/Extavia) 7264
GA 20mg SC once daily 6704
GA 40mg three times a week with at least 48 hours between doses 6681
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Disutilities associated with caring for people with MS were included in the RSS analyses. However, it
appears that carers included in the analysis represent informal/unpaid carers. The NICE reference case
suggests that the perspective should be all direct health effects, whether for patients or other people.
Hence, the assessment group has excluded carers’ disutilities from the main analysis. We present analyses
including carer disutilities in Appendix 8.
Base case cost-effectiveness analysis
The Markov model was developed and programmed to choose the base-case model inputs to assess the
cost-effectiveness of DMTs for the management of people with RRMS. The model estimated the mean
costs and health benefits associated with each DMT and assumed that the starting age of the population
was 30 years. We considered the RSS model base case with changes made to avoid double counting of
mortality and the removal of carer disutilities to be our base case. The analysis was undertaken from a NHS
and PSS perspective in a specialist MS care setting and outcomes were reported as ICERs, expressed in
terms of cost per QALY gained. All costs and outcomes were discounted at 3.5% per annum.
Sensitivity analyses
The following multiway sensitivity analyses were undertaken:
l SA1 – pooled estimates of effectiveness for on-scheme DMTs from the assessment group review. In this
analysis we used inputs from our review of the evidence pooled across all on-scheme DMTs. We used
the aggregated HR for disability progression confirmed at 3 months, the aggregated ARR and the
aggregated discontinuation rate.
l SA2 – estimates of effectiveness of individual drugs from the assessment group review.
i. Individual drugs from the assessment group review, progression confirmed at 3 months: we used the
HR for disability progression confirmed at 3 months derived from our clinical effectiveness review
and the RR for ARR derived from our clinical effectiveness review, as well as relevant discontinuation
rates and list prices.
ii. Individual drugs from the assessment group review, progression confirmed at 6 months: we used the
HR for disability progression confirmed at 6 months derived from our clinical effectiveness review
and the RR for ARR derived from our clinical effectiveness review, as well as relevant discontinuation
rates and list prices.
l SA3 – HRs from the manufacturers’ submissions. We used the HRs (confirmed disease progression)
reported by each manufacturer with the ARRs reported by each manufacturer, as well as relevant
discontinuation rates and list prices.
l SA4 – time horizon changed. In this analysis we used estimates of effectiveness of individual drugs
from the assessment group review, progression confirmed at 3 months and relapse rates from the
clinical effectiveness review and relevant discontinuation rates and list prices, using a time horizon of
20 years or 30 years.
l SA5 – parameter uncertainty analysis for the base case and SA1 models. We varied the HR for disability
progression, the RR for ARRs, the costs of the DMTs and the annual discontinuation rate by ±10% for
the base case and SA1 models.
Probabilistic sensitivity analysis
We undertook probabilistic sensitivity analyses on the base case and SA1 models to determine the
uncertainty of the key model input parameters.
In the probabilistic sensitivity analysis we varied the HR for disability progression, the RR for ARR, utility
values for each EDSS state, the disutility associated with relapses, management costs by EDSS state and
the cost of relapses and assigned distributions, which reflected the amount and pattern of variation.
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The cost-effectiveness results were calculated by simultaneously selecting random values from each
distribution. The process was repeated 1000 times in a Monte Carlo simulation of the model to give an
indication of how variation in the model parameters leads to variation in the ICERs for a given treatment
combination (e.g. DMT compared with BSC).
In Table 71 we present the point estimates and the appropriate distribution for the input parameters. This
type of analysis allows all parameter uncertainties to be incorporated into the analysis. Sampling parameter
values from probability distributions rather than from a simple range defined by the upper and lower bounds
places greater weight on the likely combinations of parameter values and the simulation results quantify the
impact of uncertainties on the model in terms of the confidence that can be placed in the analysis results.
Sensitivity analyses 1–4 are summarised in Table 72 with respect to key model parameters.
Results of the cost-effectiveness analysis
In this section we present the results relating to the base-run model. Further results relating to the
time-varying model are provided in Appendix 8.
TABLE 71 Input parameters for the RRMS economic assessment
Variable Base-case value 95% CIs Distribution Source
Baseline distribution of people in the RSS model, n
EDSS 0 135 – Fixed Base-case values obtained
from the RSS model
EDSS 1 689 – Fixed Base-case values obtained
from the RSS model
EDSS 2 1088 – Fixed Base-case values obtained
from the RSS model
EDSS 3 970 – Fixed Base-case values obtained
from the RSS model
EDSS 4 652 – Fixed Base-case values obtained
from the RSS model
EDSS 5 441 – Fixed Base-case values obtained
from the RSS model
EDSS 6 242 – Fixed Base-case values obtained
from the RSS model
EDSS 7 0 – Fixed Base-case values obtained
from the RSS model
EDSS 8 0 – Fixed Base-case values obtained
from the RSS model
EDSS 9 0 – Fixed Base-case values obtained
from the RSS model
EDSS 10 0 – Fixed Base-case values obtained
from the RSS model
RRMS: relapse frequency (% of RRMS patients)
EDSS 0 0.8895 (100) – Fixed Base-case values obtained
from the RSS model
EDSS 1 0.7885 (86.1) – Fixed Base-case values obtained
from the RSS model
EDSS 2 0.6478 (86.1) – Fixed Base-case values obtained
from the RSS model
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TABLE 71 Input parameters for the RRMS economic assessment (continued )
Variable Base-case value 95% CIs Distribution Source
EDSS 3 0.6155 (80.6) – Fixed Base-case values obtained
from the RSS model
EDSS 4 0.5532 (54.5) – Fixed Base-case values obtained
from the RSS model
EDSS 5 0.5249 (34.3) – Fixed Base-case values obtained
from the RSS model
EDSS 6 0.5146 (27.0) – Fixed Base-case values obtained
from the RSS model
EDSS 7 0.4482 (5.3) – Fixed Base-case values obtained
from the RSS model
EDSS 8 0.3665 (0.0) – Fixed Base-case values obtained
from the RSS model
EDSS 9 0.2964 (0.0) – Fixed Base-case values obtained
from the RSS model
EDSS 10 0.0000 (0.0) – Fixed Base-case values obtained
from the RSS model
SPMS: relapse frequency (% of SPMS patients)
EDSS 0 0.0000 (0.0) – Fixed Base-case values obtained
from the RSS model
EDSS 1 0.0000 (13.9) – Fixed Base-case values obtained
from the RSS model
EDSS 2 0.6049 (13.9) – Fixed Base-case values obtained
from the RSS model
EDSS 3 0.5154 (19.4) – Fixed Base-case values obtained
from the RSS model
EDSS 4 0.4867 (45.5) – Fixed Base-case values obtained
from the RSS model
EDSS 5 0.4226 (65.7) – Fixed Base-case values obtained
from the RSS model
EDSS 6 0.3595 (73.0) – Fixed Base-case values obtained
from the RSS model
EDSS 7 0.3025 (94.7) – Fixed Base-case values obtained
from the RSS model
EDSS 8 0.2510 (100) – Fixed Base-case values obtained
from the RSS model
EDSS 9 0.2172 (100) – Fixed Base-case values obtained
from the RSS model
EDSS 10 0.0000 (100) – Fixed Base-case values obtained
from the RSS model
HR
Disability progression
in the RSS model
0.7913 0.7708 to 0.8123 Log-normal
Disability progression
in the assessment
group model
0.6955 0.5530 to 0.8747 Log-normal Derived from the
assessment group analysis
continued
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TABLE 71 Input parameters for the RRMS economic assessment (continued )
Variable Base-case value 95% CIs Distribution Source
RR
ARR in the RSS model 0.7200 0.6118 to 0.8309 Log-normal Base-case value obtained
from the RSS model and
CIs estimated by the
Department of Health
ARR in the assessment
group model
0.6494 0.5572 to 0.7567 Log-normal Derived from the
assessment group analysis
Management costs by EDSS state (£)
EDSS 0 1195 Assumed to be
log-normally distributed
with a standard error of
10% of the mean value
Log-normal Base-case values obtained
from the RSS model
EDSS 1 1195 Log-normal
EDSS 2 1195 Log-normal
EDSS 3 2203 Log-normal
EDSS 4 2283 Log-normal
EDSS 5 8045 Log-normal
EDSS 6 8974 Log-normal
EDSS 7 27,385 Log-normal
EDSS 8 42,521 Log-normal
EDSS 9 54,055 Log-normal
EDSS 10 0 Fixed
Management of relapse
Cost of relapse (£) 4263 Assumed to be
log-normally distributed
with a standard error of
10% of the mean value
Log-normal Base-case values obtained
from the RSS model
Utility values
EDSS 0 0.9248 0.8650 to 0.9581 Log-normal Base-case values obtained
from the RSS model and
the ScHARR model275EDSS 1 0.7614 0.7079 to 0.8051 Log-normal
EDSS 2 0.6741 0.6165 to 0.7230 Log-normal
EDSS 3 0.5643 0.5143 to 0.6092 Log-normal
EDSS 4 0.5643 0.4965 to 0.6230 Log-normal
EDSS 5 0.4906 0.4333 to 0.5421 Log-normal
EDSS 6 0.4453 0.3722 to 0.5099 Log-normal
EDSS 7 0.2686 0.2190 to 0.3150 Log-normal
EDSS 8 0.0076 –0.0705 to 0.0800 Log-normal
EDSS 9 –0.2304 –0.3086 to –0.1569 Log-normal
Dead 0 – Fixed By definition
Disutility of a relapse –0.0277 ±10% Log-normal Assumption
Other
Mortality (age-specific
death rates)
Life tables – Fixed ONS,290 as cited in the
Biogen Idec Ltd
submission
Discount rate per
annum (costs and
QALYs)
3.5% – Fixed
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Base-case and sensitivity analyses
Base case
In Table 73 we present the findings from our base-case analysis, taking into account the concerns
described above. The results showed that over a 50-year time horizon the DMT strategy was more costly
and more effective than BSC. The DMT strategy was approximately £31,900 more costly per person than
the BSC strategy and produced 0.943 more QALYs, with an ICER of approximately £33,800 per QALY.
SA1: Pooled estimates of effectiveness for on-scheme disease-modifying therapies from
the assessment group review
We used two key estimates of treatment effectiveness from our clinical effectiveness review: the aggregated
HR for disability progression confirmed at 3 months and the aggregated ARR.
In Table 74 the results are presented in terms of cost per QALY. The results show that the DMT strategy was
more costly and more effective than BSC alone. The DMT strategy was approximately £23,300 more costly
than BSC and produced 1.822 more QALYs, which equated to an ICER of approximately £12,800 per QALY.
This indicates that for every additional QALY from DMTs there is an incremental cost of £12,800.
SA2a: Estimates of effectiveness of individual drugs from the assessment group review,
progression confirmed at 3 months (preferred analysis)
In this model we used the HRs (DMT vs. placebo) for disability progression confirmed at 3 months
(see Table 68) and ARR (see Table 67) derived from our clinical effectiveness review and applied them to
the individual DMTs.
The results from this sensitivity analysis (Table 75) show that BSC was the least expensive strategy and
30 µg of IM IFN-β-1a once weekly (Avonex) was the most expensive strategy. In terms of QALYs, BSC is
expected to result in the fewest QALYs (8.664) and 125 µg of SC pegIFN-β-1a every 2 weeks (Plegridy) is
expected to yield the most QALYs (11.223). Treatment with 125 µg of SC pegIFN-β-1a every 2 weeks
(Plegridy) dominated all other DMT strategies, being less costly and more effective. Compared with BSC,
125 µg of SC pegIFN-β-1a every 2 weeks (Plegridy) was approximately £17,800 more costly and more
effective by an expected mean gain of 2.559 QALYs, with an ICER of £7000 per QALY.
TABLE 73 Base-case results: cost per QALY
Strategy
Cost (£) QALYs
ICER (£)Mean Incremental Mean Incremental
BSC 362,100 – 8.664 – –
DMTs 394,000 31,900 9.607 0.943 33,800
TABLE 74 Pooled estimates of effectiveness for on-scheme DMTs from the assessment group review (SA1):
cost per QALY
Strategy
Cost (£) QALYs
ICER (£)Mean Incremental Mean Incremental
BSC 362,100 – 8.664 – –
DMTs 385,400 23,300 10.486 1.822 12,800
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SA2b: Estimates of effectiveness of individual drugs from the assessment group review,
progression confirmed at 6 months
In this sensitivity analysis we used HRs for disability progression confirmed at 6 months derived from our
clinical effectiveness review. The findings showed that 125 µg of SC pegIFN-β-1a every 2 weeks (Plegridy)
was the least costly and most effective treatment strategy, dominating other treatment strategies included
in this analysis (Table 76). We did not include 250 µg of SC IFN-β-1b every other day (Betaferon/Extavia) in
this analysis as its value for progression confirmed at 6 months was (1) extreme, (2) derived from indirect
evidence and (3) driven by one open-label trial using an imputed HR.
SA3: Hazard ratios from manufacturer submissions
When we used the estimates for treatment effectiveness (ARR and disability progression) reported by each
manufacturer, BSC was the least expensive strategy and 44 µg of SC IFN-β-1a three times a week (Rebif) was
the most expensive (Table 77). In terms of QALYs, BSC is expected to result in the fewest QALYs (8.664) and
125 µg of SC pegIFN-β-1a every 2 weeks (Plegridy) is expected to yield the most QALYs (9.931). The results
showed that 125 µg of SC pegIFN-β-1a every 2 weeks (Plegridy) dominated all other DMT strategies.
Compared with BSC, 125 µg of SC pegIFN-β-1a every 2 weeks (Plegridy) had an ICER of £3300 per QALY.
SA4: Time horizon changed from 50 years to 20 years and 30 years
Tables 78 and 79 show the results of the sensitivity analyses based on a 20-year and 30-year time horizon,
respectively. The GA treatment strategy was extendedly dominated by 125 µg of SC pegIFN-β-1a every 2 weeks
(Plegridy) in both analyses. Additionally, 125 µg of SC pegIFN-β-1a every 2 weeks (Plegridy) dominated both
30 µg of IM IFN-β-1a once weekly (Avonex) and 44 µg of SC pegIFN-β-1a three times a week (Rebif). Excluding
all dominated strategies, 125 µg of SC pegIFN-β-1a every 2 weeks (Plegridy) compared with BSC had ICERs of
approximately £21,200 and £10,600 per QALY for the 20-year and 30-year time horizons respectively.
TABLE 76 Estimates of effectiveness of individual drugs from the assessment group review, progression confirmed
at 6 months (SA2b): cost per QALY
Strategy
Cost (£) QALYs
ICER (£)Mean Incremental Mean Incremental
PegIFN-β-1a 125 µg SC every 2 weeks (Plegridy) 347,000 – 12.583 – –
BSC 362,100 15,100 8.664 –3.919 Dominated
IFN-β-1a 44 µg SC three times a week (Rebif) 377,600 30,600 12.041 –0.542 Dominated
GA 20mg SC once daily (Copaxone) 391,800 44,800 9.650 –2.933 Dominated
IFN-β-1a 30 µg IM once weekly (Avonex) 397,200 50,200 10.717 –1.866 Dominated
TABLE 75 Estimates of effectiveness of individual drugs from the assessment group review, progression confirmed
at 3 months (SA2a): cost per QALY
Strategy
Cost (£) QALYs
ICER (£)Mean Incremental Mean Incremental
BSC 362,100 – 8.664 – –
PegIFN-β-1a 125 µg every 2 weeks (Plegridy) 379,900 17,800 11.223 2.559 7000
GA 20mg SC once daily (Copaxone) 381,400 1500 10.012 –1.211 Dominated
IFN-β-1b 250 µg every other day
(Betaferon/Extavia)
393,400 13,500 9.934 –1.289 Dominated
IFN-β-1a 44 µg SC three times a week (Rebif) 404,800 24,900 10.867 –0.356 Dominated
IFN-β-1a 30 µg IM once weekly (Avonex) 406,400 26,500 10.348 –0.875 Dominated
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SA5: Parameter uncertainty analysis
Figure 25 shows a graphical representation (also known as a tornado diagram) of the impact on the base
case of varying key model input parameters. In this analysis we varied the HR for disability progression, the
RR for ARRs, the cost of DMTs and the annual discontinuation rate by ±10%. Additionally, we assessed the
impact on the base-case results of varying the model time horizon by ±10%. The results show that changes
to the HR for disability progression have the greatest impact on the cost-effectiveness results. A decrease in
the treatment effect (increase in the HR) by 10% resulted in an ICER of approximately £74,500 per QALY.
An increase in the treatment effect (decrease in the HR) by 10% resulted in an ICER of approximately
£15,300 per QALY. The model remained robust to changes to the treatment discontinuation rate and the
model time horizon.
TABLE 78 Time horizon changed to 20 years (SA4): cost per QALY
Strategy
Cost (£) QALYs
ICER (£)Mean Incremental Mean Incremental
BSC 196,900 – 6.644 – –
GA 20mg SC once daily (Copaxone) 220,900 24,000 7.436 0.792 Extendedly
dominated
PegIFN-β-1a 125 µg SC every 2 weeks (Plegridy) 225,800 28,900 8.007 1.363 21,200
IFN-β-1a 30 µg IM once weekly (Avonex) 242,900 17,100 7.570 –0.437 Dominated
IFN-β-1a 44 µg SC three times a week (Rebif) 245,200 19,400 7.882 –0.125 Dominated
TABLE 79 Time horizon changed to 30 years (SA4): cost per QALY
Strategy
Cost (£) QALYs
ICER (£)Mean Incremental Mean Incremental
BSC 279,400 – 7.774 – –
GA 20mg SC once daily (Copaxone) 299,400 20,000 8.874 1.1 Extendedly
dominated
PegIFN-β-1a 125 µg SC every 2 weeks (Plegridy) 300,400 21000 9.756 1.982 10,600
IFN-β-1a 44 µg SC three times a week (Rebif) 322,900 22500 9.532 –0.224 Dominated
IFN-β-1a 30 µg IM once weekly (Avonex) 323,300 22,900 9.103 –0.653 Dominated
TABLE 77 Hazard ratios from manufacturer submissions (SA3): cost per QALY
Strategy
Cost (£) QALYs
ICER (£)Mean Incremental Mean Incremental
BSC 362,100 – 8.664 – –
PegIFN-β-1a 125 µg SC every 2 weeks (Plegridy) 366,300 4200 9.931 1.267 3300
GA 40mg SC three times weekly (Copaxone) 374,600 8300 9.821 –0.11 Dominated
IFN-β-1a 30 µg IM once weekly (Avonex) 387,600 21,300 9.563 –0.368 Dominated
IFN-β-1a 44 µg SC three times a week (Rebif) 412,900 46,600 9.719 –0.212 Dominated
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In Figure 26 we show the impact on the model estimated in SA1 of varying key model input parameters. In SA1,
model input parameters were based on pooled estimates of treatment effectiveness for on-scheme DMTs. To
determine the robustness of these results we varied the HR for disability progression, the RR for ARRs, the cost of
DMTs, the annual discontinuation rate and the model time horizon. The results show that the model was
sensitive to changes in the cost of DMTs. An increase of 10% in the cost of DMTs led to an increase in the ICER
of 41%. A decrease of 10% in the cost of DMTs led to a decrease in the ICER of approximately 42%. The results
remained robust to changes made to the ARR, the model time horizon and the annual discontinuation rate.
Probabilistic sensitivity analysis conducted on the base case
Table 80 presents the results of the probabilistic sensitivity analysis conducted on the base case, that is,
when the RSS data were used to estimate the HR for disability progression and the RR for ARRs. These
results show that the DMT strategy was more costly and more effective than BSC, with an ICER of
approximately £34,000 per QALY.
Figure 27 shows the cost-effectiveness plane for the results from the 1000 simulations from the
probabilistic sensitivity analysis conducted on the base case and Figure 28 shows the proportion of these
simulations at various willingness-to-pay thresholds in the form of a cost-effectiveness acceptability curve.
0 5 10 15 20 25 30
Time horizon
Discontinuation of treatment
RR for ARR
Cost of DMTs
HR for disability progression
ICER (£000)
FIGURE 26 Tornado diagram for DMTs compared with BSC: SA1.
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RR for ARR
Cost of DMTs
HR for disability progression
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FIGURE 25 Tornado diagram for DMTs compared with BSC: base case.
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FIGURE 27 Cost-effectiveness plane: probabilistic sensitivity analysis conducted on the base case.
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FIGURE 28 Cost-effectiveness acceptability curve: probabilistic sensitivity analysis conducted on the base case.
WTP, willingness to pay.
TABLE 80 Findings from the probabilistic sensitivity analysis conducted on the base case
Strategy
Cost (£) QALYs
ICER (£)Mean Incremental Mean Incremental
BSC 363,600 – 8.64 – –
DMTs 395,200 31,600 9.57 0.93 34,000
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The cost-effectiveness plane shows that all of the simulations are in the north-east quadrant, where DMTs
are more effective and more costly than BSC. We believe that the HR for disability progression is likely to
be one of the key drivers of the economic model. The results from the cost-effectiveness acceptability
curve show that, at a willingness-to-pay threshold of £30,000 per QALY, DMTs have a probability of being
cost-effective of 0.23 compared with BSC.
Probabilistic sensitivity analysis conducted on SA1
Table 81 presents the results of the probabilistic sensitivity analysis when the findings from the assessment
group review were used to estimate the pooled HR for disability progression and the pooled RR for ARRs.
The ICER for DMTs compared with BSC was approximately £10,100 per QALY.
The results of the simulations are presented on a cost-effectiveness plane in Figure 29. Figure 30 provides
the cost-effectiveness acceptability curve. The results from the 1000 simulations show that a substantial
number of points are in the north-east quadrant. Importantly, a significant number of simulations are in
the south-east quadrant, where DMTs could be considered more effective and less costly than BSC. The
cost-effectiveness acceptability curve shows that, at a willingness-to-pay threshold of £30,000 per QALY,
DMTs have a probability of being cost-effective of 0.84 compared with BSC.
Through visual inspection of the cost-effectiveness plane, it appears that the incremental cost of providing
DMTs is correlated with the incremental effects of receiving treatment. We undertook further model
simulations (not presented here) in which we kept the HR for disability progression constant and varied
other parameters. This resulted in the majority of the plots concentrated in the north-east quadrant, with
no correlation seen. This finding, in addition to the findings presented in Figures 29 and 30, highlights the
fact that the HR for disability progression is likely to be one of the key drivers in the economic model.
The more effective DMTs are at slowing disease progression, the more likely they are to be cost-effective.
–100
–80
–60
–40
–20
0
20
40
60
80
0 1 2 3 4 5 6 7 8
In
cr
em
en
ta
l c
o
st
s 
(£
00
0)
Incremental QALYs
FIGURE 29 Cost-effectiveness plane: probabilistic sensitivity analysis conducted on SA1.
TABLE 81 Findings from the probabilistic sensitivity analysis conducted on SA1
Strategy
Cost (£) QALYs
ICER (£)Mean Incremental Mean Incremental
BSC 363,500 – 8.635 – –
DMTs 383,100 19,600 10.573 1.938 10,100
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Discussion of the economic assessment of disease modifying treatments
for relapsing–remitting multiple sclerosis
Summary of the results
In this chapter we describe a variety of sensitivity analyses that were carried out to address our concerns
with the RSS model. In the base case we drew on the RSS model and made a number of changes
relating to mortality and carers’ disutilities. Additionally, we undertook probabilistic sensitivity analyses to
incorporate uncertainty around key model input parameters. The deterministic results showed that DMT
was more costly and more effective than BSC, with an ICER of approximately £33,800 per QALY. The
probabilistic sensitivity analysis results, using the RSS data to estimate the parameters for treatment
effectiveness, showed that DMT had a probability of 0.23 of being cost-effective compared with BSC
at a willingness-to-pay threshold of £30,000 per QALY. Even at higher willingness-to-pay thresholds
(e.g. £50,000 per QALY), the probability of DMTs being cost-effective did not reach 1.
We undertook a number of further sensitivity analyses in which we used HRs for disability progression and
RRs for ARRs derived from our NMAs. The deterministic results showed that DMT had an ICER of
approximately £12,800 per QALY compared with BSC. The probabilistic results, using the assessment
group data, showed that, compared with BSC, DMT had a probability of 0.84 of being cost-effective at a
willingness-to-pay threshold of £30,000 per QALY.
Strengths and limitations
There were several strengths to our analyses. First, we assessed the RSS model in detail and undertook a
number of sensitivity analyses, including probabilistic sensitivity analyses, to explore our concerns with the
model. Second, we drew on rigorous evidence to carry out a comprehensive set of sensitivity analyses
and used probabilistic sensitivity analyses to explore uncertainty. We were able to use clinical inputs from
our own rigorous systematic review of the clinical effectiveness evidence, including our NMAs, for key
treatment effectiveness parameters. This enabled us to compare the implications of different estimates of
treatment effectiveness, including the RSS model estimates, the pooled on-scheme DMT effect sizes from
our clinical effectiveness review, effect sizes for individual DMTs from the NMAs contained in our clinical
effectiveness review and effectiveness estimates supplied in the manufacturers’ submissions.
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FIGURE 30 Cost-effectiveness acceptability curve: probabilistic sensitivity analysis conducted on SA1.
WTP, willingness to pay.
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However, there were also limitations to our analyses. When CIs for input parameters were not provided for
probabilistic sensitivity analyses, we had to apply commonly used approaches to model uncertainty. The
effect of these strategies may be to incorrectly estimate the uncertainty around input parameters and thus
overestimate or underestimate the probability of DMTs being cost-effective at given willingness-to-pay
thresholds. We were unable to include uncertainty around parameters for the natural history cohort used
as a comparator in the RSS model.
Moreover, any cost-effectiveness analyses undertaken using the estimates from our clinical effectiveness
review propagate the major weaknesses identified with that evidence, including the sparse networks of
evidence, the generally short-term follow-up times used and the differential risk of bias across comparisons.
In particular, some estimates of intervention effectiveness relied on few studies; our assessment of 125 µg
of SC pegIFN-β-1a every 2 weeks (Plegridy), relied on one trial with 1 year of follow-up connected to
evidence networks through the placebo arm only.
Finally, we chose as our base case the RSS model, which draws on observational evidence from a
non-contemporaneous, historical cohort. However, we believe that the long-term follow-up, relevance to
the NHS and to current clinical practice and the rigorous methods used to collect and report data made it
the best choice as the base case. In contrast, the evidence derived from the clinical effectiveness review
had serious limitations, discussed in the conclusion to Chapter 5. These limitations led us to believe, on
balance, that the RSS model was a better choice for the base case.
Conclusions of the cost-effectiveness analysis
Based on the model and its inputs, the results of the base case, which draws on the evidence from the
RSS, suggest that, compared with BSC, DMT has a probability of 0.23 of being cost-effective at a
willingness-to-pay threshold of £30,000 per QALY gained. The results from our pooled analysis of RCTs
suggest a probability of 0.84 of DMT being cost-effective compared with BSC at a willingness-to-pay
threshold of £30,000 per QALY gained. The impact of DMTs on disability progression was found to be a
key driver of cost-effectiveness. Previously we have highlighted the differences between estimates of
effectiveness of DMTs derived from the RSS data and those derived from the NMA of clinical trials. The
cost-effectiveness analysis in this section highlights how these differences in clinical effectiveness translate
into apparent differences in conclusions related to cost-effectiveness. However, any analyses undertaken
on data from our review of clinical effectiveness propagate the weaknesses in that evidence, including the
short-term follow-up times used and the sparse number of data for each comparison.
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Chapter 12 Health economic assessment: clinically
isolated syndrome
Health economics methods
Objective
Our objective was to undertake a cost-effectiveness analysis to estimate the incremental cost per QALY
gained from providing DMTs to patients with CIS. We developed a decision-analytic modelling framework,
which used longitudinal data from natural history cohorts and RCTs to provide information on progression
from CIS to RRMS. The modelling framework was informed by literature searches on model-based
economic evaluations of interventions used to treat people with CIS and longitudinal studies that
tracked the progression/conversion of CIS to RRMS. The objective of the model was to estimate the
cost-effectiveness of DMTs within their marketing authorisation for people with CIS. In the model,
the results are presented in terms of cost per QALY gained.
Developing the model structure
To assess the cost-effectiveness of DMTs for treating CIS, we developed a de novo economic model using
TreeAge Pro 2013 software (TreeAge Software, Inc., Williamstown, MA, USA).
The model represents, as far as possible, the clinical pathways that people would take while receiving
treatment for CIS. Figure 31 shows an illustrative model structure. The model was structured in two stages:
(1) treatment of people with CIS and further progression to RRMS and (2) disease progression while in the
RRMS health state. In the model we compared six strategies:
1. BSC for people with CIS and RRMS
2. BSC for people with CIS and DMTs for people converting to RRMS
3. treatment with 30 µg of IM IFN-β-1a once weekly (Avonex) for people with CIS, continuing on DMTs
after converting to RRMS
4. treatment with 250 µg of SC IFN-β-1b every other day (Betaferon/Extavia) for people with CIS,
continuing on DMTs after converting to RRMS
Dead
CIS and on
treatment 
CIS and
discontinued
treatment
RRMS as seen
in the RSS model
FIGURE 31 Illustrative model structure.
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5. treatment with 44 µg of SC IFN-β-1a three times weekly (Rebif) for people with CIS, continuing on
DMTs after converting to RRMS
6. treatment with 20 mg of SC GA once daily (Copaxone) for people with CIS, continuing on DMTs after
converting to RRMS.
Overview of strategies
An overview of how these strategies relate to the decision-analytic model is provided in Figure 32.
Best supportive care arm for clinically isolated syndrome and relapsing–remitting
multiple sclerosis
In this strategy, people receive BSC as treatment for CIS. People who are alive can remain in this health
state or progress to RRMS. People who progress to the RRMS health state are assumed to follow the
pathway for people in the natural history cohort of the RSS model.
Best supportive care for clinically isolated syndrome and disease-modifying therapies for
people with relapsing–remitting multiple sclerosis
In this strategy, people receive BSC as treatment for CIS. People who are alive can remain in this health
state or progress to RRMS. People who progress to the RRMS health state are assumed to follow the
pathway for people in the DMT arm of the RSS model.
Disease-modifying therapy for clinically isolated syndrome and relapsing–remitting
multiple sclerosis
People in this strategy receive a DMT for CIS. People can continue receiving treatment or discontinue
treatment. People who continue treatment can remain in this health state or progress to the RRMS health
state. People who convert to RRMS are assumed to follow the pathway for people in the DMT arm of the
RSS model. People who discontinue CIS treatment can remain in this health state while receiving BSC or
can convert to RRMS. We assumed that people who convert to RRMS follow the pathway for people in the
DMT arm of the RSS model. The pathway for people in the DMT arm of the RSS model reflects the pooled
estimates for all DMTs in the RSS model (e.g. drug acquisition costs) and consequently takes into account
that, although patients with CIS may discontinue the modelled DMT, when they progress to RRMS they
may be started on an alternative DMT. The pathways for all DMTs for CIS being compared in the model
are the same.
Model assumptions
A number of assumptions were required to undertake these analyses:
1. Starting population: people aged 30 years and with CIS, that is, who had experienced a clinically
diagnosed, single demyelinating event in one or several areas of the CNS within the last 2 months and
with no evidence of RRMS on a MRI scan.
2. People who have converted to RRMS have no residual treatment benefit based on previous treatment in
the CIS health state.
3. People who have converted to RRMS are assumed to follow the same pathway as people in the
RSS model.
4. Patients with CIS who discontinue a DMT (e.g. because of AEs) will be started on an alternative DMT
once they progress to RRMS. The risk of patients with RRMS discontinuing a DMT is not dependent on
whether they had discontinued a DMT while they had CIS.
Data required for the model
The model was populated with information identified from the clinical effectiveness and cost-effectiveness
review and supplemented with information from secondary sources. Information required to parameterise
the model included transition probabilities, resource use and costs and utilities. These are discussed in turn
in the following sections.
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Transition probabilities and proportions
Information was required on the risk of disease progression from CIS to RRMS, for an untreated cohort
and for a treated cohort of people with CIS. For the untreated cohort, progression rates could be derived
from a natural history cohort, a patient registry or from CIS patients registered on the placebo arm of a
trial. In the base case for the BSC arm, we identified one study295 based on a literature review that provided
useful information on time to progression to RRMS for people diagnosed with CIS with no asymptomatic
lesions on MRI. We reconstructed the Kaplan–Meier survival curve of time from first attack to conversion to
RRMS based on baseline MRI (no asymptomatic lesion) and then fitted various parametric models to these
data. According to the Akaike information criterion and Bayesian information criterion, we found that the
Weibull and log-logistic models provided the best fits to the Kerbrat et al.295 data. Figure 33 shows the
reconstructed Kaplan–Meier curve with the Weibull parametric model. From this, annual transition
probabilities generated by the Weibull model were used for the BSC arm. To derive the transition probabilities
for conversion to RRMS for the treatment arms, we applied the HRs derived from our clinical review. Table 82
shows the estimates used to derive transition probabilities for conversion to RRMS in the model.
Proportion of people discontinuing disease-modifying therapy
We included the annual proportion of people who discontinued DMTs as a result of AEs in the model.
These proportions were derived from the CIS and RRMS studies included in our clinical review. Studies
reported the instantaneous rate of people who discontinued treatment as a result of AEs. We converted
this to an annual probability using the equation [probability = 1 – exp(–rt)], where r is rate and t is time.
When discontinuation rates were not available from CIS studies, we used studies that followed up people
with RRMS and assumed that the discontinuation rates would be applicable to those with CIS. Table 83
shows the proportions obtained from the studies and the annual probability of discontinuation for each
DMT used in the base-case analysis.
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FIGURE 33 Reconstructed Kaplan–Meier survival curve and Weibull model for time to conversion to RRMS on BSC
by annual cycles. Source: Kerbrat et al.295
HEALTH ECONOMIC ASSESSMENT: CLINICALLY ISOLATED SYNDROME
NIHR Journals Library www.journalslibrary.nihr.ac.uk
210
Resource use and costs
The resource use and costs utilised were those directly incurred by the NHS and PSS. Resource use and
costs were required for DMTs, drug administration and monitoring and CIS with no treatment. Unit costs
are presented in Table 84 and resource use estimates used to derive costs are provided in Appendix 9.
The costs of DMT were obtained from the BNF.21 The annual cost of £8502 for treatment with IFN-β-1a
(Avonex) was based on a dosage of 30 µg once a week. The annual cost of £10,572 for treatment with
IFN-β-1a (Rebif) was based on a dosage of 44 µg three times per week. We derived annual costs of £7264
and £6704 for treatment with 250 µg of SC IFN-β-1b every other day (Betaferon/Extavia) and 20 mg of SC
GA daily (Copaxone) respectively.
The costs of monitoring were derived based on clinical expert opinion for resource use, which was valued
using NHS reference costs285 and information from Curtis and Burns.278 Monitoring costs were derived for
initiating treatment and for subsequent monitoring. We derived a cost of £553.20 for monitoring those
who received treatment with 30 µg of IM IFN-β-1a once a week (Avonex), 250 µg of SC IFN-β-1b every
other day (Betaferon/Extavia) and 20 mg of SC GA daily (Copaxone) during the first year of commencing
treatment. We assumed that patients required visits to a neurologist and a MS nurse and received a series
of blood tests and a MRI scan. For those who commenced treatment with 44 µg of SC IFN-β-1a three
times per week (Rebif), we derived a cost of £560.33. This included the costs of the same resources used
in the monitoring of other DMTs plus the cost of a thyroid function test. For subsequent monitoring, we
derived a cost of £323.77 for all DMTs. For this we assumed that patients required visits to a neurologist
and a MS nurse and received an annual MRI scan.
TABLE 82 Values used for progression from CIS to RRMS
Treatment Base-case value HR (95% CI)
BSC Weibull (λ = 0.0906; γ = 0.6768) –
IFN-β-1a 30 µg IM once a week (Avonex) 0.516 (0.389 to 0.684)
IFN-β-1a 44 µg SC three times per week (Rebif) 0.480 (0.314 to 0.738)
IFN-β-1b 250 µg every other day (Betaferon/Extavia) 0.500 (0.36 to 0.699)
GA 20mg SC once daily (Copaxone) 0.549 (0.397 to 0.762)
Note
Source: Kerbrat et al.295 – reconstructed individual patient data and Weibull model was a good parametric fit; applied HRs
derived from the clinical effectiveness review.
TABLE 83 Proportion of people discontinuing treatment following AEs
Parameter
Type
of MS
Cumulative
hazard (%)
Length of
trial (years)
Annual
probability Reference
IFN-β-1a 30 µg IM once a week (Avonex) RRMS 4.4 2 0.0222 Derived from
Jacobs et al.172
IFN-β-1a 44 µg SC three times per week
(Rebif)
RRMS 6.0 1.85 0.0330 Derived from
Mikol et al.192
IFN-β-1b 250 µg every other day
(Betaferon/Extavia)
CIS 8.2 2 0.0419 Derived from
Kappos et al.171
GA 20mg SC once daily (Copaxone) CIS 5.8 3 0.0197 Derived from
Comi et al.174
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We calculated an annual cost of drug administration of £225. For this we assumed that a specialist nurse
(community), employed at band 6 on the NHS Agenda for Change scale (£75 per hour of patient-related
work), would spend 3 hours of contact time teaching patients how to self-administer DMTs.
Utility values
Health outcomes were measured in QALYs. In the model, we assigned the same utility values to all the
CIS health states. For this we have derived a weighted utility value based on two pooled utility values by
EDSS health states (MS Trust survey 2002 and 2005) and weighted by the proportion of individuals at
each EDSS health state observed on entry to the RSS cohort. The disutility associated with AEs from DMTs
was based on the estimates from Tappenden et al.275 This was the approach used in the cost-effectiveness
analysis of DMTs in RRMS. Table 85 shows the utility values used in the model.
Cost-effectiveness analysis
A Markov model was constructed and programmed to choose the base-case model inputs to assess
the cost-effectiveness of various DMTs for the management of people with CIS. The model estimated
the mean costs and health benefits associated with each DMT and assumed that the starting age of the
population was 30 years. The analysis was undertaken from a NHS and PSS perspective and outcomes
were reported as ICERs, expressed in terms of cost per QALY gained. All costs and outcomes were
discounted at 3.5% per annum.
TABLE 84 Unit costs required for the CIS model
Parameter
Base-case value
(£, 2015 prices) Source
DMTs
IFN-β-1a 30 µg IM once a week (Avonex) 8502 BNF21
IFN-β-1a 44 µg SC three times per week (Rebif) 10,572 BNF21
IFN-β-1b 250 µg every other day (Betaferon/Extavia) 7264 BNF21
GA 20mg SC once daily (Copaxone) 6704 BNF21
Monitoring costs
IFN-β-1a 30 µg IM once a week (Avonex) 553.20 Estimates of resource use obtained from
clinical expert (see Appendix 9) and unit costs
obtained from the BNF,21 NHS reference costs
2014/15285 and Curtis and Burns278
IFN-β-1a 44 µg SC three times per week (Rebif) 560.33
IFN-β-1b 250 µg every other day (Betaferon/Extavia) 553.20
GA 20mg SC once daily (Copaxone) 553.20
Cost of subsequent monitoring 323.77
Other costs
Drug administration 225.00 Assumption with regard to resource use
information and unit costs from Curtis and
Burns278
Health state costs
CIS no treatment 350.49 Assumption with regard to resource use
information and unit costs from Curtis and
Burns278 and NHS reference costs 2014/15285
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Sensitivity analyses
Deterministic sensitivity analyses were undertaken for the base-case results for the cost per QALY
outcome measures:
l SA1 – changing the time horizon to 20 years and 30 years
l SA2 – assuming that 5% of people with CIS would discontinue treatment with DMTs.
In addition, we assessed the impact of varying key model input parameters on our base-case results.
Results of the cost-effectiveness analysis
Base-case cost-effectiveness analysis
In the base-case analysis, providing BSC for people with CIS and continuing BSC on conversion to RRMS was
the least costly strategy, with a mean cost of approximately £136,800, and the least effective strategy, with a
mean of 12.78 QALYs gained (Table 86). The strategy in which people with CIS receive treatment with 20mg
of SC GA daily (Copaxone) and then receive a DMT when they convert to RRMS dominated the 30 µg of IM
IFN-β-1a once weekly (Avonex) and 44 µg of SC IFN-β-1a three times weekly (Rebif) treatment strategies.
Excluding all dominated and extendedly dominated strategies, the optimal strategy was treatment with 20mg
of SC GA daily (Copaxone) for CIS followed by a DMT for those with progression to RRMS. In comparison to
BSC, providing 20mg of SC GA once daily (Copaxone) for patients with CIS and then a DMT on progression
to RRMS was associated with an ICER of £16,500 per QALY gained.
TABLE 85 Utility values used in the CIS model
Parameter Base-case value Source
Health state utility value
CIS 0.6218 Assumption
Disutility associated with AEs
IFN-β-1a 30 µg IM once a week (Avonex) –0.02 Tappenden et al.275
IFN-β-1a 44 µg SC three times per week (Rebif) –0.02 Tappenden et al.275
IFN-β-1b 250 µg every other day (Betaferon/Extavia) –0.02 Tappenden et al.275
GA 20mg SC once daily (Copaxone) –0.02 Tappenden et al.275
TABLE 86 Base-case results: cost per QALY
Strategy
Cost (£) QALYs
ICER (£)Mean Incremental Mean Incremental
BSC for CIS and RRMS 136,800 – 12.78 – –
BSC for CIS and DMTs for RRMS 176,400 39,600 13.16 0.38 Extendedly
dominated
IFN-β-1b 250 µg SC every other day
(Betaferon/Extavia) for CIS and DMTs for RRMS
216,800 80,000 16.85 3.69 Extendedly
dominated
GA 20mg SC once daily (Copaxone) for CIS
and DMTs for RRMS
235,200 98,400 18.73 5.95 16,500
IFN-β-1a 30 µg IM once a week (Avonex) for
CIS and DMTs for RRMS
252,100 16,900 18.57 –0.16 Dominated
IFN-β-1a 44 µg SC three times per week (Rebif)
for CIS and DMTs for RRMS
260,300 25,100 17.61 –1.12 Dominated
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SA1: Changing the time horizon to 20 years and 30 years
Tables 87 and 88 show the findings when the model was run over time horizons of 20 years and 30 years
respectively. Over these shorter time horizons, treatment of CIS with 20 mg of SC GA daily (Copaxone)
and then a DMT for those who progress to RRMS remained cost-effective, and the 30 µg of IM IFN-β-1a
weekly (Avonex) and 44 µg of SC IFN-β-1a (Rebif) treatment strategies continued to be dominated by the
20 mg of SC GA daily (Copaxone) strategy.
SA2: Assuming that 5% of people with clinically isolated syndrome discontinue
treatment with disease-modifying therapies
Table 89 shows the findings when we assumed that approximately 5% of those treated with DMTs for CIS
discontinue treatment every year. In this scenario, the 250 µg of SC IFN-β-1b every other day (Betaferon/
Extavia) treatment strategy was cost-effective, with an ICER of £20,900 per QALY. Treatment with 20 mg
of SC GA daily (Copaxone) followed by a DMT for those progressing to RRMS remained cost-effective.
The 30 µg of IM IFN-β-1a weekly (Avonex) treatment strategy continued to be dominated and the 44 µg of
SC IFN-β-1a three times weekly (Rebif) treatment strategy was associated with an extremely high ICER.
TABLE 88 Changing the time horizon to 30 years (SA1): cost per QALY
Strategy
Cost (£) QALYs
ICER (£)Mean Incremental Mean Incremental
BSC for CIS and RRMS 173,100 – 12.02 – –
BSC for CIS and DMTs for RRMS 197,100 24,000 12.46 0.44 Extendedly
dominated
IFN-β-1b 250 µg SC every other day
(Betaferon/Extavia) for CIS and DMTs for RRMS
220,600 47,500 14.89 2.87 Extendedly
dominated
GA 20mg SC once daily (Copaxone) for CIS and
DMTs for RRMS
234,700 61,600 15.88 3.86 16,000
IFN-β-1a 30 µg IM once a week (Avonex) for CIS
and DMTs for RRMS
249,800 15,100 15.78 –0.10 Dominated
IFN-β-1a 44 µg SC three times per week (Rebif)
for CIS and DMTs for RRMS
259,300 24,600 15.28 –0.60 Dominated
TABLE 87 Changing the time horizon to 20 years (SA1): cost per QALY
Strategy
Cost (£) QALYs
ICER (£)Mean Incremental Mean Incremental
BSC for CIS and RRMS 155,100 – 10.33 – –
BSC for CIS and DMTs for RRMS 166,400 21,600 10.73 0.40 Extendedly
dominated
IFN-β-1b 250 µg SC every other day
(Betaferon/Extavia) for CIS and DMTs for RRMS
181,600 33,600 11.99 1.66 Extendedly
dominated
GA 20mg SC once daily (Copaxone) for CIS and
DMTs for RRMS
190,400 42,700 12.46 2.13 20,000
IFN-β-1a 30 µg IM once a week (Avonex) for CIS
and DMTs for RRMS
204,100 13,400 12.39 –0.07 Dominated
IFN-β-1a 44 µg SC three times per week (Rebif)
for CIS and DMTs for RRMS
215,000 24,000 12.15 –0.31 Dominated
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In Figure 34 we present graphically the impact of varying key model input parameters on the cost-effectiveness
results. To determine the robustness of the results, we varied the utility value for the CIS health state and the
probability of treatment discontinuation, as well as the mode of drug administration, the disutility associated
with AEs and the annual cost of BSC. The results show that the model was most sensitive to a ±10% change in
the utility of the CIS health state. A 10% increase in the health state utility of CIS would give a value of 0.6898.
However, this would still give an ICER for 20mg of SC GA daily (Copaxone) compared with BSC of £18,600,
well within the normal expected levels of willingness to pay.
Discussion of the economic assessment of disease-modifying therapies
for clinically isolated syndrome
Summary of the results
Having estimated the treatment effect of each DMT on conversion to RRMS, we then assessed the
cost-effectiveness of DMTs in people who were diagnosed with CIS in the absence of evidence for RRMS on
a MRI scan. We developed a decision-analytic model, taking the NHS and PSS perspective, and presented
outcomes in terms of cost per QALY gained. We considered six strategies in our analysis, which included
treatment with BSC in addition to the DMTs available for people with CIS. The base-case deterministic
TABLE 89 Assuming that 5% of people with CIS discontinue treatment with DMTs (SA2): cost per QALY
Strategy
Cost (£) QALYs
ICER (£)Mean Incremental Mean Incremental
BSC for CIS and RRMS 136,800 – 12.78 – –
BSC for CIS and DMTs for RRMS 176,400 39,600 13.16 0.38 Extendedly
dominated
GA 20mg SC once daily (Copaxone) for CIS and
DMTs for RRMS
209,800 73,000 16.22 3.44 Extendedly
dominated
IFN-β-1b 250 µg SC every other day
(Betaferon/Extavia) for CIS and DMTs for RRMS
211,500 74,700 16.36 3.58 20,900
IFN-β-1a 30 µg IM once a week (Avonex) for CIS
and DMTs for RRMS
224,700 13,200 16.31 –0.05 Dominated
IFN-β-1a 44 µg SC three times per week (Rebif)
for CIS and DMTs for RRMS
242,300 30,800 16.41 0.05 616,000
10 11 12 13 14 15 16 17 18 19 20
Mode of drug administration
Annual cost of BSC
Disutility associated with AEs
Probability of discontinuing treatment
Utility value for CIS health state
ICER (£000)
FIGURE 34 Tornado diagram for 20mg of SC GA daily compared with BSC.
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results showed that treating people with 20 mg of SC GA daily (Copaxone) followed by a DMT on
conversion to RRMS dominated the 30 µg of IM IFN-β-1a once a week (Avonex) and 44 µg of SC IFN-β-1a
three times per week (Rebif) treatment strategies. We found that the 250 µg of SC IFN-β-1b every other day
(Betaferon/Extavia) treatment strategy was extendedly dominated and, although it was cost-effective in
comparison to BSC, the ICER was higher than that for the 20 mg of SC GA once daily (Copaxone) treatment
strategy. Excluding all dominated strategies, the ICER for 20 mg of SC GA once daily (Copaxone) for
patients with CIS and then a DMT on progression to RRMS was approximately £16,500 per QALY gained.
The sensitivity analysis showed that treatment of CIS with 250 µg of SC IFN-β-1b every other day (Betaferon/
Extavia) followed by a DMT on progression to RRMS would also be a cost-effective option if discontinuation
rates for all of the drug treatments were comparable. The sensitivity analysis did not suggest that the 30 µg
of IM IFN-β-1a once a week (Avonex) treatment strategy or the 44 µg of SC IFN-β-1a three times per week
(Rebif) treatment strategy was a cost-effective option in the UK. The results further showed that the
model is likely to be sensitive to the utility associated with the CIS health state and to the treatment
discontinuation rate while in the CIS state.
Strengths and limitations
Our analysis had several strengths. We built a de novo model for CIS and we were able to incorporate
evidence from our systematic review of clinical effectiveness. We also incorporated long-term costs and
consequences of progressing to, and receiving DMTs for, RRMS. We also used evidence from the RSS
observational cohort to model the effect of conversion to RRMS.
However, our analysis was limited in several important ways. We did not undertake probabilistic sensitivity
analysis. Moreover, because of the paucity of HRQoL information in people with CIS, we assumed CIS to
be comparable to early-phase RRMS. However, we investigated the effect of varying this input parameter
by ±10% on the cost-effectiveness results and found that the ICERs were still well within the expected
levels of willingness to pay. Finally, our findings from the clinical effectiveness review relied on a
population diagnosed with CIS before the revised 2010 McDonald criteria54 reclassified many who
would have previously been classified as having CIS as in fact having RRMS.
Conclusions
Our cost-effectiveness findings suggest that, in people with CIS, it would be cost-effective to start DMTs.
We found that, of the evaluated DMTs, 20 mg of SC GA daily (Copaxone) was the optimal choice. Greater
understanding around discontinuation rates of DMTs in CIS patients would be valuable, as these may
impact on whether or not 250 µg of SC IFN-β-1b every other day (Betaferon/Extavia) is also a cost-effective
option. The results are presented in the light of some limitations/uncertainty, mainly around the utility
values for the CIS health state and disutilities associated with AEs. Our analyses drew on utility values
obtained from people with RRMS and, because of the complexity of the modelling approach and lack of
data, we were unable to quantify this uncertainty by undertaking probabilistic sensitivity analysis. Until more
reliable information on utility values becomes available, these results should be interpreted with caution.
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Chapter 13 Discussion
Summary
Clinical effectiveness
We systematically reviewed and synthesised the evidence relating to the effectiveness of IFNs and GA
within their marketing authorisations for CIS, RRMS and SPMS. We exhaustively searched databases to
update previous high-quality reviews for each of these MS types and used standard systematic review
methodology to select, appraise and extract data from relevant studies. Our search identified 35 primary
studies: five in CIS, 27 in RRMS, of which 24 reported clinical effectiveness outcomes of interest, and three
in SPMS. We synthesised the findings from these trials narratively and, when appropriate, using pairwise
meta-analyses and NMAs. Across MS types, studies were variable in quality. Most studies were sponsored
by the manufacturers of the DMTs. We also judged that many studies were at high risk of unblinding of
participants and personnel because of injection site reactions, with potential implications for the blinding
of outcome assessors. Many trials, especially of head-to-head comparisons, were open-label trials.
The clinical effectiveness evidence suggested that IFNs and GA were effective for key outcomes and across
MS types and there was little evidence from the NMAs that any one drug was superior to any other for
different clinical outcomes. In CIS, each drug included showed evidence of delaying time to CDMS. In
RRMS, drugs showed good evidence of reducing the relapse rate, including the rate of moderate or severe
relapses and, in most cases, the rate of steroid-treated relapses. Most drugs delayed disability progression
confirmed at 3 months, although the findings were less consistent for disability progression confirmed at
6 months. Finally, in SPMS, all drugs reduced the relapse rate, although the network was sparse and relied
on three studies. Time to confirmed disability progression at 3 months was measured in only two studies,
which showed variable effects across treatments. We undertook analyses of discontinuation following AEs
in RRMS and SPMS. These analyses, which were intended to be indicative, did not offer evidence that one
drug was more likely than any other to result in discontinuation following an AE.
We synthesised the findings for additional outcomes in the scope141 (MS symptoms, HRQoL and freedom
from disease activity) narratively but were unable to undertake meta-analyses because of heterogeneity,
sparsity of data and poor reporting for these outcomes. The findings suggested a generally beneficial
effect of DMTs on freedom from disease activity, but findings for MS symptoms and HRQoL were poorly
reported and inconsistent. Additionally, no studies reported discontinuation because of loss of effect
attributed to NABs.
Cost-effectiveness
As part of our assessment of cost-effectiveness, we undertook four related work packages. First, we
systematically reviewed, appraised and synthesised the recent cost-effectiveness evidence on DMTs for people
with CIS and MS. Second, we critically appraised the year 10 RSS economic model, including checking the
model and reviewing inputs to and assumptions made in the model. Third, we assessed the cost-effectiveness
of DMTs for the treatment of RRMS. Fourth, we assessed the cost-effectiveness of DMTs for the treatment of
CIS. We assessed cost-effectiveness using a modified RSS model, with clinical effectiveness inputs in the base
case derived from the year 10 RSS analyses. We conducted several additional analyses: (1) using pooled
estimates of the effectiveness of on-scheme DMTs from our systematic review of clinical effectiveness,
(2) using estimates of the effectiveness of each DMT from our systematic review of clinical effectiveness
and (3) using estimates of the effectiveness of each DMT from manufacturer submissions.
We identified 10 studies in RRMS and nine studies in CIS that reported evidence on a decision model used
to estimate the cost-effectiveness of DMTs. In general, most studies used appropriate model structures to
capture/simulate disease progression. According to best practice for reporting cost-effectiveness analyses,
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all studies performed satisfactorily in terms of outlining the decision problem, stating the perspective of the
analysis, adhering to the scope of the model and outlining the structural assumptions. However, there
were some limitations of these studies. First, we consider the time horizon to be short in some studies and
these analyses may not have captured the full costs and benefits of DMTs. Second, the choice of model
structure in several studies did not accurately reflect disability progression associated with MS. Third, the
authors did not provide sufficient details on the meta-analytical methods used to estimate the treatment
effects of DMTs or sufficient details on how treatment effects had been extrapolated beyond the trial
time horizons.
We considered the RSS model to be appropriate for estimating the cost-effectiveness of DMTs compared
with BSC. The model drew on the best available evidence on disease progression, resource use and costs
and utility values. However, our appraisal highlighted concerns with the RSS model relating to mortality,
carers’ disutilities, discontinuation rates and how the ARR was estimated.
In our base-case assessment of the cost-effectiveness of DMTs for RRMS, our results suggested that it is
not cost-effective to treat people who have RRMS with DMTs. Using as our base case the RSS model with
modifications made to the assumptions relating to mortality and carers’ disutilities, we found that DMTs
were more costly and more effective than BSC, with an ICER of approximately £33,800 per QALY gained.
We also used pooled estimates derived from our clinical effectiveness review for all on-scheme DMTs,
which showed that, although DMTs were more costly than BSC, they also produced more QALYs, with an
ICER of approximately £12,800 per QALY gained. When we compared each DMT, 125 µg of SC pegIFN-β-1a
every 2 weeks (Plegridy) appeared to be the most cost-effective treatment, but clinical effectiveness estimates
for this drug were based on one trial with 1 year of follow-up. Results from the probabilistic sensitivity
analysis conducted on the RSS data showed that, at a willingness-to-pay threshold of £30,000 per QALY
gained, DMTs had a probability of being cost-effective of 0.23.
We also assessed the cost-effectiveness of DMTs for CIS. Our base-case analysis suggested that treatment
with 20mg of SC GA daily (Copaxone) followed by a DMT on progression to RRMS was cost-effective relative
to BSC, with an ICER of £16,500 per QALY gained, and dominated all other strategies in the base case.
Strengths and limitations
Study searches, inclusion and exclusion criteria and study selection
We used a rigorous and exhaustive search strategy to locate primary studies, including updating
high-quality systematic reviews. Additionally, we used auditable and transparent methods to select
and synthesise studies. When appropriate, we undertook post hoc sensitivity analyses in our clinical
effectiveness study to check the robustness of our findings.
A limitation of our work, inherent to all systematic reviews, is publication bias. Methods for detecting
publication bias in NMAs are still in development and we did not have enough studies for any one
comparison to test for small-study bias. This may be especially relevant as many of the early trials of IFNs
and GA for MS were small trials.
Another important limitation was the selective and inconsistent reporting of outcomes. For example,
one of the reasons that we did not undertake a meta-analysis of time to first relapse estimates was the
inconsistent and often poor reporting, especially across multiple reports of the same study, which
prevented imputation of HRs. This was especially a problem for the findings relating to MS symptoms
and QoL in individual trials, with the findings often reported as significance thresholds (e.g. p < 0.05 or
p > 0.05), without reporting of the magnitude of the effects.
Finally, we elected to include only studies and arms of studies examining interventions within their
marketing authorisations, that is, we did not include study arms examining additional, non-licensed doses
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of the study drugs. Although this means that our analysis perhaps more closely represents clinical practice
today, it does mean that additional information on the effectiveness of these drugs was not included in
the analysis. Moreover, because our scope was limited to IFNs and GA, we could not include information
on additional newer drugs. This was a limitation in that additional trials would have strengthened the
resultant study networks analysed (see the following section).
Synthesis methods and statistical analyses of clinical effectiveness
For most outcomes we were able to complement narrative syntheses with pairwise and NMAs, but this
was not always possible (e.g. magnitude of EDSS change in RRMS or relapse severity in SPMS).
Our analyses also had several statistical advantages. In examining the effect of IFNs and GA on disability
progression, we used time-to-event outcomes and HRs instead of calculating risk ratios or ORs at different
follow-up points. Thus, trial findings were reported at their fullest ‘maturity’167 and all relevant data were
included. Although HRs are not immune to selection bias, they may be less likely than relative risks to
depend on the time points chosen in the analysis.
Related to our decision to use HRs, we were able to use the full complement of methods to estimate
effect sizes from available study-level data. This meant that more studies were included in our analyses
than would otherwise have been the case. However, this may also be a limitation in that indirect methods
(e.g. integrating underneath the survivor function to estimate the cumulative hazard) are not preferable to
direct estimates of intervention effects.
Our decision to estimate NMAs with effects for relapse rate, relapse severity and time to confirmed
disability progression across time points was justified in that RRs for relapses account for person-years and
thus, under an assumption of a constant rate, should not depend on time to follow-up. Similarly, HRs
represent ‘instantaneous’ risk and thus, under a proportional hazards assumption, should not depend on
time to follow-up. However, this decision is not without its drawbacks. On the one hand, we were unable
to verify empirically whether HRs and RRs were time varying because of few comparisons on every node of
the study networks. On the other hand, we judged that stratifying analyses by time to follow-up would
have resulted in excessively sparse networks that would have been difficult to interpret collectively. Thus,
our decision to pool study estimates across follow-up times for analyses of clinical outcomes was both a
strength and a potential limitation. Notably, we did stratify analyses by time to follow-up in NMAs of
discontinuations as a result of AEs because we judged that the only feasible estimator in these analyses
was the risk ratio.
Finally, one issue inherent to the clinical effectiveness evidence was that different sources of bias were
spread differentially throughout the networks. Most notably, trials involving an active drug compared with
an active drug in RRMS were frequently open label in design and thus participants were aware of the
drugs that they were receiving. This might have posed a greater risk to the unblinding of outcome
assessors than in ostensibly double-blinded trials.
Synthesis methods and statistical analyses of cost-effectiveness
One strength of our cost-effectiveness analyses was the considerable effort made to identify the best
available evidence on model input parameters and model structure. In addition, several of our analyses
were based on estimates derived from our systematic review and NMAs of clinical effectiveness, which
were themselves based on rigorous searches and analysis. We also appraised the RSS model and were
then able to modify the assumptions that we found concerning. Our extensive sensitivity analyses, both
deterministic and probabilistic, allowed us to explore a variety of data sources. Finally, we were able to
develop a de novo model structure for a hypothetical cohort of people with CIS.
However, one limitation of the analyses undertaken using data from the NMAs is that they at times relied
on sparse networks with an uneven risk of bias throughout the networks. For example, analyses relating to
125 µg of SC pegIFN-β-1a (Plegridy) relied on one trial that was not connected to any other trials except by
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a placebo comparator. Thus, any issues with the estimates derived from our review of clinical effectiveness
would have been propagated through the analysis of cost-effectiveness.
Another limitation was the difficulty of estimating uncertainty for key parameters in the RSS model. In
conducting our probabilistic sensitivity analysis based on our modified RSS model, we used uncertainty
estimates for the ARRs derived from the clinical effectiveness review rather than from the RSS itself.
Additionally, our findings were restricted to IFNs and GA. It is possible that other RRMS or CIS treatments
may be more cost-effective.
Choice of the base case for the economic analysis
As noted above, we used a modified version of the RSS model as our base case. Although cost-effectiveness
estimates derived from the RSS model and from the review of clinical effectiveness evidence have comparative
strengths and weaknesses, we decided on balance that estimates from the RSS model provided the best
estimates of cost-effectiveness. Although the RSS model relied on a historical (i.e. non-contemporaneous)
comparator, and thus non-randomised evidence likely to be prone to selection bias, we believe that the
long-term follow-up, relevance to the NHS and to current clinical practice and rigorous methods used in
collecting and reporting data made it the best choice for the base case. In contrast, although the estimates
from our review of clinical effectiveness were derived from randomised evidence, the predominantly
short-term nature of the included trials, the high risk of other biases (including as a result of manufacturer
sponsorship and from open-label active drug vs. active drug trials), the imbalance of these risks of bias across
the networks of evidence and the sparseness of the evidence for some DMTs raised doubts about its value for
the base case. Although both sources of evidence were at high risk of bias, we believe that the RSS model
best represented a relevant base case for MS treatment in the NHS.
Views of patients and carers
The submission from the RSS supports the use of DMTs for MS, including the use of IFNs and GA, based
on the results of the RSS, clinical trial data and research on perspectives gathered by the MS Society. These
perspectives included several patient case studies reporting that DMTs had significantly reduced or prevented
relapses and symptoms, enabling patients to lead more independent active lifestyles. The treatment had
improved their mental health by reducing their fear of future relapses and increasing feelings of confidence
and control. The MS Society noted that DMTs promote patient choice by allowing individuals to weigh up
lower-risk moderate-efficacy treatments compared with higher-risk and higher-efficacy treatments. The
range of treatment options allows for the differential way that MS can affect individuals and their differential
responses to DMTs.
Previous research
Our findings updated a number of previous reviews, although the comparability of the findings is limited.
Compared with the review by Clerico et al.,158 the key review that we used for analyses of CIS, we
included only trials reporting the use of IFNs and GA within their marketing authorisations. We also
included several trials published after the publication of their review.173–175 We were also able to use NMAs
for time to CDMS to examine the relative effectiveness of drugs. Our findings substantially update their
review and provide additional evidence of the effectiveness of IFNs and GA for CIS.
Compared with the review by Tramacere et al.,159 which broadly examined immunomodulators and
immunosuppressants for RRMS, we included only trials examining IFNs and GA against each other and against
a no-treatment comparator and only doses and formulations within the marketing authorisations. Because
Tramacere et al.159 included studies across different dosages, drug classes and indications and because they
used risk ratios as the sole outcome estimator, our analyses and theirs are largely incommensurate. However,
our analyses of treatment discontinuation as a result of AEs agreed with their analyses in that neither review
suggested that any one drug had a significant effect on discontinuation as a result of AEs relative to placebo.
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Implications for practice
We did not include formulations outside the recommended usage in the UK. In addition, our study was
specifically designed to exclude the clinical effectiveness and cost-effectiveness of newer MS treatments
such as newer monoclonal antibodies (alemtuzumab, daclizumab). This review should be considered in
conjunction with newer NICE and other guidance on the clinical effectiveness and cost-effectiveness of
these agents.
Our findings agree with the Association of British Neurologists classification of IFNs and GA as drugs of
‘moderate efficacy’.281 Our analysis does suggest that these drugs are effective in controlling the relapse
rate and disability progression.
Protocol variations
We originally presented our protocol at a stakeholder information meeting and subsequently registered
this protocol on the PROSPERO database (registration number CRD42016043278). Our methods differed
slightly from those detailed in the protocol in the following ways.
In the clinical effectiveness systematic review we did not use data from the RSS as prior distributions in a
Bayesian meta-analysis. This was because of the mismatch between the time to follow-up in the trials and
the time to follow-up in the year 10 RSS data and the different analytical methods used between the trials
and the RSS analyses. Subsequently, we did not use Bayesian methodology in our NMA models. We also
decided to exclude trials that examined only IFN or GA doses outside the marketing authorisation. Finally,
we did not search the database Current Controlled Trials as this would have duplicated searches already
carried out.
Although these were not strictly variations from our protocol, we subsequently refined our definitions of
several outcomes. We operationalised relapse severity as the RRs of relapses graded as moderate or severe
or as the RRs of relapses requiring steroid treatment. We also took advice from our clinical consultants and
examined combined clinical–MRI outcomes for freedom from disease activity.
Recommendations for future research
One key flaw in the assembled clinical effectiveness evidence was the lack of long-term follow-up. The RSS
was designed to collect longer-term observational data in this area; however, a large-scale, longitudinal RCT
comparing active first-line agents would contribute meaningfully towards resolving uncertainty about the
relative benefits of different IFN or GA formulations. We note that the submission from the MS Society
identified a similar research priority. It may be that using blinded adjudicator panels for relapses and disease
progression could attenuate the risk of bias accruing in an open-label trial. Because of this lack of long-term
follow-up, DMT trials are generally not informative on whether drugs delay progression to SPMS.
There is also a need to reach consensus on the different stages of MS, the distinctiveness of which are
open to question. Related to this, there is a need to understand how changing imaging technologies and
changes in clinical practice (e.g. changes in the classification of CIS under new diagnostic criteria) impact
on diagnosis and management. From an epidemiological perspective, a priority for research should be to
understand how and under what circumstances MS progresses through different types (e.g. from CIS to
RRMS and then to SPMS). We note that the submission from the MS Society identified a similar research
priority. Related to this, there is a need to develop outcomes that meaningfully reflect MS symptoms, such
as disability progression. Many have enumerated the issues with the EDSS, and it is possible that time to
progression sustained at 3 months does not reliably capture disability progression, given the variable time
for recovery from relapses.
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The scope of this assessment was limited to IFNs and GA and thus we did not include more recently
approved DMTs, such as oral agents or monoclonal antibodies, that are increasingly used as first-line
treatment for patients with RRMS. Therefore, future research comparing the clinical effectiveness and
cost-effectiveness of IFNs and GA with those of these new agents could be considered to better reflect the
therapeutic options available to patients within the NHS.
Another priority for research is to focus on patients who are not on the lower end of the EDSS. This may
be of value for populations with MS as survival rates improve and advances are made in terms of support
and aids for those with disabilities.
Additionally, valuation of health benefits continues to be a vexing area for MS. This was an issue identified
in the original guidance resulting from TA32.24 One possible way to address this issue is through systematic
review and metasynthesis of qualitative studies relating to the lived experience of MS, with particular
attention given to the dominant clinical features, for example relapse and disability progression. This could
provide a basis for an understanding of the relevant health states and benefits that more closely matches
the preferences and experiences of people living with the target condition.
Finally, above and beyond the population-average evidence that DMTs reduce the relapse rate, there is a need
to understand who responds best to DMTs, especially who does not respond to IFNs or GA early on, to enable
more targeted therapeutic decisions to be made. Although several trials included in our clinical effectiveness
review used subgroup analyses based, for example, on presenting lesions or demographic characteristics,
a more fine-grained understanding could help patients and clinicians make better-informed decisions.
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Appendix 1 Searches undertaken for the
systematic reviews of clinical effectiveness
Multiple sclerosis searches
Review articles checked for both included studies and studies excluded with reasons
l Cochrane reviews: Filippini et al.160 and Tramacere et al.159
l Other systematic reviews: Tolley et al.296
MEDLINE (via Ovid)
Database: Ovid MEDLINE® 1946 to January week 2 2016.
Searched on 27 January 2016.
TABLE 90 MEDLINE search: RRMS clinical effectiveness review
ID Search Hits
1 exp Multiple Sclerosis/ 46,764
2 multiple sclerosis.tw. 49,799
3 1 or 2 57,188
4 randomized controlled trial.pt. 403,450
5 controlled clinical trial.pt. 89,937
6 clinical trial, phase ii/ or clinical trial, phase iii/ or clinical trial, phase iv/ 35,683
7 (random* or ‘controlled trial*’ or ‘clinical trial*’ or rct).tw. 873,696
8 4 or 5 or 6 or 7 1,065,585
9 Animals/ 5,743,229
10 Humans/ 15,593,111
11 9 not 10 4,140,900
12 8 not 11 964,542
13 3 and 12 4921
14 (metaanalys* or ‘meta analys*’ or ‘meta-analys*’).tw. 69,140
15 ‘systematic* review*’.mp. 61,461
16 meta analysis.pt. 60,117
17 14 or 15 or 16 122,687
18 3 and 17 635
19 limit 3 to systematic reviews 1136
20 18 or 19 1233
21 13 or 20 5694
22 limit 21 to yr=‘2012 -Current’ 1545
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MEDLINE In-Process & Other Non-Indexed Citations (via Ovid)
Database: Ovid MEDLINE® In-Process & Other Non-Indexed Citations 26 January 2016.
Searched on 27 January 2016.
EMBASE (via Ovid)
Database: Ovid EMBASE 1974 to 2016 week 04.
Searched on 27 January 2016.
TABLE 92 EMBASE search: RRMS clinical effectiveness review
ID Search Hits
1 *multiple sclerosis/ 64,389
2 multiple sclerosis.tw. 80,240
3 1 or 2 87,466
4 randomized controlled trial/ 392,971
5 (random* or ‘controlled trial*’ or ‘clinical trial*’ or rct).tw. 1,306,964
6 4 or 5 1,388,801
7 3 and 6 8813
8 meta analysis/ 103,317
9 (metaanalys* or ‘meta analys*’ or ‘meta-analys*’).tw. 110,582
10 ‘systematic review’/ 100,520
11 ‘systematic* review*’.tw. 96,391
12 8 or 9 or 10 or 11 222,654
13 3 and 12 1280
14 7 or 13 9616
15 limit 14 to yr = ‘2012 -Current’ 4527
16 limit 15 to (conference abstract or conference paper or conference proceeding) 2363
17 15 not 16 2164
TABLE 91 MEDLINE In-Process & Other Non-Indexed Citations search: RRMS clinical effectiveness review
ID Search Hits
1 multiple sclerosis.tw. 4892
2 (random* or ‘controlled trial*’ or ‘clinical trial*’ or rct).tw. 108,317
3 1 and 2 610
4 (metaanalys* or ‘meta analys*’ or ‘meta-analys*’).tw. 14,094
5 ‘systematic* review*’.tw. 15,189
6 4 or 5 23,570
7 1 and 6 118
8 3 or 7 684
9 limit 8 to yr=‘2012 -Current’ 563
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The Cochrane Library (via Wiley Online Library)
Searched on 27 January 2016.
Distribution of results from The Cochrane Library search:
l Cochrane reviews, n = 44:
¢ reviews, n = 39
¢ protocols, n = 5
l other reviews (DARE), n = 60
l trials (CENTRAL), n = 1702
l methods studies, n = 0
l technology assessments (HTA database), n = 28
l economic evaluations, n = 27
l Cochrane groups, n = 0.
Science Citation Index (Web of Knowledge)
Searched on 27 January 2016.
TABLE 93 The Cochrane Library search: RRMS effectiveness review
ID Search Hits
#1 MeSH descriptor: [Multiple Sclerosis] explode all trees 1916
#2 multiple sclerosis:ti,ab,kw (Word variations have been searched) 4921
#3 #1 or #2 4925
#4 #1 or #2 Publication Year from 2012 to 2016 1861
TABLE 94 Science Citation Index search: RRMS clinical effectiveness review
ID Hits Search
#1 85,913 TS= ‘multiple sclerosis’
Indexes = SCI-EXPANDED Timespan = All years
#2 1,388,789 TS= (random* or (clinical NEAR/1 trial*) or (controlled NEAR/1 trial*) or rct)
Indexes = SCI-EXPANDED Timespan = All years
#3 80,440 TS= (systematic* NEAR/1 review*)
Indexes = SCI-EXPANDED Timespan = All years
#4 166,410 TS= (metaanalys* or meta-analys* or (meta NEAR/1 analys*))
Indexes = SCI-EXPANDED Timespan = All years
#5 216,848 #4 OR #3
Indexes = SCI-EXPANDED Timespan = All years
#6 8425 #2 AND #1
Indexes = SCI-EXPANDED Timespan = All years
continued
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UK Clinical Research Network (UKCRN) Portfolio Database
Searched on 27 January 2016.
Total hits: 265.
Search
Keyword: multiple sclerosis
AND
Status: closed
AND
Study Design: Interventional
Total hits: 41.
Cochrane MS Group Specialised Register
Searched 26 February 2016
Keywords
(interferon\*) OR (interferon beta) OR (beta-1 interferon) OR (beta 1 interferon) OR (interferon beta-1\*)
OR (rebif) OR (avonex) OR (Betaseron) OR (beta-seron) OR (betaferon) OR (beta-IFN-1\*) OR (interferon
beta-1\*) OR (Interferon-beta\*) OR (interferon beta\*) OR (recombinant interferon beta-1\*) OR (beta-1a
interferon) OR (beta 1a interferon) OR (interferon beta-1a) OR (beta 1b interferon) OR (interferon beta1b) OR
(IFNb-1b) OR (IFNbeta-1b) OR (interferon beta-1b) OR (copolymer-1) OR (cop-1) OR (copaxone) OR (glatiramer
acetate) OR (cpx) OR (cop1) OR (copolymer) OR (glatiramer) OR (polyethylene glycol-interferon-beta-1a) OR
(PEG IFN-beta-1a) OR (Pegylated interferon beta-1a) OR (Ocrelizumab)
AND
(relapsing remitting) OR (relapsing–remitting) OR (remitting-relapsing) OR (remitting relapsing) OR
(secondary progressive)
TABLE 94 Science Citation Index search: RRMS clinical effectiveness review (continued )
ID Hits Search
#7 1326 #5 AND #1
Indexes = SCI-EXPANDED Timespan = All years
#8 9263 #7 OR #6
Indexes = SCI-EXPANDED Timespan = All years
#9 3485 #8
Indexes = SCI-EXPANDED Timespan = 2012–2016
#10 237 (#9) AND DOCUMENT TYPES: (Meeting Abstract OR Proceedings Paper)
Indexes = SCI-EXPANDED Timespan = All years
#11 3248 #9 not #10
Indexes = SCI-EXPANDED Timespan = All years
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Clinically isolated syndrome searches
Review articles checked for included studies and studies excluded with reasons
l Cochrane reviews: Clerico et al.158
MEDLINE (Ovid)
Database: Ovid MEDLINE® 1946 to January week 4 2016.
Searched on 9 February 2016.
TABLE 95 MEDLINE search: CIS clinical effectiveness review
ID Search Hits
1 Demyelinating Diseases/ 10,446
2 Myelitis, Transverse/ 1153
3 exp Optic Neuritis/ 6737
4 Encephalomyelitis, Acute Disseminated/ 1689
5 Demyelinating Autoimmune Diseases, CNS/ 316
6 demyelinating disease*.tw. 4725
7 transverse myelitis.tw. 1356
8 neuromyelitis optica.tw. 1735
9 optic neuritis.tw. 3792
10 acute disseminated encephalomyelitis.tw. 1098
11 devic.tw. 107
12 ADEM.tw. 574
13 demyelinating disorder.tw. 335
14 clinically isolated syndrome.tw. 644
15 first demyelinating event.tw. 68
16 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 24,564
17 randomised controlled trial.pt. 404,260
18 (random* or ‘controlled trial*’ or ‘clinical trial*’ or rct).tw. 875,933
19 17 or 18 975,513
20 (metaanalys* or ‘meta analys*’ or ‘meta-analys*’).tw. 69,583
21 ‘systematic* review*’.mp. 61,879
22 meta analysis.pt. 60,490
23 20 or 21 or 22 123,386
24 16 and 19 661
25 16 and 23 74
26 24 or 25 713
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MEDLINE In-Process & Other Non-Indexed Citations (via Ovid)
Database: Ovid MEDLINE® In-Process & Other Non-Indexed Citations 8 February 2016.
Searched on 9 February 2016.
TABLE 96 MEDLINE In-Process & Other Non-Indexed Citations search: CIS clinical effectiveness review
ID Search Hits
1 demyelinating disease*.tw. 405
2 transverse myelitis.tw. 148
3 neuromyelitis optica.tw. 317
4 optic neuritis.tw. 356
5 acute disseminated encephalomyelitis.tw. 128
6 devic.tw. 6
7 ADEM.tw. 83
8 demyelinating disorder.tw. 55
9 clinically isolated syndrome.tw. 115
10 first demyelinating event.tw. 6
11 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 1249
12 (random* or ‘controlled trial*’ or ‘clinical trial*’ or rct).tw. 108,853
13 (metaanalys* or ‘meta analys*’ or ‘meta-analys*’).tw. 14,202
14 ‘systematic* review*’.tw. 15,358
15 13 or 14 23,763
16 11 and 12 63
17 11 and 15 17
18 16 or 17 73
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EMBASE (via Ovid)
Database: Ovid EMBASE 1974 to 2016 week 06.
Searched on 9 February 2016.
TABLE 97 EMBASE search: CIS clinical effectiveness review
ID Search Hit
1 demyelinating disease/ 12,216
2 myelitis/ 6771
3 optic neuritis/ 6979
4 acute disseminated encephalomyelitis/ 1378
5 myelooptic neuropathy/ 4897
6 demyelinating disease*.tw. 7443
7 transverse myelitis.tw. 2462
8 neuromyelitis optica.tw. 4162
9 optic neuritis.tw. 6551
10 acute disseminated encephalomyelitis.tw. 1762
11 devic.tw. 229
12 ADEM.tw. 1211
13 demyelinating disorder.tw. 624
14 clinically isolated syndrome.tw. 1758
15 first demyelinating event.tw. 159
16 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 34,739
17 randomized controlled trial/ 394,252
18 (random* or ‘controlled trial*’ or ‘clinical trial*’ or rct).tw. 1,311,256
19 17 or 18 1,393,301
20 meta analysis/ 103,826
21 (metaanalys* or ‘meta analys*’ or ‘meta-analys*’).tw. 111,288
22 ‘systematic review’/ 101,172
23 ‘systematic* review*’.tw. 97,114
24 20 or 21 or 22 or 23 223,913
25 16 and 19 1706
26 16 and 24 322
27 25 or 26 1914
28 limit 27 to (conference abstract or conference paper or conference proceeding or ‘conference review’) 493
29 27 not 28 1421
30 limit 29 to human 1340
31 limit 29 to animals 59
32 31 not 30 59
33 29 not 32 1362
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The Cochrane Library (via Wiley Online Library)
Searched on 9 February 2016.
Distribution of results from The Cochrane Library search:
l Cochrane reviews, n = 41
l other reviews, n = 8
l trials, n = 1369
l methods studies, n = 4
l technology assessments, n = 6
l economic evaluations, n = 8
l Cochrane Groups, n = 0.
Science Citation Index (Web of Knowledge)
Searched on 10 February 2016.
TABLE 98 The Cochrane Library search: CIS clinical effectiveness review
ID Search Hits
#1 MeSH descriptor: [Multiple Sclerosis] explode all trees 2125
#2 multiple sclerosis:ti,ab,kw (Word variations have been searched) 5081
#3 #1 or #2 5081
#4 first or early or ‘clinically isolated’:ti,ab,kw (Word variations have been searched) 166,444
#5 #3 and #4 1037
#6 MeSH descriptor: [Demyelinating Diseases] this term only 71
#7 MeSH descriptor: [Myelitis, Transverse] this term only 6
#8 MeSH descriptor: [Optic Neuritis] explode all trees 95
#9 MeSH descriptor: [Encephalomyelitis, Acute Disseminated] this term only 3
#10 MeSH descriptor: [Demyelinating Autoimmune Diseases, CNS] this term only 2
#11 demyelinating next disease*:ti,ab,kw (Word variations have been searched) 186
#12 transverse myelitis:ti,ab,kw (Word variations have been searched) 14
#13 neuromyelitis optica:ti,ab,kw (Word variations have been searched) 20
#14 optic neuritis:ti,ab,kw (Word variations have been searched) 220
#15 acute disseminated encephalomyelitis:ti,ab,kw (Word variations have been searched) 13
#16 devic:ti,ab,kw (Word variations have been searched) 2
#17 ADEM:ti,ab,kw (Word variations have been searched) 4
#18 demyelinating disorder:ti,ab,kw (Word variations have been searched) 49
#19 clinically isolated syndrome:ti,ab,kw (Word variations have been searched) 114
#20 first demyelinating event:ti,ab,kw (Word variations have been searched) 72
#21 single demyelinating event:ti,ab,kw (Word variations have been searched) 9
#22 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or
#20 or #21
1436
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TABLE 99 Science Citation Index search: CIS clinical effectiveness review
ID Hits Search
#1 6786 TS= (demyelinating NEAR/2 (disease* OR disorder*))
Indexes = SCI-EXPANDED Timespan = All years
#2 1699 TS= (transverse NEAR/1 myelitis)
Indexes = SCI-EXPANDED Timespan = All years
#3 4584 TS= ‘optic neuritis’
Indexes = SCI-EXPANDED Timespan = All years
#4 3531 TS= ‘neuromyelitis optica’
Indexes = SCI-EXPANDED Timespan = All years
#5 1596 TS= (‘acute disseminated’ NEAR/1 encephalomyelitis)
Indexes = SCI-EXPANDED Timespan = All years
#6 462 TS= ‘devic’
Indexes = SCI-EXPANDED Timespan = All years
#7 687 TS= ‘ADEM’
Indexes = SCI-EXPANDED Timespan = All years
#8 1195 TS= ‘clinically isolated syndrome’
Indexes = SCI-EXPANDED Timespan = All years
#9 96 TS= ‘first demyelinating event’
Indexes = SCI-EXPANDED Timespan = All years
#10 16,869 #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
Indexes = SCI-EXPANDED Timespan = All years
#11 1,393,569 TS= (random* or (clinical NEAR/1 trial*) or (controlled NEAR/1 trial*) or rct)
Indexes = SCI-EXPANDED Timespan = All years
#12 80,440 TS= (systematic* NEAR/1 review*)
Indexes = SCI-EXPANDED Timespan = All years
#13 167,718 TS= (metaanalys* or meta-analys* or (meta NEAR/1 analys*))
Indexes = SCI-EXPANDED Timespan = All years
#14 216,848 #13 OR #12
Indexes = SCI-EXPANDED Timespan = All years
#15 1039 #11 AND #10
Indexes = SCI-EXPANDED Timespan = All years
#16 122 #14 AND #10
Indexes = SCI-EXPANDED Timespan = All years
#17 1123 #16 OR #15
Indexes = SCI-EXPANDED Timespan = All years
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Cochrane MS Group Specialised Register
Searched on 26 February 2016.
Total hits: 188.
Keywords for CIS
(interferon\*) OR (interferon beta) OR (beta-1 interferon) OR (beta 1 interferon) OR (interferon beta-1\*)
OR (rebif) OR (avonex) OR (Betaseron) OR (beta-seron) OR (betaferon) OR (beta-IFN-1\*) OR (interferon
beta-1\*) OR (Interferon-beta\*) OR (interferon beta\*) OR (recombinant interferon beta-1\*) OR (beta-1a
interferon) OR (beta 1a interferon) OR (interferon beta-1a) OR (beta 1b interferon) OR (interferon beta1b )
OR (IFNb-1b) OR (IFNbeta-1b) OR (interferon beta-1b) OR (copolymer-1) OR (cop-1) OR (copaxone) OR
(glatiramer acetate) OR (cpx) OR (cop1) OR (copolymer) OR (glatiramer) OR (polyethylene glycol-interferon-
beta-1a) OR (PEG IFN-beta-1a) OR (Pegylated interferon beta-1a) OR (Ocrelizumab)
AND
clinically isolated syndrome* OR first demyelinating event* OR first demyelinating episode OR first
demyelinating attack OR First event OR first episode OR first clinical episode OR single clinical episodes OR
first demyelinating event/* OR clinically isolated syndrome*
Additional searches for both multiple sclerosis and clinically isolated
syndrome
ClinicalTrials.gov
Searched on 3 May 2016.
Hits: 182.
Advanced search
Interventional Studies | multiple sclerosis OR clinically isolated syndrome OR CNS demyelinating OR
transverse myelitis OR neuromyelitis optica | interferon OR glatiramer OR betaferon OR betaseron OR
avonex OR plegridy OR rebif OR extavia OR copaxone | Phase 2, 3, 4
World Health Organization (WHO)’s International Clinical Trials Registry Platform (ICTRP)
Searched on 14 July 2016.
Hits: 588 records for 175 trials.
(Relapsing Remitting Multiple Sclerosis OR RRMS OR clinically isolated syndrome OR CNS demyelinating OR
transverse myelitis OR neuromyelitis optica) in the Condition
TABLE 99 Science Citation Index search: CIS clinical effectiveness review (continued )
ID Hits Search
#18 93 (#17) AND DOCUMENT TYPES: (Meeting Abstract OR Proceedings Paper)
Indexes = SCI-EXPANDED Timespan = All years
#19 1030 #17 NOT #18
Indexes = SCI-EXPANDED Timespan = All years
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AND
(interferon OR glatiramer OR betaferon OR betaseron OR avonex OR plegridy OR rebif OR extavia OR
copaxone) in the Intervention
Websites
TABLE 100 Websites searched: RRMS and CIS clinical effectiveness reviews
Name (trade name) URL Date searched
Companies and sponsors
Bayer (Betaferon) www.bayer.co.uk/http://pharma.bayer.com/ 26 April 2016
Biogen Idec Ltd (Avonex and Plegridy) www.biogen-international.com/https://www.
biogen.uk.com/
28 April 2016
Merck Serono (Rebif) http://biopharma.merckgroup.com/en/index.html
Novartis (Extavia) www.novartis.com https://www.novartis.co.uk/ 28 April 2016
Teva Pharmaceuticals (Copaxone) www.tevapharm.com/research_development/
http://www.tevauk.com/
1 May 2016
Patient/carer groups
Brain and Spine Foundation www.brainandspine.org.uk 1 May 2016
Multiple Sclerosis National Therapy
Centres
www.msntc.org.uk 1 May 2016
MS UK www.ms-uk.org 1 May 2016
Multiple Sclerosis Society www.mssociety.org.uk 1 May 2016
Multiple Sclerosis Trust www.mstrust.org.uk 1 May 2016
Neurological Alliance www.neural.org.uk 1 May 2016
The Brain Charity (formerly known as
Neurosupport)
www.thebraincharity.org.uk 1 May 2016
Sue Ryder www.sueryder.org 1 May 2016
Professional groups
Association of British Neurologists www.theabn.org 1 May 2016
British Neuropathological Society www.bns.org.uk 1 May 2016
Institute of Neurology www.ucl.ac.uk/ion 1 May 2016
www.ucl.ac.uk/ion/departments/
neuroinflammation
5 May 2016
http://discovery.ucl.ac.uk 10 May 2016
Primary Care Neurology Society www.p-cns.org.uk 1 May 2016
Therapists in MS www.mstrust.org.uk/health-professionals/
professional-networks/therapists-ms-tims/research
1 May 2016
UK Multiple Sclerosis Specialist Nurse
Association
www.ukmssna.org.uk 1 May 2016
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TABLE 100 Websites searched: RRMS and CIS clinical effectiveness reviews (continued )
Name (trade name) URL Date searched
Relevant research groups
Brain Research Trust www.brt.org.uk/research 1 May 2016
British Neurological Research Trust www.ukscf.org; www.ukscf.org/about-us/bnrt.html 1 May 2016
Cochrane Multiple Sclerosis and Rare
Diseases of the Central Nervous
System Group
www.cochranelibrary.com; http://msrdcns.
cochrane.org/our-reviews
1 May 2016
National Institute for Health Research www.nihr.ac.uk/research/; www.nihr.ac.uk/
industry/; www.nihr.ac.uk/policy-and-standards/
1 May 2016
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Appendix 2 Sample data extraction sheet for
clinical effectiveness reviews
TABLE 101 Blank data extraction form: clinical effectiveness reviews
Study acronym/ID:
Name of reviewer:
Number of publications extracted:
Study details
Study ID (EndNote):
First author surname:
Year of publication:
Country:
Study setting:
Number of centres:
Study period:
Follow-up period:
Funding:
Subtypes of MS included:
Definition of CIS used:
Aim of the study:
Participants:
Inclusion criteria:
Exclusion criteria:
Total number of participants:
Sample attrition/dropout:
Number of participants analysed:
Characteristics of participants
Mean age:
Mean sex:
Race:
EDSS score at baseline:
Relapse rate at baseline:
Time from diagnosis of MS:
Other clinical features of MS:
continued
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TABLE 101 Blank data extraction form: clinical effectiveness reviews (continued )
Intervention (repeat if necessary for multiple intervention arms)
Type of drug:
Method of administration:
Dose:
Frequency:
Drug indication as stated:
Best supportive care as described
Outcomes
Primary outcomes:
Secondary outcomes:
Method of assessing outcomes:
If freedom from disease activity is an outcome, how was it defined?
Timing of assessment:
Adverse event:
Health-related quality of life: yes/no; which measures used?
Number of participants Intervention Comparator, if present
Screened
Excluded
Randomised/included
Missing participants (people who were lost to follow-up during the trial)
Withdrawals (all who did not complete, including those lost to follow-up)
Patient baseline characteristics
Age (years)
Sex
Race
EDSS score at baseline
Relapse rate at baseline
Time from diagnosis of MS
Outcome data: relapses, disability
Relapse rate
Severity of relapse
Disability, including as measured by the EDSS
Freedom from disease activity
Outcome data: MS symptoms (add rows as necessary)
Fatigue
Visual disturbance
Cognition
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TABLE 101 Blank data extraction form: clinical effectiveness reviews (continued )
Outcome data: additional outcomes
Mortality
Health-related quality of life
Progression to MS (CIS only)
Discontinuation due to neutralising antibody formation
Adverse events (add rows as necessary for adverse events reported in RCTs)
Risk of bias assessment
Random sequence generation High risk Unclear risk Low risk
Description in trial
Allocation concealment High risk Unclear risk Low risk
Description in trial
Blinding of participants and personnel High risk Unclear risk Low risk
Description in trial
Blinding of outcome assessment High risk Unclear risk Low risk
Description in trial
Incomplete outcome data High risk Unclear risk Low risk
Description in trial
Selective reporting High risk Unclear risk Low risk
Description in trial
Other sources of bias High risk Unclear risk Low risk
Description in trial
Authors’ conclusion
Reviewer’s conclusion
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Appendix 3 Documentation of excluded studies
TABLE 102 Frequency of reasons for record exclusion in the clinical effectiveness review
Reasons Number
Conference abstract 10
DMT used with a non-recommended dose regimen 15
Irrelevant comparator/intervention 58
Irrelevant comparator/intervention/outcome 1
Irrelevant comparator/intervention/population 1
Irrelevant comparator/intervention/study type 4
Irrelevant comparator/population 5
Irrelevant comparator/population/study type 1
Irrelevant intervention 7
Irrelevant intervention/population 2
Irrelevant intervention/study type 8
Irrelevant outcome 13
Irrelevant outcome/study type 2
Irrelevant outcome/study type/population 1
Irrelevant population 11
Irrelevant population/outcome 1
Irrelevant population/study type 7
Irrelevant study type 24
Non-English-language study 1
No results are provided, refers to results from a conference abstract 1
Not a primary research study 3
Protocol only with no results 15
Study evaluating a treatment-switch strategy 1
Systematic review that did not enable location of further primary studies 18
Use of an unlicensed drug formulation 1
Total 211
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TABLE 103 Records excluded from the clinical effectiveness review with reasons
Reference Reason for exclusion
Aggarwal S, Kumar S, Topaloglu H. Comparison of network meta-analysis and
traditional meta-analysis for prevention of relapses in multiple sclerosis. Value
Health 2015;18:A660. http://dx.doi.org/10.1016/j.jval.2015.09.2394
Conference abstract
Agius M, Meng X, Chin P, Grinspan A, Hashmonay R. Fingolimod therapy in early
multiple sclerosis: an efficacy analysis of the TRANSFORMS and FREEDOMS studies
by time since first symptom. CNS Neurosci Ther 2014;20:446–51
Irrelevant comparator/intervention
Åivo J, Lindsrom BM, Soilu-Hanninen M. A randomised, double-blind, placebo-
controlled trial with vitamin D3 in MS: subgroup analysis of patients with baseline
disease activity despite interferon treatment. Mult Scler Int 2012;2012:802796
Irrelevant comparator/intervention
Andersen O, Elovaara I, Färkkilä M, Hansen HJ, Mellgren SI, Myhr KM, et al.
Multicentre, randomised, double blind, placebo controlled, phase III study of
weekly, low dose, subcutaneous interferon beta-1a in secondary progressive
multiple sclerosis. J Neurol Neurosurg Psychiatry 2004;75:706–10
DMT used with a non-recommended
dose regimen
Andersen O, Elovaara I, Färkkilä M, Hansen HJ, Mellgren SI, Myhr KM, et al.
Multicentre, randomised, double blind, placebo controlled, phase III study of
weekly, low dose, subcutaneous interferon beta-1a in secondary progressive
multiple sclerosis. J Neurol Neurosurg Psychiatry 2004;75:706–10
DMT used with a non-recommended
dose regimen
Anderson G, Meyer D, Herrman CE, Sheppard C, Murray R, Fox EJ, et al.
Tolerability and safety of novel half milliliter formulation of glatiramer acetate for
subcutaneous injection: an open-label, multicenter, randomized comparative study.
J Neurol 2010;257:1917–23
Use of an unlicensed drug
formulation
Anonymous. Visual function 5 years after optic neuritis: experience of the Optic
Neuritis Treatment Trial. The Optic Neuritis Study Group. Arch Ophthalmol
1997;115:1545–52
Irrelevant comparator/intervention
Anonymous. Early administration of interferon-beta-1a in multiple sclerosis.
Eur J Pediatr 2001;160:135–6
Irrelevant study type
Anonymous. Baseline MRI characteristics of patients at high risk for multiple
sclerosis: results from the CHAMPS trial. Controlled High-risk subjects Avonex
Multiple sclerosis Prevention Study. Mult Scler 2002;8:330–8
Irrelevant outcome
Anonymous. Developing Neuroprotection and Repair Strategies in MS: Phase IIa
Randomized, Controlled Trial of Minocycline in Acute Optic Neuritis (ON).
ClinicalTrials.gov. National Institutes of Health; 2010. URL: https://clinicaltrials.gov/
ct2/show/NCT01073813 (accessed 1 June 2016)
Irrelevant intervention
A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose
Rebif® in Patients With Early, Active Relapsing–Remitting Multiple Sclerosis.
ClinicalTrials.gov, National Institutes of Health; 2002. URL: https://clinicaltrials.gov/
ct2/show/NCT00050778 (accessed 15 June 2017)
Protocol only with no results
A Randomized, International, Multi Centre Study to Assess the Efficacy and Safety
of Intravenous PEG-Liposomal Prednisolone Sodium Phosphate (Nanocort®) vs
Intravenous Methylprednisolone (Solu-Medrol®) Treatment in Patients with Acute
Exacerbation of Relapsing–Remitting Multiple Sclerosis or in Patients with Clinically
Isolated Syndrome. ClinicalTrials.gov, National Institutes of Health; 2009.
URL: https://clinicaltrials.gov/ct2/show/NCT01039103 (accessed 15 June 2017)
Protocol only with no results
Arnold DL, Narayanan S, Antel S. Neuroprotection with glatiramer acetate:
evidence from the PreCISe trial. J Neurol 2013;260:1901–6. http://dx.doi.org/
10.1007/s00415-013-6903-5
Irrelevant outcome
Ashtari F, Savoj MR. Effects of low dose methotrexate on relapsing–remitting
multiple sclerosis in comparison to Interferon β-1α: a randomized controlled trial.
J Res Med Sci 2011;16:457–62
Irrelevant intervention
Balak DM, Hengstman GJ, Cakmak A, Thio HB. Cutaneous adverse events
associated with disease-modifying treatment in multiple sclerosis: a systematic
review. Mult Scler 2012;18:1705–17
Systematic review that did not
enable location of further primary
studies
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TABLE 103 Records excluded from the clinical effectiveness review with reasons (continued )
Reference Reason for exclusion
Balcer LJ, Galetta SL, Calabresi PA, Confavreux C, Giovannoni G, Havrdova E, et al.
Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurol
2007;68:1299–304
Irrelevant comparator/intervention
Bandari D, Wynn D, Miller T, Singer B, Wray S, Bennett R, et al. Rebif(®) Quality of
Life (RebiQoL): a randomized, multicenter, Phase IIIb study evaluating quality-of-life
measures in patients receiving the serum-free formulation of subcutaneous
interferon beta-1a for the treatment of relapsing forms of multiple sclerosis.
Mult Scler Relat Disord 2013;2:45–56
Irrelevant comparator/intervention
Barkhof F, Polman CH, Radue EW, Kappos L, Freedman MS, Edan G, et al.
Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study:
integrated 2-year results. Arch Neurol 2007;64:1292–8
Irrelevant outcome
Barkhof F, Rocca M, Francis G, Van Waesberghe JH, Uitdehaag BM, Hommes OR,
et al. Validation of diagnostic magnetic resonance imaging criteria for multiple
sclerosis and response to interferon beta1a. Ann Neurol 2003;53:718–24
DMT used with a non-recommended
dose regimen
Beck RW. The optic neuritis treatment trial: three-year follow-up results. Arch
Ophthalmol 1995;113:136–7
Irrelevant comparator/intervention/
study type
Beck RW, Trobe JD. The Optic Neuritis Treatment Trial. Putting the results in
perspective. The Optic Neuritis Study Group. J Neuroophthalmol 1995;15:131–5
Irrelevant comparator/intervention
Berkovich, R, Amezcua L, Subhani D, Cen S. Pilot study of monthly pulse
adrenocorticotropic hormone (ACTH) or methylprednisolone as an add-on
therapy to beta-interferons for long-term treatment of multiple sclerosis. Neurol
2013;80:e205-6
Irrelevant comparator/intervention
Bermel RA, Weinstock-Guttman B, Bourdette D, Foulds P, You X, Rudick RA.
Intramuscular interferon beta-1a therapy in patients with relapsing–remitting
multiple sclerosis: a 15-year follow-up study. Mult Scler 2010;16:588–96
Irrelevant comparator/intervention
Bornstein MB, Miller A, Slagle S, Weitzman M, Drexler E, Keilson M, et al.
A placebo-controlled, double-blind, randomised, two-centre, pilot trial of Cop 1
in chronic progressive multiple sclerosis. Neurol 1991;41:533–9
Irrelevant population
Brex PA, Molyneux PD, Smiddy P, Barkhof F, Filippi M, Yousry TA, et al. The effect
of IFNbeta-1b on the evolution of enhancing lesions in secondary progressive MS.
Neurology 2001;57:2185–90
Irrelevant outcome
Brunetti L, Wagner ML, Maroney M, Ryan M. Teriflunomide for the treatment
of relapsing multiple sclerosis: a review of clinical data. Ann Pharmacother
2013;47:1153–60. http://dx.doi.org/10.1177/1060028013500647
Irrelevant intervention/study type
Calkwood J, Cree B, Crayton H, Kantor D, Steingo B, Barbato L, et al. Impact of a
switch to fingolimod versus staying on glatiramer acetate or beta interferons on
patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc
analyses of the EPOC trial. BMC Neurol 2014;14:220. http://dx.doi.org/10.1186/
s12883-014-0220-1
Irrelevant comparator/intervention
Canadian Agency for Drugs and Technologies in Health. Clinical Review Report.
Teriflunomide (Aubagio – Genzyme Canada) Indication: Relapsing–Remitting
Multiple Sclerosis. 2014. URL: www.cadth.ca/sites/default/files/cdr/clinical/SR0350_
Aubagio_CL_Report_e.pdf (accessed 1 June 2016)
Irrelevant intervention/study type
Chan CK, Lam DS. Optic neuritis treatment trial:10-year follow-up results. Am J
Ophthalmol 2004;138:695
Irrelevant study type
Chinea Martinez AR, Correale J, Coyle PK, Meng X, Tenenbaum N. Efficacy and
safety of fingolimod in Hispanic patients with multiple sclerosis: pooled clinical trial
analyses. Adv Ther 2014;31:1072–81
Irrelevant comparator/intervention
Clerico M, Contessa G, Durelli L. Interferon-beta1a for the treatment of multiple
sclerosis. Expert Opin Biol Ther 2007;7:535–42. http://dx.doi.org/10.1517/
14712598.7.4.535
Irrelevant study type
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TABLE 103 Records excluded from the clinical effectiveness review with reasons (continued )
Reference Reason for exclusion
Clerico M, Schiavetti I, Mercanti SF, Piazza F, Gned D, Morra VB, et al. Treatment
of relapsing–remitting multiple sclerosis after 24 doses of natalizumab: evidence
from an Italian spontaneous, prospective, and observational study (the TY-STOP
study). JAMA Neurol 2014;71:954–60
Irrelevant study type
ClinicalTrials.gov. An Efficacy and Safety Comparison Study of Two Marketed
Drugs in Patients With Relapsing–Remitting MS (ABOVE). URL: https://clinicaltrials.
gov/ct2/show/NCT00206648 (accessed 1 June 2016)
Study evaluating a treatment-switch
strategy
Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral
fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J
Med 2010;362:402–15. http://dx.doi.org/10.1056/NEJMoa0907839
Irrelevant comparator/intervention
Cohen JA, Barkhof F, Comi G, Izquierdo G, Khatri B, Montalban X, et al.
Fingolimod versus intramuscular interferon in patient subgroups from
TRANSFORMS. J Neurol 2013;260:2023–32. http://dx.doi.org/10.1007/
s00415-013-6932-0
Irrelevant comparator/intervention
Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, et al.
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with
relapsing–remitting multiple sclerosis: a randomised controlled Phase 3 trial. Lancet
2012;380:1819–28
Irrelevant comparator/intervention
Cohen JA, Coles AJ, Arnold DL, Confavreu C, Fox EJ, Hartung HP, et al.
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with
relapsing–remitting multiple sclerosis: a randomised controlled Phase 3 trial. Lancet
2012;380:1819–28
Irrelevant comparator/intervention
Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF,
et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive
MS. Neurology 2002;59:679–87
DMT used with a non-recommended
dose regimen
Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF,
et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive
MS. Neurology 2002;59:679–87
DMT used with a non-recommended
dose regimen
Cohen JA, Rovaris M, Goodman AD, Ladkani D, Wynn D, Filippi M, 9006 Study
Group. Randomized, double-blind, dose-comparison study of glatiramer acetate in
relapsing–remitting MS. Neurology 2007;68:939–44
Irrelevant comparator/intervention/
population
Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, et al.
Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med
2008;359:1786–801. http://dx.doi.org/10.1056/NEJMoa0802670
Irrelevant comparator/intervention
Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, et al.
Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med
2008;359:1786–801. http://dx.doi.org/10.1056/NEJMoa0802670
Irrelevant comparator/intervention
Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, et al. Alemtuzumab
versus interferon β-1a in early relapsing–remitting multiple sclerosis: post-hoc and
subset analyses of clinical efficacy outcomes. Lancet Neurol 2011;10:338–48
Irrelevant comparator/population
Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, et al. Alemtuzumab
more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial.
Neurology 2012;78:1069–78. http://dx.doi.org/10.1212/WNL.0b013e31824e8ee7
Irrelevant comparator/intervention
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, et al.
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying
therapy: a randomised controlled Phase 3 trial. Lancet 2012;380:1829–39
Irrelevant comparator/intervention
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, et al.
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying
therapy: a randomised controlled Phase 3 trial. Lancet 2012;380:1829–39
Irrelevant comparator/intervention
Comi G, Barkhof F, Durelli L, Edan G, Fernandez O, Filippi M, et al. Early treatment
of multiple sclerosis with Rebif (recombinant human interferon beta): design of the
study. Mult Scler 1995;1:S24–7
Protocol only with no results
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TABLE 103 Records excluded from the clinical effectiveness review with reasons (continued )
Reference Reason for exclusion
Comi G, Cohen JA, Arnold DL, Wynn D, Filippi M, FORTE Study Group. Phase III
dose-comparison study of glatiramer acetate for multiple sclerosis. Ann Neurol
2011;69:75–82. http://dx.doi.org/10.1002/ana.22316
Irrelevant comparator/intervention
Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernández O, et al. Effect of early
interferon treatment on conversion to definite multiple sclerosis: a randomised
study. Lancet 2001;357:1576–82
DMT used with a non-recommended
dose regimen
Comi G, Martinelli V, Rodegher M, Moiola L, Leocani L, Bajenaru O, et al. Effects
of early treatment with glatiramer acetate in patients with clinically isolated
syndrome. Mult Scler 2013;19:1074–83
Irrelevant population/study type
Comi G, O’Connor P, Montalban X, Antel J, Radue EW, Karlsson G, et al. Phase II
study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler
2010;16:197–207. http://dx.doi.org/10.1177/1352458509357065
Irrelevant comparator/intervention
Cooper K, Bryant J, Harris P, Loveman E, Jones J, Welch K. Alemtuzumab for the
Treatment of Relapsing-Remitting Multiple Sclerosis: a Single Technology Appraisal.
2013. URL: www.nets.nihr.ac.uk/projects/hta/128301 (accessed 21 April 2017)
Irrelevant comparator/intervention
Dalfampridine After Optic Neuritis to Improve Visual Function in Multiple Sclerosis.
ClinicalTrials.gov, National Institutes of Health; 2011. URL: http://clinicaltrials.gov/
ct2/show/NCT01337986 (accessed June 2017)
Protocol only with no results
Daniels GH, Vladic A, Brinar V, Zavalishin I, Valente W, Oyuela P, et al.
Alemtuzumab-related thyroid dysfunction in a Phase 2 trial of patients with
relapsing–remitting multiple sclerosis. J Clin Endocrinol Metab 2014;99:80–9
Irrelevant comparator/intervention
De Stefano N, Comi G, Kappos L, Freedman MS, Polman CH, Uitdehaag BM, et al.
Efficacy of subcutaneous interferon beta-1a on MRI outcomes in a randomised
controlled trial of patients with clinically isolated syndromes. J Neurol Neurosurg
Psychiatry 2014;85:647–53
Irrelevant outcome
De Stefano N, Curtin F, Stubinski B, Blevins G, Drulovic J, Issard D, et al.
Rapid benefits of a new formulation of subcutaneous interferon beta-1a in
relapsing–remitting multiple sclerosis. Mult Scler 2010;16:888–92. http://dx.doi.
org/10.1177/1352458510362442
Irrelevant outcome
Deisenhammer F, Hegen H. Alemtuzumab more effective than interferon β-1a
at 5-year follow-up of CAMMS223 clinical trial. Neurology 2012;79:1071–2.
http://dx.doi.org/10.1212/01.wnl.0000419501.12719.38
Irrelevant study type
Del Santo F, Maratea D, Fadda V, Trippoli S, Messori A. Treatments for
relapsing–remitting multiple sclerosis: summarising current information by network
meta-analysis. Eur J Clin Pharmacol 2012;68:441–8
Systematic review that did not
enable location of further primary
studies
Double-Blind Extension of the Study 27025 (REFLEX) to Obtain Long-Term
Follow-up Data in Patients with Clinically Definite MS and Patients with a First
Demyelinating Event at High Risk of Converting to MS, Treated With Rebif® New
Formulation (REFLEXION). ClinicalTrials.gov, National Institutes of Health; 2009.
URL: https://clinicaltrials.gov/ct2/show/NCT00813709 (accessed 15 June 2017)
Protocol only with no results
Edan G, Kappos L, Montalbán X, Polman CH, Freedman MS, Hartung HP, et al.
Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of
BENEFIT. J Neurol Neurosurg Psychiatr 2014;85:1183–9. http://dx.doi.org/10.1136/
jnnp-2013-306222
Irrelevant comparator/population/
study type
Etemadifar M, Janghorbani M, Shaygannejad V. Comparison of interferon beta
products and azathioprine in the treatment of relapsing–remitting multiple sclerosis.
J Neurol 2007;254:1723–8. http://dx.doi.org/10.1007/s00415-007-0637-1
Irrelevant comparator/intervention
Etemadifar M, Janghorbani M, Shaygannejad V. Comparison of interferon beta
products and azathioprine in the treatment of relapsing–remitting multiple sclerosis.
J Neurol 2007;254:1723–8. http://dx.doi.org/10.1007/s00415-007-0637-1
Irrelevant comparator/population
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TABLE 103 Records excluded from the clinical effectiveness review with reasons (continued )
Reference Reason for exclusion
Evidence of interferon beta-1a dose response in relapsing–remitting MS:
the OWIMS Study. The Once Weekly Interferon for MS Study Group. Neurol
1999;53:679–86
DMT used with a non-recommended
dose regimen
Filippi M, Rovaris M, Inglese M, Barkhof F, Stefano N, Smith S, et al. Interferon
beta-1a for brain tissue loss in patients at presentation with syndromes suggestive
of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet
2004;364:1489–96
DMT used with a non-recommended
dose regimen
Fox E, Arnold D, Brinar V, Cohen J, Coles A, Confavreux C. Relapse outcomes with
alemtuzumab vs. Rebif(®) in treatment-naive relapsing–remitting multiple sclerosis
(CARE-MS I): secondary and tertiary endpoints. Neurol 2010;78
Irrelevant comparator/intervention
Fox RJ, Cree BA, De Sèze J, Gold R, Hartung HP, Jeffery D, et al. MS disease
activity in RESTORE: a randomized 24-week natalizumab treatment interruption
study. Neurol 2014;82:1491–8. [Erratum in Neurology 201;84:862.]
Irrelevant comparator/intervention
Fox RJ, Cree BA, De Sèze J, Gold R, Hartung HP, Jeffery D, et al. MS disease
activity in RESTORE: a randomized 24-week natalizumab treatment interruption
study. Neurol 2014;82:1491–8
Irrelevant population
Fox E, Edwards K, Burch G, Wynn DR, LaGanke C, Crayton H, et al. Outcomes
of switching directly to oral fingolimod from injectable therapies: results of the
randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in
relapsing multiple sclerosis. Mult Scler Relat Disord 2014;3:607–19
Irrelevant comparator/intervention
Freedman MS. Evidence for the efficacy of interferon beta-1b in delaying the
onset of clinically definite multiple sclerosis in individuals with clinically isolated
syndrome. Ther Adv Neurol Disord 2014;7:279–88
Irrelevant intervention/population
Freedman MS, Truffinet P, Comi G, Kappos L, Miller AE, Olsson TP, et al.
A randomized trial of teriflunomide added to glatiramer acetate in relapsing
multiple sclerosis. Mult Scler J Exp Transl Clin 2015;1:1–10
Irrelevant intervention
Freedman MS, Wolinsky JS, Wamil B, Confavreux C, Comi G, Kappos L, et al.
Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized
Phase II trial. Neurology 2012;78:1877–85
Irrelevant intervention
Freedman MS, Wolinsky JS, Wamil B, Confavreux C, Comi G, Kappos L, et al.
Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized
Phase II trial. Neurology 2012;78:1877–85. http://dx.doi.org/10.1212/WNL.
0b013e318258f7d4
Irrelevant comparator/intervention
Frohman EM, Havrdova E, Lublin F, Barkhof F, Achiron A, Sharief MK, et al. Most
patients with multiple sclerosis or a clinically isolated demyelinating syndrome
should be treated at the time of diagnosis. Arch Neurol 2006;63:614–19
Irrelevant study type
Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg-Sorensen P.
Safety and efficacy of oral cladribine in patients with relapsing–remitting multiple
sclerosis: results from the 96 week Phase IIIB extension trial to the clarity study.
Neurology 2013;80(7 Suppl.):P07.119
Irrelevant intervention
Giovannoni G, Southam E, Waubant E. Systematic review of disease-modifying
therapies to assess unmet needs in multiple sclerosis: tolerability and adherence.
Mult Scler 2012;18:932–46
Systematic review that did not
enable location of further primary
studies
Gobbi C, Meier DS, Cotton F, Sintzel M, Leppert D, Guttmann CR, Zecca C.
Interferon beta 1b following natalizumab discontinuation: one year, randomized,
prospective, pilot trial. BMC Neurol 2013;13:101. http://dx.doi.org/10.1186/
1471-2377-13-101
Irrelevant comparator/intervention/
study type
Goodin DS, Ebers GC, Cutter G, Cook SD, O’Donnell T, Reder AT, et al. Cause of
death in MS: long-term follow-up of a randomised cohort, 21 years after the start
of the pivotal IFNbeta-1b study. BMJ Open 2012;2(6)
Irrelevant intervention/study type
Goodin DS, Reder AT, Ebers GC, Cutter G, Kremenchutzky M, Oger J, et al.
Survival in MS: a randomized cohort study 21 years after the start of the pivotal
IFNbeta-1b trial. Neurology 2012;78:1315–22
Irrelevant comparator/intervention/
study type
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TABLE 103 Records excluded from the clinical effectiveness review with reasons (continued )
Reference Reason for exclusion
Gotkine M. Neuromyelitis optica and the Optic Neuritis Treatment Trial. Arch
Neurol 2008;65:1545–6. http://dx.doi.org/10.1001/archneur.65.11.1545-c
Irrelevant study type
Govindappa K, Sathish J, Park K, Kirkham J, Pirmohamed M. Development of
interferon beta-neutralising antibodies in multiple sclerosis – a systematic review
and meta-analysis. Eur J Clin Pharmacol 2015;71:1287–98
Irrelevant outcome/study type
Hadden RD, Sharrack B, Bensa S, Soudain SE, Hughes RA. Randomized trial of
interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy.
Neurology 1999;53:57–61
Irrelevant population
Hadjigeorgiou GM, Doxani C, Miligkos M, Ziakas P, Bakalos G, Papadimitriou D,
et al. A network meta-analysis of randomized controlled trials for comparing the
effectiveness and safety profile of treatments with marketing authorization for
relapsing multiple sclerosis. J Clin Pharm Ther 2013;38:433–9
Systematic review that did not
enable location of further primary
studies
Hartung HP, Freedman MS, Polman CH, Edan G, Kappos L, Miller DH, et al.
Interferon beta-1b-neutralizing antibodies 5 years after clinically isolated syndrome.
Neurology 2011;77:835–43. [Erratum in Neurology 2011;77(13):1317.]
Irrelevant study type
Hartung H, Vollmer T, Arnold D, Cohen J, Coles A, Confavreux C. Alemtuzumab
reduces MS disease activity in active relapsing–remitting multiple sclerosis patients
who had disease activity on prior therapy. Neurology 2013;80(7 Suppl.):P07.093
Conference abstract
Havrdova E, Giovannoni G, Stefoski D, Umans K, Greenberg S, Mehta L.
Proportion of disease-activity free patients with relapsing–remitting multiple
sclerosis following 1 year of treatment with daclizumab high-yield process in the
select study. Neurology 2013;80(7 Suppl.):P07.105
Conference abstract
Havrdova E, Zivadinov R, Krasensky J, Dwyer MG, Novakova I, Dolezal O, et al.
Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose
corticosteroids in multiple sclerosis. Mult Scler 2009;15:965–76. http://dx.doi.org/
10.1177/1352458509105229
Irrelevant comparator/intervention
Hersh CM, Cohen JA. Alemtuzumab for the treatment of relapsing–remitting
multiple sclerosis. Immunotherapy 2014;6:249–59. http://dx.doi.org/10.2217/
imt.14.7
Irrelevant study type
Hutchinson M, Fox RJ, Havrdova E, Kurukulasuriya NC, Sarda SP, Agarwal S, et al.
Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying
therapies for the treatment of relapsing–remitting multiple sclerosis: a systematic
review and mixed treatment comparison. Curr Med Res Opin 2014;30:613–27
Systematic review that did not
enable location of further primary
studies
Hutchinson M, Fox RJ, Miller DH, Phillips JT, Kita M, Havrdova E. Clinical efficacy of
BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis:
subgroup analyses of the CONFIRM study. J Neurol 2013;260:2286–96
Systematic review that did not
enable location of further primary
studies
Jacobs LD, Beck RW, Simon JH. Interferon beta-1a prevented the development of
clinically definite multiple sclerosis after a first demyelinating event. Evid Based
Med 2001;6:78
Irrelevant study type
Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al.
A Phase III trial of intramuscular recombinant interferon beta as treatment for
exacerbating–remitting multiple sclerosis: design and conduct of study and
baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group
(MSCRG). Mult Scler 1995;1:118–35
Protocol only with no results
Jacque F, Gaboury I, Christie S, Grand’Maison F. Combination therapy of
interferon beta-1b and tacrolimus: a pilot safety study. Mult Scler Int
2012;2012:935921
Irrelevant comparator/intervention
Johnson KP, Brooks BR, Ford CC, Goodman AD, Lisak RP, Myers LW, et al.
Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy
in a six-year organized multiple sclerosis trial. Mult Scler 2003;9:585–91
Irrelevant population
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TABLE 103 Records excluded from the clinical effectiveness review with reasons (continued )
Reference Reason for exclusion
Kalincik T, Horakova D, Dolezal O, Krasensky J, Vaneckova M, Seidl Z, et al.
Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up
of the ASA cohort. Clin Neurol Neurosurg 2012;114:940–6
Irrelevant comparator/intervention
Kamm CP, El-Koussy M, Humpert S, Findling O, Burren Y, Schwegler G, et al.
Atorvastatin added to interferon beta for relapsing multiple sclerosis: 12-month
treatment extension of the randomized multicenter SWABIMS trial. PLOS ONE
2014;9:e86663
Irrelevant comparator/intervention
Kamm CP, El-Koussy M, Humpert S, Findling O, von Bredow F, Burren Y, et al.
Atorvastatin added to interferon beta for relapsing multiple sclerosis: a randomized
controlled trial. J Neurol 2012;259:2401–13
Irrelevant comparator/intervention
Kappos L, Antel J, Comi G, Montalban X, O’Connor P, Polman CH, et al.
Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med
2006;355:1124–40
Irrelevant comparator/intervention
Kappos L, Edan G, Freedman M, Montalban X, Miller D, Polman C. Benefit 11:
long-term follow-up study of patients with clinically isolated syndrome treated with
interferon beta-1b. J Neurol Sci 2013;333:e383
Conference abstract
Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, et al. Effect
of early versus delayed interferon beta-1b treatment on disability after a first
clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the
BENEFIT study. Lancet 2007;370:389–97
Irrelevant intervention/study type
Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, et al.
Long-term effect of early treatment with interferon beta-1b after a first clinical
event suggestive of multiple sclerosis: 5-year active treatment extension of the
phase 3 BENEFIT trial. Lancet Neurol 2009;8:987–97
Irrelevant intervention/study type
Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, et al.
Efficacy and safety of oral fumarate in patients with relapsing–remitting multiple
sclerosis: a multicentre, randomised, double-blind, placebo-controlled Phase IIb
study. Lancet 2008;372:1463–72
Irrelevant comparator/intervention
Kappos L, Traboulsee A, Constantinescu C, Erälinna JP, Forrestal F, Jongen P,
et al. Long-term subcutaneous interferon beta-1a therapy in patients with
relapsing–remitting MS. Neurology 2006;67:944–53
Irrelevant population/study type
Kappos L, Wiendl H, Selmaj K, Arnold DL, Havrdova E, Boyko A, et al. Daclizumab
HYP versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med
2015;373:1418–28. http://dx.doi.org/10.1056/NEJMoa1501481
Irrelevant comparator/intervention
Katz B. The Tübingen Study on Optic Neuritis Treatment – a prospective,
randomized and controlled trial. Surv Ophthalmol 1994;39:262–3
Irrelevant comparator/intervention
Keltner JL, Johnson CA, Cello KE, Dontchev M, Gal RL, Beck RW, et al. Visual field
profile of optic neuritis: a final follow-up report from the optic neuritis treatment
trial from baseline through 15 years. Arch Ophthalmol 2010;128:330–7
Irrelevant comparator/intervention/
outcome
Keltner JL, Johnson CA, Spurr JO, Beck RW. Visual field profile of optic neuritis.
One-year follow-up in the Optic Neuritis Treatment Trial. Arch Ophthalmol
1994;112:946–53
Irrelevant comparator/intervention/
study type
Kieseier BC, Arnold DL, Balcer LJ, Boyko AA, Pelletier J, Liu S, et al. Peginterferon
beta-1a in multiple sclerosis: 2-year results from ADVANCE. Mult Scler
2015;21:1025–35. http://dx.doi.org/10.1177/1352458514557986
Irrelevant comparator/intervention
Kinkel RP, Dontchev M, Kollman C, Skaramagas TT, O’Connor PW, Simon JH, et al.
Association between immediate initiation of intramuscular interferon beta-1a at
the time of a clinically isolated syndrome and long-term outcomes: a 10-year
follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study
in Ongoing Neurological Surveillance. Arch Neurol 2012;69:183–90
Irrelevant comparator/intervention
Kinkel RP, Kollman C, O’Connor P, Murray TJ, Simon J, Arnold D, et al. IM
interferon beta-1a delays definite multiple sclerosis 5 years after a first
demyelinating event. Neurology 2006;66:678–84
Irrelevant comparator/intervention
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TABLE 103 Records excluded from the clinical effectiveness review with reasons (continued )
Reference Reason for exclusion
Kinkel RP, Simon JH, O’Connor P, Hyde R, Pace A. Early MRI activity predicts
treatment nonresponse with intramuscular interferon beta-1a in clinically isolated
syndrome. Mult Scler Relat Disord 2014;3:712–19
Irrelevant population
Koch-Henriksen N, Sørensen PS. The Danish National Project of interferon-beta
treatment in relapsing–remitting multiple sclerosis. The Danish Multiple Sclerosis
Group. Mult Scler 2000;6:172–5
DMT used with a non-recommended
dose regimen
Koch-Henriksen N, Sørensen PS, Christensen T, Frederiksen J, Ravnborg M,
Jensen K, et al. A randomized study of two interferon-beta treatments in
relapsing–remitting multiple sclerosis. Neurology 2006;66:1056–60
DMT used with a non-recommended
dose regimen
Kott E, Kessler A, Biran S. Optic neuritis in multiple sclerosis patients treated with
Copaxone. J Neurol 1997;244:S23–4
Conference abstract
La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F, et al.
Interferons-beta versus glatiramer acetate for relapsing–remitting multiple sclerosis.
Cochrane Database Syst Rev 2014;7:CD009333
Systematic review that did not
enable location of further primary
studies
La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F, et al.
Comparative efficacy of interferon beta versus glatiramer acetate for
relapsing–remitting multiple sclerosis. J Neurol Neurosurg Psychiatry
2015;86:1016–20
Systematic review that did not
enable location of further primary
studies
La Mantia L, Vacchi L, Di Pietrantonj C, Ebers G, Rovaris M, Fredrikson S, et al.
Interferon beta for secondary progressive multiple sclerosis. Cochrane Database
Syst Rev 2012;1:CD005181
Systematic review that did not
enable location of further primary
studies
La Mantia L, Vacchi L, Rovaris M, Di Pietrantonj C, Ebers G, Fredrikson S, et al.
Interferon beta for secondary progressive multiple sclerosis: a systematic review.
J Neurol Neurosurg Psychiatry 2013;84:420–6
Systematic review that did not
enable location of further primary
studies
Lacy M, Hauser M, Pliskin N, Assuras S, Valentine MO, Reder A. The effects of
long-term interferon-beta-1b treatment on cognitive functioning in multiple
sclerosis: a 16-year longitudinal study. Mult Scler 2013;19:1765–72
Irrelevant comparator/intervention
Lam S, Wang S, Gottesman M. Interferon-beta1b for the treatment of multiple
sclerosis. Expert Opin Drug Metab Toxicol 2008;4:1111–17. http://dx.doi.org/
10.1517/17425255.4.8.1111
Irrelevant study type
Leary SM, Miller DH, Stevenson VL, Brex PA, Chard DT, Thompson AJ. Interferon
beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.
Neurology 2003;60:44–51
Irrelevant population
Lessell S. Corticosteroid treatment of acute optic neuritis. N Engl J Med
1992;326:634–5. http://dx.doi.org/10.1056/NEJM199202273260909
Irrelevant study type
Likhar N, Mothe RK, Esam H, Kinra G, Shah C, Dang A. Epidemiology and
current treatment of neuromyelitis optica: a systematic review. Value Health
2015;18:A750–1. http://dx.doi.org/10.1016/j.jval.2015.09.2904
Conference abstract
Liu Y, Duan Y, He Y, Wang J, Xia M, Yu C, et al. Altered topological organization
of white matter structural networks in patients with neuromyelitis optica. PLOS
ONE 2012;7:e48846. http://dx.doi.org/10.1371/journal.pone.0048846
Irrelevant study type
Mahdi-Rogers M, van Doorn PA, Hughes RAC. Immunomodulatory treatment
other than corticosteroids, immunoglobulin and plasma exchange for chronic
inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev
2013;6:CD003280. http://dx.doi.org/10.1002/14651858.CD003280.pub4
Irrelevant population/study type
Manova MG, Kostadinova II, Akabaliev VC. A clinical study of multiple sclerosis
patients treated with betaferon. Folia Med 2008;50:24–9
Irrelevant intervention/population
Manova MG, Kostadinova II. Adverse drug reactions after 24-month treatment
with two-dosage regimens of betaferon in patients with multiple sclerosis. Folia
Med 2009;51:31–6
Irrelevant population
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TABLE 103 Records excluded from the clinical effectiveness review with reasons (continued )
Reference Reason for exclusion
Martínez Férez IM, Flores Moreno S, Rodríguez López R. Efficacy and Safety of the
Immunoregulatory Drugs Interferon Beta and Glatiramer in the Treatment of
Relapsing Remitting Multiple Sclerosis. 2013. URL: www.juntadeandalucia.es/salud/
servicios/contenidos/nuevaaetsa/up/AETSA_4_2013_InterferonGlatiramero_EM.pdf
(accessed 1 June 2016)
Non-English-language study
Massacesi L, Tramacere I, Amoroso S, Battaglia MA, Benedetti MD, Filippini G,
et al. (2014). Azathioprine versus beta interferons for relapsing–remitting multiple
sclerosis: a multicentre randomized non-inferiority trial. PLOS ONE 2014;9:e113371
Irrelevant comparator/intervention
Mazdeh M, Mobaien AR. Efficacy of doxycycline as add-on to interferon beta-1a in
treatment of multiple sclerosis. Iran J Neurol 2012;11:70–3
Irrelevant comparator/intervention
Meca-Lallana JE, Hernández-Clares R, Carreón-Guarnizo E. Spasticity in multiple
sclerosis and role of glatiramer acetate treatment. Brain Behav 2015;5:e00367.
http://dx.doi.org/10.1002/brb3.367
Irrelevant study type
Melo A, Rodrigues B, Bar-Or A. Beta interferons in clinically isolated syndromes:
a meta-analysis. Arq Neuropsiquiatr 2008;66:8–10
Systematic review that did not
enable location of further primary
studies
Meng X, Chin PS, Hashmonay R, Zahur Islam M, Cutter G. Effect of switching from
intramuscular interferon beta-1a to oral fingolimod on time to relapse in patients
with relapsing–remitting multiple sclerosis enrolled in a 1-year extension of
TRANSFORMS. Contemp Clin Trials 2015;41:69–74
Irrelevant comparator/intervention
Menon V, Saxena R, Misra R, Phuljhele S. Management of optic neuritis. Indian J
Ophthalmol 2011;59:117–22. http://dx.doi.org/10.4103/0301-4738.77020
Irrelevant study type
Messori A, Fadda V, Maratea D, Trippoli S. Indirect meta-analytical comparison of
azathioprine and of beta interferon effectiveness in all forms of multiple sclerosis
pooled together. J Neurol Sci 2014;347:408–10
Irrelevant study type
Miller D, Rudick RA, Hutchinson M. Patient-centered outcomes: translating
clinical efficacy into benefits on health-related quality of life. Neurology
2010;74(Suppl. 3):24–35. http://dx.doi.org/10.1212/WNL.0b013e3181dbb884
No results are provided, refers to
results from a conference abstract
Miller DH, Fox RJ, Phillips JT, Hutchinson M, Havrdova E, Kita M, et al. Effects of
delayed-release dimethyl fumarate on MRI measures in the Phase 3 CONFIRM
study. Neurology 2015;84:1145–52. http://dx.doi.org/10.1212/WNL.
0000000000001360
Irrelevant outcome
Minagara A, Murray TJ, PROOF Study Investigators. Efficacy and tolerability of
intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a
in relapsing MS: results from PROOF. Curr Med Res Opin 2008;24:1049–55.
http://dx.doi.org/10.1185/030079908X280545
Irrelevant population/study type
Minocycline in Clinically Isolated Syndromes (CIS). ClinicalTrials.gov, National
Institutes of Health; 2010. URL: https://clinicaltrials.gov/ct2/show/NCT00666887
(accessed 15 June 2017)
Protocol only with no results
Montalban X, Sastre-Garriga J, Tintore M, Brieva L, Aymerich FX, Rio J, et al. A
single-centre, randomised, double-blind, placebo-controlled study of interferon
beta-1b on primary progressive and transitional multiple sclerosis. Mult Scler
2009;15:1195–205
Irrelevant population
Motamed MR, Najimi N, Fereshtehnejad SM. The effect of interferon-beta1a on
relapses and progression of disability in patients with clinically isolated syndromes
(CIS) suggestive of multiple sclerosis. Clin Neurol Neurosurg 2007;109:344–9
DMT used with a non-recommended
dose regimen
Nafissi S, Azimi A, Amini-Harandi A, Salami S, Shahkarami MA, Heshmat R.
Comparing efficacy and side effects of a weekly intramuscular biogeneric/biosimilar
interferon beta-1a with Avonex in relapsing remitting multiple sclerosis: a double
blind randomized clinical trial. Clin Neurol Neurosurg 2012;114:986–9
Irrelevant comparator/intervention
Nagtegaal GJ, Pohl C, Wattjes MP, Hulst HE, Freedman MS, Hartung HP, et al.
Interferon beta-1b reduces black holes in a randomised trial of clinically isolated
syndrome. Mult Scler 2014;20:234–42
Irrelevant outcome
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
270
TABLE 103 Records excluded from the clinical effectiveness review with reasons (continued )
Reference Reason for exclusion
National Horizon Scanning Centre. Glatiramer Acetate (Copaxone) for a Single
Demyelinating Event with an Active Inflammatory Process. Horizon Scanning
Technology Briefing. Birmingham: National Horizon Scanning Centre; 2008
Not a primary research study
National Horizon Scanning Centre. Laquinimod for Multiple Sclerosis: Relapsing–
Remitting – First or Second Line. Horizon Scanning Review. Birmingham: National
Horizon Scanning Centre; 2011
Not a primary research study
National Horizon Scanning Centre. Teriflunomide for Relapsing Multiple Sclerosis
(MS) – First Line. Horizon Scanning Review. Birmingham: National Horizon
Scanning Centre; 2011
Not a primary research study
Neuroprotection with Riluzole Patients with Early Multiple Sclerosis. ClinicalTrials.gov,
National Institutes of Health; 2006. URL: https://clinicaltrials.gov/ct2/show/
NCT00501943 (accessed 15 June 2017)
Protocol only with no results
Nicholas R, Straube S, Schmidli H, Pfeiffer S, Friede T. Time-patterns of annualized
relapse rates in randomized placebo-controlled clinical trials in relapsing multiple
sclerosis: a systematic review and meta-analysis. Mult Scler 2012;18:1290–6
Irrelevant intervention/study type
NIHR Horizon Scanning Centre. Ocrelizumab for Relapsing–Remitting Multiple
Sclerosis. 2014. URL: www.hsric.nihr.ac.uk/topics/ocrelizumab-for-relapsing–
remitting-multiple-sclerosis/ (accessed 1 June 2016)
Irrelevant study type
Norman G, Rice S, O’Connor J, Lewis-Light K, Craig D, McDaid C. Dimethyl
Fumarate for the Treatment of Relapsing Remitting Multiple Sclerosis. CRD and
CHE Technology Assessment Group Report. 2013. URL: www.nets.nihr.ac.uk/
projects/hta/128101 (accessed 1 June 2016)
Irrelevant study type
Optic Neuritis Study Group. The 5-year risk of MS after optic neuritis. Experience of
the optic neuritis treatment trial. Neurology 1997;49:1404–13
Irrelevant comparator/intervention
Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: final optic
neuritis treatment trial follow-up. Arch Neurol 2008;65:727–32
Irrelevant study type
Optic Neuritis Study Group. Visual function 15 years after optic neuritis: a final
follow-up report from the Optic Neuritis Treatment Trial. Ophthalmology
2008;115:1079–82.e1075
Irrelevant comparator/intervention
Optic Neuritis Treatment Trial (ONTT). ClinicalTrials.gov, National Institutes of
Health; 2006. URL: https://clinicaltrials.gov/ct2/show/NCT00000146 (accessed
15 June 2017)
Protocol only with no results
Oral Cladribine in Early Multiple Sclerosis (MS). ClinicalTrials.gov, National Institutes
of Health; 2010. URL: https://clinicaltrials.gov/ct2/show/NCT00725985 (accessed
15 June 2017)
Protocol only with no results
Pakdaman H, Fallah A, Sahraian MA, Pakdaman R, Meysamie A. Treatment of
early onset multiple sclerosis with suboptimal dose of interferon beta-1a.
Neuropediatrics 2006;37:257–60. http://dx.doi.org/10.1055/s-2006-924723
DMT used with a non-recommended
dose regimen
Panitch HS. Interferons in multiple sclerosis. A review of the evidence. Drugs
1992;44:946–62
Irrelevant study type
Paolillo A, Pozzilli C, Giugni E, Tomassini V, Gasperini C, Fiorelli M, et al. A 6-year
clinical and MRI follow-up study of patients with relapsing–remitting multiple
sclerosis treated with interferon-beta. Eur J Neurol 2002;9:645–55
Irrelevant population
Patten SB, Metz LM. Hopelessness ratings in relapsing–remitting and secondary
progressive multiple sclerosis. Int J Psychiatry Med 2002;32:155–65
Irrelevant outcome
Perry M, Swain S, Kemmis-Betty S, Cooper P, Guideline Development Group of the
National Institute for Health and Care Excellence. Multiple sclerosis: summary of
NICE guidance. BMJ 2014;349:g5701. http://dx.doi.org/10.1136/bmj.g5701
Irrelevant study type
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TABLE 103 Records excluded from the clinical effectiveness review with reasons (continued )
Reference Reason for exclusion
Phase III Study with Teriflunomide Versus Placebo in Patients with First Clinical
Symptom of Multiple Sclerosis. ClinicalTrials.gov, National Institutes of Health;
2008. URL: https://clinicaltrials.gov/ct2/show/NCT00622700 (accessed
15 June 2017)
Protocol only with no results
Phase IV, Rater-blinded, Randomized Study, Comparing the Effects of 250 mg of
Betaseron with 20 mg of Copaxone in Patients with the Relapsing–Remitting or
Clinically Isolated Forms of Multiple Sclerosis using 3 Tesla MRI with Triple-Dose
Gadolinium. ClinicalTrials.gov, National Institutes of Health; 2003. URL: https://
clinicaltrials.gov/ct2/show/NCT00176592 (accessed 15 June 2017)
Protocol only with no results
Pöllmann W, Erasmus LP, Feneberg W, Straube A. The effect of glatiramer
acetate treatment on pre-existing headaches in patients with MS. Neurology
2006;66:275–7
Irrelevant population/study type
Putzki N, Bell SH, Reynolds JN, Kinkel RP, Dontchev M, Tanner JP, et al.
CHAMPIONS extension: 10-year outcomes in interferon beta-1a-treated patients
at high risk for developing multiple sclerosis after a clinically isolated syndrome.
J Neurol Sci 2009;285:S119–20
Conference abstract
Qizilbash N, Mendez I, Sanchez-de la Rosa R. Benefit–risk analysis of glatiramer
acetate for relapsing–remitting and clinically isolated syndrome multiple sclerosis.
Clin Ther 2012;34:159–76.e155
Systematic review that did not
enable location of further primary
studies
REbif FLEXible Dosing in Early Multiple Sclerosis (MS). ClinicalTrials.gov, National
Institutes of Health; 2010. URL: https://clinicaltrials.gov/ct2/show/NCT00404352
(accessed 15 June 2017)
Protocol only with no results
Remington GM, Treadaway K, Frohman T, Salter A, Stuve O, Racke MK, et al.
A one-year prospective, randomized, placebo-controlled, quadruple-blinded,
Phase II safety pilot trial of combination therapy with interferon beta-1a and
mycophenolate mofetil in early relapsing–remitting multiple sclerosis (TIME MS).
Ther Adv Neurol Disord 2010;3:3–13
Irrelevant comparator/population
Roskell NS, Zimovetz EA, Rycroft CE, Eckert BJ, Tyas DA. Annualized relapse rate
of first-line treatments for multiple sclerosis: a meta-analysis, including indirect
comparisons versus fingolimod. Curr Med Res Opin 2012;28:767–80
Systematic review that did not
enable location of further primary
studies
Rovaris M, Comi G, Rocca MA, Valsasina P, Ladkani D, Pieri E, et al. Long-term
follow-up of patients treated with glatiramer acetate: a multicentre, multinational
extension of the European/Canadian double-blind, placebo-controlled,
MRI-monitored trial. Mult Scler 2007;13:502–8
Irrelevant population/study type
Rovaris M, Comi G, Rocca MA, Wolinsky JS, Filippi M. Short-term brain volume
change in relapsing–remitting multiple sclerosis: effect of glatiramer acetate and
implications. Brain 2001;124:1803–12
Irrelevant outcome
Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, et al.
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med
2006;354:911–23
Irrelevant comparator/intervention
Rudick R, Miller DM, Weinstock-Guttman B, Bourdette DN, Foulds P, You X.
The relationship between baseline clinical measures and quality of life in patients
with relapsing multiple sclerosis: analyses from the Phase 3 trial of intramuscular
interferon beta-1a. Mult Scler 2008;14:S293
Conference abstract
Saida T, Kikuchi S, Itoyama Y, Hao Q, Kurosawa T, Nagato K, et al. A randomized,
controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis.
Mult Scler 2012;18:1269–77. http://dx.doi.org/10.1177/1352458511435984
Irrelevant comparator/intervention
Saida T, Tashiro K, Itoyama Y, Sato T, Ohashi Y, Zhao Z, Interferon Beta-1b
Multiple Sclerosis Study Group of Japan. Interferon beta-1b is effective in Japanese
RRMS patients: a randomized, multicenter study. Neurology 2005;64:621–30
DMT used with a non-recommended
dose regimen
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TABLE 103 Records excluded from the clinical effectiveness review with reasons (continued )
Reference Reason for exclusion
Seddighzadeh A, Hung S, Selmaj K, Cui Y, Liu S, Sperling B, et al. Single-use
autoinjector for peginterferon-beta1a treatment of relapsing–remitting multiple
sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN
study. Expert Opin Drug Deliv 2014;11:1713–20
Irrelevant intervention/study type
Sellner J, Boggild M, Clanet M, Hintzen RQ, Illes Z, Montalban X, et al. EFNS
guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol
2010;17:1019–32. http://dx.doi.org/10.1111/j.1468-1331.2010.03066.x
Irrelevant intervention/study type
Siddiqui MA, Wellington K. Intramuscular interferon-beta-1a: in patients at high
risk of developing clinically definite multiple sclerosis. CNS Drugs 2005;19:55–61
Irrelevant study type
Simon, JH, Jacobs LD, Campion M, Wende K, Simonian N, Cookfair DL, et al.
Magnetic resonance studies of intramuscular interferon beta-1a for relapsing
multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol
1998;43:79–87
Irrelevant outcome
Simvastatin Treatment of Patients with Acute Optic Neuritis. ClinicalTrials.gov,
National Institutes of Health; 2006. URL: https://clinicaltrials.gov/ct2/show/
NCT00261326 (accessed 15 June 2017)
Protocol only with no results
Soilu-Hanninen M, Aivo J, Lindstrom BM, Elovaara I, Sumelahti ML, Farkkila M,
et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an
add on treatment to interferon beta-1b in patients with multiple sclerosis. J Neurol
Neurosurg Psychiatry 2012;83:565–71
Irrelevant comparator/intervention
Sorensen PS, Lisby S, Grove R, Derosier F, Shackelford S, Havrdova E, et al.
Safety and efficacy of ofatumumab in relapsing–remitting multiple sclerosis:
a Phase 2 study. Neurology 2014;82:573–81. http://dx.doi.org/10.1212/
WNL.0000000000000125
Irrelevant comparator/intervention
Sormani MP, Bruzzi P, Beckmann K, Wagner K, Miller DH, Kappos L, et al. MRI
metrics as surrogate endpoints for EDSS progression in SPMS patients treated with
IFN beta-1b. Neurology 2003;60:1462–6
Irrelevant outcome
Ste˛pien´ A, Chalimoniuk M, Lubina-Dabrowska N, Chrapusta SJ, Galbo H, Langfort J.
Effects of interferon β-1a and interferon β-1b monotherapies on selected serum
cytokines and nitrite levels in patients with relapsing–remitting multiple sclerosis:
a 3-year longitudinal study. Neuroimmunomodulation 2013;20:213–22
Irrelevant population/outcomes
Study to Compare Double-Dose Betaferon to the Approved Dose, for Patients with
Early Secondary Progressive Multiple Sclerosis (SPMS). ClinicalTrials.gov, National
Institutes of Health; 2008. URL: https://clinicaltrials.gov/ct2/show/NCT00313976
(accessed 15 June 2017)
Protocol only with no results
Sühs KW, Hein K, Pehlke JR, Käsmann-Kellner B, Diem R. Retinal nerve fibre layer
thinning in patients with clinically isolated optic neuritis and early treatment with
interferon-beta. PLOS ONE 2012;7:e51645. http://dx.doi.org/10.1371/journal.pone.
0051645
Irrelevant study type
Tolley K, Hutchinson M, You X, Wang P, Sperling B, Taneja A, et al. A Network
meta-analysis of efficacy and evaluation of safety of subcutaneous pegylated
interferon beta-1a versus other injectable therapies for the treatment of
relapsing–remitting multiple sclerosis. PLOS ONE 2015;10:e0127960
Systematic review that did not
enable location of further primary
studies
Tsivgoulis G, Katsanos AH, Grigoriadis N, Hadjigeorgiou GM, Heliopoulos I,
Kilidireas C. The effect of disease modifying therapies on brain atrophy in patients
with relapsing–remitting multiple sclerosis: a systematic review and meta-analysis.
PLOS ONE 2015;10:e0116511
Irrelevant outcome/study type
Tsivgoulis G, Katsanos AH, Grigoriadis N, Hadjigeorgiou GM, Heliopoulos I,
Papathanasopoulos P, et al. The effect of disease modifying therapies on disease
progression in patients with relapsing–remitting multiple sclerosis: a systematic
review and meta-analysis. PLOS ONE 2015;10:e0144538
Systematic review that did not
enable location of further primary
studies
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TABLE 103 Records excluded from the clinical effectiveness review with reasons (continued )
Reference Reason for exclusion
Tsivgoulis G, Katsanos AH, Grigoriadis N, Hadjigeorgiou GM, Heliopoulos I,
Papathanasopoulos P, et al. The effect of disease-modifying therapies on brain
atrophy in patients with clinically isolated syndrome: a systematic review and
meta-analysis. Ther Adv Neuro Disord 2015;8:193–202
Irrelevant outcome/study type/
population
Vermersch P, Czlonkowska A, Grimaldi LM, Confavreux C, Comi G, Kappos L,
et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with
relapsing multiple sclerosis: a randomised, controlled Phase 3 trial. Mult Scler
2014;20:705–16
Irrelevant comparator/intervention
Vollmer T, Jeffery D, Goodin D, Kappos L, Lublin F, Radue EW. Long-term safety
of fingolimod in patients with relapsing–remitting multiple sclerosis: results from
Phase 3 FREEDOMS II extension study. Neurology 2013;80(7 Suppl.):P01.165
Irrelevant comparator/intervention
Vollmer T, Panitch H, Bar-Or A, Dunn J, Freedman MS, Gazda SK, et al. Glatiramer
acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis.
Mult Scler 2008;14:663–70
Irrelevant comparator/population
Vollmer TL, Sorensen PS, Selmaj K, Zipp F, Havrdova E, Cohen JA, et al. A
randomized placebo-controlled Phase III trial of oral laquinimod for multiple sclerosis.
J Neurol 2014;261:773–83. http://dx.doi.org/10.1007/s00415-014-7264-4
Conference abstract
Voskuhl RR, Wang H, Wu TC, Sicotte NL, Nakamura K, Kurth F, et al. Estriol
combined with glatiramer acetate for women with relapsing–remitting multiple
sclerosis: a randomised, placebo-controlled, Phase 2 trial. Lancet Neurol
2016;15:35–46
Irrelevant comparator/intervention
Waubant E, Maghzi AH, Revirajan N, Spain R, Julian L, Mowry EM, et al.
A randomized controlled Phase II trial of riluzole in early multiple sclerosis. Ann Clin
Transl Neurol 2014;1:340–7
Irrelevant comparator/intervention
Waubant E, Pelletier D, Mass M, Cohen JA, Kita M, Cross A, et al. Randomized
controlled trial of atorvastatin in clinically isolated syndrome. The STAyCIS study.
Neurology 2012;78:1171–8
Irrelevant comparator/intervention
Weinshenker BG. Review: in relapsing–remitting multiple sclerosis, disease-
modifying agents reduce annual relapse rates. Ann Intern Med 2014;160:JC5
Conference abstract
Weinstock-Guttman B, Galetta SL, Giovannoni G, Havrdova E, Hutchinson M,
Kappos L, et al. Additional efficacy endpoints from pivotal natalizumab trials in
relapsing–remitting MS. J Neurol 2012;259:898–905. http://dx.doi.org/10.1007/
s00415-011-6275-7
Irrelevant comparator/intervention
Wolinsky JS, Borresen TE, Dietrich DW, Wynn D, Sidi Y, Steinerman JR, et al.
GLACIER: an open-label, randomized, multicenter study to assess the safety and
tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily
in patients with relapsing–remitting multiple sclerosis. Mult Scler Relat Disord
2015;4:370–6
Irrelevant study type
Wolinsky JS, Narayana PA, O’Connor P, Coyle PK, Ford C, Johnson K, et al.
Glatiramer acetate in primary progressive multiple sclerosis: results of a
multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol
2007;61:14–24
Irrelevant population
Wynn D, Kaufman M, Montalban X, Vollmer T, Simon J, Elkins J, et al. Daclizumab
in active relapsing multiple sclerosis (CHOICE study): a Phase 2, randomised,
double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol
2010;9:381–90
Irrelevant intervention
Zagmutt FJ, Carroll CA. Meta-analysis of adverse events in recent randomized clinical
trials for dimethyl fumarate, glatiramer acetate and teriflunomide for the treatment
of relapsing forms of multiple sclerosis. Int J Neurosci 2015;125:798–807
Systematic review that did not
enable location of further primary
studies
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TABLE 103 Records excluded from the clinical effectiveness review with reasons (continued )
Reference Reason for exclusion
Ziemssen T, Hoffman J, Apfel R, Kern S. Effects of glatiramer acetate on fatigue
and days of absence from work in first-time treated relapsing–remitting multiple
sclerosis. Health Qual Life Outcomes 2008;6:67. http://dx.doi.org/10.1186/
1477-7525-6-67
Irrelevant population/study type
Zintzaras E, Doxani C, Mprotsis T, Schmid CH, Hadjigeorgiou GM. Network
analysis of randomized controlled trials in multiple sclerosis. Clin Ther
2012;34:857–69.e859
Systematic review that did not
enable location of further primary
studies
Zivadinov R, Dwyer MG, Ramasamy DP, Davis MD, Steinerman JR, Khan O. The
effect of three times a week glatiramer acetate on cerebral T1 hypointense lesions
in relapsing–remitting multiple sclerosis. J Neuroimaging 2015;25:989–95
Irrelevant outcome
Note
Includes several duplicate records that we had not identified as such before analysis at full-text.
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Appendix 4 Studies included in the clinical
effectiveness review with relevant publications
Study ID Title Full article(s): main Full article(s): other
ADVANCE
2014
A Multicenter, Randomized, Double-Blind,
Parallel-Group, Placebo-Controlled Study to
Evaluate the Efficacy and Safety of PEGylated
Interferon Beta-1a (BIIB017) in Subjects With
Relapsing Multiple Sclerosis
Calabresi et al.213 Arnold et al.214 (MRI),
Newsome et al.215 (HRQoL)
AVANTAGE
2014
Safety Study in Relapsing–remitting Multiple
Sclerosis (RRMS) Patients Receiving Betaferon
or Rebif
No formal publication;
results on company
website182 and
ClinicalTrials.gov
BECOME 2009 Phase IV, Rater-blinded, Randomized Study,
Comparing 250mg of Betaseron With
20mg of Copaxone in Patients With the
Relapsing–remitting (RR) or CIS Forms of ms
Using 3 Tesla(3 T) Magnetic Resonance
Imaging (MRI) With Triple-dose Gadolinium
Cadavid et al.184 Cadavid et al.212
BENEFIT 2006 The BEtaferon in Newly Emerging Multiple
Sclerosis for Initial Treatment (BENEFIT) trial
Kappos et al.171 Polman et al.179 (subgroup
analysis), Penner et al.180
(cognitive performance in
CIS)
BEYOND 2009 International, Randomized, Multicenter, Phase
IIIb Study in Patients With Relapsing-Remitting
Multiple Sclerosis Comparing Over a
Treatment Period of at Least 104 Weeks:
1. Double-Blinded Safety, Tolerability, and
Efficacy of Betaseron/Betaferon 250 µg
(8 MIU) and Betaseron/-Betaferon 500 µg
(16 MIU), Both Given Subcutaneously Every
Other Day, and 2. Rater-Blinded Safety,
Tolerability, and Efficacy of Betaseron/
-Betaferon s.c. Every Other Day With
Copaxone 20mg s.c. Once Daily
O’Connor et al.190 Filippi et al.226 (post hoc
analysis of MRI scans)
Bornstein
1987
A pilot trial of Cop 1 in exacerbating-remitting
multiple sclerosis
Bornstein et al.170
BRAVO 2014 A Multinational, Multicenter, Randomized,
Parallel-group Study Performed in Subjects
With RRMS to Assess the Efficacy, Safety and
Tolerability of Laquinimod Over Placebo in a
Double-blind Design and a Reference Arm of
Interferon β–1a (Avonex®) in a Rater-blinded
Design
Vollmer et al.198
Calabrese
2012
Effect of disease-modifying drugs on cortical
lesions and atrophy in relapsing–remitting
multiple sclerosis
Calabrese et al.188
CHAMPS
2000
Intramuscular interferon beta-1a therapy
initiated during a first demyelinating event in
multiple sclerosis
Jacobs et al.172 Beck et al.176 (subgroup
analysis, CHAMPS Study
Group227 (subgroup of
acute optic neuritis),
O’Connor228 (subgroup
analysis), O’Connor et al.177
(subgroup analysis)
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Study ID Title Full article(s): main Full article(s): other
CombiRx 2013 A Multi-Center, Double-Blind, Randomized
Study Comparing the Combined Use of
Interferon Beta-1a and Glatiramer Acetate to
Either Agent Alone in Patients With Relapsing-
Remitting Multiple Sclerosis (CombiRx)
Lublin et al.191 Lindsey et al.229 (protocol)
CONFIRM
2012
A Randomized, Multicenter, Placebo-
Controlled and Active Reference (Glatiramer
Acetate) Comparison Study to Evaluate the
Efficacy and Safety of BG00012 in Subjects
With Relapsing-Remitting Multiple Sclerosis
Fox et al.216 Kita et al.230 (HRQoL)
Cop1 MSSG
1995
Copolymer 1 reduces relapse rate and
improves disability in relapsing-remitting
multiple sclerosis: results of a phase III
multicenter, double-blind placebo-controlled
trial
Johnson et al.217 (initial
findings)
Johnson et al.218 (final
results)
ECGASG 2001 European/Canadian multicenter, double-blind,
randomized, placebo-controlled study of the
effects of glatiramer acetate on magnetic
resonance imaging–measured disease activity
and burden in patients with relapsing multiple
sclerosis
Comi et al.219
ESG 1998 Placebo-controlled multicentre randomised
trial of interferon-1b in treatment of
secondary progressive multiple sclerosis
European Study Group
on Interferon Beta-1b in
Secondary Progressive
MS222
Kappos et al.225 (final
results)
Etemadifar
2006
Comparison of Betaferon, Avonex, and Rebif
in treatment of relapsing–remitting multiple
sclerosis
Etemadifar et al.185
EVIDENCE
2007
Full results of the Evidence of Interferon
Dose-Response-European North American
Comparative Efficacy (EVIDENCE) study: a
multicenter, randomized, assessor-blinded
comparison of low-dose weekly versus
high-dose, high-frequency interferon beta-1a
for relapsing multiple sclerosis
Schwid and Panitch195 Panitch et al.193
(comparative results),
Panitch et al.194 (final
comparative results),
Sandberg-Wollheim et al.206
(AEs)
GALA 2013 Three times weekly glatiramer acetate in
relapsing–remitting multiple sclerosis
Khan et al.221
GATE 2015 Multi-centre, Randomized, Double-blind,
Placebo-controlled, Parallel-group, 9 Month,
Equivalence Trial Comparing the Efficacy and
Safety and Tolerability of GTR (Synthon BV) to
Copaxone® (Teva) in Subjects With Relapsing
Remitting Multiple Sclerosis Followed by an
Open-label 15 Month GTR Treatment Part
Evaluating the Long-term GTR Treatment
Effects
Cohen et al.220
IFNB MSSG
1995
Interferon beta-1b is effective in
relapsing–remitting multiple sclerosis. I.
Clinical results of a multicenter, randomized,
double-blind, placebo-controlled trial
IFNB Multiple Sclerosis
Study Group209
IFNB Multiple Sclerosis
Study Group210 (additional
data and further details)
IMPROVE
2012
A Two-arm, Randomized, Double-blind,
Control Group-compared, Multicenter,
Phase IIIb Study With Monthly MRI and
Biomarker Assessments to Evaluate the
Efficacy, Safety, and Tolerability of Rebif® New
Formulation (IFN Beta-1a) in Subjects With
Relapsing Remitting Multiple Sclerosis
De Stefano et al.207
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Study ID Title Full article(s): main Full article(s): other
INCOMIN
2002
Every-other-day interferon beta-1b versus
once-weekly interferon beta-1a for multiple
sclerosis: results of a 2-year prospective
randomised multicentre study (INCOMIN)
Durelli et al.196
Kappos 2011 Phase II, Multicenter, Randomized, Parallel-
Group, Partially Blinded, Placebo and Avonex
Controlled Dose Finding Study to Evaluate the
Efficacy As Measured by Brain MRI Lesions,
and Safety of 2 Dose Regimens of
Ocrelizumab in Patients With RRMS
Kappos et al.199
Knobler 1993 Systemic recombinant human interferon-β
treatment of relapsing-remitting multiple
sclerosis: pilot study analysis and six-year
follow-up
Knobler et al.211
Mokhber
2014
Cognitive dysfunction in patients with
multiple sclerosis treated with different types
of interferon beta: a randomized clinical trial
Mokhber et al.186 Mokhber et al.187 (HRQoL)
MSCRG 1996 Intramuscular interferon beta-1a for disease
progression in relapsing multiple sclerosis
Jacobs et al.200 Fischer et al.,203 Goodkin
et al.,202 Granger et al.,204
Miller et al.,205 Rudick et al.201
NASG 2004 Interferon beta-1b in secondary progressive
MS
Panitch et al.223
Pakdaman
2007
Effect of early interferon beta-1a therapy on
conversion to multiple sclerosis in Iranian
patients with a first demyelinating event
Pakdaman et al.173
PreCISe 2009 A Multinational, Multicenter, Randomized,
Double-Blind, Placebo Controlled, Parallel
Group Study to Evaluate the Effect of Early
Glatiramer Acetate Treatment in Delaying the
Conversion to Clinically Definite Multiple
Sclerosis (CDMS) of Subjects Presenting With
Clinically Isolated Syndrome (CIS)
Comi et al.174
PRISMS 1998 Randomised double-blind placebo-controlled
study of interferon beta-1a in relapsing/
remitting multiple sclerosis
PRISMS Study Group189 Patten and Metz208
(depression), Gold et al.231
(4-year safety and
tolerability)
REFLEX 2012 A Phase III, Randomized, Double-blind,
Placebo-controlled, Multicenter Clinical Trial
of Rebif New Formulation (44 Microgram
[Mcg] Three Times Weekly [Tiw] and 44 Mcg
Once Weekly [ow]) in Subjects at High Risk of
Converting to Multiple Sclerosis (REFLEX)
Comi et al.175 Freedman et al.178
(subgroup analysis),
CADTH232
REFORMS
2012
A Randomized, Multicenter, Two Arm,
Open Label, Twelve Week Phase IIIb Study
to Evaluate the Tolerability of Rebif (New
Formulation) (IFN Beta-1a) and Betaseron (IFN
Beta-1b) in IFN-naive Subjects With Relapsing
Remitting Multiple Sclerosis (RRMS) Followed
by a Single Arm, Eighty-two Week Minimum,
Rebif (New Formulation) Only Safety Extension
Singer et al.197
REGARD 2008 Phase IV, Multicenter, Open Label,
Randomized Study of Rebif® 44 mcg
Administered Three Times Per Week by
Subcutaneous Injection Compared With
Copaxone® 20 mg Administered Daily by
Subcutaneous Injection in the Treatment of
Relapsing Remitting Multiple Sclerosis
Mikol et al.192
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Study ID Title Full article(s): main Full article(s): other
REMAIN 2012 Phase IV, Multicenter, Open Label,
Randomized Study of Rebif® 44mcg
Administered Three Times Per Week by
Subcutaneous Injection Compared With no
Treatment in the Therapy of Relapsing
Multiple Sclerosis After Mitoxantrone
Rieckmann et al.183
Schwartz 1997 The quality-of-life effects of interferon
beta-1b in multiple sclerosis
Schwartz et al.181
SPECTRIMS
2001
Randomized controlled trial of interferon
beta-1a in secondary progressive MS
SPECTRIMS Study
Group224
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Appendix 5 Overview of systematic reviews in
relapsing–remitting multiple sclerosis, secondary
progressive multiple sclerosis and clinically isolated
syndrome: methods and results
Objective
To provide an overview of systematic reviews, published in the last 5 years, of studies that assessed the
cost-effectiveness of treating RRMS, SPMS and/or CIS.
Search strategy
The following electronic databases were searched from January 2011 to January 2016: MEDLINE (via Ovid);
MEDLINE In-Process & Other Non-Indexed Citations (via Ovid) and MEDLINE Daily Update (via Ovid);
EMBASE (via Ovid); The Cochrane Library (via Wiley Online Library), including the NHS EED and HTA
database; Science Citation Index (Web of Knowledge); RePEc; and the CEA Registry. The database
searches were kept broad with search terms for MS and CIS combined with economic/HRQoL terms and
systematic review terms (based on recognised search filters239–242 when appropriate). Searches for MS
and CIS were performed separately but the results were deduplicated and then combined for assessment.
A full record of the searches is provided at the end of this appendix. The searches were limited to reviews
published in or after 2011. All bibliographic records identified through the electronic searches were
collected in a managed reference database. The reference lists of included studies were also checked.
Grey literature searches were undertaken using the online resources of various regulatory bodies, health
service research agencies, professional societies and patient organisations.
Study selection and inclusion criteria
The selection of studies was undertaken by Peter Auguste and checked by Hendramoorthy Maheswaran
using the following defined criteria. Systematic reviews of economic evaluations that involved the use of
economic models in RRMS/SPMS/CIS were included. Systematic reviews of HRQoL studies in RRMS/SPMS/
CIS were also selected at this stage for later review.
Quality appraisal
The studies were appraised against the AMSTAR framework for best practice in undertaking systematic
reviews.164 The AMSTAR assessment tool consists of a series of criteria/questions (e.g. a priori design, study
selection and data extraction, comprehensive literature search or methods used to combine the findings) to
assess key quality indicators in systematic reviews. Appraisal of the methodological quality of the studies
was undertaken by two reviewers (Hendramoorthy Maheswaran and Peter Auguste). Study quality
assessed by one reviewer was cross-checked by the other reviewer. Any disagreements were resolved by
discussion or by recourse to a third-party reviewer (Jason Madan).
DOI: 10.3310/hta21520 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 52
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Melendez-Torres et al. under the terms of a commissioning contract issued by the Secretary of State
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
281
Results
The electronic database searches identified 1566 records (Figure 35). After removing duplicates, 1023
records were screened for inclusion. On the basis of title and abstract, 966 records were excluded and the
remaining 57 records were included for full-text screening. A further 48 articles were excluded at the
full-text stage, leaving nine systematic reviews,245–253 of which eight were economic evaluation studies245–252
and one was a systematic review of studies that used a generic tool to measure HRQoL in people with
multiple sclerosis.253
Summary
We identified nine245–253 systematic reviews published since January 2011, which included eight reviews of
economic evaluation studies245–252 and one review that looked at generic tools used to measure HRQoL in
people with MS.253
We appraised these studies against the AMSTAR methodological assessment tool. Details on how each
review performed are provided in Table 104. Based on our appraisal, systematic reviews generally
performed satisfactorily in terms of stating an a prori design of the review, stating the characteristics of all
included studies and stating the status of the publication. However, these reviews were also subject to
some limitations. First, most studies were unclear on whether study selection and data extraction were
carried out in duplicate or did not carry out study selection and data extraction in duplicate. Second,
although some authors245–251,253 provided a list of included studies, not all of these authors246,248–250,253
provided a list of excluded studies. Third, it was unclear or not stated whether some authors assessed
and/or documented the scientific quality of the included studies.
Records identified 
through database 
searching
(n = 1566)
Additional records 
identified through 
other sources
(n = 0)
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Records identified
(total before deduplication)
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Full-text articles 
assessed for eligibility
(n = 57)
Studies included in 
qualitative synthesis 
(n = 9)
Duplicate records 
removed
(n = 543)
Records excluded at 
title and abstract level 
(n = 966)
Total number of studies
excluded
(n = 48)
FIGURE 35 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart: systematic
reviews of economic evaluations.
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Based on the quality assessment of these reviews, we considered six studies245,247–251 to be methodologically
robust and likely to capture economic analyses pre 2012. Hence, we undertook a search of primary studies
(for RRMS) with the search date limited to 2012 and later.
Full record of searches
Relapsing–remitting multiple sclerosis searches
MEDLINE (via Ovid)
Database: Ovid MEDLINE® 1946 to January week 2 2016.
Searched on 26 January 2016.
TABLE 105 MEDLINE systematic review search: RRMS cost-effectiveness review
ID Search Hits
1 exp Multiple Sclerosis/ 46,764
2 multiple sclerosis.tw. 49,799
3 1 or 2 57,188
4 exp Economics/ 517,314
5 exp ‘Costs and Cost Analysis’/ 193,082
6 Health Status/ 63,909
7 exp ‘Quality of Life’/ 131,614
8 exp Quality-Adjusted Life Years/ 7896
9 (pharmacoeconomic* or pharmaco-economic* or economic* or cost*).tw. 475,628
10 (health state* or health status).tw. 41,055
11 (qaly* or utilit* or EQ5D or EQ-5D or euroqol or euro-qol or SF-36 or SF36 or SF-6D or SF-6D or SF6D
or HUI).tw.
140,813
12 (markov or time trade off or TTO or standard gamble or hrql or hrqol or disabilit* or disutilit*).tw. 133,533
13 (quality adj2 life).tw. 154,937
14 (decision adj2 model).tw. 4073
15 (visual analog* scale* or discrete choice experiment* or health* year* equivalen* or (willing* adj2
pay)).tw.
33,173
16 (‘resource use’ or resource utili?ation).tw. 9570
17 (well-being or wellbeing).tw. 46,483
18 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 1,328,233
19 3 and 18 9165
20 (metaanalys* or meta analys* or meta-analys*).tw. 69,140
21 (systematic* and review*).mp. 94,951
22 meta analysis.pt. 60,117
23 (literature and review*).mp. 315,101
24 (review* adj10 (model* or cost* or economic* or ‘quality of life’ or HRQoL or HRQL or utilit*)).tw. 37,856
25 20 or 21 or 22 or 23 or 24 452,492
26 19 and 25 551
27 limit 19 to systematic reviews 409
28 26 or 27 698
29 limit 28 to yr=‘2011 -Current’ 305
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MEDLINE In-Process & Other Non-Indexed Citations (via Ovid)
Database: Ovid MEDLINE® In-Process & Other Non-Indexed Citations 25 January 2016.
Searched on 26 January 2016.
TABLE 106 MEDLINE In-Process & Other Non-Indexed Citations systematic review search: RRMS cost-effectiveness
review
ID Search Hits
1 multiple sclerosis.tw. 4878
2 (pharmacoeconomic* or pharmaco-economic* or economic* or cost*).tw. 69,030
3 (health state* or health status).tw. 4219
4 (qaly* or utilit* or EQ5D or EQ-5D or euroqol or euro-qol or SF-36 or SF36 or SF-6D or SF-6D or SF6D or
HUI).tw.
19,706
5 (markov or time trade off or TTO or standard gamble or hrql or hrqol or disabilit* or disutilit*).tw. 16,928
6 (quality adj2 life).tw. 22,185
7 (decision adj2 model).tw. 500
8 (visual analog* scale* or discrete choice experiment* or health* year* equivalen* or (willing* adj2
pay)).tw.
5276
9 (‘resource use’ or resource utili?ation).tw. 1372
10 (well-being or wellbeing).tw. 6440
11 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 126,738
12 1 and 11 1295
13 (metaanalys* or meta analys* or meta-analys*).tw. 14,035
14 (systematic* and review*).tw. 18,717
15 (literature and review*).tw. 40,052
16 (review* adj10 (model* or cost* or economic* or ‘quality of life’ or HRQoL or HRQL or utilit*)).tw. 6244
17 13 or 14 or 15 or 16 62,995
18 12 and 17 93
19 limit 12 to systematic reviews 63
20 18 or 19 105
21 limit 20 to yr=‘2011 -Current’ 91
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EMBASE (via Ovid)
Database: Ovid EMBASE 1974 to 2016 week 04.
Searched on 26 January 2016.
TABLE 107 EMBASE systematic review search: RRMS cost-effectiveness review
ID Search Hits
1 multiple sclerosis/ 93,609
2 multiple sclerosis.tw. 80,240
3 1 or 2 101,212
4 exp health economics/ 677,659
5 exp health status/ 164,988
6 exp ‘quality of life’/ 325,811
7 exp quality adjusted life year/ 15,391
8 (pharmacoeconomic* or pharmaco-economic* or economic* or cost*).tw. 713,057
9 (health state* or health status).tw. 57,400
10 (qaly* or utilit* or EQ5D or EQ-5D or euroqol or euro-qol or SF-36 or SF36 or SF-6D or SF6D or SF-6D
or HUI).tw.
223,035
11 (markov or time trade off or TTO or standard gamble or hrql or hrqol or disabilit* or disutilit*).tw. 208,655
12 (quality adj2 life).tw. 270,996
13 (decision adj2 model).tw. 6739
14 (visual analog* scale* or discrete choice experiment* or health* year* equivalen*).tw. 49,099
15 (‘resource use’ or resource utili?ation).tw. 17,555
16 (well-being or wellbeing or (willing* adj2 pay)).tw. 74,545
17 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 1,972,705
18 3 and 17 20,936
19 meta analysis/ 103,317
20 (metaanalys* or meta analys* or meta-analys*).tw. 110,582
21 ‘systematic review’/ 100,520
22 (systematic* adj3 review*).tw. 103,537
23 (literature adj3 review*).tw. 245,646
24 (review* adj10 (model* or cost* or economic* or ‘quality of life’ or HRQoL or HRQL or utilit*)).tw. 56,320
25 19 or 20 or 21 or 22 or 23 or 24 486,435
26 18 and 25 994
27 limit 18 to ‘systematic review’ 312
28 26 or 27 994
29 limit 28 to yr=‘2011 -Current’ 566
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Database of Abstracts of Reviews of Effects (DARE) (The Cochrane Library)
Searched on 13 January 2016.
Total all databases: 1048.
Other reviews (DARE): 11.
Health Technology Assessment (HTA) database (Centre for Reviews and Dissemination)
Searched on 13 January 2016.
Total: 38.
Search strategy
Any field: multiple sclerosis
AND
Publication year 2011 to 2016
AND
HTA selected
TABLE 108 Database of Abstracts of Reviews of Effects (DARE) systematic review search: RRMS cost-effectiveness review
ID Search Hits
#1 MeSH descriptor: [Multiple Sclerosis] explode all trees 1916
#2 multiple sclerosis:ti,ab,kw 4938
#3 #1 or #2 4942
#4 MeSH descriptor: [Economics] explode all trees 25,789
#5 MeSH descriptor: [Costs and Cost Analysis] explode all trees 23,940
#6 MeSH descriptor: [Health Status] explode all trees 5540
#7 MeSH descriptor: [Quality of Life] explode all trees 15,431
#8 MeSH descriptor: [Quality-Adjusted Life Years] explode all trees 3942
#9 (pharmacoeconomic* or pharmaco-economic* or economic* or cost*):ti,ab,kw 51,646
#10 (health next (state* or status)):ti,ab,kw 7475
#11 (qaly* or utilit* or EQ5D or EQ-5D or euroqol or euro-qol or SF-36 or SF36 or SF-6D or SF-6D or SF6D or
HUI):ti,ab,kw
12,645
#12 (markov or ‘time trade off’ or TTO or ‘standard gamble’ or hrql or hrqol or disabilit* or disutilit*):ti,ab,kw 18,569
#13 (quality near/2 life):ti,ab,kw 42,732
#14 (decision near/2 model):ti,ab,kw 393
#15 ((visual next analog* next scale*) or (‘discrete choice’ next experiment*) or (health* next year* next
equivalen*) or (willing* near/2 pay)):ti,ab,kw
19,706
#16 (‘resource use’ or resource next utili?ation):ti,ab,kw 1571
#17 (well-being or wellbeing):ti,ab,kw 5981
#18 #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 125,705
#19 #3 and #18 Publication Year from 2011 to 2016 1048
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NHS Economic Evaluation Database (NHS EED) (The Cochrane Library)
Searched on 13 January 2016.
Note: since March 2015, NHS EED is no longer updated.
All databases: 282.
Economic evaluations (NHS EED): 31.
Science Citation Index (Web of Knowledge)
Searched on 26 January 2016.
TABLE 109 NHS Economic Evaluation Database (NHS EED) systematic review search: RRMS cost-effectiveness review
ID Search Hits
#1 MeSH descriptor: [Multiple Sclerosis] explode all trees 1916
#2 multiple sclerosis:ti,ab,kw 4938
#3 #1 or #2 4942
#4 (metaanalys* or (meta next analys*) or meta-analys*):ti,ab,kw 26655
#5 review* or literature or systematic*:ti,ab,kw 112066
#6 #4 or #5 114328
#7 #3 and #6 Publication Year from 2011 to 2016 282
TABLE 110 Science Citation Index systematic review search: RRMS cost-effectiveness review
ID Hits Search
#1 29,661 TS= ‘multiple sclerosis’
Indexes = SCI-EXPANDED Timespan = 2011–2016
#2 573,437 TS= (‘quality of life’ or QoL or hrql or hrqol or (‘quality adjusted life’ NEAR/1 year*) or QALY* or cost* or
economic* or pharmacoeconomic* or pharmaco-economic* or euro-qol or utilit* or disutilit* or euroqol
or ‘euro qol’ or EQ5D or EQ-5D or SF-36 or SF36 or SF-6D or SF6D or HUI or (time NEAR/1 trade*) or TTO
or ‘standard gamble’ or markov or (decision NEAR/2 model*) or (visual NEAR/1 analog*) or ‘discrete
choice’ or ((health* NEAR/1 year*) NEAR/1 equivalen*) or (health NEAR/1 stat*) or ‘willingness to pay’ or
‘resource use’ or (resource NEAR/1 utili?ation) or wellbeing or well-being)
Indexes = SCI-EXPANDED Timespan = 2011–2016
#3 102,963 TS= (metaanalys* or (meta NEAR/1 analys*))
Indexes = SCI-EXPANDED Timespan = 2011–2016
#4 60,945 TS= (systematic* AND review*)
Indexes = SCI-EXPANDED Timespan = 2011–2016
#5 99,993 TS= (literature AND review*)
Indexes = SCI-EXPANDED Timespan = 2011–2016
#6 24,398 TS= (review* NEAR/10 (model* or cost* or economic* or ‘quality of life’ or HRQoL or HRQL or utilit*))
Indexes = SCI-EXPANDED Timespan = 2011–2016
#7 232,254 #6 OR #5 OR #4 OR #3
Indexes = SCI-EXPANDED Timespan = 2011–2016
#8 394 #7 AND #2 AND #1
Indexes = SCI-EXPANDED Timespan = 2011–2016
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Research Papers in Economics (RePEc)
Searched on 13 January 2016.
l EconPapers.
l Free text: ‘multiple sclerosis’.
l 125.
l Sorted by item date.
l Total number published from 2011 to 2016: 36.
Cost-effectiveness Analysis (CEA) Registry
Searched on 13 January 2016.
Contained details of articles up to 2013 at time of search.
l Basic search.
l Articles.
l Full search contents: multiple sclerosis.
l Total number published from 2011 to 2016: 14.
School of Health and Related Research (ScHARR) Health Utilities Database (HUD)
Searched on 13 January 2016.
Total: nine.
Search strategy
multiple sclerosis in any field
AND
2011 to 2016 in Year Published
Clinically isolated syndrome searches
MEDLINE (via Ovid)
Database: Ovid MEDLINE® 1946 to January week 4 2016.
Searched on 10 February 2016.
TABLE 111 MEDLINE systematic review search: CIS cost-effectiveness review
ID Search Hits
1 Demyelinating Diseases/ 10,446
2 Myelitis, Transverse/ 1153
3 exp Optic Neuritis/ 6737
4 Encephalomyelitis, Acute Disseminated/ 1689
5 Demyelinating Autoimmune Diseases, CNS/ 316
6 demyelinating disease*.tw. 4725
7 transverse myelitis.tw. 1356
8 neuromyelitis optica.tw. 1735
9 optic neuritis.tw. 3792
10 acute disseminated encephalomyelitis.tw. 1098
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Total not including reviews already screened as part of the search for cost systematic reviews in RRMS: 11
TABLE 111 MEDLINE systematic review search: CIS cost-effectiveness review (continued )
ID Search Hits
11 devic.tw. 107
12 ADEM.tw. 574
13 demyelinating disorder.tw. 335
14 clinically isolated syndrome.tw. 644
15 first demyelinating event.tw. 68
16 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 24,564
17 exp Economics/ 517,857
18 exp ‘Costs and Cost Analysis’/ 193,384
19 Health Status/ 64,061
20 exp ‘Quality of Life’/ 131,967
21 exp Quality-Adjusted Life Years/ 7948
22 (pharmacoeconomic* or pharmaco-economic* or economic* or cost*).tw. 476,878
23 (health state* or health status).tw. 41,167
24 (qaly* or utilit* or EQ5D or EQ-5D or euroqol or euro-qol or SF-36 or SF36 or SF-6D or SF-6D or SF6D
or HUI).tw.
141,292
25 (markov or time trade off or TTO or standard gamble or hrql or hrqol or disabilit* or disutilit*).tw. 133,897
26 (quality adj2 life).tw. 155,431
27 (decision adj2 model).tw. 4092
28 (visual analog* scale* or discrete choice experiment* or health* year* equivalen* or (willing* adj2
pay)).tw.
33,282
29 (‘resource use’ or resource utili?ation).tw. 9601
30 (well-being or wellbeing).tw. 46,641
31 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 1,331,084
32 (metaanalys* or meta analys* or meta-analys*).tw. 69,583
33 (systematic* and review*).mp. 95,472
34 meta analysis.pt. 60,490
35 (literature and review*).mp. 315,829
36 (review* adj10 (model* or cost* or economic* or ‘quality of life’ or HRQoL or HRQL or utilit*)).tw. 37,973
37 32 or 33 or 34 or 35 or 36 453,843
38 16 and 31 1437
39 37 and 38 82
40 limit 38 to systematic reviews 51
41 39 or 40 107
42 limit 41 to yr=‘2011 -Current’ 51
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MEDLINE In-Process & Other Non-Indexed Citations (via Ovid)
Database: Ovid MEDLINE® In-Process & Other Non-Indexed Citations 10 February 2016.
Searched on 11 February 2016.
Total not including reviews already screened as part of the search for cost systematic reviews in RRMS: 5
TABLE 112 MEDLINE In-Process & Other Non-Indexed Citations systematic review search: CIS cost-effectiveness review
ID Search Hits
1 demyelinating disease*.tw. 406
2 transverse myelitis.tw. 148
3 neuromyelitis optica.tw. 322
4 optic neuritis.tw. 360
5 acute disseminated encephalomyelitis.tw. 128
6 devic.tw. 6
7 ADEM.tw. 84
8 demyelinating disorder.tw. 56
9 clinically isolated syndrome.tw. 118
10 first demyelinating event.tw. 6
11 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 1259
12 (pharmacoeconomic* or pharmaco-economic* or economic* or cost*).tw. 69,098
13 (health state* or health status).tw. 4217
14 (qaly* or utilit* or EQ5D or EQ-5D or euroqol or euro-qol or SF-36 or SF36 or SF-6D or SF-6D or SF6D or
HUI).tw.
19,723
15 (markov or time trade off or TTO or standard gamble or hrql or hrqol or disabilit* or disutilit*).tw. 16,916
16 (quality adj2 life).tw. 22,287
17 (decision adj2 model).tw. 492
18 (visual analog* scale* or discrete choice experiment* or health* year* equivalen* or (willing* adj2
pay)).tw.
5321
19 (‘resource use’ or resource utili?ation).tw. 1372
20 (well-being or wellbeing).tw. 6423
21 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 126,925
22 (metaanalys* or meta analys* or meta-analys*).tw. 13,978
23 (systematic* and review*).tw. 18,746
24 (literature and review*).tw. 40,310
25 (review* adj10 (model* or cost* or economic* or ‘quality of life’ or HRQoL or HRQL or utilit*)).tw. 6282
26 22 or 23 or 24 or 25 63,191
27 11 and 21 186
28 limit 27 to systematic reviews 7
29 26 and 27 12
30 28 or 29 14
31 limit 30 to yr= ‘2011 -Current’ 11
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EMBASE (via Ovid)
Database: Ovid EMBASE 1974 to 2016 week 06.
Searched on 11 February 2016.
TABLE 113 EMBASE systematic review search: CIS cost-effectiveness review
ID Search Hits
1 demyelinating disease/ 12,216
2 myelitis/ 6771
3 optic neuritis/ 6979
4 acute disseminated encephalomyelitis/ 1378
5 myelooptic neuropathy/ 4897
6 demyelinating disease*.tw. 7443
7 transverse myelitis.tw. 2462
8 neuromyelitis optica.tw. 4162
9 optic neuritis.tw. 6551
10 acute disseminated encephalomyelitis.tw. 1762
11 devic.tw. 229
12 ADEM.tw. 1211
13 demyelinating disorder.tw. 624
14 clinically isolated syndrome.tw. 1758
15 first demyelinating event.tw. 159
16 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 34,739
17 exp health economics/ 679,154
18 exp health status/ 165,534
19 exp ‘quality of life’/ 327,227
20 exp quality adjusted life year/ 15,498
21 (pharmacoeconomic* or pharmaco-economic* or economic* or cost*).tw. 715,448
22 (health state* or health status).tw. 57,542
23 (qaly* or utilit* or EQ5D or EQ-5D or euroqol or euro-qol or SF-36 or SF36 or SF-6D or SF6D or SF-6D
or HUI).tw.
223,904
24 (markov or time trade off or TTO or standard gamble or hrql or hrqol or disabilit* or disutilit*).tw. 209,301
25 (quality adj2 life).tw. 272,302
26 (decision adj2 model).tw. 6788
27 (visual analog* scale* or discrete choice experiment* or health* year* equivalen*).tw. 49,341
28 (‘resource use’ or resource utili?ation).tw. 17,623
29 (well-being or wellbeing or (willing* adj2 pay)).tw. 74,888
30 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 1,979,047
31 meta analysis/ 103,826
32 (metaanalys* or meta analys* or meta-analys*).tw. 111,288
33 ‘systematic review’/ 101,172
34 (systematic* adj3 review*).tw. 104,294
35 (literature adj3 review*).tw. 246,476
36 (review* adj10 (model* or cost* or economic* or ‘quality of life’ or HRQoL or HRQL or utilit*)).tw. 56,523
continued
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Total not including reviews already screened as part of the search for cost systematic reviews in RRMS: 47
Database of Abstracts of Reviews of Effects (DARE) (The Cochrane Library)
Searched on 13 January 2016.
TABLE 113 EMBASE systematic review search: CIS cost-effectiveness review (continued )
ID Search Hits
37 31 or 32 or 33 or 34 or 35 or 36 488,476
38 16 and 30 3989
39 37 and 38 212
40 limit 38 to ‘systematic review’ 64
41 39 or 40 212
42 limit 41 to yr=‘2011 -Current’ 113
TABLE 114 Database of Abstracts of Reviews of Effects (DARE) systematic review search: CIS cost-effectiveness
review
ID Search Hits
#1 MeSH descriptor: [Demyelinating Diseases] this term only 71
#2 MeSH descriptor: [Myelitis, Transverse] this term only 6
#3 MeSH descriptor: [Optic Neuritis] explode all trees 95
#4 MeSH descriptor: [Encephalomyelitis, Acute Disseminated] this term only 3
#5 MeSH descriptor: [Demyelinating Autoimmune Diseases, CNS] this term only 2
#6 demyelinating next disease*:ti,ab,kw (Word variations have been searched) 186
#7 transverse myelitis:ti,ab,kw (Word variations have been searched) 14
#8 neuromyelitis optica:ti,ab,kw (Word variations have been searched) 20
#9 optic neuritis:ti,ab,kw (Word variations have been searched) 220
#10 acute disseminated encephalomyelitis:ti,ab,kw (Word variations have been searched) 13
#11 devic:ti,ab,kw (Word variations have been searched) 2
#12 ADEM:ti,ab,kw (Word variations have been searched) 4
#13 demyelinating disorder:ti,ab,kw (Word variations have been searched) 49
#14 clinically isolated syndrome:ti,ab,kw (Word variations have been searched) 114
#15 first demyelinating event:ti,ab,kw (Word variations have been searched) 72
#16 single demyelinating event:ti,ab,kw (Word variations have been searched) 9
#17 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 561
#18 MeSH descriptor: [Economics] explode all trees 26,697
#19 MeSH descriptor: [Costs and Cost Analysis] explode all trees 24,728
#20 MeSH descriptor: [Health Status] explode all trees 6149
#21 MeSH descriptor: [Quality of Life] explode all trees 17,692
#22 MeSH descriptor: [Quality-Adjusted Life Years] explode all trees 4063
#23 (pharmacoeconomic* or pharmaco-economic* or economic* or cost*):ti,ab,kw 53,199
#24 (health next (state* or status)):ti,ab,kw 7906
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Total all databases: 97.
Other reviews (DARE): none.
NHS Economic Evaluation Database (NHS EED) and Health Technology Assessment (HTA)
database (The Cochrane Library)
Searched on 11 February 2016.
TABLE 114 Database of Abstracts of Reviews of Effects (DARE) systematic review search: CIS cost-effectiveness
review (continued )
ID Search Hits
#25 (qaly* or utilit* or EQ5D or EQ-5D or euroqol or euro-qol or SF-36 or SF36 or SF-6D or SF-6D or SF6D or
HUI):ti,ab,kw
13,317
#26 (markov or ‘time trade off’ or TTO or ‘standard gamble’ or hrql or hrqol or disabilit* or disutilit*):ti,ab,kw 19,514
#27 (quality near/2 life):ti,ab,kw 44,945
#28 (decision near/2 model):ti,ab,kw 418
#29 ((visual next analog* next scale*) or (‘discrete choice’ next experiment*) or (health* next year* next
equivalen*) or (willing* near/2 pay)):ti,ab,kw
20,672
#30 (‘resource use’ or resource next utili?ation):ti,ab,kw 1657
#31 (well-being or wellbeing):ti,ab,kw 6305
#32 #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 130,941
#33 #17 and #32 Publication Year from 2011 to 2016 97
TABLE 115 NHS Economic Evaluation Database (NHS EED) and HTA database systematic review search:
CIS cost-effectiveness review
ID Search Hits
#1 MeSH descriptor: [Demyelinating Diseases] this term only 71
#2 MeSH descriptor: [Myelitis, Transverse] this term only 6
#3 MeSH descriptor: [Optic Neuritis] explode all trees 95
#4 MeSH descriptor: [Encephalomyelitis, Acute Disseminated] this term only 3
#5 MeSH descriptor: [Demyelinating Autoimmune Diseases, CNS] this term only 2
#6 demyelinating next disease*:ti,ab,kw (Word variations have been searched) 186
#7 transverse myelitis:ti,ab,kw (Word variations have been searched) 14
#8 neuromyelitis optica:ti,ab,kw (Word variations have been searched) 20
#9 optic neuritis:ti,ab,kw (Word variations have been searched) 220
#10 acute disseminated encephalomyelitis:ti,ab,kw (Word variations have been searched) 13
#11 devic:ti,ab,kw (Word variations have been searched) 2
#12 ADEM:ti,ab,kw (Word variations have been searched) 4
#13 demyelinating disorder:ti,ab,kw (Word variations have been searched) 49
#14 clinically isolated syndrome:ti,ab,kw (Word variations have been searched) 114
#15 first demyelinating event:ti,ab,kw (Word variations have been searched) 72
#16 single demyelinating event:ti,ab,kw (Word variations have been searched) 9
#17 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16
Publication Year from 2011 to 2016
241
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Total all databases: 241.
Technology assessments (HTA database): one.
Economic evaluations (NHS EED): two.
Science Citation Index (Web of Knowledge)
Searched on 24 February 2016.
TABLE 116 Science Citation Index systematic review search: CIS cost-effectiveness review
ID Hits Search
#1 6814 TS = (demyelinating NEAR/2 (disease* OR disorder*))
Indexes = SCI-EXPANDED Timespan = All years
#2 1703 TS = (transverse NEAR/1 myelitis)
Indexes = SCI-EXPANDED Timespan = All years
#3 4593 TS = ‘optic neuritis’
Indexes = SCI-EXPANDED Timespan = All years
#4 3547 TS = ‘neuromyelitis optica’
Indexes = SCI-EXPANDED Timespan = All years
#5 1605 TS = (‘acute disseminated’ NEAR/1 encephalomyelitis)
Indexes = SCI-EXPANDED Timespan = All years
#6 464 TS = ‘devic’
Indexes = SCI-EXPANDED Timespan = All years
#7 690 TS = ‘ADEM’
Indexes = SCI-EXPANDED Timespan = All years
#8 1202 TS = ‘clinically isolated syndrome’
Indexes = SCI-EXPANDED Timespan = All years
#9 96 TS = ‘first demyelinating event’
Indexes = SCI-EXPANDED Timespan = All years
#10 16,921 #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
Indexes = SCI-EXPANDED Timespan = All years
#11 1,495,884 TS = (‘quality of life’ or QoL or hrql or hrqol or (‘quality adjusted life’ NEAR/1 year*) or QALY* or cost*
or economic* or pharmacoeconomic* or pharmaco-economic* or euro-qol or utilit* or disutilit* or
euroqol or ‘euro qol’ or EQ5D or EQ-5D or SF-36 or SF36 or SF-6D or SF6D or HUI or (time NEAR/1
trade*) or TTO or ‘standard gamble’ or markov or (decision NEAR/2 model*) or (visual NEAR/1
analog*) or ‘discrete choice’ or ((health* NEAR/1 year*) NEAR/1 equivalen*) or (health NEAR/1 stat*)
or ‘willingness to pay’ or ‘resource use’ or (resource NEAR/1 utili?ation) or wellbeing or well-being)
Indexes = SCI-EXPANDED Timespan = All years
#12 168,986 TS = (metaanalys* or (meta NEAR/1 analys*))
Indexes = SCI-EXPANDED Timespan = All years
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Total not including reviews already screened as part of the search for cost systematic reviews in RRMS: four.
Research Papers in Economics (RePEc)
Searched on 24 February 2016.
l EconPapers first search.
¢ Free text: demyelinating OR myelitis OR ‘neuromyelitis optica’ OR ‘optic neuritis’ OR ‘acute
disseminated encephalomyelitis’ OR ‘clinically isolated syndrome’.
¢ Two.
¢ Sorted by item date.
¢ Total number published from 2011 to 2016: one.
l EconPapers second search.
¢ Keywords and title: devic OR ADEM.
¢ none.
l Total: one.
l Total not including reviews already screened as part of the search for cost systematic reviews in
RRMS: one.
Cost-effectiveness Analysis (CEA) Registry
Searched on 24 February 2016.
l Contained details of articles up to 2013 at time of search.
l Basic Search.
l Articles.
l Full Search Contents: demyelinating: three.
l Full Search Contents: myelitis: one.
TABLE 116 Science Citation Index systematic review search: CIS cost-effectiveness review (continued )
ID Hits Search
#13 104,464 TS= (systematic* AND review*)
Indexes = SCI-EXPANDED Timespan = All years
#14 253,207 TS= (literature AND review*)
Indexes = SCI-EXPANDED Timespan = All years
#15 62,256 TS= (review* NEAR/10 (model* or cost* or economic* or ‘quality of life’ or HRQoL or HRQL or utilit*))
Indexes = SCI-EXPANDED Timespan = All years
#16 497,345 #15 OR #14 OR #13 OR #12
Indexes = SCI-EXPANDED Timespan = All years
#17 59 #16 AND #11 AND #10
Indexes = SCI-EXPANDED Timespan = All years
#18 41 #17
Indexes = SCI-EXPANDED Timespan = 2011–2016
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l Full Search Contents: neuromyelitis optica: none.
l Full Search Contents: optic neuritis: none.
l Full Search Contents: encephalomyelitis: none.
l Full Search Contents: clinically isolated syndrome: two.
l Total: six.
l Total number published from 2011 to 2016: one.
l Total not including reviews already screened as part of the search for cost systematic reviews in
RRMS: none.
School of Health and Related Research (ScHARR) Health Utilities Database (HUD)
Searched on 24 February 2016.
l Demyelinating in any field: none.
l Myelitis in any field: none.
l Neuromyelitis optica in any field: none.
l Optic neuritis in any field: none.
l Acute disseminated encephalomyelitis in any field: none.
l Clinically isolated syndrome in any field: none.
l Total: none.
Grey literature
Searches of websites were undertaken concurrently for both clinical effectiveness and cost-effectiveness
studies. For a record of these searches, see Appendix 1.
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Appendix 6 Cost-effectiveness review of clinically
isolated syndrome studies
Full record of searches
Main searches
MEDLINE (via Ovid)
Database: Ovid MEDLINE® 1946 to March week 4 2016.
Searched on 6 April 2016.
TABLE 117 MEDLINE primary search: CIS cost-effectiveness review
ID Search Hits
1 Demyelinating Diseases/ 10,532
2 Myelitis, Transverse/ 1165
3 exp Optic Neuritis/ 6821
4 Encephalomyelitis, Acute Disseminated/ 1696
5 Demyelinating Autoimmune Diseases, CNS/ 323
6 demyelinating disease*.tw. 4779
7 transverse myelitis.tw. 1371
8 neuromyelitis optica.tw. 1786
9 optic neuritis.tw. 3828
10 acute disseminated encephalomyelitis.tw. 1109
11 devic.tw. 107
12 ADEM.tw. 583
13 demyelinating disorder.tw. 339
14 clinically isolated syndrome.tw. 660
15 first demyelinating event.tw. 69
16 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 24,812
17 exp Economics/ 522,024
18 exp ‘Costs and Cost Analysis’/ 195,358
19 exp Quality-Adjusted Life Years/ 8146
20 (pharmacoeconomic* or pharmaco-economic* or economic* or cost*).tw. 484,557
21 (decision adj2 model).tw. 4186
22 (‘resource use’ or resource utili?ation).tw. 9821
23 (qaly* or (generic adj2 (instrument* or measure*)) or EQ5D or EQ-5D or euroqol or euro-qol or SF-36 or
SF36 or SF-6D or SF-6D or SF6D or Health Utilities Index or HUI or 15D or Assessment of Quality of Life or
AQOL or Quality of Well-Being or QWB).tw.
27,152
24 17 or 18 or 19 or 20 or 21 or 22 or 23 885,600
25 16 and 24 195
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MEDLINE In-Process & Other Non-Indexed Citations (via Ovid)
Database: Ovid MEDLINE® In-Process & Other Non-Indexed Citations 5 April 2016.
Searched on 6 April 2016.
EMBASE (via Ovid)
Database: Ovid EMBASE 1974 to 2016 week 14.
Searched on 6 April 2016.
TABLE 118 MEDLINE In-Process & Other Non-Indexed Citations: CIS cost-effectiveness review
ID Search Hits
1 demyelinating disease*.tw. 415
2 transverse myelitis.tw. 150
3 neuromyelitis optica.tw. 329
4 optic neuritis.tw. 380
5 acute disseminated encephalomyelitis.tw. 136
6 devic.tw. 6
7 ADEM.tw. 85
8 demyelinating disorder.tw. 58
9 clinically isolated syndrome.tw. 122
10 first demyelinating event.tw. 6
11 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 1298
12 (pharmacoeconomic* or pharmaco-economic* or economic* or cost*).tw. 71,278
13 (decision adj2 model).tw. 511
14 (‘resource use’ or resource utili?ation).tw. 1444
15 (qaly* or (generic adj2 (instrument* or measure*)) or EQ5D or EQ-5D or euroqol or euro-qol or SF-36 or
SF36 or SF-6D or SF-6D or SF6D or Health Utilities Index or HUI or 15D or Assessment of Quality of Life or
AQOL or Quality of Well-Being or QWB).tw.
3504
16 quality-adjusted life year*.tw. 949
17 12 or 13 or 14 or 15 or 16 74,654
18 11 and 17 23
TABLE 119 EMBASE primary search: CIS cost-effectiveness review
ID Search Hits
1 demyelinating disease/ 12,351
2 myelitis/ 6889
3 optic neuritis/ 7109
4 acute disseminated encephalomyelitis/ 1437
5 myelooptic neuropathy/ 4987
6 demyelinating disease*.tw. 7511
7 transverse myelitis.tw. 2498
8 neuromyelitis optica.tw. 4242
9 optic neuritis.tw. 6631
10 acute disseminated encephalomyelitis.tw. 1792
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NHS Economic Evaluation Database (NHS EED) and Health Technology Assessment (HTA)
database (The Cochrane Library)
Searched on 6 April 2016.
TABLE 119 EMBASE primary search: CIS cost-effectiveness review (continued )
ID Search Hits
11 devic.tw. 231
12 ADEM.tw. 1224
13 demyelinating disorder.tw. 633
14 clinically isolated syndrome.tw. 1789
15 first demyelinating event.tw. 159
16 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 35,248
17 multiple sclerosis/ 94,999
18 multiple sclerosis.tw. 81,514
19 17 or 18 102,763
20 exp *health economics/ 212,668
21 exp quality adjusted life year/ 15,786
22 (pharmacoeconomic* or pharmaco-economic* or economic* or cost*).ti. 164,671
23 (decision adj2 model).tw. 6901
24 (‘resource use’ or resource utili?ation).tw. 17,938
25 (qaly* or (generic adj2 (instrument* or measure*)) or EQ5D or EQ-5D or euroqol or euro-qol or SF-36 or
SF36 or SF-6D or SF-6D or SF6D or Health Utilities Index or HUI or 15D or Assessment of Quality of Life or
AQOL or Quality of Well-Being or QWB).tw.
50,631
26 20 or 21 or 22 or 23 or 24 or 25 371,080
27 16 and 26 173
TABLE 120 NHS Economic Evaluation Database (NHS EED) and HTA database primary search: CIS cost-effectiveness
review
ID Search Hits
#1 MeSH descriptor: [Demyelinating Diseases] this term only 71
#2 MeSH descriptor: [Myelitis, Transverse] this term only 6
#3 MeSH descriptor: [Optic Neuritis] explode all trees 95
#4 MeSH descriptor: [Encephalomyelitis, Acute Disseminated] this term only 3
#5 MeSH descriptor: [Demyelinating Autoimmune Diseases, CNS] this term only 2
#6 demyelinating next disease*:ti,ab,kw (Word variations have been searched) 187
#7 transverse myelitis:ti,ab,kw (Word variations have been searched) 14
#8 neuromyelitis optica:ti,ab,kw (Word variations have been searched) 20
#9 optic neuritis:ti,ab,kw (Word variations have been searched) 222
#10 acute disseminated encephalomyelitis:ti,ab,kw (Word variations have been searched) 13
#11 devic:ti,ab,kw (Word variations have been searched) 3
#12 ADEM:ti,ab,kw (Word variations have been searched) 4
#13 demyelinating disorder:ti,ab,kw (Word variations have been searched) 49
#14 clinically isolated syndrome:ti,ab,kw (Word variations have been searched) 116
#15 first demyelinating event:ti,ab,kw (Word variations have been searched) 72
#16 single demyelinating event:ti,ab,kw (Word variations have been searched) 9
#17 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 566
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Total all databases: 566.
Technology assessments (HTA database): two.
Economic evaluations (NHS EED): three.
Science Citation Index and Conference Proceedings Citation Index – Science
(Web of Knowledge)
Searched on 6 April 2016.
TABLE 121 Science Citation Index and Conference Proceedings Citation Index – Science primary search: CIS
cost-effectiveness review
ID Hits Search
#1 6912 TS= (demyelinating NEAR/2 (disease* OR disorder*))
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
#2 1732 TS= (transverse NEAR/1 myelitis)
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
#3 4703 TS= ‘optic neuritis’
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
#4 3616 TS= ‘neuromyelitis optica’
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
#5 1620 TS= (‘acute disseminated’ NEAR/1 encephalomyelitis)
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
#6 474 TS= ‘devic’
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
#7 711 TS= ‘ADEM’
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
#8 1225 TS= ‘clinically isolated syndrome’
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
#9 96 TS= ‘first demyelinating event’
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
#10 17,216 #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
#11 1,280,769 TS= (cost* or economic* or pharmacoeconomic* or pharmaco-economic*)
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
#12 80,174 TS= ((‘quality adjusted life’ NEAR/1 year*) or QALY* or (generic NEAR/2 (instrument* or measure*)) or
euro-qol or euroqol or ‘euro qol’ or EQ5D or EQ-5D or SF-36 or SF36 or SF-6D or SF6D or ‘health
utilities index’ or HUI or 15D or ‘assessment of quality of life’ or AQOL or ‘Quality of Well-Being’ or
QWB or (decision NEAR/2 model*) or ‘resource use’ or (resource NEAR/1 utili?ation))
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
#13 1,335,874 #11 or #12
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
#14 210 #13 AND #10
Indexes = SCI-EXPANDED, CPCI-S Timespan = All years
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Research Papers in Economics (RePEc)
Searched on 6 April 2016.
l EconPapers first search.
¢ Free text: demyelinating OR myelitis OR ‘neuromyelitis optica’ OR ‘optic neuritis’ OR ‘acute
disseminated encephalomyelitis’ OR ‘clinically isolated syndrome’.
¢ Two.
l EconPapers second search.
¢ Keywords and Title: devic OR ADEM.
¢ None.
l Total: two.
Cost-effectiveness Analysis (CEA) Registry
Searched on 6 April 2016.
Contained details of articles up to 2014 at time of search
l Basic search.
l Articles.
l Full search contents: demyelinating: three.
l Full search contents: myelitis: one.
l Full search contents: neuromyelitis optica: none.
l Full search contents: optic neuritis: none.
l Full search contents: encephalomyelitis: none.
l Full search contents: clinically isolated syndrome: two.
l Total: six.
School of Health and Related Research (ScHARR) Health Utilities Database (HUD)
Searched on 6 April 2016.
l Demyelinating in any field: none.
l Myelitis in any field: none.
l Neuromyelitis optica in any field: none.
l Optic neuritis in any field: none.
l Acute disseminated encephalomyelitis in any field: none.
l Clinically isolated syndrome in any field: none.
l Total: none.
Additional searches
CIS (or RRMS post 2011) registers or cohort natural history.
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MEDLINE (via Ovid)
Database: Ovid MEDLINE® 1946 to June week 1 2016.
Searched on 16 June 2016.
TABLE 122 MEDLINE registers and cohort searches: CIS and RRMS cost-effectiveness reviews
ID Search
1 Demyelinating Diseases/
2 Myelitis, Transverse/
3 exp Optic Neuritis/
4 Encephalomyelitis, Acute Disseminated/
5 Demyelinating Autoimmune Diseases, CNS/
6 demyelinating disease*.tw.
7 transverse myelitis.tw.
8 neuromyelitis optica.tw.
9 optic neuritis.tw.
10 acute disseminated encephalomyelitis.tw.
11 devic.tw.
12 ADEM.tw.
13 demyelinating disorder.tw.
14 clinically isolated syndrome.tw.
15 first demyelinating event.tw.
16 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15
17 exp Registries/
18 (registry or registries).tw.
19 (register or registers).tw.
20 17 or 18 or 19
21 exp Cohort Studies/
22 (cohort adj (study or studies)).tw.
23 cohort analy$.tw.
24 (follow up adj (study or studies)).tw.
25 21 or 22 or 23 or 24
26 natural history.tw.
27 natural course.tw.
28 untreated.tw.
29 ((‘no’ or ‘not’) adj2 (treat* or therap*)).tw.
30 (natural adj2 (progression or development)).tw.
31 26 or 27 or 28 or 29 or 30
32 16 and 20
33 16 and 25 and 31
34 32 or 33
35 Multiple Sclerosis, Relapsing-Remitting/
36 relapsing remitting multiple sclerosis.tw.
37 35 or 36
38 limit 37 to yr=‘2011 -Current’
39 20 and 38
40 25 and 31 and 38
41 39 or 40
42 34 or 41
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Blank data extraction form for cost-effectiveness studies: clinically
isolated syndrome
TABLE 123 Studies excluded from the cost-effectiveness review of CIS
Reference Reason for exclusion
Casado V, Gubieras L, Romero-Pinel L, Matas E, Bau L, Lopez M, et al. Cost of the diagnosis of
multiple sclerosis. J Neurol 2009;256:S126
Not a full economic
evaluation
Fredrikson S, Prayoonwiwat N, Wicklein EM, Scherer P, Langdon D. Psychosocial aspects of
clinically isolated syndrome (CIS) in Asia: baseline data from the CogniCIS study Asian cohort.
J Neurol Sci 2009;285:S95
Not an economic
analysis
Fredrikson S, Wicklein EM, Prayoonwiwat N, Beckmann K, Scherer P, Langdon D. Cognitive
performance and health-related quality of life in clinically isolated syndrome (CIS) suggestive of
multiple sclerosis: 2-year data from CogniCIS, a multinational, longitudinal study. Eur J Neurol
2010;17:57
Not an economic
analysis
Kinkel RP, Laforet G, You X. Disease-related determinants of quality of life 10 years after
clinically isolated syndrome. Int J MS Care 2015;17:26–34
Not an economic
analysis
Prayoonwiwat N, Nidhinandana S, Chankrachang S, Asawavichienjinda T, Tantirittisak T,
Fredrikson S, et al. Psychosocial aspects of clinically isolated syndrome (CIS) in Asia: baseline
data from the CogniCIS study Asian cohort. Mult Scler 2010;16:266–7
Not an economic
analysis
Sanchez-Solino O, Grau C, Parra JC, Arroyo E. Quality of life in patients with high-risk
clinically isolated syndrome treated with Avonex: interim results of the AREMIN study. J Neurol
2010;257:S190
Not an economic
analysis
Stourac P, Horakova D, Tyblova M, Klimova E, Szilasiova J, Fenclova I, et al. Interim analysis of
AMETYST: a Phase 4 observational study of the impact of intramuscular interferon b-1a on
quality of life, disability, and cognition in patients with clinically isolated syndrome/clinically
definite multiple sclerosis. Mult Scler 2012;1:486
No model included
Vermersch P, de Seze J, Delisse B, Lemaire S, Stojkovic T. Quality of life in multiple sclerosis:
influence of interferon-beta1 a (Avonex) treatment. Mult Scler 2002;8:377–81
Not an economic
analysis
TABLE 124 Blank data extraction form: CIS cost-effectiveness studies
Date:
Study ID:
Name of first reviewer:
Name of second reviewer:
Study details
Study title
First author
Co-authors
Source of publication: Journal yy;vol.(issue):pp
Language
Publication type
continued
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TABLE 124 Blank data extraction form: CIS cost-effectiveness studies (continued )
Inclusion criteria/study eligibility/PICOS
Population
Intervention(s)
Comparator(s)
Outcome(s)
Study design
Methods
Setting and location
Study perspective
Comparators
Time horizon
Discount rate
Outcomes
Measurement of effectiveness
Measurement and valuation of preference-based outcomes
Resource use and costs
Currency, price date and conversion
Model type
Assumptions
Analytical methods
Results
Study parameters
Incremental costs and outcomes
Characterising uncertainty
Study findings
Limitations
Generalisability
Source of funding
Conflicts of interest
Comments
Authors’ conclusion
Reviewer’s conclusion
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Quality assessment of economic evaluations in clinically isolated syndrome
TABLE 125 Quality assessment of economic evaluations in CIS: CHEERS checklist243
Assessment
Study
Fredrikson
2013254
Iskedjian
2005257
Lazzaro
2009256
Kobelt
2007255
Arbizu
2009258
Caloyeras
2009260
Caloyeras
2008259
Caloyeras
2012261
Zarco
2014262
Title Y Y Y Y Y Y Y Y Y
Abstract Y Y Y Y Y Y Y N Y
Introduction
Background and
objectives
Y Y Y N Y Y Y Y Y
Methods
Target
population and
subgroups
Y Y Y Y Y Y Y Y Y
Setting and
location
N N N N Y Y Y Y Y
Study
perspective
Y Y Y Y Y Y Y Y Y
Comparators Y Y Y Y Y Y Y Y Y
Time horizon Y Y Y Y Y Y Y Y Y
Discount rate Y Y Y Y Y Y Y Y Y
Choice of health
outcomes
Y Y Y Y Y Y Y Y Y
Measurement of
effectiveness
Y Y Y Y U U Y Y Y
Measurement
and valuation of
preference-
based outcomes
N N N N U U Y Y NA
Estimating
resources and
costs
Y Y Y N Y Y Y Y Y
Currency, price
date and
conversion
Y Y Y Y Y Y Y Y Y
Choice of model Y Y Y Y U U U Y Y
Assumptions Y Y Y N U U Y Y U
Analytical
methods
Y Y Y Y Y Y Y N Y
Study
parameters
(results)
Y Y Y Y U U Y N Y
Incremental
costs and
outcomes
Y Y Y Y U U Y Y Y
continued
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TABLE 125 Quality assessment of economic evaluations in CIS: CHEERS checklist243 (continued )
Assessment
Study
Fredrikson
2013254
Iskedjian
2005257
Lazzaro
2009256
Kobelt
2007255
Arbizu
2009258
Caloyeras
2009260
Caloyeras
2008259
Caloyeras
2012261
Zarco
2014262
Characterising
uncertainty
Y Y Y Y U U U N Y
Study findings
(discussion)
Y Y Y Y Y Y Y Y Y
Limitations Y Y Y N U U U Y Y
Generalisability Y Y Y U U U U Y Y
Other
Source of
funding (other)
Y Y Y N U U U Y N
Conflicts of
interest
Y Y Y N U U U Y N
N, no; NA, not applicable; U, unclear; Y, yes.
TABLE 126 Quality assessment of studies including an economic model in CIS: Philips et al.244 checklist
Criteria
Study
Fredrikson
2013254
Iskedjian
2005257
Lazzaro
2009256
Kobelt
2007255
Arbizu
2009258
Caloyeras
2008259
Caloyeras
2009260
Caloyeras
2012261
Zarco
2014262
Structure
Is there a clear
statement of
the decision
problem?
Y Y Y Y Y Y Y Y Y
Is the objective
of the model
specified and
consistent with
the stated
decision
problem?
Y Y Y Y Y Y Y Y Y
Is the primary
decision-maker
specified?
Y Y Y Y Y Y Y Y Y
Is the perspective
of the model
stated clearly?
Y Y Y Y Y Y Y Y Y
Are the model
inputs consistent
with the stated
perspective?
Y Y Y U U Y Y Y Y
Has the scope of
the model been
stated and
justified?
Y Y Y U U Y U Y Y
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TABLE 126 Quality assessment of studies including an economic model in CIS: Philips et al.244 checklist (continued )
Criteria
Study
Fredrikson
2013254
Iskedjian
2005257
Lazzaro
2009256
Kobelt
2007255
Arbizu
2009258
Caloyeras
2008259
Caloyeras
2009260
Caloyeras
2012261
Zarco
2014262
Are the
outcomes of the
model consistent
with the
perspective,
scope and overall
objective of the
model?
Y Y Y Y U U U Y Y
Is the structure
of the model
consistent with a
coherent theory
of the health
condition under
evaluation?
Y Y Y U U U U Y N
Are the sources
of the data used
to develop the
structure of the
model specified?
Y Y Y U U Y U Y Y
Are the causal
relationships
described by the
model structure
justified
appropriately?
Y Y Y U U U U Y U
Are the structural
assumptions
transparent and
justified?
Y Y Y U U U U Y U
Are the structural
assumptions
reasonable given
the overall
objective,
perspective and
scope of the
model?
Y Y Y U U U U Y U
Is there a clear
definition of the
options under
evaluation?
Y Y Y Y Y Y Y Y Y
Have all feasible
and practical
options been
evaluated?
N N N N Y Y Y N N
Is there
justification for
the exclusion of
feasible options?
N N N N U NA U N N
continued
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TABLE 126 Quality assessment of studies including an economic model in CIS: Philips et al.244 checklist (continued )
Criteria
Study
Fredrikson
2013254
Iskedjian
2005257
Lazzaro
2009256
Kobelt
2007255
Arbizu
2009258
Caloyeras
2008259
Caloyeras
2009260
Caloyeras
2012261
Zarco
2014262
Is the chosen
model type
appropriate
given the
decision problem
and specified
causal
relationships
within the
model?
Y Y Y Y Y Y Y Y N
Is the time
horizon of the
model sufficient
to reflect all
important
differences
between the
options?
Y N Y Y Y Y Y Y N
Are the time
horizon of the
model and the
duration of
treatment
described and
justified?
Y Y Y U Y Y Y Y Y
Do the disease
states (state
transition model)
or the pathways
(decision tree
model) reflect
the underlying
biological
process of the
disease in
question and the
impact of
interventions?
Y Y Y U Y Y Y Y N
Is the cycle
length defined
and justified in
terms of the
natural history of
disease?
Y Y Y N Y Y Y Y NA
Data
Are the data
identification
methods
transparent and
appropriate
given the
objectives of the
model?
Y Y Y U U U U Y U
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TABLE 126 Quality assessment of studies including an economic model in CIS: Philips et al.244 checklist (continued )
Criteria
Study
Fredrikson
2013254
Iskedjian
2005257
Lazzaro
2009256
Kobelt
2007255
Arbizu
2009258
Caloyeras
2008259
Caloyeras
2009260
Caloyeras
2012261
Zarco
2014262
Where choices
have been made
between data
sources are
these justified
appropriately?
N N N U U U U Y U
Has particular
attention
been paid to
identifying data
for the important
parameters of
the model?
U Y Y U U U U U U
Has the quality
of the data
been assessed
appropriately?
U N N U U U U U U
Where expert
opinion has been
used are the
methods
described and
justified?
Y Y Y U U U U N U
Is the data
modelling
methodology
based on
justifiable
statistical and
epidemiological
techniques?
Y Y Y U U U U Y U
Is the choice of
baseline data
described and
justified?
Y Y Y U U U U Y Y
Are transition
probabilities
calculated
appropriately?
Y Y Y U U U U Y U
Has a half-cycle
correction been
applied to both
costs and
outcomes?
N N N U U U U N NA
If not, has the
omission been
justified?
N N N U U U U N NA
If relative
treatment effects
have been
derived from
trial data, have
they been
synthesised using
appropriate
techniques?
N N N U U U U Y U
continued
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TABLE 126 Quality assessment of studies including an economic model in CIS: Philips et al.244 checklist (continued )
Criteria
Study
Fredrikson
2013254
Iskedjian
2005257
Lazzaro
2009256
Kobelt
2007255
Arbizu
2009258
Caloyeras
2008259
Caloyeras
2009260
Caloyeras
2012261
Zarco
2014262
Have the
methods and
assumptions
used to
extrapolate
short-term
results to final
outcomes been
documented and
justified?
Y Y Y U Y Y U Y NA
Have alternative
extrapolation
assumptions
been explored
through
sensitivity
analysis?
N N N U U U U Y NA
Have
assumptions
regarding the
continuing effect
of treatment
once treatment
is complete been
documented and
justified?
Y Y Y U U U U Y NA
Have alternative
assumptions
regarding the
continuing effect
of treatment
been explored
through
sensitivity
analysis?
Y N N U U U U U Y
Are the costs
incorporated into
the model
justified?
Y Y Y Y Y Y Y Y Y
Has the source
for all costs been
described?
Y Y Y N U U U Y Y
Have discount
rates been
described and
justified given
the target
decision-maker?
Y Y Y Y Y Y Y Y Y
Are the utilities
incorporated into
the model
appropriate?
U Y Y Y Y Y Y Y Y
Is the source of
utility weights
referenced?
Y Y Y N U Y U Y Y
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TABLE 126 Quality assessment of studies including an economic model in CIS: Philips et al.244 checklist (continued )
Criteria
Study
Fredrikson
2013254
Iskedjian
2005257
Lazzaro
2009256
Kobelt
2007255
Arbizu
2009258
Caloyeras
2008259
Caloyeras
2009260
Caloyeras
2012261
Zarco
2014262
Are the methods
of derivation
for the utility
weights justified?
Y Y N N U U U Y U
Have all data
incorporated into
the model been
described and
referenced in
sufficient detail?
Y Y N N U U U Y N
Has the use
of mutually
inconsistent
data been
justified (i.e. are
assumptions
and choices
appropriate?)
Y Y Y N U U U Y U
Is the process
of data
incorporation
transparent?
U U Y N U U U U N
If data have been
incorporated as
distributions, has
the choice of
distributions for
each parameter
been described
and justified?
N N N N U U U N Y
If data have been
incorporated
as distributions,
is it clear that
second-order
uncertainty is
reflected?
N N N N U U U N U
Have the four
principal types of
uncertainty been
addressed?
N N N N U U U N N
If not, has the
omission of
particular forms
of uncertainty
been justified?
N N N N U U U U N
Have
methodological
uncertainties
been addressed
by running
alternative
versions of the
model with
different
methodological
assumptions?
Y Y Y U U U U N N
continued
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TABLE 126 Quality assessment of studies including an economic model in CIS: Philips et al.244 checklist (continued )
Criteria
Study
Fredrikson
2013254
Iskedjian
2005257
Lazzaro
2009256
Kobelt
2007255
Arbizu
2009258
Caloyeras
2008259
Caloyeras
2009260
Caloyeras
2012261
Zarco
2014262
Is there evidence
that structural
uncertainties have
been addressed
via sensitivity
analysis?
N N N N U U U N N
Has
heterogeneity
been dealt with
by running
the model
separately for
different
subgroups?
NA NA NA U U U U N N
Are the methods
of assessment of
parameter
uncertainty
appropriate?
Y Y Y Y U U U Y Y
If data are
incorporated as
point estimates,
are the ranges
used for sensitivity
analysis stated
clearly and
justified?
Y Y Y U U U U NA Y
Is there evidence
that the
mathematical
logic of the
model has
been tested
thoroughly
before use?
U U U U U U U U N
Are any
counterintuitive
results from
the model
explained and
justified?
NA Y NA U U U U U NA
If the model has
been calibrated
against
independent
data, have any
differences been
explained and
justified?
NA NA NA U U U U NA U
Have the results
been compared
with those
of previous
models and any
differences
in results
explained?
Y Y Y U U U U N Y
N, no; NA, not applicable; U, unclear; Y, yes.
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Appendix 7 Cost-effectiveness review of
relapsing–remitting multiple sclerosis studies
Full record of searches
Main searches: 2012–16
MEDLINE (via Ovid)
Database: Ovid MEDLINE® 1946 to March week 4 2016.
Searched on 5 April 2016.
TABLE 127 MEDLINE primary search: RRMS cost-effectiveness review
ID Search Hits
1 exp Multiple Sclerosis/ 47,422
2 multiple sclerosis.tw. 50,604
3 1 or 2 58,051
4 exp Economics/ 522,024
5 exp ‘Costs and Cost Analysis’/ 195,358
6 exp Quality-Adjusted Life Years/ 8146
7 (pharmacoeconomic* or pharmaco-economic* or economic* or cost*).tw. 484,557
8 (decision adj2 model).tw. 4186
9 (‘resource use’ or resource utili?ation).tw. 9821
10 (qaly* or (generic adj2 (instrument* or measure*)) or EQ5D or EQ-5D or euroqol or euro-qol or SF-36 or
SF36 or SF-6D or SF-6D or SF6D or Health Utilities Index or HUI or 15D or Assessment of Quality of Life or
AQOL or Quality of Well-Being or QWB).tw.
27,152
11 4 or 5 or 6 or 7 or 8 or 9 or 10 885,600
12 3 and 11 1860
13 limit 12 to yr=‘2012 -Current’ 507
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MEDLINE In-Process & Other Non-Indexed Citations (via Ovid)
Database: Ovid MEDLINE® In-Process & Other Non-Indexed Citations 4 April 2016.
Searched on 5 April 2016.
EMBASE (via Ovid)
Database: Ovid EMBASE 1974 to 2016 week 14.
Searched on 5 April 2016.
TABLE 128 MEDLINE In-Process & Other Non-Indexed Citations search: RRMS cost-effectiveness review
ID Search Hits
1 multiple sclerosis.tw. 4995
2 (pharmacoeconomic* or pharmaco-economic* or economic* or cost*).tw. 71,051
3 (decision adj2 model).tw. 511
4 (‘resource use’ or resource utili?ation).tw. 1438
5 (qaly* or (generic adj2 (instrument* or measure*)) or EQ5D or EQ-5D or euroqol or euro-qol or SF-36 or
SF36 or SF-6D or SF-6D or SF6D or Health Utilities Index or HUI or 15D or Assessment of Quality of Life or
AQOL or Quality of Well-Being or QWB).tw.
3483
6 quality-adjusted life year*.tw. 945
7 2 or 3 or 4 or 5 or 6 74,406
8 1 and 7 239
9 limit 8 to yr=‘2012 -Current’ 198
TABLE 129 EMBASE primary search: RRMS cost-effectiveness review
ID Search Hits
1 multiple sclerosis/ 94,999
2 multiple sclerosis.tw. 81,514
3 1 or 2 102,763
4 exp *health economics/ 212,668
5 exp quality adjusted life year/ 15,786
6 (pharmacoeconomic* or pharmaco-economic* or economic* or cost*).ti. 164,671
7 (decision adj2 model).tw. 6901
8 (‘resource use’ or resource utili?ation).tw. 17,938
9 (qaly* or (generic adj2 (instrument* or measure*)) or EQ5D or EQ-5D or euroqol or euro-qol or SF-36 or
SF36 or SF-6D or SF-6D or SF6D or Health Utilities Index or HUI or 15D or Assessment of Quality of Life or
AQOL or Quality of Well-Being or QWB).tw.
50,631
10 4 or 5 or 6 or 7 or 8 or 9 371,080
11 3 and 10 2024
12 limit 11 to yr=‘2012 -Current’ 988
13 limit 12 to (conference abstract or conference paper or conference proceeding or ‘conference review’) 550
14 12 not 13 438
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NHS Economic Evaluation Database (NHS EED) and Health Technology Assessment (HTA)
database (The Cochrane Library)
Searched on 5 April 2016.
Total all databases: 2064.
Technology assessments (HTA database): 30.
Economic evaluations (NHS EED): 27.
Science Citation Index (Web of Knowledge)
Searched on 5 April 2016.
TABLE 130 NHS Economic Evaluation Database (NHS EED) and HTA database primary search: RRMS
cost-effectiveness review
ID Search Hits
#1 MeSH descriptor: [Multiple Sclerosis] explode all trees 2127
#2 multiple sclerosis:ti,ab,kw 5131
#3 #1 or #2 Publication Year from 2012 to 2016 2064
TABLE 131 Science Citation Index primary search: RRMS cost-effectiveness review
ID Hits Search
#1 87,043 TS= ‘multiple sclerosis’
Indexes = SCI-EXPANDED Timespan = All years
#2 53,184 TI= (cost* or economic* or pharmacoeconomic* or pharmaco-economic*)
Indexes = SCI-EXPANDED Timespan = 2012–2016
#3 24,433 TS= ((‘quality adjusted life’ NEAR/1 year*) or QALY* or (generic NEAR/2 (instrument* or measure*)) or
euro-qol or euroqol or ‘euro qol’ or EQ5D or EQ-5D or SF-36 or SF36 or SF-6D or SF6D or ‘health utilities
index’ or HUI or 15D or ‘assessment of quality of life’ or AQOL or ‘Quality of Well-Being’ or QWB or
(decision NEAR/2 model*) or ‘resource use’ or (resource NEAR/1 utili?ation))
Indexes = SCI-EXPANDED Timespan = 2012–2016
#4 73,283 #3 OR #2
Indexes = SCI-EXPANDED Timespan = 2012–2016
#5 472 #4 AND #1
Indexes = SCI-EXPANDED Timespan = 2012–2016
#6 157 (#5) AND DOCUMENT TYPES: (Meeting Abstract OR Meeting Summary OR Proceedings Paper)
Indexes = SCI-EXPANDED Timespan = 2012–2016
#7 315 #5 not #6
Indexes = SCI-EXPANDED Timespan = 2012–2016
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Research Papers in Economics (RePEc)
Searched on 5 April 2016.
l EconPapers.
l Free text: ‘multiple sclerosis’.
l 128.
l Sorted by item date.
l Total number published from 2012 to 2016: 32.
Cost-effectiveness Analysis (CEA) Registry
Searched on 5 April 2016.
Contained details of articles up to 2014 at time of search
l Basic search.
l Articles.
l Full search contents: multiple sclerosis.
l Total number published from 2012 to 2016: 17.
School of Health and Related Research (ScHARR) Health Utilities Database (HUD)
Searched on 5 April 2016.
Total: seven.
Search strategy
multiple sclerosis in any field
AND
2012 to 2016 in Year Published
Main searches: health-related quality of life studies with generic measures up to 2011
MEDLINE (via Ovid)
Database: Ovid MEDLINE® 1946 to March week 4 2016.
Searched on 6 April 2016.
TABLE 132 MEDLINE HRQoL search: RRMS cost-effectiveness review
ID Search Hits
1 exp Multiple Sclerosis/ 47,422
2 multiple sclerosis.tw. 50,604
3 1 or 2 58,051
4 (qaly* or (generic adj2 (instrument* or measure*)) or EQ5D or EQ-5D or euroqol or euro-qol or SF-36 or
SF36 or SF-6D or SF-6D or SF6D or Health Utilities Index or HUI or 15D or Assessment of Quality of Life or
AQOL or Quality of Well-Being or QWB).tw.
27,152
5 3 and 4 355
6 limit 5 to yr=‘1902 - 2011’ 248
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MEDLINE In-Process & Other Non-Indexed Citations (via Ovid)
Database: Ovid MEDLINE® In-Process & Other Non-Indexed Citations 5 April 2016.
Searched on 6 April 2016.
EMBASE (via Ovid)
Database: Ovid EMBASE 1974 to 2016 week 14.
Searched on 6 April 2016.
TABLE 133 MEDLINE In-Process & Other Non-Indexed Citations HRQoL search: RRMS cost-effectiveness review
ID Search Hits
1 multiple sclerosis.tw. 5010
2 (qaly* or (generic adj2 (instrument* or measure*)) or EQ5D or EQ-5D or euroqol or euro-qol or SF-36 or SF36
or SF-6D or SF-6D or SF6D or Health Utilities Index or HUI or 15D or Assessment of Quality of Life or AQOL or
Quality of Well-Being or QWB).tw.
3504
3 1 and 2 46
4 limit 3 to yr=‘1860 - 2011’ 7
TABLE 134 EMBASE HRQoL search: RRMS cost-effectiveness review
ID Search Hits
1 multiple sclerosis/ 94,999
2 multiple sclerosis.tw. 81,514
3 1 or 2 102,763
4 (qaly* or (generic adj2 (instrument* or measure*)) or EQ5D or EQ-5D or euroqol or euro-qol or SF-36 or
SF36 or SF-6D or SF-6D or SF6D or Health Utilities Index or HUI or 15D or Assessment of Quality of Life or
AQOL or Quality of Well-Being or QWB).tw.
50,631
5 3 and 4 885
6 limit 5 to yr= ‘1902 - 2011’ 427
7 limit 6 to (conference abstract or conference paper or conference proceeding or ‘conference review’) 158
8 6 not 7 269
DOI: 10.3310/hta21520 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 52
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Melendez-Torres et al. under the terms of a commissioning contract issued by the Secretary of State
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
319
Science Citation Index (Web of Knowledge)
Searched on 6 April 2016.
Cost-effectiveness Analysis (CEA) Registry
Searched on 6 April 2016.
Contained details of articles up to 2014 at time of search.
l Basic search.
l Articles.
l Full search contents: multiple sclerosis.
l Total number published from 1997 to 2011: 22.
School of Health and Related Research (ScHARR) Health Utilities Database (HUD)
Searched on 6 April 2016.
Total: two.
Search strategy
multiple sclerosis in any field
AND
2000 to 2011 in Year Published
Additional searches
Targeted database search to identify any additional MS patient registries that included data from
before 1995.
TABLE 135 Science Citation Index HRQoL search: RRMS cost-effectiveness review
ID Hits Search
#1 61,623 TS = ‘multiple sclerosis’
Indexes = SCI-EXPANDED Timespan = 1900–2011
#2 20,713 TS = (QALY* or (generic NEAR/2 (instrument* or measure*)) or euro-qol or euroqol or ‘euro qol’ or EQ5D
or EQ-5D or SF-36 or SF36 or SF-6D or SF6D or ‘health utilities index’ or HUI or 15D or ‘assessment of
quality of life’ or AQOL or ‘Quality of Well-Being’ or QWB)
Indexes = SCI-EXPANDED Timespan = 1900–2011
#3 351 #2 AND #1
Indexes = SCI-EXPANDED Timespan = 1900–2011
#4 19 (#3) AND DOCUMENT TYPES: (Meeting Abstract OR Meeting Summary OR Proceedings Paper)
Indexes = SCI-EXPANDED Timespan = 1900–2011
#5 332 #3 not #4
Indexes = SCI-EXPANDED Timespan = 1900–2011
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MEDLINE (via Ovid)
Database: Ovid MEDLINE® 1946 to May week 4 2016.
Searched on 31 May 2016.
Excluded studies (cost-effectiveness studies and health-related quality
of life studies)
TABLE 137 Studies excluded from the systematic review of cost-effectiveness in RRMS
Reference Reason for exclusion
Abolfazli R, Hosseini A, Gholami K, Javadi MR, Torkamandi H, Emami S. Quality of life
assessment in patients with multiple sclerosis receiving interferon beta-1a: a comparative
longitudinal study of Avonex and its biosimilar CinnoVex. ISRN Neurology 2012;2012:786526
Intervention not of interest
Acaster S, Perard R, Chauhan D, Lloyd AJ. A forgotten aspect of the NICE reference case:
an observational study of the health related quality of life impact on caregivers of people
with multiple sclerosis. BMC Health Serv Res 2013;13:346. http://dx.doi.org/10.1186/
1472-6963-13-346
Not relevant
Ayuso GI. [Multiple sclerosis: socioeconomic effects and impact on quality of life.] Med Clin
(Barc) 2014;143(Suppl. 3):7–12
Not relevant
Baumstarck K, Butzkueven H, Fernandez O, Flachenecker P, Stecchi S, Idiman E, et al.
Responsiveness of the Multiple Sclerosis International Quality of Life questionnaire to
disability change: a longitudinal study. Health Qual Life Outcomes 2013;11:127
Generic preference-based
measure not used
Baumstarck K, Pelletier J, Aghababian V, Reuter F, Klemina I, Berbis J, et al. Is the concept of
quality of life relevant for multiple sclerosis patients with cognitive impairment? Preliminary
results of a cross-sectional study. PLOS ONE 2012;7:e30627
Generic preference-based
measure not used
Baumstarck K, Pelletier J, Boucekine M, Auquier P, MusiQoL study group. Predictors of
quality of life in patients with relapsing–remitting multiple sclerosis: a 2-year longitudinal
study. Rev Neurol 2015;171:173–80. http://dx.doi.org/10.1016/j.neurol.2014.09.005
Generic preference-based
measure not used
Baumstarck K, Pelletier J, Butzkueven H, Fernández O, Flachenecker P, Idiman E, et al.
Health-related quality of life as an independent predictor of long-term disability for
patients with relapsing–remitting multiple sclerosis. Eur J Neurol 2013;20:907–14, e78–9.
http://dx.doi.org/10.1111/ene.12087
Generic preference-based
measure not used
Beckerman H, Kempen JC, Knol DL, Polman CH, Lankhorst GJ, de Groot V. The first 10 years
with multiple sclerosis: the longitudinal course of daily functioning. J Rehabil Med
2013;45:68–75. http://dx.doi.org/10.2340/16501977-1079
Generic preference-based
measure not used
continued
TABLE 136 MEDLINE targeted patient registry search: RRMS cost-effectiveness review
1 exp Multiple Sclerosis/ 48,148
2 multiple sclerosis.tw. 51,476
3 1 or 2 58,975
4 exp Registries/ 67,800
5 (registry or registries).tw. 70,207
6 (register or registers).tw. 45,934
7 4 or 5 or 6 140,237
8 3 and 7 755
9 limit 8 to yr=‘1902 - 2005’ 178
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TABLE 137 Studies excluded from the systematic review of cost-effectiveness in RRMS (continued )
Reference Reason for exclusion
Bergvall N, Tambour M, Henriksson F, Fredrikson S. Cost-minimization analysis of fingolimod
compared with natalizumab for the treatment of relapsing–remitting multiple sclerosis in
Sweden. J Med Econ 2013;16:349–57. http://dx.doi.org/10.3111/13696998.2012.755537
Intervention not of interest
Boeru G, Milanov I, De Robertis F, Kozubski W, Lang M, Rojas-Farreras S, et al. ExtaviJect®
30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a
prospective European study. Med Devices (Auckl) 2013;6:175–84
Not relevant
Boucekine M, Loundou A, Baumstarck K, Minaya-Flores P, Pelletier J, Ghattas B, Auquier P.
Using the random forest method to detect a response shift in the quality of life of multiple
sclerosis patients: a cohort study. BMC Med Res Methodol 2013;13:20. http://dx.doi.org/
10.1186/1471-2288-13-20
Generic preference-based
measure not used
Brandes DW, Raimundo K, Agashivala N, Kim E. Implications of real-world adherence on
cost-effectiveness analysis in multiple sclerosis. J Med Econ 2013;16:547–51 http://dx.doi.org/
10.3111/13696998.2013.774281
Not relevant
Brown MG. Cost of disease-modifying therapies for multiple sclerosis. Neurology
2015;84:e181–5 http://dx.doi.org/10.1212/WNL.0000000000001676
Not a full economic
analysis
Buchanan RJ, Johnson O, Zuniga MA, Carrillo-Zuniga G, Chakravorty BJ. Health-related
quality of life among Latinos with multiple sclerosis. J Soc Work Disabil Rehabil
2012;11:240–57 http://dx.doi.org/10.1080/1536710X.2012.730846
Generic preference-based
measure not used
Buhse M, Della Ratta C, Galiczewski J, Eckardt P. Caregivers of older persons with multiple
sclerosis: determinants of health-related quality of life. J Neurosci Nurs 2015;47:E2–12.
http://dx.doi.org/10.1097/JNN.0000000000000117
Not relevant
Calkwood J, Cree B, Crayton H, Kantor D, Steingo B, Barbato L, et al. Impact of a switch
to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and
physician-reported outcomes in relapsing multiple sclerosis: analyses of the EPOC trial.
BMC Neurol 2014;14:220
Intervention not of interest
Caloyeras JP, Zhang B, Wang C, Eriksson M, Fredrikson S, Beckmann K, et al.
Cost-effectiveness analysis of interferon beta-1b for the treatment of patients with a first
clinical event suggestive of multiple sclerosis. Clin Ther 2012;34:1132–44. http://dx.doi.org/
10.1016/j.clinthera.2012.03.004
Not relevant for RRMS
review
Campbell JD, Ghushchyan V, Brett McQueen R, Cahoon-Metzger S, Livingston T, Vollmer T,
et al. Burden of multiple sclerosis on direct, indirect costs and quality of life: national US
estimates. Mult Scler Relat Disord 2014;3:227–36
Results not reported by
EDSS level
Campbell JD, McQueen RB, Miravalle A, Corboy JR, Vollmer TL, Nair K. Comparative
effectiveness of early natalizumab treatment in JC virus-negative relapsing–remitting multiple
sclerosis. Am J Manag Care 2013;19:278–85
Intervention not of interest
Carlson JJ, Hansen RN, Dmochowski RR, Globe DR, Colayco DC, Sullivan SD. Estimating the
cost-effectiveness of onabotulinumtoxinA for neurogenic detrusor overactivity in the United
States. Clin Ther 2013;35:414–24. http://dx.doi.org/10.1016/j.clinthera.2013.02.020
Intervention not of interest
Chruzander C, Ytterberg C, Gottberg K, Einarsson U, Widen Holmqvist L, Johansson S.
A 10-year follow-up of a population-based study of people with multiple sclerosis in
Stockholm, Sweden: changes in health-related quality of life and the value of different factors
in predicting health-related quality of life. J Neurol Sci 2014;339:57–63
Results not reported by
EDSS level
Cioncoloni D, Innocenti I, Bartalini S, Santarnecchi E, Rossi S, Rossi A, Ulivelli M. Individual
factors enhance poor health-related quality of life outcome in multiple sclerosis patients.
Significance of predictive determinants. J Neurol Sci 2014;345:213–19. http://dx.doi.org/
10.1016/j.jns.2014.07.050
Generic preference-based
measure not used
Coleman CI, Sidovar MF, Roberts MS, Kohn C. Impact of mobility impairment on indirect
costs and health-related quality of life in multiple sclerosis. PLOS ONE 2013;8:e54756.
http://dx.doi.org/10.1371/journal.pone.0054756
Generic measure not
used; indirect costs
estimated
Cooper K, Bryant J, Harris P, Loveman E, Jones J, Welch K. Alemtuzumab for the Treatment
of Relapsing–Remitting Multiple Sclerosis: a Single Technology Appraisal. Southampton:
SHTAC; 2013
Intervention not of interest
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TABLE 137 Studies excluded from the systematic review of cost-effectiveness in RRMS (continued )
Reference Reason for exclusion
Crespo C, Izquierdo G, García-Ruiz A, Granell M, Brosa M. Cost minimisation analysis of
fingolimod vs natalizumab as a second line of treatment for relapsing–remitting multiple
sclerosis. Neurologia 2014;29:210–17. http://dx.doi.org/10.1016/j.nrl.2013.04.003
Interventions not of
interest
de la Rosa RS, García-Bujalance L, Meca-Lallana J. Cost analysis of glatiramer acetate versus
interferon-β for relapsing–remitting multiple sclerosis in patients with spasticity: the Escala
study. Health Econ Rev 2015;5:1–9
No decision-analytic model
Devy R, Lehert P, Varlan E, Genty M, Edan G. A short and validated multiple sclerosis-specific
health-related quality of life measurement for routine medical practice. Eur J Neurol
2013;20:935–41
Generic preference-based
measure not used
Di Filippo M, Proietti S, Gaetani L, Gubbiotti M, Di Gregorio M, Eusebi P, et al. Lower urinary
tract symptoms and urodynamic dysfunction in clinically isolated syndromes suggestive of
multiple sclerosis. Eur J Neurol 2014;21:648–53
Generic preference-based
measure not used
Ertekin O, Ozakbas S, Idiman E. Caregiver burden, quality of life and walking ability in
different disability levels of multiple sclerosis. Neurorehabilitation 2014;34:313–21
Generic preference-based
measure not used
Fernández-Muñoz JJ, Morón-Verdasco A, Cigarán-Méndez M, Muñoz-Hellín E,
Pérez-de-Heredia-Torres M, Fernández-de-las-Peñas C. Disability, quality of life, personality,
cognitive and psychological variables associated with fatigue in patients with multiple
sclerosis. Acta Neurol Scand 2015;132:118–24. http://dx.doi.org/10.1111/ane.12370
Generic preference-based
measure not used
Fiest KM, Fisk JD, Patten SB, Tremlett H, Wolfson C, Warren S, et al. Comorbidity is associated
with pain-related activity limitations in multiple sclerosis. Mult Scler Relat Disord 2015;4:470–6.
http://dx.doi.org/10.1016/j.msard.2015.07.014
Not relevant
Finès P, Garner R, Bancej C, Bernier J, Manuel DG. Development and implementation of
microsimulation models of neurological conditions. Health Rep 2016;27:3–9
Not relevant
Flensner G, Landtblom AM, Soderhamn O, Ek AC. Work capacity and health-related quality
of life among individuals with multiple sclerosis reduced by fatigue: a cross-sectional study.
BMC Public Health 2013;13:224
Generic preference-based
measure not used
Fogarty E, Walsh C, Adams R, McGuigan C, Barry M, Tubridy N. Relating health-related
quality of life to disability progression in multiple sclerosis, using the 5-level EQ-5D. Mult Scler
2013;19:1190–6. http://dx.doi.org/10.1177/1352458512474860
No decision-analytic model
Fredrikson S, McLeod E, Henry N, Pitcher A, Lowin J, Cuche M, et al. A cost-effectiveness
analysis of subcutaneous interferon beta-1a 44mcg 3-times a week vs no treatment
for patients with clinically isolated syndrome in Sweden. J Med Econ 2013;16:756–62.
http://dx.doi.org/10.3111/13696998.2013.792824
Not relevant for RRMS
review
Garattini L, Ghislandi F, Da Costa MR. Cost-effectiveness modeling in multiple sclerosis:
playing around with non-healthcare costs? Pharmacoeconomics 2015;33:1241–4.
http://dx.doi.org/10.1007/s40273-015-0322-7
Not relevant
Gavelova M, Nagyova I, Rosenberger J, Krokavcova M, Gdovinova Z, Groothoff JW, et al.
Importance of an individual’s evaluation of functional status for health-related quality of life
in patients with multiple sclerosis. Disabil Health J 2015;8:372–9
Generic preference-based
measure not used
Ghajarzadeh M, Azizi S, Moghadasi AN, Sahraian MA, Azimi A, Mohammadifar M, et al.
Validity and reliability of the Persian version of the PERception de la Scle’rose En Plaques et
de ses Pousse’es Questionnaire evaluating multiple sclerosis-related quality of life. Int J Prev
Med 2016;7:25
Generic preference-based
measure not used
Giordano A, Ferrari G, Radice D, Randi G, Bisanti L, Solari A, POSMOS study. Health-related
quality of life and depressive symptoms in significant others of people with multiple sclerosis:
a community study. Eur J Neurol 2012;19:847–54. http://dx.doi.org/10.1111/j.1468-1331.
2011.03638.x
Not relevant
Goodwin E, Green C. A quality-adjusted life-year measure for multiple sclerosis: developing
a patient-reported health state classification system for a multiple sclerosis-specific
preference-based measure. Value Health 2015;18:1016–24
Generic preference-based
measure not used
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TABLE 137 Studies excluded from the systematic review of cost-effectiveness in RRMS (continued )
Reference Reason for exclusion
Goodwin E, Green C, Spencer A. Estimating a preference-based index for an
eight-dimensional health state classification system for multiple sclerosis. Value Health
2015;18:1025–36
Generic preference-based
measure not used
Grytten N, Aarseth JH, Espeset K, Berg Johnsen G, Wehus R, Lund C, et al. Health-related
quality of life and disease-modifying treatment behaviour in relapsing–remitting
multiple sclerosis – a multicentre cohort study. Acta Neurol Scand Suppl 2012;195:51–7.
http://dx.doi.org/10.1111/ane.12033
Generic preference-based
measure not used
Guia de Practica Clinica Sobre la Atencion a las Personas con Esclerosis Multiple. [Clinical
Practice Guideline of Care for People with Multiple Sclerosis.] Barcelona: Catalan Agency for
Health Information, Assessment and Quality (CAHIAQ); 2012
Non-English language
Hadianfard H, Ashjazadeh N, Feridoni S, Farjam E. The role of psychological resilience,
severity of disease and treatment adherence in the prediction of health-related quality of life
in patients with multiple sclerosis. Neurol Asia 2015;20:263–8
Generic preference-based
measure not used
Hawton A, Green C, Telford CJ, Wright DE, Zajicek JP. The use of multiple sclerosis
condition-specific measures to inform health policy decision-making: mapping from the
MSWS-12 to the EQ-5D. Mult Scler 2012;18:853–61
Excluded from systematic
review, but retained for
information on inputs
Hawton A, Green C, Telford C, Zajicek J, Wright D. Using the Multiple Sclerosis Impact Scale
to estimate health state utility values: mapping from the MSIS-29, version 2, to the EQ-5D
and the SF-6D. Value Health 2012;15:1084–91
Excluded from systematic
review, but retained for
information on inputs
Heisen M, Treur MJ, van der Hel WS, Frequin ST, Groot MT, Verheggen BG. Fingolimod
reduces direct medical costs compared to natalizumab in patients with relapsing–remitting
multiple sclerosis in the Netherlands. J Med Econ 2012;15:1149–58
Interventions not of
interest; not full economic
analysis
Jones KH, Ford DV, Jones PA, John A, Middleton RM, Lockhart-Jones H, et al. How people
with multiple sclerosis rate their quality of life: an EQ-5D survey via the UK MS register.
PLOS ONE 2013;8:e65640. http://dx.doi.org/10.1371/journal.pone.0065640
Excluded from systematic
review, but retained for
information on inputs
Kappos L, Gold R, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, et al. Quality of life
outcomes with BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple
sclerosis: the DEFINE study. Mult Scler 2014;20:243–52. http://dx.doi.org/10.1177/
1352458513507817
Not relevant
Karampampa K, Gustavsson A, Miltenburger C, Eckert B. Treatment experience, burden
and unmet needs (TRIBUNE) in MS study: results from five European countries. Mult Scler
2012;18(2 Suppl.):7–15
Excluded from systematic
review, but retained for
information on inputs
Karampampa K, Gustavsson A, Miltenburger C, Kindundu CM, Selchen DH. Treatment
experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of
MS patients in Canada. J Popul Ther Clin Pharmacol 2012;19:e11–25
Excluded from systematic
review, but retained for
information on inputs
Karampampa K, Gustavsson A, Miltenburger C, Mora S, Arbizu T. Treatment experience,
burden and unmet needs (TRIBUNE) in MS study: results from Spain. Mult Scler
2012;18(2 Suppl.):35–9
Excluded from systematic
review, but retained for
information on inputs
Karampampa K, Gustavsson A, Miltenburger C, Neidhardt K, Lang M. Treatment experience,
burden and unmet needs (TRIBUNE) in MS study: results from Germany. Mult Scler
2012;18(2 Suppl.):23–7
Excluded from systematic
review, but retained for
information on inputs
Karampampa K, Gustavsson A, Miltenburger C, Teruzzi C, Fattore G. Treatment
experience, burden and unmet needs (TRIBUNE) in MS study: results from Italy. Mult Scler
2012;18(2 Suppl.):29–34
Excluded from systematic
review, but retained for
information on inputs
Karampampa K, Gustavsson A, Miltenburger C, Tyas D. Treatment experience, burden
and unmet needs (TRIBUNE) in MS study: results from the United Kingdom. Mult Scler
2012;18(2 Suppl.):41–5
Excluded from systematic
review, but retained for
information on inputs
Karampampa K, Gustavsson A, van Munster ET, Hupperts RM, Sanders EA, Mostert J, et al.
Treatment experience, burden, and unmet needs (TRIBUNE) in Multiple Sclerosis study:
the costs and utilities of MS patients in the Netherlands. J Med Econ 2013;16:939–50.
http://dx.doi.org/10.3111/13696998.2013.807267
Excluded from systematic
review, but retained for
information on inputs
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TABLE 137 Studies excluded from the systematic review of cost-effectiveness in RRMS (continued )
Reference Reason for exclusion
Kerling A, Keweloh K, Tegtbur U, Kück M, Grams L, Horstmann H, Windhagen A.
Physical capacity and quality of life in patients with multiple sclerosis. Neurorehabilitation
2014;35:97–104. http://dx.doi.org/10.3233/NRE-141099
Generic preference-based
measure not used
Khan F, Amatya B, Kesselring J. Longitudinal 7-year follow-up of chronic pain in persons with
multiple sclerosis in the community. J Neurol 2013;260:2005–15. http://dx.doi.org/10.1007/
s00415-013-6925-z
Generic preference-based
measure not used
Kinkel RP, Laforet G, You X. Disease-related determinants of quality of life 10 years after
clinically isolated syndrome. Int J MS Care 2015;17:26–34
Generic preference-based
measure not used
Kita M, Fox RJ, Gold R, Giovannoni G, Phillips JT, Sarda SP, et al. Effects of delayed-release
dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing–remitting
multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies.
Clin Ther 2014;36:1958–71
Intervention not of interest
Klevan G, Jacobsen CO, Aarseth JH, Myhr KM, Nyland H, Glad S, et al. Health related
quality of life in patients recently diagnosed with multiple sclerosis. Acta Neurol Scand
2014;129:21–6. http://dx.doi.org/10.1111/ane.12142
Generic preference-based
measure not used
Kohlmann T, Wang C, Lipinski J, Hadker N, Caffrey E, Epstein M, et al. The impact of a
patient support program for multiple sclerosis on patient satisfaction and subjective health
status. J Neurosci Nurs 2013;45:E3–14. http://dx.doi.org/10.1097/JNN.0b013e31828a4161
Not relevant
Kohn CG, Sidovar MF, Kaur K, Zhu Y, Coleman CI. Estimating a minimal clinically important
difference for the EuroQol 5-Dimension health status index in persons with multiple sclerosis.
Health Qual Life Outcomes 2014;12:66
Not relevant
Kuspinar A, Mayo NE. Do generic utility measures capture what is important to the
quality of life of people with multiple sclerosis? Health Qual Life Outcomes 2013;11:71.
http://dx.doi.org/10.1186/1477-7525-11-71
Excluded from systematic
review, but retained for
information on inputs
Labuz-Roszak B, Kubicka-Baczyk K, Pierzchala K, Horyniecki M, Machowska-Majchrzak A,
Augustynska-Mutryn D, et al. [Quality of life in multiple sclerosis – association with clinical
features, fatigue and depressive syndrome.] Psychiatr Pol 2013;47:433–42
Excluded from systematic
review, but retained for
information on inputs
Learmonth YC, Hubbard EA, McAuley E, Motl RW. Psychometric properties of quality of life
and health-related quality of life assessments in people with multiple sclerosis. Qual Life Res
2014;23:2015–23. http://dx.doi.org/10.1007/s11136-014-0639-2
Generic preference-based
measure not used
Limone BL, Sidovar MF, Coleman CI. Estimation of the effect of dalfampridine-ER on health
utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients. Health Qual Life
Outcomes 2013;11:105. http://dx.doi.org/10.1186/1477-7525-11-105
Intervention not of interest
Lukoschek C, Sterr A, Claros-Salinas D, Gütler R, Dettmers C. Fatigue in multiple sclerosis
compared to stroke. Front Neurol 2015;6:116. http://dx.doi.org/10.3389/fneur.2015.00116
Not relevant
Magistrale G, Pisani V, Argento O, Incerti CC, Bozzali M, Cadavid D, et al. Validation of the
World Health Organization Disability Assessment Schedule II (WHODAS-II) in patients with
multiple sclerosis. Mult Scler 2015;21:448–56
Not relevant
Marrie RA, Horwitz R, Cutter G, Tyry T. Cumulative impact of comorbidity on quality of life in
MS. Acta Neurol Scand 2012;125:180–6. http://dx.doi.org/10.1111/j.1600-0404.2011.01526.x
Generic measure not used
Maruszczak MJ, Montgomery SM, Griffiths MJ, Bergvall N, Adlard N. Cost–utility of
fingolimod compared with dimethyl fumarate in highly active relapsing–remitting multiple
sclerosis (RRMS) in England. J Med Econ 2015;18:874–85
Interventions not in scope
Mäurer M, Comi G, Freedman MS, Kappos L, Olsson TP, Wolinsky JS, et al. Multiple sclerosis
relapses are associated with increased fatigue and reduced health-related quality of life –
a post hoc analysis of the TEMSO and TOWER studies. Mult Scler Relat Disord 2016;7:33–40
Interventions not in scope
Mauskopf J, Fay M, Iyer R, Sarda S, Livingston T. Cost-effectiveness of delayed-release
dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United
States. J Med Econ 2016;19:432–42. http://dx.doi.org/10.3111/13696998.2015.1135805
Interventions not in scope
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TABLE 137 Studies excluded from the systematic review of cost-effectiveness in RRMS (continued )
Reference Reason for exclusion
Mikula P, Nagyova I, Krokavcova M, Vitkova M, Rosenberger J, Szilasiova J, et al. Social
participation and health-related quality of life in people with multiple sclerosis. Disabil Health
J 2015;8:29–34. http://dx.doi.org/10.1016/j.dhjo.2014.07.002
Generic preference-based
measure not used
Mitosek-Szewczyk K, Kułakowska A, Bartosik-Psujek H, Hoz˙ejowski R, Drozdowski W,
Stelmasiak Z. Quality of life in Polish patients with multiple sclerosis. Adv Med Sci
2014;59:34–8. http://dx.doi.org/10.1016/j.advms.2013.07.002
Not relevant
Motl RW, McAuley E. Physical activity and health-related quality of life over time in adults
with multiple sclerosis. Rehabil Psychol 2014;59:415–21. http://dx.doi.org/10.1037/a0037739
Generic preference-based
measure not used
National Institute for Health and Care Excellence. Teriflunomide for Treating Relapsing–
Remitting Multiple Sclerosis. Technology appraisal guidance TA303. London: NICE; 2014.
URL: www.nice.org.uk/guidance/ta303 (accessed 15 June 2017)
Intervention not of interest
Newsome SD, Guo S, Altincatal A, Proskorovsky I, Kinter E, Phillips G, et al. Impact of
peginterferon beta-1a and disease factors on quality of life in multiple sclerosis. Mult Scler
Relat Disord 2015;4:350–7. http://dx.doi.org/10.1016/j.msard.2015.06.004
Generic preference-based
measure not used
Norman G, Rice S, O’Connor J, Lewis-Light K, Craig D, McDaid C. Dimethyl Fumarate for
Treating Relapsing-Remitting Multiple Sclerosis: a Single Technology Appraisal. CRD and CHE
Technology Assessment Group; 2013. URL: http://onlinelibrary.wiley.com/o/cochrane/clhta/
articles/HTA-32013000873/frame.html (accessed 15 June 2017)
Intervention not of interest
O’Day K, Meyer K, Stafkey-Mailey D, Watson C. Cost-effectiveness of Natalizumab vs
Fingolimod for the Treatment of Relapsing–Remitting Multiple Sclerosis: Analyses in Sweden.
2014. URL: http://onlinelibrary.wiley.com/o/cochrane/cleed/articles/NHSEED-22014043467/
frame.html (accessed 25 April 2017)
Abstract
O’Day K, Meyer K, Stafkey-Mailey D, Watson C. Cost-effectiveness of natalizumab vs
fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden.
J Med Econ 2015;18:295–302. http://dx.doi.org/10.3111/13696998.2014.991786
Interventions not in scope
Oleen-Burkey M, Castelli-Haley J, Lage MJ, Johnson KP. Burden of a multiple sclerosis relapse:
the patient’s perspective. Patient 2012;5:57–69
Excluded from systematic
review, but retained for
information on inputs
Palace J, Bregenzer T, Tremlett H, Oger J, Zhu F, Boggild M, et al. UK multiple sclerosis
risk-sharing scheme: a new natural history dataset and an improved Markov model. BMJ
Open 2014;4:e004073. [Erratum published in BMJ Open 2014;4:e004073corr1.]
Not an economic analysis
Péntek M, Gulácsi L, Rózsa C, Simó M, Iljicsov A, Komoly S, Brodszky V. Health status
and costs of ambulatory patients with multiple sclerosis in Hungary. Ideggyogy Sz
2012;65:316–24
Excluded from systematic
review, but retained for
information on inputs
Pierzchala K, Adamczyk-Sowa M, Dobrakowski P, Kubicka-Baczyk K, Niedziela N, Sowa P.
Demographic characteristics of MS patients in Poland’s upper Silesia region. Int J Neurosci
2015;125:344–51. http://dx.doi.org/10.3109/00207454.2014.937002
Not relevant
Raikou M, Kalogeropoulou M, Rombopoulos G. A cost-effectiveness analysis of fingolimod
versus dimethyl fumarate as a second-line disease modifying treatment in patients with highly
active relapsing–remitting multiple sclerosis. Value Health 2015;18:A758
Interventions not in scope
Reese JP, Wienemann G, John A, Linnemann A, Balzer-Geldsetzer M, Mueller UO, et al.
Preference-based health status in a German outpatient cohort with multiple sclerosis. Health
Qual Life Outcomes 2013;11:162
Excluded from systematic
review, but retained for
information on inputs
Ruutiainen J, Viita AM, Hahl J, Sundell J, Nissinen H. Burden of illness in multiple sclerosis
(DEFENSE) study: the costs and quality-of-life of Finnish patients with multiple sclerosis. J Med
Econ 2016;19:21–33. http://dx.doi.org/10.3111/13696998.2015.1086362
Excluded from systematic
review, but retained for
information on inputs
Sabanov AV, Luneva AV, Matveev NV. [Pharmacoeconomic analysis of the efficacy of
natalizumab in relapsing–remitting multiple sclerosis.] Zh Nevrol Psikhiatr Im SS Korsakova
2014;114:65–9
Query full economic
analysis
Salehpoor G, Rezaei S, Hosseininezhad M. Quality of life in multiple sclerosis (MS) and role of
fatigue, depression, anxiety, and stress: a bicenter study from north of Iran. Iran J Nurs
Midwifery Res 2014;19:593–9
Not relevant
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TABLE 137 Studies excluded from the systematic review of cost-effectiveness in RRMS (continued )
Reference Reason for exclusion
Sanchez-de la Rosa R, Sabater E, Casado MA. Cost analysis of glatiramer acetate vs.
fingolimod for the treatment of patients with relapsing–remitting multiple sclerosis in Spain.
Health Econ Rev 2013;3:13
Review
Sidovar MF, Limone BL, Coleman CI. Mapping of Multiple Sclerosis Walking Scale (MSWS-12)
to five-dimension EuroQol (EQ-5D) health outcomes: an independent validation in a
randomized control cohort. Patient Relat Outcome Meas 2016;7:13–18
Excluded from systematic
review, but retained for
information on inputs
Sidovar MF, Limone BL, Lee S, Coleman CI. Mapping the 12-item multiple sclerosis walking
scale to the EuroQol 5-dimension index measure in North American multiple sclerosis
patients. BMJ Open 2013;3(5)
Excluded from systematic
review, but retained for
information on inputs
Svensson M, Fajutrao L. Costs of formal and informal home care and quality of life
for patients with multiple sclerosis in Sweden. Mult Scler Int 2014;2014:529878.
http://dx.doi.org/10.1155/2014/529878
Results not stratified by
EDSS level but by severity
level
Takemoto ML, Lopes da Silva N, Ribeiro-Pereira AC, Schilithz AO, Suzuki C. Differences in
utility scores obtained through Brazilian and UK value sets: a cross-sectional study. Health
Qual Life Outcomes 2015;13:119
Results not stratified by
EDSS level but by fatigue
level
Thomas S, Thomas PW, Kersten P, Jones R, Green C, Nock A, et al. A pragmatic parallel arm
multi-centre randomised controlled trial to assess the effectiveness and cost-effectiveness of a
group-based fatigue management programme (FACETS) for people with multiple sclerosis.
J Neurol Neurosurg Psychiatr 2013;84:1092–9. http://dx.doi.org/10.1136/jnnp-2012-303816
No decision-analytic model
Tosh J, Dixon S, Carter A, Daley A, Petty J, Roalfe A, et al. Cost effectiveness of a pragmatic
exercise intervention (EXIMS) for people with multiple sclerosis: economic evaluation of a
randomised controlled trial. Mult Scler 2014;20:1123–30
Intervention not of interest
Versteegh MM, Leunis A, Luime JJ, Boggild M, Uyl-de Groot CA, Stolk EA. Mapping
QLQ-C30, HAQ, and MSIS-29 on EQ-5D. Med Decis Making 2012;32:554–68.
http://dx.doi.org/10.1177/0272989X11427761
No utility values available
for people with an EDSS
level of > 7
Versteegh MM, Leunis A, Uyl-de Groot CA, Stolk EA. Condition-specific preference-based
measures: benefit or burden? Value Health 2012;15:504–13. http://dx.doi.org/10.1016/
j.jval.2011.12.003
Not relevant
Yamout B, Issa Z, Herlopian A, El Bejjani M, Khalifa A, Ghadieh AS, Habib RH. Predictors of
quality of life among multiple sclerosis patients: a comprehensive analysis. Eur J Neurol
2013;20:756–64. http://dx.doi.org/10.1111/ene.12046
Not relevant
Zarco LA, Millán SP, Londoño D, Parada L, Taborda A, Borda MG. [The cost-effectiveness of
interferon beta treatment in patients with a clinically isolated syndrome in Colombia.]
Biomedica 2014;34:110–17. http://dx.doi.org/10.1590/S0120-41572014000100014
Not relevant for RRMS
review
Zhang X, Hay JW, Niu X. Cost effectiveness of fingolimod, teriflunomide, dimethyl fumarate
and intramuscular interferon-beta1a in relapsing–remitting multiple sclerosis. CNS Drugs
2015;29:71–81
Interventions not in scope
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TABLE 138 Studies excluded from the MS HRQoL searches
Reference Reason for exclusion
Acquadro C, Lafortune L, Mear I. Quality of life in multiple sclerosis: translation in French
Canadian of the MSQoL-54. Health Qual Life Outcomes 2003;1:70. http://dx.doi.org/10.1186/
1477-7525-1-70
No generic preference-
based measure used
Amato MP, Ponziani G, Rossi F, Liedl CL, Stefanile C, Rossi L. Quality of life in multiple
sclerosis: the impact of depression, fatigue and disability. Mult Scler 2001;7:340–4
No generic preference-
based measure used
Anonymous. Burden of illness of multiple sclerosis: part II: quality of life. The Canadian
Burden of Illness Study Group. Can J Neurol Sci 1998;25:31–8
No generic preference-
based measure used
Argyriou AA, Karanasios P, Ifanti AA, Iconomou G, Assimakopoulos K, Makridou A, et al.
Quality of life and emotional burden of primary caregivers: a case–control study of multiple
sclerosis patients in Greece. Qual Life Res 2011;20:1663–8. http://dx.doi.org/10.1007/
s11136-011-9899-2
Not relevant
Arnoldus JH, Killestein J, Pfennings LE, Jelles B, Uitdehaag BM, Polman CH. Quality of life
during the first 6 months of interferon-beta treatment in patients with MS. Mult Scler
2000;6:338–42
No generic preference-
based measure used
Aymerich M, Guillamon I, Jovell AJ. Health-related quality of life assessment in people with
multiple sclerosis and their family caregivers. A multicenter study in Catalonia (Southern
Europe). Patient Prefer Adherence 2009;3:311–21
No generic preference-
based measure used
Aymerich M, Guillamon I, Perkal H, Nos C, Porcel J, Berra S, et al. Spanish adaptation of
the disease-specific questionnaire MSQOL-54 in multiple sclerosis patients. Neurologia
2006;21:181–7
No generic preference-
based measure used
Baker JG, Granger CV, Ottenbacher KJ. Validity of a brief outpatient functional assessment
measure. Am J Phys Med Rehabil 1996;75:356–63
No generic preference-
based measure used
Baumstarck-Barrau K, Pelletier J, Simeoni MC, Auquier P, MusiQol Study G. [French validation
of the Multiple Sclerosis International Quality of Life Questionnaire.] Rev Neurol (Paris)
2011;167:511–21
No generic preference-
based measure used
Baumstarck-Barrau K, Simeoni MC, Reuter F, Klemina I, Aghababian V, Pelletier J, Auquier P.
Cognitive function and quality of life in multiple sclerosis patients: a cross-sectional study.
BMC Neurol 2011;11:17. http://dx.doi.org/10.1186/1471-2377-11-17
No generic preference-
based measure used
Bermel RA, Weinstock-Guttman B, Bourdette D, Foulds P, You X, Rudick RA. Intramuscular
interferon beta-1a therapy in patients with relapsing–remitting multiple sclerosis: a 15-year
follow-up study. Mult Scler J 2010;16:588–96
Not relevant
Brunet DG, Hopman WM, Singer MA, Edgar CM, MacKenzie TA. Measurement of
health-related quality of life in multiple sclerosis patients. Can J Neurol Sci 1996;23:99–103
No generic preference-
based measure used
Casado V, Romero L, Gubieras L, Alonso L, Moral E, Martinez-Yelamos S, et al. An approach
to estimating the intangible costs of multiple sclerosis according to disability in Catalonia,
Spain. Mult Scler 2007;13:800–4
Not relevant
Casetta I, Riise T, Wamme Nortvedt M, Economou NT, De Gennaro R, Fazio P, et al. Gender
differences in health-related quality of life in multiple sclerosis. Mult Scler 2009;15:1339–46.
http://dx.doi.org/10.1177/1352458509107016
Not relevant
Delgado-Mendilívar JM, Cadenas-Díaz JC, Fernández-Torrico JM, Navarro-Mascarell G,
Izquierdo G. [A study of the quality of life in cases of multiple sclerosis.] Rev Neurol
2005;41:257–62
No generic preference-
based measure used
Di Fabio RP, Choi T, Soderberg J, Hansen CR. Health-related quality of life for patients with
progressive multiple sclerosis: influence of rehabilitation. Phys Ther 1997;77:1704–16
No generic preference-
based measure used
Drulovic J, Pekmezovic T, Matejic B, Mesaros S, Manigoda M, Dujmovic I, et al. Quality of life
in patients with multiple sclerosis in Serbia. Acta Neurol Scand 2007;115:147–52
No generic preference-
based measure used
Drulovic J, Riise T, Nortvedt M, Pekmezovic T, Manigoda M. Self-rated physical health predicts
change in disability in multiple sclerosis. Mult Scler 2008;14:999–1002 http://dx.doi.org/
10.1177/1352458508088917
No generic preference-
based measure used
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TABLE 138 Studies excluded from the MS HRQoL searches (continued )
Reference Reason for exclusion
Earnshaw SR, Graham J, Oleen-Burkey M, Castelli-Haley J, Johnson K. Cost effectiveness of
glatiramer acetate and natalizumab in relapsing–remitting multiple sclerosis. Appl Health Econ
Health Policy 2009;7:91–108
Economic analysis pre
2012
Fernandez O, Baumstarck-Barrau K, Simeoni MC, Auquier P, MusiQoL Study Group. Patient
characteristics and determinants of quality of life in an international population with multiple
sclerosis: assessment using the MusiQoL and SF-36 questionnaires.Mult Scler 2011;17:1238–49
No generic preference-
based measure used
Fischer JS, LaRocca NG, Miller DM, Ritvo PG, Andrews H, Paty D. Recent developments in the
assessment of quality of life in multiple sclerosis (MS). Mult Scler 1999;5:251–9
No generic preference-
based measure used
Fisk JD, Brown MG, Sketris IS, Metz LM, Murray TJ, Stadnyk KJ. A comparison of health utility
measures for the evaluation of multiple sclerosis treatments. J Neurol Neurosurg Psychiatr
2005;76:58–63
HRQoL results not
presented by EDSS level
Forbes A, While A, Mathes L. Informal carer activities, carer burden and health status in
multiple sclerosis. Clin Rehabil 2007;21:563–75
Carers’ disutilities
Forbes A, While A, Mathes L, Griffiths P. Health problems and health-related quality of life in
people with multiple sclerosis. Clin Rehabil 2006;20:67–78
No generic preference-
based measure used
Forbes RB, Lees A, Waugh N, Swingler RJ. Population based cost utility study of interferon
beta-1b in secondary progressive multiple sclerosis. BMJ 1999;319:1529–33
Population not of interest
Freeman JA, Hobart JC, Langdon DW, Thompson AJ. Clinical appropriateness: a key factor
in outcome measure selection: the 36 item short form health survey in multiple sclerosis.
J Neurol Neurosurg Psychiatr 2000;68:150–6
No generic preference-
based measure used
Freeman JA, Hobart JC, Thompson AJ. Does adding MS-specific items to a generic measure
(the SF-36) improve measurement? Neurology 2001;57:68–74
Results not presented by
EDSS level
Freeman JA, Langdon DW, Hobart JC, Thompson AJ. Health-related quality of life in people
with multiple sclerosis undergoing inpatient rehabilitation. J Neurol Rehabil 1996;10:185–94
No generic preference-
based measure used
Gani R, Giovannoni G, Bates D, Kemball B, Hughes S, Kerrigan J. Cost-effectiveness analyses
of natalizumab (Tysabri) compared with other disease-modifying therapies for people with
highly active relapsing–remitting multiple sclerosis in the UK. Pharmacoeconomics
2008;26:617–27
Economic analysis pre
2012
Gottberg K, Einarsson U, Ytterberg C, de Pedro Cuesta J, Fredrikson S, von Koch L, et al.
Health-related quality of life in a population-based sample of people with multiple sclerosis in
Stockholm County. MultScler 2006;12:605–12
No generic preference-
based measure used
Guarnaccia JB, Aslan M, O’Connor TZ, Hope M, Kazis L, Kashner CM, Booss J. Quality of life
for veterans with multiple sclerosis on disease-modifying agents: relationship to disability.
J Rehabil Res Dev 2006;43:35–44
Not relevant
Haupts M, Elias G, Hardt C, Langenbahn H, Obert H, Pöhlau D, et al. [Quality of life in
patients with remitting–relapsing multiple sclerosis in Germany.] Nervenarzt 2003;74:144–50.
http://dx.doi.org/10.1007/s00115-002-1446-5
Non-English language
Heiskanen S, Meriläinen P, Pietilä AM. Health-related quality of life – testing the reliability of
the MSQOL-54 instrument among MS patients. Scand J Caring Sci 2007;21:199–206
Generic measure not used
Hermann BP, Vickrey B, Hays RD, Cramer J, Devinsky O, Meador K, et al. A comparison of
health-related quality of life in patients with epilepsy, diabetes and multiple sclerosis. Epilepsy
Res 1996;25:113–18
Not relevant
Hincapie-Zapata ME, Suarez-Escudero JC, Pineda-Tamayo R, Anaya JM. [Quality of life in
multiple sclerosis and other chronic autoimmune and non-autoimmune diseases.] Rev Neurol
2009;48:225–30
Mixed population
Hobart J, Lamping D, Fitzpatrick R, Riazi A, Thompson A. The Multiple Sclerosis Impact Scale
(MSIS-29) – a new patient-based outcome measure. Brain 2001;124:962–73
No generic preference-
based measure used
Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ. Measuring the impact of MS on
walking ability: the 12-Item MS Walking Scale (MSWS-12). Neurology 2003;60:31–6
No generic preference-
based measure used
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TABLE 138 Studies excluded from the MS HRQoL searches (continued )
Reference Reason for exclusion
Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ. Improving the evaluation of
therapeutic interventions in multiple sclerosis: development of a patient-based measure
of outcome. Health Technol Assess 2004;8(9)
No generic preference-
based measure used
Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ. How responsive is the Multiple
Sclerosis Impact Scale (MSIS-29)? A comparison with some other self report scales. J Neurol
Neurosurg Psychiatr 2005;76:1539–43
No generic preference-
based measure used
Hopman WM, Coo H, Pavlov A, Day AG, Edgar CM, McBride EV, Brunet DG. Multiple
sclerosis: change in health-related quality of life over two years. Can J Neurol Sci
2009;36:554–61
No generic preference-
based measure used
Jankovic SM, Kostic M, Radosavljevic M, Tesic D, Stefanovic-Stoimenov N, Stevanovic I, et al.
Cost-effectiveness of four immunomodulatory therapies for relapsing–remitting multiple
sclerosis: a Markov model based on data a Balkan country in socioeconomic transition.
Vojnosanit Pregl 2009;66:556–62
Economic analysis pre
2012
Jones CA, Pohar SL, Warren S, Turpin KV, Warren KG. The burden of multiple sclerosis:
a community health survey. Health Qual Life Outcomes 2008;6:1. http://dx.doi.org/10.1186/
1477-7525-6-1
Results not presented by
EDSS level
Kendrick M, Johnson KI. Long-term treatment of multiple sclerosis with interferon-beta may
be cost effective. Pharmacoeconomics 2000;18:45–53
Economic analysis pre
2012
Kikuchi H, Kikuchi S, Ohbu S, Suzuki N, Maezaw M. [A survey on constitutive elements of
quality of life in patients with multiple sclerosis.] Brain Nerve 2007;59:617–22
No generic preference-
based measure used
Kobelt G. Costs and quality of life for patients with multiple sclerosis in Belgium. Eur J Health
Econ 2006;7(Suppl. 2):S24–33
Excluded from systematic
review, but retained for
information on inputs
Kobelt G, Berg J, Atherly D, Hadjimichael O. Costs and quality of life in multiple sclerosis:
a cross-sectional study in the United States. Neurology 2006;66:1696–702
Not relevant
Kobelt G, Berg J, Lindgren P, Anten B, Ekman M, Jongen PJ, et al. Costs and quality of life in
multiple sclerosis in the Netherlands. Eur J Health Econ 2006;7(Suppl. 2):S55–64. [Erratum
published in Eur J Health Econ 2007;8:359.]
< 30% of population
with RRMS
Kobelt G, Berg J, Lindgren P, Battaglia M, Lucioni C, Uccelli A. Costs and quality of life of
multiple sclerosis in Italy. Eur J Health Econ 2006;7(Suppl. 2):45–54. http://dx.doi.org/10.1007/
s10198-006-0385-7
50% of the population
had PPMS. Results not
stratified by type of MS
Kobelt G, Berg J, Lindgren P, Gerfin A, Lutz J. Costs and quality of life of multiple sclerosis in
Switzerland. Eur J Health Econ 2006;7(Suppl. 2):S86–95
Excluded from systematic
review, but retained for
information on inputs
Kobelt G, Jönsson L, Fredrikson S. Cost–utility of interferon beta1b in the treatment of
patients with active relapsing–remitting or secondary progressive multiple sclerosis. Eur J
Health Econ 2003;4:50–9. http://dx.doi.org/10.1007/s10198-002-0163-0
Economic analysis pre
2012
Kobelt G, Jönsson L, Henriksson F, Fredrikson S, Jönsson B. Cost–utility analysis of interferon
beta-1b in secondary progressive multiple sclerosis. Int J Technol Assess Health Care
2000;16:768–80
Population not of interest
Kobelt G, Lindgren P, Smala A, Bitsch A, Haupts M, Kolmel HW, et al. Costs and quality of life
in multiple sclerosis. An observational study in Germany. Eur J Health Econ 2001;2:60–8
HRQoL results grouped by
EDSS levels
Kobelt G, Texier-Richard B, Lindgren P. The long-term cost of multiple sclerosis in France
and potential changes with disease-modifying interventions. Mult Scler 2009;15:741–51.
http://dx.doi.org/10.1177/1352458509102771
Economic analysis pre
2012
Laosanguanek N, Wiroteurairuang T, Siritho S, Prayoonwiwat N. Reliability of the Thai version
of SF-36 questionnaire for an evaluation of quality of life in multiple sclerosis patients in
multiple sclerosis clinic at Siriraj Hospital. J Med Assoc Thai 2011;94(Suppl. 1):84–8
No generic preference-
based measure used
Malkova NA, Riabukhina OV, Babenko LA, Ionova TI, Kishtovich AV. [Health-related quality of
life in patients with multiple sclerosis.] Zh Nevrol Psikhiatr Im SS Korsakova 2005;105:31–7
Full text not available in
English language
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TABLE 138 Studies excluded from the MS HRQoL searches (continued )
Reference Reason for exclusion
McCrone P, Heslin M, Knapp M, Bull P, Thompson A. Multiple sclerosis in the UK: service use,
costs, quality of life and disability. Pharmacoeconomics 2008;26:847–60
MS type not of interest
Michalski D, Liebig S, Thomae E, Singer S, Hinz A, Bergh FT. Anxiety, depression and impaired
health-related quality of life are therapeutic challenges in patients with multiple sclerosis.
Ment Illn 2010;2:e5
Not relevant
Miller A, Dishon S. Health-related quality of life in multiple sclerosis: psychometric analysis of
inventories. Mult Scler 2005;11:450–8
No generic preference-
based measure used
Miller A, Dishon S. Health-related quality of life in multiple sclerosis: the impact of disability,
gender and employment status. Qual Life Res 2006;15:259–71. http://dx.doi.org/10.1007/
s11136-005-0891-6
No generic preference-
based measure used
Mo F, Choi BC, Li FC, Merrick J. Using Health Utility Index (HUI) for measuring the impact on
health-related quality of life (HRQL) among individuals with chronic diseases. Sci World J
2004;4:746–57
Mixed population
Moore F, Wolfson C, Alexandrov L, Lapierre Y. Do general and multiple sclerosis-specific
quality of life instruments differ? Can J Neurol Sci 2004;31:64–71
HRQoL results grouped by
EDSS levels
Morales Rde R, Morales Nde M, Rocha FC, Fenelon SB, Pinto Rde M, Silva CH. [Health-related
quality of life in multiple sclerosis.] Arq Neuropsiquiatr 2007;65:454–60
No generic preference-
based measure used
Murrell RC, Kenealy PM, Beaumont JG, Lintern TC. Assessing quality of life in persons with
severe neurological disability associated with multiple sclerosis: the psychometric evaluation of
two quality of life measures. Br J Health Psychol 1999;4:349–62
No generic preference-
based measure used
Myers JA, McPherson KM, Taylor WJ, Weatherall M, McNaughton HK. Duration of condition
is unrelated to health-state valuation on the EuroQoL. Clin Rehabil 2003;17:209–15
Not relevant
Nicholl CR, Lincoln NB, Francis VM, Stephan TF. Assessing quality of life in people with
multiple sclerosis. Disabil Rehabil 2001;23:597–603
Results not presented by
EDSS levels
Nicholl L, Hobart JC, Cramp AF, Lowe-Strong AS. Measuring quality of life in multiple
sclerosis: not as simple as it sounds. Mult Scler 2005;11:708–12
No generic preference-
based measure used
Nortvedt MW, Riise T, Myhr KM, Nyland HI. Quality of life in multiple sclerosis: measuring the
disease effects more broadly. Neurology 1999;53:1098–103
Intervention is not of
interest
Nortvedt MW, Riise T, Myhr KM, Nyland HI. Performance of the SF-36, SF-12, and RAND-36
summary scales in a multiple sclerosis population. Med Care 2000;38:1022–8
No generic preference-
based measure used
Nortvedt MW, Riise T, Myhr KM, Nyland HI. Quality of life as a predictor for change in
disability in MS. Neurology 2000;55:51–4
No generic preference-
based measure used
Nortvedt MW, Riise T, Myhr KM, Nyland HI, Hanestad BR. Type I interferons and the quality of
life of multiple sclerosis patients. Results from a clinical trial on interferon alfa-2a. Mult Scler
1999;5:317–22
Intervention is not of
interest
Noyes K, Bajorska A, Chappel A, Schwid SR, Mehta LR, Weinstock-Guttman B, et al.
Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based
study. Neurology 2011;77:355–63. http://dx.doi.org/10.1212/WNL.0b013e3182270402
Economic analysis pre
2012
Nuijten MJ, Hutton J. Cost-effectiveness analysis of interferon beta in multiple sclerosis:
a Markov process analysis. Value Health 2002;5:44–54
Economic analysis pre
2012
Orme M, Kerrigan J, Tyas D, Russell N, Nixon R. The effect of disease, functional status,
and relapses on the utility of people with multiple sclerosis in the UK. Value Health
2007;10:54–60
Excluded from systematic
review, but retained for
information on inputs
Ozakbas S, Akdede BB, Kösehasanogullari G, Aksan O, Idiman E. Difference between generic
and multiple sclerosis-specific quality of life instruments regarding the assessment of
treatment efficacy. J Neurol Sci 2007;256:30–4
Not relevant
Pakpour AH, Yekaninejad MS, Mohammadi NK, Molsted S, Zarei F, Patti F, Harrison A.
Health-related quality of life in Iranian patients with multiple sclerosis: a cross-cultural study.
Neurol Neurochir Pol 2009;43:517–26
No generic preference-
based measure used
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TABLE 138 Studies excluded from the MS HRQoL searches (continued )
Reference Reason for exclusion
Parkin D, Jacoby A, McNamee P, Miller P, Thomas S, Bates D. Treatment of multiple sclerosis
with interferon beta: an appraisal of cost-effectiveness and quality of life. J Neurol Neurosurg
Psychiatr 2000;68:144–9
Economic analysis pre
2012
Parkin D, McNamee P, Jacoby A, Miller P, Thomas S, Bates D. A cost–utility analysis of
interferon beta for multiple sclerosis. Health Technol Assess 1998;2(4)
Economic analysis pre
2012
Parkin D, Rice N, Jacoby A, Doughty J. Use of a visual analogue scale in a daily patient diary:
modelling cross-sectional time-series data on health-related quality of life. Soc Sci Med
2004;59:351–60. http://dx.doi.org/10.1016/j.socscimed.2003.10.015
Not relevant
Patti F, Amato MP, Battaglia MA, Pitaro M, Russo P, Solaro C, Trojano M. Caregiver quality of
life in multiple sclerosis: a multicentre Italian study. Mult Scler 2007;13:412–19
Not relevant
Patti F, Cacopardo M, Palermo F, Ciancio MR, Lopes R, Restivo D, Reggio A. Health-related
quality of life and depression in an Italian sample of multiple sclerosis patients. J Neurol Sci
2003;211:55–62
Caregiver quality of life
Patti F, Russo P, Pappalardo A, Macchia F, Civalleri L, Paolillo A, FAMS study group. Predictors
of quality of life among patients with multiple sclerosis: an Italian cross-sectional study.
J Neurol Sci 2007;252:121–9
Not relevant
Pfennings L, Cohen L, Adèr H, Polman C, Lankhorst G, Smits R, van der Ploeg H. Exploring
differences between subgroups of multiple sclerosis patients in health-related quality of life.
J Neurol 1999;246:587–91
Not relevant
Pfennings LE, Van der Ploeg HM, Cohen L, Bramsen I, Polman CH, Lankhorst GJ, Vleugels L.
A health-related quality of life questionnaire for multiple sclerosis patients. Acta Neurol Scand
1999;100:148–55
No generic preference-
based measure used
Phillips CJ. The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents
in its treatment. CNS Drugs 2004;18:561–74
Economic analysis pre
2012
Phillips CJ, Gilmour L, Gale R, Palmer M. A cost utility model of interferon beta-1b in the
treatment of relapsing–remitting multiple sclerosis. J Med Econ 2001;4:35–50
Economic analysis pre
2012
Phillips JT, Giovannoni G, Lublin FD, O’Connor PW, Polman CH, Willoughby E, et al. Sustained
improvement in Expanded Disability Status Scale as a new efficacy measure of neurological
change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing
multiple sclerosis. Mult Scler 2011;17:970–9
Not relevant
Pittock SJ, Mayr WT, McClelland RL, Jorgensen NW, Weigand SD, Noseworthy JH, Rodriguez M.
Quality of life is favorable for most patients with multiple sclerosis: a population-based cohort
study. Arch Neurol 2004;61:679–86. http://dx.doi.org/10.1001/archneur.61.5.679
No relevant information
Popova EV, Riabukhina OV, Vorob’eva OV, Malkova NA, Boiko AN. Changes in quality of life in
patients with remitted multiple sclerosis during the specific treatment with disease-modifying
drugs: a comparative study of populations of Moscow and Novosibirsk. Zh Nevrol Psikhiatr Im
SS Korsakova 2010;110:67–70
No relevant information
Pozzilli C, Palmisano L, Mainero C, Tomassini V, Marinelli F, Ristori G, et al. Relationship
between emotional distress in caregivers and health status in persons with multiple sclerosis.
Mult Scler 2004;10:442–6
Carers’ disutilities
Prosser LA, Kuntz KM, Bar-Or A, Weinstein MC. Patient and community preferences for
treatments and health states in multiple sclerosis. Mult Scler 2003;9:311–19
Results not reported for
all EDSS levels
Prosser LA, Kuntz KM, Bar-Or A, Weinstein MC. Cost-effectiveness of interferon beta-1a,
interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive
multiple sclerosis. Value Health 2004;7:554–68. http://dx.doi.org/10.1111/j.1524-4733.2004.
75007.x
Economic analysis pre
2012
Putzki N, Fischer J, Gottwald K, Reifschneider G, Ries S, Siever A, et al. Quality of life in
1000 patients with early relapsing–remitting multiple sclerosis. Eur J Neurol 2009;16:713–20
Excluded from systematic
review, but retained for
information on inputs
Riazi A, Hobart JC, Lamping DL, Fitzpatrick R, Freeman JA, Jenkinson C, et al. Using the SF-36
measure to compare the health impact of multiple sclerosis and Parkinson’s disease with
normal population health profiles. J Neurol Neurosurg Psychiatry 2003;74:710–14
No generic preference-
based measure used
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TABLE 138 Studies excluded from the MS HRQoL searches (continued )
Reference Reason for exclusion
Rivera-Navarro J, Benito-León J, Oreja-Guevara C, Pardo J, Dib WB, Orts E, et al. Burden and
health-related quality of life of Spanish caregivers of persons with multiple sclerosis. Mult Scler
2009;15:1347–55. http://dx.doi.org/10.1177/1352458509345917
Carers’ disutilities
Robinson D Jr, Zhao N, Gathany T, Kim LL, Cella D, Revicki D. Health perceptions and clinical
characteristics of relapsing–remitting multiple sclerosis patients: baseline data from an
international clinical trial. Curr Med Res Opin 2009;25:1121–30
No generic preference-
based measure used
Rothwell PM, McDowell Z, Wong CK, Dorman PJ. Doctors and patients don’t agree: cross
sectional study of patients’ and doctors’ perceptions and assessments of disability in multiple
sclerosis. BMJ 1997;314:1580–3
Not relevant
Rubio-Terres C, Aristegui Ruiz I, Medina Redondo F, Izquierdo Ayuso G. [Cost–utility analysis
of multiple sclerosis treatment with glatiramer acetate or interferon beta in Spain.] Farm Hosp
2003;27:159–65
Economic analysis pre
2012
Rubio-Terres C, Dominguez-Gil Hurle A. [Cost–utility analysis of relapsing–remitting multiple
sclerosis treatment with azathioprine or interferon beta in Spain.] Rev Neurol 2005;40:705–10
Economic analysis pre
2012
Rudick RA, Miller DM. Health-related quality of life in multiple sclerosis – current evidence,
measurement and effects of disease severity and treatment. CNS Drugs 2008;22:827–39
No generic preference-
based measure used
Rudick RA, Miller D, Hass S, Hutchinson M, Calabresi PA, Confavreux C, et al. Health-related
quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol 2007;62:335–46.
http://dx.doi.org/10.1002/ana.21163
Intervention is not of
interest
Sehanovic A, Dostovic Z, Smajlovic D, Avdibegovic E. Quality of life in patients suffering from
Parkinson’s disease and multiple sclerosis. Med Arh 2011;65:291–4
No generic preference-
based measure used
Senol V, Sipahioglu MH, Ozturk A, Argün M, Utas¸ C. Important determinants of quality of life
in a peritoneal dialysis population in Turkey. Ren Fail 2010;32:1196–201. http://dx.doi.org/
10.3109/0886022X.2010.517349
Not relevant
Shawaryn MA, Schiaffino KM, LaRocca NG, Johnston MV. Determinants of health-related
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Blank data extraction form for cost-effectiveness studies:
relapsing–remitting multiple sclerosis
TABLE 139 Blank data extraction form, RRMS cost-effectiveness studies
Date:
Study ID:
Name of first reviewer:
Name of second reviewer:
Study details
Study title
First author
Co-authors
Source of publication: Journal yy;vol.(issue):pp
Language
Publication type
Inclusion criteria/study eligibility/PICOS
Population
Intervention(s)
Comparator(s)
Outcome(s)
Study design
Methods
Setting and location
Study perspective
Comparators
Time horizon
Discount rate
Outcomes
Measurement of effectiveness
Measurement and valuation of preference-based outcomes
Resource use and costs
Currency, price date and conversion
Model type
Assumptions
Analytical methods
Results
Study parameters
Incremental costs and outcomes
Characterising uncertainty
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TABLE 139 Blank data extraction form, RRMS cost-effectiveness studies (continued )
Discussion
Study findings
Limitations
Generalisability
Other
Source of funding
Conflicts of interest
Comments
Authors’ conclusion
Reviewer’s conclusion
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Results of additional searches: potentially relevant studies from the patient
registry and cohort search
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Appendix 8 Additional analyses undertaken by
the assessment group
Time-varying model
In Table 142 the results are presented in terms of cost per QALY gained for the time-varying model.
Analyses used information from the NMA. These results show that the DMT treatment strategy was more
costly and more effective than BSC alone. The DMT treatment strategy was approximately £33,600 more
costly than BSC and produced 1.461 more QALYs, which equated to an ICER of approximately £23,000
per QALY. This indicates that for every additional QALY from DMTs there is an incremental cost of
£23,000.
SA2a: Estimates of effectiveness of individual drugs from the assessment
group review, progression confirmed at 3 months and individual drug
annualised relapse rates
Results based on the time-varying model by individual drug showed that BSC was the least costly and least
effective strategy (Table 143). Of the DMTs considered, 125 µg of SC pegIFN-β-1a every 2 weeks (Plegridy)
was the most cost-effective strategy by ICER. Both 30 µg of IM IFN-β-1a once weekly (Avonex) and 44 µg of
SC IFN-β-1a three times a week (Rebif) were dominated by 125 µg of SC pegIFN-β-1a every 2 weeks (Plegridy).
TABLE 143 Time-varying model (SA2a): cost per QALY
Strategy
Cost (£) QALYs
ICER (£)Mean Incremental Mean Incremental
BSC 362,100 – 8.664 – –
GA 20mg (Copaxone) 388,400 26,300 9.770 1.105 Extendedly
dominated
IFN-β-1b 250 µg every other day (Betaferon/Extavia) 390,500 28,400 10.139 1.475 Extendedly
dominated
PegIFN-β-1a 125 µg (Plegridy) 395,500 33,400 10.642 1.978 16,900
IFN-β-1a 30 µg IM (Avonex) 415,900 20,400 9.994 –0.648 Dominated
IFN-β-1a 44 µg (Rebif) 416,100 20,600 10.420 –0.222 Dominated
TABLE 142 Time-varying model: cost per QALY
Strategy
Cost (£) QALYs
ICER (£)Mean Incremental Mean Incremental
BSC 362,100 – 8.664 – –
DMTs 395,700 33,600 10.125 1.461 23,000
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SA2b: Estimates of effectiveness of individual drugs from the assessment
group review, progression confirmed at 6 months and individual drug
annualised relapse rates
The results based on the time-varying model are reported in Table 144. Treatment with 125 µg of SC
pegIFN-β-1a every 2 weeks (Plegridy) dominated all other DMT treatment strategies. Compared with BSC,
125 µg of SC pegIFN-β-1a every 2 weeks (Plegridy) was more expensive and more effective and had an
ICER of approximately £3200 per QALY.
Incorporating carers’ disutilities
The following analyses relate to the base-run model.
Cost-effectiveness analysis results: base case and sensitivity analyses
Base case
In Table 145 we present the findings from our base-case analysis with the inclusion of carers’ disutilities.
The DMT treatment strategy was more costly and more effective than BSC. The DMT treatment strategy
was approximately £31,900 more costly per person than the BSC strategy and produced 1.046 more
QALYs, with an ICER of approximately £30,500 per QALY.
SA1: Pooled estimates of effectiveness for on-scheme disease-modifying therapies
from the assessment group review
We used two key estimates of treatment effectiveness from our clinical effectiveness review: the
aggregated HR for disability progression confirmed at 3 months and the aggregated ARR.
In Table 146 the results show that the DMT treatment strategy was more costly and more effective than
BSC alone. The DMT treatment strategy was approximately £23,300 more costly than BSC and produced
2.031 more QALYs, which equated to an ICER of approximately £11,500 per QALY.
TABLE 144 Time-varying model (SA2b): cost per QALY
Strategy
Cost (£) QALYs
ICER (£)Mean Incremental Mean Incremental
BSC 362,100 – 8.664 – –
PegIFN-β-1a 125 µg every 2 weeks (Plegridy) 371,500 9400 11.608 2.944 3200
IFN-β-1a 44 µg SC three times a week (Rebif) 395,700 24,200 11.290 –0.318 Dominated
GA 20mg SC once daily (Copaxone) 396,500 25,000 9.485 –2.123 Dominated
IFN-β-1a 30 µg IM once weekly (Avonex) 409,200 37,700 10.267 –1.341 Dominated
TABLE 145 Base-case results: cost per QALY
Strategy
Cost (£) QALYs
ICER (£)Mean Incremental Mean Incremental
BSC 362,100 – 7.148 – –
DMTs 394,000 31,900 8.194 1.046 30,500
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SA2a: Estimates of effectiveness of individual drugs from the assessment group review,
progression confirmed at 3 months (preferred analysis)
The results for this analysis were robust to the inclusion of carers’ disutilities (Table 147). Treatment with
125 µg of pegIFN-β-1a every 2 weeks (Plegridy) remained dominant compared with all other DMT
treatment strategies. Compared with BSC, 125 µg of SC pegIFN-β-1a every 2 weeks (Plegridy) was
approximately £17,800 more costly and produced 2.868 more QALYs, with an ICER of £6200 per QALY.
SA2b: Estimates of effectiveness of individual drugs from the assessment group review,
progression confirmed at 6 months
Similarly, the results for this analysis were robust to the inclusion of carers’ disutilities. Treatment with
125 µg of SC pegIFN-β-1a every 2 weeks (Plegridy) remained dominant compared with all other strategies
included in the analysis (Table 148).
SA3: Hazard ratios from manufacturer submissions
When we used the estimates for treatment effectiveness (ARR and disability progression) reported by
each manufacturer and included carers’ disutilities, 125 µg of SC pegIFN-β-1a every 2 weeks (Plegridy)
dominated all other DMT treatment strategies (Table 149). Compared with BSC, 125 µg of SC pegIFN-β-1a
every 2 weeks (Plegridy) resulted in an ICER of £3000 per QALY.
SA4: Time horizon changed from 50 years to 20 years and 30 years
Tables 150 and 151 show the results based on a 20-year and 30-year time horizon respectively. With the
inclusion of carers’ disutilities, in both analyses the GA treatment strategy continued to be extendedly
dominated by 125 µg of SC pegIFN-β-1a every 2 weeks (Plegridy). Additionally, 125 µg of SC pegIFN-β-1a
every 2 weeks (Plegridy) dominated both 30 µg of IM IFN-β-1a once weekly (Avonex) and 44 µg of SC
IFN-β-1a three times a week (Rebif). Excluding all dominated strategies, 125 µg of SC pegIFN-β-1a every
2 weeks (Plegridy) compared with BSC had an ICER of approximately £18,200 and £9300 per QALY for
the 20-year and 30-year time horizons respectively.
TABLE 146 Pooled estimates of effectiveness for on-scheme DMTs from the assessment group review (SA1): cost
per QALY
Strategy
Cost (£) QALYs
ICER (£)Mean Incremental Mean Incremental
BSC 362,100 – 7.148 – –
DMTs 385,400 23,300 9.179 2.031 11,500
TABLE 147 Estimates of effectiveness of individual drugs from the assessment group review, progression confirmed
at 3 months (SA2a): cost per QALY
Strategy
Cost (£) QALYs
ICER (£)Mean Incremental Mean Incremental
BSC 362,100 – 7.148 – –
PegIFN-β-1a 125 µg every 2 weeks (Plegridy) 379,900 17,800 10.016 2.868 6200
GA 20mg SC once daily (Copaxone) 381,000 1100 8.646 –1.552 Dominated
IFN-β-1b 250 µg every other day (Betaferon/Extavia) 393,400 13,500 8.556 –1.46 Dominated
IFN-β-1a 44 µg SC three times a week (Rebif) 404,800 24,900 9.614 –0.402 Dominated
IFN-β-1a 30 µg IM once weekly (Avonex) 406,100 26,200 9.027 –0.989 Dominated
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TABLE 149 Hazard ratios from manufacturer submissions (SA3): cost per QALY
Strategy
Cost (£) QALYs
ICER (£)Mean Incremental Mean Incremental
BSC 362,100 – 7.148 – –
PegIFN-β-1a 125 µg SC every 2 weeks (Plegridy) 366,300 4200 8.566 1.418 3000
GA 20mg SC once daily (Copaxone) 374,600 8300 8.432 –0.134 Dominated
IFN-β-1a 30 µg IM once weekly (Avonex) 387,600 21,300 8.149 –0.417 Dominated
IFN-β-1a 44 µg SC three times a week (Rebif) 412,900 46,600 8.318 –0.248 Dominated
TABLE 150 Time horizon changed from 50 years to 20 years (SA4): cost per QALY
Strategy
Cost (£) QALYs
ICER (£)Mean Incremental Mean Incremental
BSC 196,900 – 5.710 – –
GA 20mg SC once daily (Copaxone) 220,500 23,600 6.628 0.918 Extendedly
dominated
PegIFN-β-1a 125 µg every 2 weeks (Plegridy) 225,800 28,900 7.301 1.591 18,200
IFN-β-1a 30 µg IM once weekly (Avonex) 242,600 16,800 6.789 –0.512 Dominated
IFN-β-1a 44 µg SC three times a week (Rebif) 245,200 19,400 7.156 –0.145 Dominated
TABLE 148 Estimates of effectiveness of individual drugs from the assessment group review, progression confirmed
at 6 months (SA2b): cost per QALY
Strategy
Cost (£) QALYs
ICER (£)Mean Incremental Mean Incremental
PegIFN-β-1a 125 µg SC every 2 weeks (Plegridy) 347,000 – 11.584 – –
BSC 362,100 15,100 7.148 –4.436 Dominated
IFN-β-1a 44 µg SC three times a week (Rebif) 377,600 30,600 10.966 –0.618 Dominated
GA 20mg SC once daily (Copaxone) 391,900 44,900 8.236 –3.348 Dominated
IFN-β-1a 30 µg IM once weekly (Avonex) 396,900 49,900 9.446 –2.138 Dominated
TABLE 151 Time horizon changed from 50 years to 30 years (SA4): cost per QALY
Strategy
Cost (£) QALYs
ICER (£)Mean Incremental Mean Incremental
BSC 279,400 – 6.540 – –
GA 20mg SC once daily (Copaxone) 298,900 19,500 7.790 1.25 Extendedly
dominated
PegIFN-β-1a 125 µg every 2 weeks (Plegridy) 300,400 21,000 8.809 2.269 9300
IFN-β-1a 44 µg SC three times a week (Rebif) 322,900 22,500 8.551 –0.258 Dominated
IFN-β-1a 30 µg IM once weekly (Avonex) 323,000 22,600 8.057 –0.752 Dominated
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Appendix 9 Details of resource use used to derive
cost inputs
This appendix describes the cost calculations used in the CIS model.
TABLE 152 Costs of monitoring people with CIS receiving BSC
Resource use Quantity Description
Unit costs
(£, 2015
prices) Source
MRI 1 RD01A 137.23 NHS Reference Costs 2014 to 2015285
Neurologist visit 1 Outpatient attendance,
Neurology 400
175.76 Assumption and consultation with clinical expert
(Professor Olga Ciccarelli, University College
London, June 2016, personal communication);
NHS Reference Costs 2014/15285
MS nurse visit 2 15 minutes 18.75 Assumption and consultation with clinical expert
(Professor Olga Ciccarelli, personal
communicationa); Curtis and Burns278
Estimated cost for monitoring people with CIS receiving BSC £350.49
a We assumed that a nurse specialist (community) employed at band 6 on the NHS Agenda for Change scale would
require 15 minutes of contact time with a patient receiving DMT; cost for a nurse specialist (community) is £75 per hour
of patient-related work (see Table 10.4 in Curtis and Burns278).
TABLE 153 Initial costs of monitoring in the first year of commencing DMTs
Resource use Quantity Description
Unit costs
(£, 2015
prices) Source
Full blood count 5 DAPS05 – haematology 3.01 Assumptions and consultation with clinical
expert on the number of full blood count, liver
functions and renal function tests required
(Professor Olga Ciccarelli, University College
London, June 2016, personal communication);
NHS Reference Costs 2014 to 2015285
Liver function
tests
5 DAPS04 – clinical
biochemistry
1.19
Thyroid function
test
1 DAPS09 – other 7.13
Renal function
tests
5 DAPS04 – clinical
biochemistry
1.19
MRI 1 RD01A 137.23 NHS Reference Costs 2014 to 2015285
Neurologist visit 2 Outpatient attendance,
Neurology 400
175.76 Assumption and consultation with clinical
expert (Professor Olga Ciccarelli, personal
communication); NHS Reference Costs 2014 to
2015285
MS nurse visit 2 15 minutes 18.75 Assumption and consultation with clinical expert
(Professor Olga Ciccarelli, personal
communicationa); Curtis and Burns278
Estimated initial cost of monitoring people in the first year of receiving
DMTs (Avonex/Plegridy, Betaferon and Copaxone)
£553.20
Estimated initial cost of monitoring people in the first year of receiving
Rebif (includes thyroid function test)
£560.33
a We assumed that a nurse specialist (community) employed at band 6 on the NHS Agenda for Change scale would
require 15 minutes of contact time with a patient receiving DMT; cost for a nurse specialist (community) is £75 per hour
of patient-related work (see Table 10.4 in Curtis and Burns278).
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TABLE 154 Subsequent costs of monitoring of treatment with DMTs
Resource use Quantity Description
Unit costs
(£, 2015
prices) Source
Full blood count 2 DAPS05 – haematology 3.01 Assumptions and consultation with clinical
expert on the number of full blood count, liver
functions and renal function tests required
(Professor Olga Ciccarelli, University College
London, June 2016, personal communication);
NHS Reference Costs 2014 to 2015285
Liver function
tests
2 DAPS04 – clinical
biochemistry
1.19
Renal function
tests
2 DAPS04 – clinical
biochemistry
1.19
MRI 1 RD01A 137.23 NHS Reference Costs 2014 to 2015285
Neurologist visit 1 Outpatient attendance,
Neurology 400
175.76 Assumption and consultation with clinical
expert (Professor Olga Ciccarelli, personal
communication)
Subsequent annual cost of monitoring people receiving DMTs £323.77
APPENDIX 9
NIHR Journals Library www.journalslibrary.nihr.ac.uk
350
Appendix 10 Results by age at onset of
relapsing–remitting multiple sclerosis
Using the base-run RSS model, we derived mean costs and mean QALYs for the BSC and DMT arms forvarious ages of onset of RRMS.
TABLE 155 Mean costs and QALYs by age at onset of RRMS
Age (years)
BSC DMTs
Mean cost (£) Mean QALYs Mean cost (£) Mean QALYs
30 362,128 8.664 393,966 9.607
31 360,392 8.643 392,218 9.583
32 358,487 8.620 390,300 9.557
33 356,426 8.596 388,226 9.528
34 354,182 8.569 385,967 9.497
35 351,763 8.540 383,532 9.464
36 349,145 8.508 380,898 9.428
37 346,303 8.474 378,039 9.388
38 343,252 8.437 374,970 9.345
39 339,985 8.397 371,685 9.299
40 336,479 8.354 368,160 9.250
41 332,764 8.309 364,429 9.197
42 328,825 8.261 360,475 9.141
43 324,639 8.208 356,273 9.081
44 320,230 8.153 351,850 9.017
45 315,615 8.095 347,226 8.950
46 310,782 8.034 342,385 8.879
47 305,740 7.969 337,339 8.804
48 300,491 7.901 332,087 8.725
49 295,059 7.829 326,658 8.642
50 289,449 7.754 321,055 8.555
51 283,682 7.677 315,301 8.465
52 277,718 7.595 309,353 8.371
53 271,632 7.511 303,291 8.273
54 265,398 7.423 297,085 8.171
55 259,060 7.333 290,784 8.067
56 252,565 7.239 284,327 7.957
57 245,948 7.141 277,753 7.844
58 239,201 7.040 271,050 7.726
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TABLE 155 Mean costs and QALYs by age at onset of RRMS (continued )
Age (years)
BSC DMTs
Mean cost (£) Mean QALYs Mean cost (£) Mean QALYs
59 232,326 6.934 264,220 7.604
60 225,352 6.825 257,293 7.477
61 218,270 6.712 250,254 7.346
62 211,077 6.595 243,098 7.210
63 203,763 6.472 235,810 7.068
64 196,405 6.345 228,471 6.922
65 189,004 6.216 221,080 6.772
66 181,530 6.081 213,596 6.616
67 174,037 5.942 206,079 6.457
68 166,497 5.798 198,486 6.292
69 158,995 5.652 190,914 6.124
70 151,501 5.501 183,319 5.951
71 144,046 5.347 175,732 5.775
72 136,611 5.187 168,119 5.593
73 129,248 5.024 160,536 5.407
74 121,999 4.858 153,024 5.219
75 114,851 4.688 145,559 5.027
76 107,837 4.515 138,172 4.833
77 101,019 4.342 130,933 4.637
78 94,362 4.165 123,791 4.440
79 87,944 3.989 116,838 4.243
80 81,775 3.814 110,087 4.048
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